



BOARD OF REGENTS

Agenda Book

**February 12, 2019
9:00 AM Open Session
Ballroom C, Student Union Building**

The Board of Regents of the University of New Mexico
Meeting in Open Session and Executive Session
February 12, 2019, 9:00 AM
Open Session - Student Union Building (SUB), Ballroom C
Closed Session-luncheon, Cherry Silver Room, SUB

AGENDA

TAB

- I. Call to Order, Confirmation of a Quorum, Adoption of the Agenda
Regent President Rob Doughty 1
- II. Approval of Minutes: January 14, 2019 regular meeting 2

Public Comment – comments related to items on the agenda (limit 3 min.)
Regent Advisors – comments related to agenda items (limit 3 min.)
Comments from Regents
- III. The President’s Administrative Report, *President Garnett S. Stokes* 3
- IV. Regent Committee Reports

Consent Docket

(Action items on Regent’s Committee agendas may move to the Board of Regents’ agenda as consent items; the below items are placed on the consent docket by the respective committee chairs; items on the consent docket received unanimous approval in committee; per Regents’ Policy 1.2, “Any member of the Board of Regents shall have the right upon request to remove any item from the Board’s consent agenda and place the item on the Board’s regular agenda for discussion.”)

1. Health Sciences Center Committee (HSCC) Consent Items, Regent Marron Lee, Chair
 - a. Request the Approval of Disposition of Assets - \$207,522.90 C-1
2. Finance and Facilities Committee (F&F) Consent Items, Regent Marron Lee, Chair
 - a. Approval of Disposition of Surplus Property for Main Campus for January 2019 C-2
 - b. Approval of Quarterly Financial Actions Report and Certification through December 31, 2018
and Information on Monthly Consolidated Financial Reports for the Month Ended December 31, 2018 C-3

Health Sciences Center Committee (HSCC), Regent Marron Lee, Chair

Information Items

1. HSC Financial Update, *Ava Lovell, Exec. Officer Finance & Administration, HSC* 4
2. UNM Health System Report, *Michael Richards, Vice Chancellor for Clinical Affairs, HSC* 5

Action Items

3. Request Approval to Appoint Leslie Andritsos, MD as the new holder of the Maralyn S. Budke
Endowed Professor in Leukemia Transplantation and Cell-Based Therapeutics 6
Cheryl Willman, Director & CEO, UNM Comprehensive Cancer Center
4. Request Approval to Appoint Diane Lidke, PhD as the new holder of Victor and Ruby Hansen
Surface Endowed Professor in Cancer Cell Signal Transduction and Cellular Imaging 7
Cheryl Willman, Director & CEO, UNM Comprehensive Cancer Center
5. Request Approval to Appoint Eric Prossnitz, PhD as the new holder of the Maralyn S. Budke
Endowed Chair in Cancer Chemical Biology and Therapeutics 8
Cheryl Willman, Director & CEO, UNM Comprehensive Cancer Center
6. Request for the Approval of Repair, Renew, Replace Capital Project – UPC-PES-Expansion
Renovation \$1,300,000, *Bonnie White, CFO, UNM Hospitals* 9
7. Request for the Approval of Repair, Renew, Replace Capital Project – UPC Adult Inpatient-Inpatient
BHICU, Comfort Rooms \$1,400,000, *Bonnie White, CFO, UNM Hospitals* 10

8. Request for the Approval of Repair, Renew, Replace Capital Project – UH Main, Safety-Fire Alarm System \$1,500,000, *Bonnie White, CFO, UNM Hospitals* 11
9. Request for the Approval of Repair, Renew, Replace Capital Project – UNMH Main 10 & 11 Roof Replacement \$979,242, *Bonnie White, CFO, UNM Hospitals* 12
10. Request for the Approval of Program Management – Modern Medical Facility \$6,789,262 13
Mike Chicarelli, COO, UNM Hospitals; Kate Becker, CEO, UNM Hospitals
11. Request for the Approval of Architect/Design – Modern Medical Facility \$33,858,800 14
Mike Chicarelli, COO, UNM Hospitals; Kate Becker, CEO, UNM Hospitals

Finance and Facilities Committee (F&F), Regent Marron Lee, Chair

Action Items

1. Approval of Athletics’ Enhanced Fiscal Oversight Program Reports and Certification through December 31, 2018, *Eddie Nunez, VP Athletics; Nicole Dopson, Director, Financial Operations* 15
2. Approval of Annual Report for STC.UNM 16
Elizabeth Kuuttila, CEO & Chief Economic Development Officer, STC.UNM; Sheila Herrera, Mass Adams
3. Approval of Contract for Life and Disability Insurance Carriers 17
Bruce Cherrin, Chief Procurement Officer
4. Approval of FY 2020 Medical Plan Projections and Proposed Strategy 18
Mike Richards, Vice Chancellor, Clinical Affairs; Dorothy Anderson, VP HR; Joey Evans, Dir., University Benefits; Eric Wwinstein, Aon Consulting

Information Items

5. Monthly Athletics’ Report on Revenue, Expenditures, and Compliance 19
Eddie Nunez, VP Athletics; Nicole Dopson, Dir., Financial Operations
6. Update on UNM Press 20
Rich Wood, Interim Provost; Richard Clement, Dean, University Libraries; Nicole Dopson, Director, Financial Operations

Public Comment – comments not related to items on the agenda (limit 3 min. per speaker)

- V. Advisors’ Comments (limit 3 min.) 21
- VI. Vote to Close the Meeting and Proceed in Executive Session (Roll Call Vote)
 1. Discussion and determination where appropriate of potential purchase, acquisition, or disposal of real property, as permitted by Section 10-15-1.H(8), NMSA (1978)
 2. Discussion, and determination where appropriate, of threatened or pending litigation as permitted by Section 10-15-1.H(7), NMSA (1978)
- VII. Vote to re-open the meeting and certification that only those matters described in Agenda Items VI. were discussed in Closed Session, and if necessary, final action on matters discussed in Executive Session that are required to be taken in Open Session
- VIII. Adjourn

Minutes of the Regular Meeting of the Board of Regents of the University of New Mexico

January 14, 2019

Student Union Building (SUB) – Main Campus

Open Session - Ballroom C

Executive Session – Cherry Silver Room

Members present

President Rob Doughty; Vice President Marron Lee; Secretary/Treasurer Tom Clifford (telephonically); Brad Hosmer; Suzanne Quillen; Michael Brasher

Administration present

Garnett S. Stokes, President; Craig White, Interim SVP for Finance and Administration; Paul Roth, Chancellor for Health Sciences; Rich Wood, Interim Provost and EVP for Academic Affairs; Loretta Martinez, Chief Legal Counsel; Richard Larson, Executive Vice Chancellor, HSC; Michael Richards, Vice Chancellor for Clinical Affairs, HSC; Gabriel Lopez, VP Research; Ava Lovell, Executive Officer for Finance & Administration, HSC; Lawrence Roybal, Interim VP for Equity and Inclusion; Eliseo "Cheo" Torres, VP Student Affairs; Dorothy Anderson, VP HR; Liz Metzger, University Controller; Terry Babbitt, President's Chief of Staff; Cinnamon Blair, Chief Marketing & Communications Officer; Kate Becker, CEO, UNM Hospitals; Eddie Nunez, Athletics Director; Francie Cordova, Interim Chief Compliance Officer and Director of OEO

Advisors present

Pamela Pyle, President, Faculty Senate; Rob Burford, President, Staff Council; Steve Borbas, President, Retiree Association; Becka Myers, President, ASUNM; Boney Mutabazi, President, GPSA President

Presenters in attendance

Lisa Todd, Moss Adams; Mark McComb, KPMG; Lisa Marbury, Exec. Director, ISS; Richard Clement, Dean College of Libraries and Learning Sciences; Fran Wilkinson, Senior Assoc. Dean, College of Libraries and Learning Sciences; Lea Briggs, Assistant Professor, College of Libraries and Learning Sciences; Bruce Cherrin, Chief Procurement Officer; Abhaya Datye, Distinguished Professor and Chair, Department of Chemical and Biological Engineering; Adrian Brearley, Distinguished Professor, Earth and Planetary Sciences; Sean Ferrera, Director of Development, Premium Seating; Tom Tkach, Director of Public Events/Popejoy Hall

Others in attendance

Members of administration, faculty, staff, students, the media and others.

CALL TO ORDER, CONFIRMATION OF A QUORUM, ADOPTION OF THE AGENDA

Regent President Rob Doughty called the meeting to order at 9:16 AM and confirmed a quorum with six members present; five members present in person and Regent Tom Clifford attended by phone. Regent Doughty clarified that currently there not a student regent on the board.

Before adoption of the agenda:

Regent Brad Hosmer requested to move the following Consent Docket items off the docket for discussion and vote under respective committee reports:

- 1.a. *Request for Approval of Repair, Renew, Replace Capital Project – Pre-Op Renovation, \$1,500,000*
- 1.b. *Request for the Approval of Repair, Renew, Replace Capital Project – UNM Family Health Clinic – DOH Licensing Improvements, \$2,200,000*
- 2.b. *Approval of Purchase of a JEOL Transmission Electron Microscope*

Regent Marron Lee requested to move HSC Committee action item #1, *Request for the Approval of the Nomination of Dr. Jennifer K. Phillips to the UNM Hospitals Board of Trustees*, up on the agenda to after the Comments section.

The motion to approve the agenda as modified passed unanimously (1st Lee; 2nd Brasher).

APPROVAL OF MINUTES

The motion to approve the minutes of the December 11, 2018 meeting passed unanimously (1st Lee; 2nd Brasher).

PUBLIC COMMENT (no comments)

REGENT ADVISORS COMMENTS (no comments)

COMMENTS FROM REGENTS (no comments)

HSC Committee Action Item: Request for the Approval of the Nomination of Dr. Jennifer K. Phillips to the UNM Hospitals Board of Trustees

Regent Lee asked UNM Hospitals CEO Kate Becker to present. Ms. Becker introduced Dr. Jennifer Phillips, the immediate past Chief of Staff of the Medical Staff. The role of the Chief of Staff for the Medical Staff at UNM Hospital is an ex-officio position of the board, and typically the immediate past Chief of staff will come onto the board as a voting member. Dr. Phillips is a full professor at UNM, specializing in women's health and primary care; a UNM graduate, Dr. Phillips has worked in the Department of Family Medicine for almost 14 years. Ms. Becker added that Dr. Phillips has been a great board member as Chief of Staff this past year and recommended the Regents' approve her nomination to the UNM Hospitals Board of Trustees.

Regent Lee thanked Dr. Phillips for her willingness to serve.

The motion to approve the Nomination of Dr. Jennifer K. Phillips to the UNM Hospitals Board of Trustees passed unanimously (1st Doughty; 2nd Brasher).

THE PRESIDENT'S ADMINISTRATIVE REPORT

President Garnett S. Stokes opened her report highlighting the Building Humanities Pathways initiative, a CNM/UNM partnership focused on innovation and student success. New Mexico ranks 48th in the US, with 25% of college students transferring to and graduating from New Mexico public colleges. UNM and CNM (Central New Mexico Community College) together will seek to expand innovative curricula and educational programming and to provide clear degree pathways for students. UNM will work closely with CNM to promote more students getting into and studying in the Humanities, but then successfully coming to the University of New Mexico. President Stokes also talked about the importance of the renewal of one of the NIH's largest and most prestigious awards, The Clinical and Translational Science Award that funds UNM's Clinical and Translational Science Center (CTSC). This program is in its 9th year, and works to accelerate health discoveries leading to better health and health care. There are only 58 funded centers nationwide and only three in the Mountain West.

Dr. Stokes gave an update on campus safety, one of the President's priorities. UNM is always working on this issue and it is clear that to tackle this issue effectively, the University must work with police and security in the neighboring areas and beyond. President Stokes spoke about collaborative efforts with the Bernalillo District Attorney's Office and UNM's Campus Safety Council (CSC). The council is charged with centralizing the broad range of campus safety discussions and initiatives and for providing recommendations to UNM leadership regarding strategic direction. President Stokes discussed other priorities and initiatives, including efforts toward enhancing UNM's environment toward becoming a more Veteran and Military-Friendly University and upcoming on-campus training designed to help people recognize, acknowledge and minimize potential blind spots or biases.

President Stokes spoke about the 2019 Legislative Session, preparations leading up to the January 15 start of the 60-day session and priorities. Besides UNM staff, lobbyists and campus experts who assist during the session, UNM is working closely with the Council of University Presidents (CUP) aligning key priorities with CUP (Eg. Funding Formula, compensation, ERB, etc.). Dr. Stokes outlined examples of past year's preparations during the interim session, including hosting 11 interim committee meetings, 43 presentations by staff and faculty leadership, and President Stokes herself met with 33 legislators, including 5 of the 8 new Bernalillo County legislators. Dr. Stokes briefly mentioned UNM's legislative priorities: Instruction and General/Funding Formula; Medical School Instruction & General Funding; Cancer Center 340B Funding Replacement; Lottery Scholarship; Compensation Funding; ERB Reform; Higher Education Endowment; and New Mexico Nursing Education Consortium (NMNEC). Regarding NMNEC, there is a serious shortage of nurses within the State, and this consortium could be an important part of the solution. President Stokes outlined UNM's capital projects and Research and Public Service Projects (RPSPs) funding requests that have been discussed in detail in prior Board of Regents meetings.

REGENT COMMITTEE REPORTS

CONSENT DOCKET

Regent Doughty addressed the consent docket. No additional items were removed for discussion other than those indicated during adoption of the agenda.

1. Health Sciences Center Committee (HSCC) Consent Items
 - a. (this item removed from the docket during adoption of the agenda)
 - b. (this item removed from the docket during adoption of the agenda)
 - c. Request for the Approval of Repair, Renew, Replace Capital Project – ACC Ambulatory Elevators – Refurbished \$786,588
2. Finance and Facilities Committee (F&F) Consent Items
 - a. Approval of Disposition of Surplus Property for Main Campus for December 2018

- b. (this item removed from the docket during adoption of the agenda)

The motion to approve the items (1.c. and 2.a.) on the Consent Docket passed unanimously (1st Lee; 2nd Brasher).

AUDIT AND COMPLIANCE COMMITTEE

Approval of FY18 University Consolidated Financial Statements External Audit Report by Moss Adams and KPMG

Regent Tom Clifford introduced the item. This is a formal activity required by the Audit Act. Liz Metzger introduced Lisa Todd, audit partner with Moss Adams and Mark McComb, audit partner with KPMG. The external audit was submitted to the State Auditor's Office in October and it has since been released from that office in December.

Lisa Todd and Mark McComb presented information similar to that which was presented at the October 15 Audit and Compliance Committee meeting and referred to slides that were made available in the eBook. Regarding the auditor's role, Moss Adams is responsible for UNM main campus and branches financial statement audit, the Single Audit of Federal Expenditures, and also for non-clinical component units and departments. Moss Adams reports on consolidated financial and internal controls, referring to portions of clinical operations that are audited by KPMG. KPMG is responsible for UNM Clinical Operations (UNM Hospital, UNM Behavioral Operations, UNM Medical Group, and SRMC), and produces four separate stand-alone reports. The audits are performed in accordance with Generally Accepted Auditing Standards, Government Auditing Standards, and the New Mexico State Auditor Rule 2.2.2 NMAC. For the Single Audit, audits of federal grants performed in accordance with OMB Uniform Guidance, the major programs tested were the Mortgage Insurance program that impacts the Hospitals and SRMC.

Regarding audit opinions and reports, there are several reports. The auditors issued a 'clean', unmodified opinion for the financial statements audit report and added the financial statements are presented fairly and in accordance with US GAAP. The following reports were also issued a 'clean', unmodified opinion: GAGAS Report on Internal Control Over Financial Reporting and on Compliance and Other Matters; report on Compliance with Requirements that could have a direct and material effect on the Major Federal Programs and on Internal Control Over Compliance in accordance with the Uniform Guidance for Federal Awards. The four clinical reports also received 'clean', unmodified opinions.

Ms. Todd and Mr. McComb presented a summary of prior-year audit findings. Three findings related to the Clinical Operations and two of those were resolved, and one finding for UNM Hospital and SRMC regarding terminated employee documentation process received a repeat finding. All other prior-year findings were found to have been resolved.

The auditors discussed findings in this year's audit. There were no findings related to the Single Audit. In all, there were three findings of 'significant deficiency' and one finding of, 'other matter'. Related to UNM Clinical Operations, there are significant related-party transactions among the health system entities, and the finding and comments were that the organization should establish written policies and procedures governing related party transactions, including associated internal controls. The second finding in related to a deficiency at the component unit level regarding Innovate ABQ financial close and reporting. Necessary audit adjustments were not material. The third finding noted an internal control deficiency associated with UNM Hospital account review and controls. The fourth finding related to UNM clinical Operations user access review, specifically controls over user access reviews are not operating effectively. This was not a deficiency, but 'other matter'.

Ms. Todd reviewed other testwork areas performed by auditors as required by the NM State audit Rule and supplemental testwork performed. No deficiencies were noted in samples selected for testwork.

The audit report can be found online, <http://fsd.unm.edu/resources/audrep18.pdf>

Regent Clifford thanked the auditors, they did a good job and they were responsive to concerns. Regarding the finding on page 8 specifying written policies are procedures are needed regarding related party transactions, Regent Clifford urged financial leadership to follow up on this and for the Audit, F&F and HSC Committees to take this on. He also recommended getting external advice on how those policies and procedures should be written. Additionally, regarding the finding on page 9 related to Innovate, there have been several issues over the last few years. This highlights that when we create these independent research park entities, financial controls are critical because these are higher-risk areas for the University. And finally, the adjustments to the books related to retirement benefit obligations, this has had a very material effect on our financial statements, and the Board needs to understand this issue better.

The motion to approve the FY18 University Consolidated Financial Statements External Audit Report passed with a unanimous vote in favor (1st Clifford; 2nd Brasher).

HEALTH SCIENCES CENTER COMMITTEE

Approval of Repair, Renew, Replace Capital Project – Pre-Op Renovation, \$1,500,000

UNM Hospitals CEO Kate Becker presented the item. This project \$1.5 million project is split between two fiscal years. This year, Phase One, will be about \$600K, and next year, Phase Two in FY2020, is estimated at \$900K. The main hospital has 16 ORs (Operating Rooms), and typically there is a 1:1 ratio of pre-operative bays to ORs. UNM Hospital currently has 5 Pre-Op bays, and this causes delays into the ORs. The addition of up to 9 bays will allow for better patient throughput and result in faster turnover times, and greater physician and patient satisfaction.

The motion to approve the Repair, Renew, Replace Capital Project for Pre-Op Renovation passed with a unanimous vote in favor (1st Brasher; 2nd Hosmer).

Approval of Repair, Renew, Replace Capital Project – UNM Family Health Clinic – DOH Licensing, \$2,200,000

Kate Becker presented the item. This project involves renovations to the Family Health Clinic, an older building that is not ADA compliant. In 2011, the Department of Health (DOH) cited UNM for noncompliance items in this clinic. UNM HSC has set aside \$2.2 million in the capital budget to do the renovations in order to ensure compliance with the DOH. UNM plans to be in this building for quite a while longer.

Regent Lee inquired if there had been a HIPPA issue as well. CEO Becker responded, yes, the triage area needs better partitioning for more private enclosure spaces.

Regent Hosmer inquired if UNMH has been operating on a waiver up to this point. CEO Becker responded the DOH has probably been patient with UNM to complete the renovations when funds became available. There was discussion that operational deficiencies will also be addressed by the redesign, with more efficient patient flow improving scheduling and patient experience.

The motion to approve the Repair, Renew, Replace Capital Project for UNM Family Health Clinic – DOH Licensing passed with a unanimous vote in favor (1st Hosmer; 2nd Brasher).

New Mexico Health Care Workforce Report Update (information item)

Regent Lee asked Richard Larson to present his report. Dr. Larson referred to slides made available in the eBook. This is the annual update on the Health Care Workforce in New Mexico. This initiative began in 2012, and this ability to track the health care workforce in New Mexico leads in the nation. There is no other state in the nation that can get the detail and granularity on the status of their health care workforce like New Mexico. This is a result of an act that was passed in 2012 - HB19, the Health Care Work Force Data Collection, Analysis and Policy Act. There are three key elements to the act: 1) it requires all licensing boards to collect certain data on all of its providers, 2) UNM HSC was designated as the steward for the storage and safe-keeping (the professional societies in New Mexico requested this so the data could be kept in a highly confidential way), and 3) it established a Health Care Workforce Committee, a state-wide committee with the makeup established in stature – it is a broad committee that includes not only representatives from the licensing boards but also from the professional societies, the NM Hospital Association, and other stakeholders. Dr. Larson chairs the committee. Each year, the committee is required to evaluate the work force situation in New Mexico and report out by October 1st to both Legislature and the Governor the status of the work force situation. The report Dr. Larson will be summarizing is the report that was delivered to the State on October 1, 2018.

This report has been incredibly instrumental in providing the evidence and the information that is needed to advance the work force in New Mexico. New Mexico is a state that has severe shortages of all health care professions. As a result of seeing the situation, there have been a number of enhancements in areas such as, funding, education, accreditation and licensing standards that have increased the ability to either produce more or recruit more health care providers to the State. Dr. Larson spoke about accomplishments since 2013, including enhancing funding for the health professional loan repayment program, nursing education expansion, Allied Health Loan for Service expansion, State-funded residency positions and GME (Graduate Medical Education) funded positions. Other impacts are in the area of telehealth services and community health worker training.

The 2018 report is based on a snapshot of data taken as of 31 December 2017. As of that time, New Mexico has a total of 9,585 licensed physicians with only 57% (5,498) practicing in New Mexico. Of note, the State has a large number of physicians who are either in the military or in the public health service, and they are able to get licensed in any state. They do choose to get licensed in NM, it appears many of them either intend to relocate to NM after their obligations are done or they license in NM because it is cheaper. Regarding certified nurse practitioners (CNP) and clinical nurse specialists (CNS), of the 2,152 total, only 68% (1,453) practice in New Mexico. Since 2016, there has been an increase of 60 physicians and 74 CNP/CNSs. Dr. Larson showed data on the trends since 2013 of the increases in numbers of MDs and Dns in the State as well as change over time in other professions such as nursing, dentists, PAs, and Pharmacists. Even though trends are up, severe shortages are still taking place in areas of the State, particularly in rural areas. New Mexico has the highest percentage of physicians over 60 years of age; more than 1/3 of physicians are over 60. The overwhelming majority of those physicians are in rural counties, many stay in practice until a replacement can be found.

Dr. Larson showed state maps depicting, by county, number of physicians in each county as well as how that compares to national benchmark numbers. As a general pattern, the southeast and the northwest part of the State are where the shortages are most severe.

Dr. Larson discussed the Behavioral Health issue in the State. About three years ago a subcommittee was formed, by statute, to analyze just Behavioral Health situation. Unfortunately in 2018, there was a glitch in the State's IT system. This issue has been worked out with the Regulation and Licensing Department.

Dr. Larson discussed the 2018 recommendations from the Work Force Committee, including identifying funding for efforts to support NMNEC (NM Nursing Education Consortium), continue funding for expanded primary and secondary care residencies in NM, and increase funding for state loan-for-service and loan repayment programs, and consider restructuring them to target most needed professions rather than highest debt. Some of these can also be used as a huge recruiting tool. New Mexico gives either a \$3K or 4%K rural tax credit for health care providers of all types, but when that legislation was passed, it left off pharmacists and social workers. This will be the second year in a row to recommend that they be included with other health care providers in that ability to get tax incentive. In another area, preceptorships; a preceptorship is when a student goes out into a rural area to have experiences with the physician there. It has been found the longer time a student spends with a physician in the rural area, the more likely they will end up practicing in a rural setting. The recommendation is to give a modest tax credit to physicians (\$500 to \$1,000) who offer those preceptorship experiences. Dr. Larson briefly discussed the Behavioral Health Subcommittee recommendations; they are repeat recommendations, including recommendations for changes regarding reimbursements and reimbursement patterns for psychiatric care.

The New Mexico Health Care Workforce Committee 2018 Annual Report can be found online:
https://www.nmhanet.org/files/NMHCWF_2018Report.pdf

Regent Lee thanked Dr. Larson for his report.

UNM Health System Report (information item)

Michael Richards, Vice Chancellor for Clinical Affairs, presented the item and referred to materials provided in the eBook. The report represents year-to-date activity through November 2018 and compares to data through November of the prior year. In the area of quality and safety metrics, UNM Hospitals and SRMC continues to see improvements across the delivery system, particularly in the area of non-infection harm events where many of these next level of targets will be set at zero, indicating there has been significant improvement in this area. Regarding health system activity, the total number of patients taken care of inside the hospital, both as inpatient and observation patients, is up 1%. The traditional inpatient volume is actually down 4%, while the categorization of those patients as observation is up 14% as compared to prior year. There has been significant improvement in the length-of-stay, with the decrease of that number by 4% which is a desired outcome. The level of severity (CMI – Case Mix Index) has not changed year-over-year. Outpatient activity is 3% higher than last year, which is due to about 10% in primary care clinic visits and 1% increase in specialty clinic visits compare to last year. Surgical volume is down and Medical Group (RVUs) are also down 1%.

As has been discussed, Emergency Department (ED) volumes are down, but with the emergence of the influenza, the ED and hospital are both extremely busy. This morning, the hospital was at 100% of its capacity, largely driven by these viral illnesses that occur this time of year.

Regarding the financial system, the net margin of the total delivery system is up \$2 million compared to this time last year. The total net position of the balance sheet is improved by 1%.

Dr. Richards touched on the Lovelace UNM Rehabilitation Hospital – Joint Venture (JV). The JV is currently in its 18th month, and probably the most significant achievement is the development of the Physical Medicine and Rehabilitation (PM&R) residency training program. This program does not exist elsewhere in New Mexico; it is about one year ahead of schedule. The initial site visit by the accrediting body has already occurred, and preliminary results have been good.

Dr. Richards gave an update on a couple of items brought up by Regent Michael Brasher in the HSC Committee meeting. The first related to the federal requirement that the hospital post its charges. These charges, for pharmaceutical, inpatient, and procedural charges, have always been available on the federal website, and they can now easily be found on the hospital's new website. Secondly, there was the question of whether the shutdown of the federal government had impacted delivery of care, particularly to the Native American population. Dr. Richard responded UNM's clinical operations have continued without any impediment during this federal shutdown.

Regent Hosmer inquired regarding the report, how the targets are set. Dr. Richards responded the targets are set internally, but national benchmarks are used. The basic way the targets have been established is by increasing the level of performance

annually. Generally, a 5% annual performance improvement is set, predominantly on the inpatient side. These are targets defined by CMS. Additionally, there is comparison to an academic peer group using a national organization called Vizient.

Regent Suzanne Quillen inquired regarding the report, why the diversions from SRMC spiked up in the 4th quarter. Dr. Richards responded SRMC's inpatient volume is now actually at capacity. Regent Quillen asked if the diversions are directed to UNMH. Dr. Richards responded many of the diversions, handled through the call transfer center, are offered hand offs into the Presbyterian and Lovelace systems.

Regent Brasher inquired if the MATS (Metropolitan Assessment and Treatment Services) Detox program is still in operation and still providing an option for emergency treatment. Dr. Roth responded the program is doing well and UNM HSC is working closely with the county which is looking to expand the program.

FINANCE AND FACILITIES COMMITTEE

Approval of Request for: Project Construction for KNME-TV ADA Stand-Alone Exterior Elevator

Lisa Marbury presented the item. This project, located at the KNME-TV station, consists of the design and construction of an exterior, stand-alone elevator structure, elevator equipment, and connecting elevated walkways. This also requires alterations to the existing electrical and special systems as well as modifications at the locations where the new elevator will connect to the existing building. This is an ADA situation for KNME. The project budget is \$478,334 that will be funded from KNME's Unrestricted Public Service Fund Surpluses.

Regent Brasher thanked Franz Joachim, General Manager NMPBS, and Richard Towne, General Manager KUNM, for the great work they do. Regent Brasher moved approval, and specified he was doing so without any conflict unless any other members objected. There were no objections.

Regent Clifford commented with regard to when these proposals are brought forward it would be helpful to know more about how they are prioritized. Particularly with regard to procurement, how are cost-effective bids identified and what were the alternatives that were examined. Regent Clifford said he was ok with approval of both of these project construction items, but he felt the Regents are not getting useful information. The drawings are not particularly helpful and he wanted to know how UNM is prioritizing the use of what is a significant part of UNM's budget. Common sense would tell us that money needs to be spent to maintain facilities, but the question is, who's thinking about scope of those facilities. They are added onto significantly every two years and at that point we take on additional obligations to maintain those. This is a huge financial obligation of the University and we are not getting information that will help us feel comfortable that we've got our hands around the right scale for facilities.

Regent Brasher thanked Regent Clifford for his comments and added in this particularly case there is obviously a real need for the project in order to meet the ADA requirements.

The motion to approve the Project Construction for KNME-TV ADA Stand-Alone Exterior Elevator passed with a unanimous vote in favor (1st Brasher; 2nd Doughty).

Approval of Request for: Project Construction for South Campus Repository

Lisa Marbury introduced the item. Dean Richard Clements, Fran Wilkinson, Senior Assoc. Dean, and Lea Briggs, Assistant Professor of the College of Libraries and Learning Sciences were also present to answer questions. This project is for the existing warehouse storage area within The University of New Mexico Press building #334 on south campus and will house the University Libraries overflow of permanent collections. The approximate 14,000 gross square feet of high bay warehouse space will be upgraded to extend the life of the new and current collections. The main component of the project is an upgrade to the HVAC systems in order to keep the temperatures and humidity at appropriate levels and interior lighting upgrades. The project budget is \$400K, to which \$300K will come from the Building Renewal and Replacement (BR&R) appropriation from the Provost's Office, and \$100K to be funded from the University Libraries Reserves.

Interim Provost Wood spoke about the ways this project is important for the academic mission of the University. This particular expense is crucial to the mission of the Libraries in four ways: 1) the Libraries centrally support the teaching and research mission, 2) UNM serves as the official state archive for many volumes, hundreds of feet each year of state archives, and UNM is the only archive for many of those materials, 3) UNM is the central point for inter-library loan for public libraries all over the State, and 4) Zimmerman Library is often full of students and this will help to free up space for students.

Regent Clifford said the specific question he had on this item had to do with utilization of the volumes in the collections, the tracking and policies for determining those. Dean Clements responded UNM Libraries is the largest library in the State of New Mexico and is arguably the only research library, and the collections have built up very carefully over the last century. Each volume has been reviewed by library selectors. Arguably, this collection, now at 3.5 million volumes, is one of the most valuable assets in the State today, and what will be done in creating this repository, is saving that asset. Research particularly

in the Humanities and Social Sciences, older books are still extraordinarily valuable. Dr. Clement mentioned the detailed data that is collected on materials, for example, how many times a book has circulated and there is work with departments to determine which materials are important for research in that department. Given the value of the collection, this proposal is the best way forward to save it for the State and people of New Mexico. Across the nation, also every single R1 university has already gone this way.

The motion to approve the Project Construction for South Campus Repository passed with a unanimous vote in favor (1st Doughty; 2nd Brasher).

Approval of Purchase of a JEOL Transmission Electron Microscope

Bruce Cherrin introduced the item. Abhaya Datye, Chair and Distinguished Professor, Department of Chemical and Biological Engineering, and the PI (Principal Investigator) of the National Science Foundation (NSF) grant which is being used to acquire this microscope; Adrian Brearley, Distinguished Professor, Earth and Planetary Sciences and Co-PI of the NSF grant, were also available to explain details and answer questions. Mr. Cherrin explained this \$2.5 million purchase will be funded mostly with a grant from the NSF, \$1.75 million, with a cost share portion of \$750K that UNM will fund. This was a sole source microscope, listed on the website for 30 days, involving extensive evaluation.

Regent Hosmer inquired more details about the funding. Dr. Datye added the \$1.75 million NSF grant was very competitive. This is a long process, and UNM has been trying for many years to get this funding because there is just no other way to upgrade the facilities. This is critical because the level of resolution goes to the atomic level; this will be a state-of-the-art modern facility. There is no other like it in New Mexico or nearby. This will give UNM students the unique opportunity for access to a state-of-the-art instrument. After much research, it was determined this microscope meets the specifications.

Dr. Brearley, who has managed the lab for about 30 years, provided more information. This instrument puts UNM at the forefront of research at the nanoscale and will be beneficial to the HSC as well. This will open up whole new areas of research and will open a huge door to great opportunities for UNM's students and faculty and will contribute to attracting first-class faculty to the University. There have been only 5 instruments like this funded by the NSF over the last 10 years. After UNM's third attempt, it was successful.

Regent Quillen inquired where the \$750K UNM will have to pay will come from. Dr. Brearley responded The NSF requires a 30% cost share in its program, so the \$750K funding will come from several parts, including UNM's VP for Research office, various funds from other department, and user fees that are also permissible cost share. Dr. Datye added that a requirement at NSF is that it must be interdisciplinary, and this spans multiple colleges at UNM. Regent Quillen added it is important to understand the bigger picture when voting on these types of items.

The motion to approve the Purchase of a JEOL Transmission Electron Microscope passed with a unanimous vote in favor (1st Lee; 2nd Hosmer).

Update on UNM Ticketing (information item)

Bruce Cherrin introduced the item and Sean Ferrera, Director of Development, Premium Seating, provided more details. The University solicited formal proposals from qualified vendors to offer strategies for the design and procurement of a ticketing, fundraising, and marketing software system. Fifty-six invitations were sent; 4 RFPs were received by the July 19, 2018 deadline. An evaluation committee recommended awarding the procurement to Paciolan as the highest ranked offeror. The ticketing system will be implemented for UNM Athletics and for Popejoy with enhanced functionality and will improve revenue streams and reduce costs. Regent Lee inquired and there was discussion about the enhanced student experience with ticket buying and with access to available data, the ability to make more granular decisions about specific ticket sales. There are zero fixed costs to UNM Athletics or Popejoy for the Paciolan Ticketing System. Any fees charged will be per transaction per ticket sold and will range between \$1 and \$5 per ticket.

Regent Lee asked Tom Tkach, Director of Public Events/Popejoy Hall, to talk about how this will help Popejoy ticketing. Mr. Tkach said the biggest gain will be in the ability to stop scalping which is a big concern with the larger shows that come to the University. Right now, there are no laws against scalping for arts tickets.

Regent Brasher commented this seems a very good idea and asked for more detail about the procurement process. Was the return of 4 RFPs a normal rate? Mr. Cherrin responded the 56 invitations that went out went to all those vendors registered on UNM's procurement site who had selected the category, and the 4 that responded are those vendors who are in this market – these are the four nationwide with this capability. Regent Brasher inquired about any additional fees that will be charged when buying tickets. Mr. Ferrera responded the additional fees will be similar to what is already charged with the current online ticket purchase system.

PUBLIC COMMENT (no comments)

ADVISORS' COMMENTS

Faculty Senate President, Pamela Pyle, thanked the outgoing regents for their service to the University.

Vote to Close the Meeting and Proceed in Executive Session

Regent Doughty noted the Regents' closed session agenda and asked for a motion to close the meeting and clarified he would take a roll call vote; Regent Brasher motioned to close the meeting; Regent Lee seconded the motion; the following votes were taken: Regent Hosmer-yes; Regent Quillen-yes; Regent Lee-yes; Regent Clifford-yes; Regent Brasher-yes; Regent Doughty-yes vote. The motion to close the meeting passed. The meeting closed at 11:14 AM. Members moved to the Cherry Silver Room.

Executive Session Agenda; six members were present during discussion and votes

1. Discussion and determination where appropriate of potential purchase, acquisition, or disposal of real property, as permitted by Section 10-15-1.H(8), NMSA (1978)
3. Discussion of "limited personnel matters" as defined in and permitted by Section 10-15-1.H(2), NMSA (1978)
 - a. Regarding employee appeal
4. Discussion, and determination where appropriate, of threatened or pending litigation as permitted by Section 10-15-1.H(7), NMSA (1978)

Vote to re-open the meeting and certification that only those matters described in the Closed Session Agenda were discussed in Closed Session, and if necessary, final action on matters discussed in Executive Session that are required to be taken in Open Session

Regent Doughty motioned to re-open the meeting; Regent Quillen seconded; all were in favor; the meeting re-opened at 1:00 PM; the doors to the Cherry Silver Room were opened. Regent Doughty certified that only those matters described in the closed session agenda were discussed, and there was one (1) item upon which action would be taken in open session:

Regent Lee motioned that the Board deny the request for discretionary appeal of an OEO decision; Regent Hosmer seconded; all were in favor; motioned passed.

ADJOURN

There being no further business, Regent Doughty asked for a motion to adjourn; Regent Brasher motioned; Regent Quillen seconded; motion passed unanimously; the meeting adjourned at 1:02 PM.

Approved:

Attest:

Robert M. Doughty III, President

Tom Clifford, Secretary/Treasurer

Minutes originated and finalized by Mallory Reviere

President's Administrative Report

Garnett S. Stokes

President Stokes' report will be presented at the meeting.

CONSENT DOCKET

(Action items on Regent's Committee agendas may move to the Board of Regents' agenda as consent items; the below items are placed on the consent docket by the respective committee chairs; items on the consent docket received unanimous approval in committee; per Regents' Policy 1.2, "Any member of the Board of Regents shall have the right upon request to remove any item from the Board's consent agenda and place the item on the Board's regular agenda for discussion.")

1. Health Sciences Center Committee (HSCC) Consent Items, Regent Marron Lee, Chair

- a. Request the Approval of Disposition of Assets - \$207,522.90.....C-1

2. Finance and Facilities Committee (F&F) Consent Items, Regent Marron Lee, Chair

- a. Approval of Disposition of Surplus Property for Main Campus for January 201.....C-2
- b. Approval of Quarterly Financial Actions Report and Certification through December 31, 2018 and Information on Monthly Consolidated Financial Reports for the Month Ended December 31, 2018.....C-3



Date: January 15, 2019

To: Bruce Cherrin
Chief Procurement Officer, Purchasing Department

From: Bonnie White
Chief Financial Officer, UNM Hospitals

Subject: Property Disposition – January 2019

Attached for your review and submission to the Board of Regents is the Property Disposition Detail list for the month of January 2019.

Consistent with UNM Board of Regents Policy 7.9 Property Management and the Disposition of Surplus Property Act, 13-6-1, NMSA 1978, and based upon documentation submitted by the UNM Hospitals' departments responsible for the equipment, I certify that the equipment identified on the list is worn-out, unusable/unlocated or beyond useful life to the extent that the items are no longer economical or safe for continued use by UNM Hospitals. I recommend that the items be deleted from UNM Hospitals inventory and disposed of in accordance with the above noted Regents Policy and Surplus Property Act.



Property Disposition request
January 2019

Reason for Disposal	Count	Acquisition Cost	Book Value	Average Age
Monitor Upgrade Project	160	\$ 2,029,559.35	\$ 196,554.08	8.69
Unable to Inventory	11	\$ 203,716.90	\$ -	10.45
Not Repairable	13	\$ 273,275.32	\$ 10,968.82	11.08
Obsolete	49	\$ 1,029,659.71	\$ -	10.86
Grand Total	233	\$ 3,536,211.28	\$ 207,522.90	9.36

Description	Count of Lawson	Sum of Acquisition Cost	Sum of Book	Average of Age
Furniture/Fixtures	8	\$ 69,161.12	\$ -	11.13
Medical Equipment	43	\$ 1,088,506.67	\$ 10,968.82	10.81
Monitors	166	\$ 2,092,466.97	\$ 196,554.08	8.74
Non Medical Equipment	1	\$ 7,190.72	\$ -	11.00
SW/Electronics	11	\$ 101,267.80	\$ -	9.64
Vehicles	4	\$ 177,618.00	\$ -	14.75
Grand Total	233	\$ 3,536,211.28	\$ 207,522.90	9.36

Lawson Number	Asset Control Number	Description	Accounting Unit	Division Description	Model	Serial Number	Acquisition Date	Acquisition Cost	Book Value	Proposed Method of Disposal	Reason for Disposal	Generalized Description	Comments
29445 91720		Monitor Central Station & UPS	12410	Pediatric Specialty Care	CIC PRO	SDY15074248A	03/01/15	\$ 28,800.00	\$ 7,200.00	Auction	Replaced	Monitors	Monitor Project
29446 91722		Monitor Central Station & UPS	12410	Pediatric Specialty Care	CIC PRO	SDY15074205A	03/01/15	\$ 28,800.00	\$ 7,200.00	Auction	Replaced	Monitors	Monitor Project
30918 95703		Carescape Monitor B450	12520	Mother & Baby Unit (3-E) BBRP	B450	SNE16170126HA	07/01/16	\$ 12,515.74	\$ 6,257.86	Auction	Replaced	Monitors	Monitor Project
30264 93678		Dash 5000 Monitor	12480	CTH Rehab-Ortho Unit	DASH 5000	SHQ153638575A	10/01/15	\$ 16,433.18	\$ 6,025.48	Auction	Replaced	Monitors	Monitor Project
30265 93679		Dash 5000 Monitor	12480	CTH Rehab-Ortho Unit	DASH 5000	SHQ153638585A	10/01/15	\$ 16,433.18	\$ 6,025.48	Auction	Replaced	Monitors	Monitor Project
30266 93680		Dash 5000 Monitor	12480	CTH Rehab-Ortho Unit	DASH 5000	SHQ153638555A	10/01/15	\$ 16,433.18	\$ 6,025.48	Auction	Replaced	Monitors	Monitor Project
30267 93681		Dash 5000 Monitor	12480	CTH Rehab-Ortho Unit	DASH 5000	SHQ153638545A	10/01/15	\$ 16,433.18	\$ 6,025.48	Auction	Replaced	Monitors	Monitor Project
30268 93682		Dash 5000 Monitor	12480	CTH Rehab-Ortho Unit	DASH 5000	SHQ153638565A	10/01/15	\$ 16,433.18	\$ 6,025.48	Auction	Replaced	Monitors	Monitor Project
29450 91764		Dash 5000 Cardiac Monitor	12480	CTH Rehab-Ortho Unit	DASH 5000	1379531	06/01/15	\$ 16,894.13	\$ 5,068.23	Auction	Replaced	Monitors	Monitor Project
29451 91785		Dash 5000 Cardiac Monitor	12480	CTH Rehab-Ortho Unit	DASH 5000	1379532	06/01/15	\$ 16,894.13	\$ 5,068.23	Auction	Replaced	Monitors	Monitor Project
29452 91786		Dash 5000 Cardiac Monitor	12480	CTH Rehab-Ortho Unit	DASH 5000	1379533	06/01/15	\$ 16,894.13	\$ 5,068.23	Auction	Replaced	Monitors	Monitor Project
29453 91787		Dash 5000 Cardiac Monitor	12480	CTH Rehab-Ortho Unit	DASH 5000	1379534	06/01/15	\$ 16,894.13	\$ 5,068.23	Auction	Replaced	Monitors	Monitor Project
29454 91788		Dash 5000 Cardiac Monitor	12480	CTH Rehab-Ortho Unit	DASH 5000	1379535	06/01/15	\$ 16,894.12	\$ 5,068.23	Auction	Replaced	Monitors	Monitor Project
30255 91801		Dash 5000 Monitor	12510	Women's Special Care	DASH 5000	SHQ151232155A	07/01/15	\$ 15,753.28	\$ 4,988.53	Auction	Replaced	Monitors	Monitor Project
30256 91802		Dash 5000 Monitor	12510	Women's Special Care	DASH 5000	SHQ151232195A	07/01/15	\$ 15,753.28	\$ 4,988.53	Auction	Replaced	Monitors	Monitor Project
30257 91803		Dash 5000 Monitor	12510	Women's Special Care	DASH 5000	SHQ151232185A	07/01/15	\$ 15,753.28	\$ 4,988.53	Auction	Replaced	Monitors	Monitor Project
30247 91789		Dash 5000 Monitor	12510	Women's Special Care	DASH 5000	SHQ151232115A	07/01/15	\$ 15,753.27	\$ 4,988.53	Auction	Replaced	Monitors	Monitor Project
30248 91794		Dash 5000 Monitor	12510	Women's Special Care	DASH 5000	SHQ151232245A	07/01/15	\$ 15,753.27	\$ 4,988.53	Auction	Replaced	Monitors	Monitor Project
30249 91795		Dash 5000 Monitor	12510	Women's Special Care	DASH 5000	SHQ151232235A	07/01/15	\$ 15,753.27	\$ 4,988.53	Auction	Replaced	Monitors	Monitor Project
30250 91796		Dash 5000 Monitor	12510	Women's Special Care	DASH 5000	SHQ151232175A	07/01/15	\$ 15,753.27	\$ 4,988.53	Auction	Replaced	Monitors	Monitor Project
30251 91797		Dash 5000 Monitor	12510	Women's Special Care	DASH 5000	SHQ151232135A	07/01/15	\$ 15,753.27	\$ 4,988.53	Auction	Replaced	Monitors	Monitor Project
30252 91798		Dash 5000 Monitor	12510	Women's Special Care	DASH 5000	SHQ151232215A	07/01/15	\$ 15,753.27	\$ 4,988.53	Auction	Replaced	Monitors	Monitor Project
30253 91799		Dash 5000 Monitor	12510	Women's Special Care	DASH 5000	SHQ151232205A	07/01/15	\$ 15,753.27	\$ 4,988.53	Auction	Replaced	Monitors	Monitor Project
30254 91800		Dash 5000 Monitor	12510	Women's Special Care	DASH 5000	SHQ151232125A	07/01/15	\$ 15,753.27	\$ 4,988.53	Auction	Replaced	Monitors	Monitor Project
30530 95276		Dash 5000 Monitor	21015	ED-North	DASH 5000	SHQ161247245A	04/01/16	\$ 10,509.37	\$ 4,904.36	Auction	Replaced	Monitors	Monitor Project
30531 95277		Dash 5000 Monitor	21015	ED-North	DASH 5000	SHQ161247075A	04/01/16	\$ 10,509.37	\$ 4,904.36	Auction	Replaced	Monitors	Monitor Project
30533 95279		Dash 5000 Monitor	21015	ED-North	DASH 5000	SHQ161247325A	04/01/16	\$ 10,509.37	\$ 4,904.36	Auction	Replaced	Monitors	Monitor Project
30534 95280		Dash 5000 Monitor	21015	ED-North	DASH 5000	SHQ161247225A	04/01/16	\$ 10,509.37	\$ 4,904.36	Auction	Replaced	Monitors	Monitor Project
30537 95283		Dash 5000 Monitor	21015	ED-North	DASH 5000	SHQ161247145A	04/01/16	\$ 10,509.37	\$ 4,904.36	Auction	Replaced	Monitors	Monitor Project
30538 95284		Dash 5000 Monitor	21015	ED-North	DASH 5000	SHQ161247285A	04/01/16	\$ 10,509.37	\$ 4,904.36	Auction	Replaced	Monitors	Monitor Project
30539 95285		Dash 5000 Monitor	21015	ED-North	DASH 5000	SHQ161247155A	04/01/16	\$ 10,509.37	\$ 4,904.36	Auction	Replaced	Monitors	Monitor Project
30536 95282		Dash 5000 Monitor	21015	ED-North	DASH 5000	SHQ161247095A	04/01/16	\$ 10,509.37	\$ 4,729.21	Auction	Replaced	Monitors	Monitor Project
31461 98680		Leica Small Linear Stainer	34655	Dermatology Clinic 1021 Med	LEICA ST4020	980	03/01/17	\$ 5,559.12	\$ 4,169.34	Auction	Not Repairable	Medical Equipment	
29764 93471		Metaneb Nebulizer	71510	Pulmonary Services	METANE8	Q002MN0001	08/01/15	\$ 6,135.00	\$ 4,089.99	Auction	Not Repairable	Medical Equipment	
31359 95944		Dash 4000 Monitor	12015	Pediatric Infusion Unit PIU	DASH 4000	SBG06482953GA	08/01/16	\$ 7,640.00	\$ 4,074.67	Auction	Replaced	Monitors	Monitor Project
31434 98293		Dash 5000 Monitor	12000	Labor and Delivery	DASH 5000	SD009285504GA	01/01/17	\$ 5,007.50	\$ 3,004.49	Auction	Replaced	Monitors	Monitor Project
31435 98294		Dash 5000 Monitor	12000	Labor and Delivery	DASH 5000	SD008168726GA	01/01/17	\$ 5,007.50	\$ 3,004.49	Auction	Replaced	Monitors	Monitor Project
31437 98643		Dash 5000 Monitor	12000	Labor and Delivery	DASH 5000	SBG06098310GA	01/01/17	\$ 5,007.50	\$ 3,004.49	Auction	Replaced	Monitors	Monitor Project
29208 91547		Dash 4000 ATO Cardiac Monitor	12510	Women's Special Care	DASH 4000	1106884	12/01/14	\$ 14,299.70	\$ 2,859.93	Auction	Replaced	Monitors	Monitor Project
29209 91548		Dash 4000 ATO Cardiac Monitor	12510	Women's Special Care	DASH 4000	14100769	12/01/14	\$ 14,299.70	\$ 2,859.93	Auction	Replaced	Monitors	Monitor Project
29210 91546		Dash 4000 ATO Cardiac Monitor	12510	Women's Special Care	DASH 4000	14100761	12/01/14	\$ 14,299.70	\$ 2,859.93	Auction	Replaced	Monitors	Monitor Project
29211 91545		Dash 4000 ATO Cardiac Monitor	12510	Women's Special Care	DASH 4000	14100749	12/01/14	\$ 14,299.70	\$ 2,859.93	Auction	Replaced	Monitors	Monitor Project
8687 73777		Thermogard Advanced Temperatur	12110	Neuroscience ICU	XP	TGXP 00253	09/01/09	\$ 36,126.44	\$ 2,709.49	Manufacturer will dispose	Not Repairable	Medical Equipment	
29212 91544		CIC V5.X Central Monitor	12510	Women's Special Care	V5.X	DT0331G0408	12/01/14	\$ 9,831.20	\$ 1,966.25	Auction	Replaced	Monitors	Monitor Project
													The neurodiagnostics lab had a BMSI 5000 System with workstations with an in-service date of 1996. The 23 year old system became obsolete and was replaced to improve quality of care and diagnostic accuracy.
14741 24640		BMSI 5000 System & Workstation	78010	Neurodiagnostics Lab	DN960213/DP960180	BMSI 5000	07/01/96	\$ 101,800.23	\$ -	None	Obsolete	Medical Equipment	
7054 None		Gen IV Cryo Console	71040	Cardiac Cath Lab	GEN IV	N-580	03/01/08	\$ 96,395.00	\$ -	None	Obsolete	Medical Equipment	
8038 VEH #1379		2008 GMC Glaval Transit Bus PI	80030	Parking and Transport	GLAVAL	1GDESV1929F401637	10/01/08	\$ 77,000.00	\$ -	UNM Surplus	Not Repairable	Vehicles	
6215 VEH #1331		2007 GMC Glaval Bus Plate #G-7	80030	Parking and Transport	29' TITAN	1GDESV1937F417794	07/01/07	\$ 76,450.00	\$ -	UNM Surplus	Obsolete	Vehicles	
16443 33617		Aura Laser System	15005	Operating Room - BBRP	AURA	27020734	04/01/99	\$ 66,392.00	\$ -	Auction	Not Repairable	Medical Equipment	
8044 None		Mammo Workstation w/Cassettes	75000	Radiology - General	FLASH PLUS	FLASH PLUS	10/01/08	\$ 66,250.00	\$ -	None	Obsolete	Medical Equipment	
6267 62508		Leica M680 Microscope Package	15500	OSIS Operating Room	M680	M680	09/01/07	\$ 65,802.50	\$ -	None	Obsolete	Medical Equipment	
4477 52042		Dryview 8900 PACS Link Laser I	75105	OSIS Mammography	8900	8900002943	02/01/05	\$ 55,960.00	\$ -	Auction	Obsolete	Medical Equipment	
6962 60039		Central Information Center Cap	12430	General Pediatrics Unit	CIC	JA106486181GA	07/01/07	\$ 48,315.36	\$ -	Auction	Replaced	Monitors	Monitor Project

9571 SCOPE	Ultrasound Bronchofibervideosc	15000	Operating Room	1010841	1010841	12/01/10	\$	46,725.75	\$	-	None	Obsolete	Medical Equipment	
26999 83225	Argon Plasma Coagulator	70025	Endoscopy/GI-Pediatric	VIO 300D	11361071	09/01/13	\$	41,359.95	\$	-	None	Unable to Inventory	Medical Equipment	
20045 70308	M-Turbo Ultrasound System	12510	Women's Special Care	M-OB/GYN OFFICE	03HMMN0	03/01/10	\$	38,137.05	\$	-	None	Obsolete	Medical Equipment	
20044 70269	M-Turbo Ultrasound System	34110	Women's Health Center	M-OB/GYN OFFICE	03HMMJN	01/01/10	\$	38,137.00	\$	-	None	Unable to Inventory	Medical Equipment	
9252 70886	SonoSite S-Nerve Ultrasound Sy	34340	Pain Clinic	S-NERVE	03JNK8	08/01/10	\$	37,220.40	\$	-	Auction	Obsolete	Medical Equipment	
7408 67164	COOLgard 3000	12460	Pediatric ICU	COOLGARD 3000	300000681	06/01/08	\$	33,546.00	\$	-	Auction	Obsolete	Medical Equipment	
16397 38206	Argon Plasma Coagulator System	70020	Endoscopy Center	APC 300JUL	B-1403	04/01/99	\$	32,934.56	\$	-	None	Unable to Inventory	Medical Equipment	
8015 67507	Spencer ST3 Bilateral System	12110	Neuroscience ICU	ST3	15218	09/01/08	\$	32,415.00	\$	-	Auction	Obsolete	Medical Equipment	
19441 52305	CIC - Central Monitor Station	12460	Pediatric ICU	CIC	JA105201993GA	09/01/05	\$	27,226.82	\$	-	Auction	Replaced	Monitors	Monitor Project
9283 70735	MultiLab Series 2CP Vascular S	71060	Vascular Lab	2-CP	MLS2C713	07/01/10	\$	26,919.00	\$	-	Auction	Obsolete	Medical Equipment	
19856 64327	CIC V5	12430	General Pediatrics Unit	CIC V5	SCH08174342GA	08/01/08	\$	26,427.44	\$	-	Auction	Replaced	Monitors	Monitor Project
6987 60536	Central Information Center Cap	12410	Pediatric Specialty Care	CIC	JA1064586196GA	07/01/07	\$	25,545.30	\$	-	Auction	Replaced	Monitors	Monitor Project
5668 52406	CIC - Central Station	12130	Trauma/Surgical ICU	CIC	JA105191922GA	11/01/05	\$	23,712.13	\$	-	Auction	Replaced	Monitors	Monitor Project
19904 None	Hardware - QS Perinatal System	12000	Labor and Delivery	Hardware - QS Perinatal	Hardware - QS Perinatal System	11/01/08	\$	21,798.00	\$	-	None	Unable to Inventory	SW/Electronics	
5904 None	Siemens Symphone Quadrature Lo	75040	Radiology - MRI	3146466	1630	04/01/07	\$	20,691.00	\$	-	None	Obsolete	Medical Equipment	
16104 29736	Solar 8000 Cardiac Monitor	95700	Clinical Engineering	SOLAR 8000I	B8MC8851G	04/01/98	\$	20,344.80	\$	-	Auction	Replaced	Monitors	Monitor Project
20079 82226	CIC Pro	12410	Pediatric Specialty Care	2037318-003	SDY10446103GA	04/01/11	\$	20,312.38	\$	-	Auction	Replaced	Monitors	Monitor Project
21244 80764	Central Patient Monitor	12480	CTH Rehab-Ortho Unit	CIC PRO	SDY11128404GA	07/01/11	\$	19,373.70	\$	-	Auction	Replaced	Monitors	Monitor Project
2855 46594	Solar8M & Tram Monitor, Multip	15000	Operating Room	SOLAR 8000	F3G46196G	09/01/03	\$	17,961.03	\$	-	Auction	Replaced	Monitors	Monitor Project
5779 None	Siemens Symphony P.A. Wrist Ar	75040	Radiology - MRI	860SI-64E	50946	10/01/06	\$	16,415.00	\$	-	None	Obsolete	Medical Equipment	
24529 83347	ECO2 ECOPoint	76020	Speech/Language Pathology	F14866	1860EC2	07/01/12	\$	16,115.00	\$	-	Auction	Obsolete	Medical Equipment	
4266 49320	Maternal/Fetal Monitor	12000	Labor and Delivery	129	RUX04293939PA	08/01/04	\$	15,672.02	\$	-	Auction	Obsolete	Monitors	
4964 52294	Dash 4000 Monitor	15040	PACU (Recovery Room 1)	DASH 4000	DSH05193085GA	08/01/05	\$	15,549.27	\$	-	Auction	Replaced	Monitors	Monitor Project
4968 52293	Dash 4000 Monitor	15040	PACU (Recovery Room 1)	DASH 4000	DSH05196246GA	08/01/05	\$	15,549.27	\$	-	Auction	Replaced	Monitors	Monitor Project
19917 STERILE	Uni EFT Probe (part of Ross #0	70020	Endoscopy Center	UNI EFT	14-44-10564	01/01/09	\$	15,256.66	\$	-	None	Unable to Inventory	Medical Equipment	
8864 70997	Dash 4000 Monitor	21010	ED - Fast Track	4000	S0009410422GA	11/01/09	\$	15,222.18	\$	-	Auction	Replaced	Monitors	Monitor Project
8866 70998	Dash 4000 Monitor	21010	ED - Fast Track	4000	S0009409971GA	11/01/09	\$	15,222.18	\$	-	Auction	Replaced	Monitors	Monitor Project
8871 70999	Dash 4000 Monitor	21010	ED - Fast Track	4000	S0009410286GA	11/01/09	\$	15,222.18	\$	-	Auction	Replaced	Monitors	Monitor Project
6154 60042	Dash 4000	12430	General Pediatrics Unit	4000	4000	06/10/07	\$	14,754.30	\$	-	Auction	Replaced	Monitors	Monitor Project
6155 38239	Dash 4000	12430	General Pediatrics Unit	4000	4000	06/10/07	\$	14,754.30	\$	-	Auction	Replaced	Monitors	Monitor Project
6156 60065	Dash 4000	12430	General Pediatrics Unit	4000	4000	06/10/07	\$	14,754.30	\$	-	Auction	Replaced	Monitors	Monitor Project
6157 60066	Dash 4000	12430	General Pediatrics Unit	4000	4000	06/10/07	\$	14,754.30	\$	-	Auction	Replaced	Monitors	Monitor Project
10418 60713	CIC Capitalize CIP 1630 Med Eq	15045	PACU - BBRP	CIC	JA106486195GA	07/01/07	\$	14,159.60	\$	-	Auction	Replaced	Monitors	Monitor Project
6107 58736	Dash 4000	12410	Pediatric Specialty Care	4000	SBG06233541GA	06/10/07	\$	13,287.55	\$	-	Auction	Replaced	Monitors	Monitor Project
6110 58729	Dash 4000	12410	Pediatric Specialty Care	4000	SBG06233553GA	06/10/07	\$	13,287.54	\$	-	Auction	Replaced	Monitors	Monitor Project
6111 58734	Dash 4000	12410	Pediatric Specialty Care	4000	SBG06233554GA	06/10/07	\$	13,287.54	\$	-	Auction	Replaced	Monitors	Monitor Project
6112 58724	Dash 4000	12410	Pediatric Specialty Care	4000	SBG06233563GA	06/10/07	\$	13,287.54	\$	-	Auction	Replaced	Monitors	Monitor Project
6115 58731	Dash 4000	12410	Pediatric Specialty Care	4000	SBG06233564GA	06/10/07	\$	13,287.54	\$	-	Auction	Replaced	Monitors	Monitor Project
6116 58728	Dash 4000	12410	Pediatric Specialty Care	4000	SBG06233567GA	06/10/07	\$	13,287.54	\$	-	Auction	Replaced	Monitors	Monitor Project
6117 58730	Dash 4000	12410	Pediatric Specialty Care	4000	SBG06233605GA	06/10/07	\$	13,287.54	\$	-	Auction	Replaced	Monitors	Monitor Project
6118 58737	Dash 4000	12410	Pediatric Specialty Care	4000	SBG06233606GA	06/10/07	\$	13,287.54	\$	-	Auction	Replaced	Monitors	Monitor Project
7758 58732	Dash 4000	12410	Pediatric Specialty Care	DASH 4000	SBG06233568GA	06/01/08	\$	13,287.54	\$	-	Auction	Replaced	Monitors	Monitor Project
9352 None	Dash 4000	75025	Radiology - Interventional Rad	DASH 4000	DASH 4000	02/01/11	\$	13,242.21	\$	-	None	Obsolete	Monitors	
19848 64318	Dash 4000	12430	General Pediatrics Unit	DASH 4000	S0008294220GA	08/01/08	\$	13,062.03	\$	-	Auction	Replaced	Monitors	Monitor Project
19849 64319	Dash 4000	12430	General Pediatrics Unit	DASH 4000	S0008283752GA	08/01/08	\$	13,062.03	\$	-	Auction	Replaced	Monitors	Monitor Project
19850 64320	Dash 4000	12430	General Pediatrics Unit	DASH 4000	S0008294223GA	08/01/08	\$	13,062.03	\$	-	Auction	Replaced	Monitors	Monitor Project
19851 64321	Dash 4000	12430	General Pediatrics Unit	DASH 4000	S0008283748GA	08/01/08	\$	13,062.03	\$	-	Auction	Replaced	Monitors	Monitor Project
19852 64322	Dash 4000	12430	General Pediatrics Unit	DASH 4000	S0008294217GA	08/01/08	\$	13,062.03	\$	-	Auction	Replaced	Monitors	Monitor Project
19853 64323	Dash 4000	12430	General Pediatrics Unit	DASH 4000	S0008294224GA	08/01/08	\$	13,062.03	\$	-	Auction	Replaced	Monitors	Monitor Project
19854 64324	Dash 4000	12430	General Pediatrics Unit	DASH 4000	S0008294221GA	08/01/08	\$	13,062.03	\$	-	Auction	Replaced	Monitors	Monitor Project
19919 None	ZepHr Recorder (part of Ross #	70020	Endoscopy Center	Zepher	F089007C	01/01/09	\$	12,626.67	\$	-	None	Unable to Inventory	Medical Equipment	
7430 67954	Dash 4000	15040	PACU (Recovery Room 1)	DASH 4000	S0008199192GA	06/01/08	\$	12,621.70	\$	-	Auction	Replaced	Monitors	Monitor Project
7743 54053	Concerto Shower Trolley	12130	Trauma/Surgical ICU	Concerto Shower Trolley	Concerto Shower Trolley	03/01/08	\$	12,477.30	\$	-	None	Obsolete	Furniture/Fixtures	
9416 None	Blood Track Control Kiosk	74070	Lab - Blood Bank	HEMONINE	I30918360	12/01/10	\$	12,403.00	\$	-	Auction	Not Repairable	Medical Equipment	
21239 80768	Dash 4000	12480	CTH Rehab-Ortho Unit	DASH 4000	SD011133655SA	07/01/11	\$	12,314.93	\$	-	Auction	Replaced	Monitors	Monitor Project
21240 80770	Dash 4000	12480	CTH Rehab-Ortho Unit	DASH 4000	SD011133487SA	07/01/11	\$	12,314.93	\$	-	Auction	Replaced	Monitors	Monitor Project
21241 80767	Dash 4000	12480	CTH Rehab-Ortho Unit	DASH 4000	SD011133492SA	07/01/11	\$	12,314.93	\$	-	Auction	Replaced	Monitors	Monitor Project
21242 80769	Dash 4000	12480	CTH Rehab-Ortho Unit	DASH 4000	SD011133636SA	07/01/11	\$	12,314.93	\$	-	Auction	Replaced	Monitors	Monitor Project
21243 80766	Dash 4000	12480	CTH Rehab-Ortho Unit	DASH 4000	SD011133631SA	07/01/11	\$	12,314.93	\$	-	Auction	Replaced	Monitors	Monitor Project
7832 67013	23" Wideview HD Flat Panel & C	15000	Operating Room	9423HDN8	08-117916	06/01/08	\$	12,281.69	\$	-	None	Obsolete	Medical Equipment	
3889 46052	DASH 4000 Monitor Capitalize C	15510	OSIS PACU	DASH 4000	H2D17257G	05/01/03	\$	12,257.60	\$	-	Auction	Replaced	Monitors	Monitor Project
6199 62130	MAC 5500 EKG Machine	32040	NE Heights Clinic	MAC 5500	SCD07016681PA	07/01/07	\$	12,201.00	\$	-	Auction	Obsolete	Medical Equipment	
7773 62692	Dash 4000	12230	Gen Med/SAC (4-W)	DASH 4000	S0007314304GA	01/01/08	\$	12,086.30	\$	-	Auction	Not Repairable	Monitors	
7775 62694	Dash 4000	12230	Gen Med/SAC (4-W)	DASH 4000	S0007324978GA	01/01/08	\$	12,086.30	\$	-	Auction	Replaced	Monitors	Monitor Project
20353 VEH #1023	1999 Chevrolet Cavalier Plate	60365	Case Management	CAVALIER	1G1JC524XX7224508	04/01/99	\$	12,084.00	\$	-	UNM Surplus	Not Repairable	Vehicles	
20354 VEH #1022	1999 Chevy Cavalier Plate #G-4	60365	Case Management	CAVALIER	1G1JC5246X7224764	04/01/99	\$	12,084.00	\$	-	UNM Surplus	Not Repairable	Vehicles	
1039 41425	Dash 4000 Monitor with Battery	12310	Adult Oncology Med/Surg	DASH 4000	E1D10966G	09/01/01	\$	12,008.38	\$	-	Auction	Replaced	Monitors	Monitor Project
7311 58947	Dash 4000 Capitalize CIP 1630	21010	ED - Fast Track	DASH 4000	SBG06462127GA	07/01/07	\$	11,764.74	\$	-	Auction	Replaced	Monitors	Monitor Project
8031 MOD	EW7 Network Workstation	70020	Endoscopy Center	EW7	0800367	10/01/08	\$	11,539.16	\$	-	None	Obsolete	Furniture/Fixtures	
19305 NR	BioView ANO-4 Ch Anorectal Man	70020	Endoscopy Center	5424-03080		07/01/03	\$	11,378.33	\$	-	None	Unable to Inventory	Medical Equipment	
19566 60073	Dash 4000	12015	Pediatric Infusion Unit PIU	DASH 4000	SBG06419230GA	07/01/07	\$	11,355.22	\$	-	Auction	Replaced	Monitors	Monitor Project
19513 58874	Dash 4000	21015	ED-North	DASH 4000	SBG06452041GA	07/01/07	\$	11,340.56	\$	-	Auction	Replaced	Monitors	Monitor Project
6988 60075	DASH 4000 Capitalize CIP 1630	12410	Pediatric Specialty Care	DASH 4000	SBG06451712GA	07/01/07	\$	10,948.57	\$	-	Auction	Replaced	Monitors	Monitor Project
6989 60076	DASH 4000 Capitalize CIP 1630	12410	Pediatric Specialty Care	DASH 4000	SBG06462733GA	07/01/07	\$	10,948.57	\$	-	Auction	Replaced	Monitors	Monitor Project
6990 60077	DASH 4000 Capitalize CIP 1630	12410	Pediatric Specialty Care	DASH 4000	SBG06462665GA	07/01/07	\$	10,948.57	\$	-	Auction	Replaced	Monitors	Monitor Project
6992 60078	DASH 4000 Capitalize CIP 1630	12410	Pediatric Specialty Care	DASH 4000	SBG06451694GA	07/01/07	\$	10,948.57	\$	-	Auction	Replaced	Monitors	Monitor Project
6993 60079	DASH 4000 Capitalize CIP 1630	12410	Pediatric Specialty Care	DASH 4000	SBG06451810GA	07/01/07	\$	10,948.57	\$	-	Auction	Replaced	Monitors	Monitor Project
6994 60080	DASH 4000 Capitalize CIP 1630	12410	Pediatric Specialty Care	DASH 4000	SBG06451720GA	07/01/07	\$	10,948.57	\$	-	Auction	Replaced	Monitors	Monitor Project

6995 60081	DASH 4000 Capitalize CIP 1630	12410	Pediatric Specialty Care	DASH 4000	SBG06452705GA	07/01/07	\$	10,948.57	\$	-	Auction	Replaced	Monitors	Monitor Project
6996 60082	DASH 4000 Capitalize CIP 1630	12410	Pediatric Specialty Care	DASH 4000	SBG06462731G8	07/01/07	\$	10,948.57	\$	-	Auction	Replaced	Monitors	Monitor Project
6997 60083	DASH 4000 Capitalize CIP 1630	12410	Pediatric Specialty Care	DASH 4000	SBG06451695GA	07/01/07	\$	10,948.57	\$	-	Auction	Replaced	Monitors	Monitor Project
6998 60084	DASH 4000 Capitalize CIP 1630	12410	Pediatric Specialty Care	DASH 4000	SBG06462452GA	07/01/07	\$	10,948.57	\$	-	Auction	Replaced	Monitors	Monitor Project
8096 68568	Dash 4000 Monitor	12210	Coronary Care Subacute	DASH 4000	S0008252705GA	12/01/08	\$	10,906.70	\$	-	Auction	Replaced	Monitors	Monitor Project
7865 55922	MAC 5500	32050	Westside Family & Senior Hlth	MAC 5500	SCD06425300PA	07/01/07	\$	10,868.85	\$	-	None	Obsolete	Medical Equipment	
19568 60068	Dash 4000	12015	Pediatric Infusion Unit PIU	DASH 4000	SBG06419253GA	07/01/07	\$	10,774.42	\$	-	Auction	Replaced	Monitors	Monitor Project
19569 60069	Dash 4000	12015	Pediatric Infusion Unit PIU	DASH 4000	SBG06419239GA	07/01/07	\$	10,774.42	\$	-	Auction	Replaced	Monitors	Monitor Project
19570 60070	Dash 4000	12015	Pediatric Infusion Unit PIU	DASH 4000	SBG06419240GA	07/01/07	\$	10,774.42	\$	-	Auction	Replaced	Monitors	Monitor Project
5266 SW	Software - Endoworks HL7 Outbo	70020	Endoscopy Center	SW	SW	04/01/06	\$	10,575.00	\$	-	None	Obsolete	SW/Electronics	
6963 60043	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06233607GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6964 60045	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06451706GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6965 60047	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06462124GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6966 60049	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG064621230GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6967 60050	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06451708GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6968 60052	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06451700GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6970 60053	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06451554GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6971 60054	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06451653GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6972 60055	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06451639GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6973 60056	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06462131GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6974 60057	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06462142GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6975 60058	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06441180GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6976 60059	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06451950GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6977 60060	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06451558GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6978 60061	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06452040GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6979 60062	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06452132GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6981 60063	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06451657GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6982 60064	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06451659GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6983 60044	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06233549GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6984 60046	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06451636GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6985 60048	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06388161GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
6986 60051	Dash 4000 Capitalize CIP 1630	12430	General Pediatrics Unit	DASH 4000	SBG06451702GA	07/01/07	\$	10,504.98	\$	-	Auction	Replaced	Monitors	Monitor Project
7340 60412	Dash 4000 Capitalize CIP 1630	12000	Labor and Delivery	DASH 4000	SBG06462706GA	07/01/07	\$	10,361.11	\$	-	Auction	Replaced	Monitors	Monitor Project
7341 60413	Dash 4000 Capitalize CIP 1630	12000	Labor and Delivery	DASH 4000	SBG06462450GA	07/01/07	\$	10,361.11	\$	-	Auction	Replaced	Monitors	Monitor Project
7342 60414	Dash 4000 Capitalize CIP 1630	12000	Labor and Delivery	DASH 4000	SBG06462724GA	07/01/07	\$	10,361.11	\$	-	Auction	Replaced	Monitors	Monitor Project
7343 60415	Dash 4000 Capitalize CIP 1630	12000	Labor and Delivery	DASH 4000	SBG06462725GA	07/01/07	\$	10,361.11	\$	-	Auction	Replaced	Monitors	Monitor Project
7344 60236	Dash 4000 Capitalize CIP 1630	12000	Labor and Delivery	DASH 4000	SBG06451819GA	07/01/07	\$	10,361.10	\$	-	Auction	Replaced	Monitors	Monitor Project
7272 58708	Dash 4000 Capitalize CIP 1630	15045	PACU - BBRP	DASH 4000	SBG06441179GA	07/01/07	\$	10,134.87	\$	-	Auction	Replaced	Monitors	Monitor Project
7273 58709	Dash 4000 Capitalize CIP 1630	15045	PACU - BBRP	DASH 4000	SBG06462659GA	07/01/07	\$	10,134.87	\$	-	Auction	Replaced	Monitors	Monitor Project
7274 58710	Dash 4000 Capitalize CIP 1630	15045	PACU - BBRP	DASH 4000	SBG06462319GA	07/01/07	\$	10,134.87	\$	-	Auction	Replaced	Monitors	Monitor Project
7277 58713	Dash 4000 Capitalize CIP 1630	15045	PACU - BBRP	DASH 4000	SBG06441172GA	07/01/07	\$	10,134.86	\$	-	Auction	Replaced	Monitors	Monitor Project
7275 58712	Dash 4000 Capitalize CIP 1630	15045	PACU - BBRP	DASH 4000	SGN06441178GA	07/01/07	\$	10,134.86	\$	-	Auction	Replaced	Monitors	Monitor Project
7276 58711	Dash 4000 Capitalize CIP 1630	15045	PACU - BBRP	DASH 4000	SBG06462454GA	07/01/07	\$	10,134.86	\$	-	Auction	Replaced	Monitors	Monitor Project
7278 58714	Dash 4000 Capitalize CIP 1630	15045	PACU - BBRP	DASH 4000	SBG06441182GA	07/01/07	\$	10,134.86	\$	-	Auction	Replaced	Monitors	Monitor Project
7281 58716	Dash 4000 Capitalize CIP 1630	15045	PACU - BBRP	DASH 4000	SBG06441183GA	07/01/07	\$	10,134.86	\$	-	Auction	Replaced	Monitors	Monitor Project
7282 58717	Dash 4000 Capitalize CIP 1630	15045	PACU - BBRP	DASH 4000	SBG06441177GA	07/01/07	\$	10,134.86	\$	-	Auction	Replaced	Monitors	Monitor Project
7284 58719	Dash 4000 Capitalize CIP 1630	15045	PACU - BBRP	DASH 4000	SBG06441187GA	07/01/07	\$	10,134.86	\$	-	Auction	Replaced	Monitors	Monitor Project
2850 46595	SLR8M Sngl Card Monitor, Multi	15000	Operating Room	SOLAR 8000	F3G46201G	09/01/03	\$	10,002.72	\$	-	Auction	Replaced	Monitors	Monitor Project
2852 46593	SLR8M Sngl Card Monitor, Multi	15000	Operating Room	SOLAR 8000	F3G46203G	09/01/03	\$	10,002.72	\$	-	Auction	Replaced	Monitors	Monitor Project
7617 None	ddR Procedure Table	15520	OSIS General	IGS 1000H	IGS 1000H	07/01/07	\$	10,000.00	\$	-	None	Obsolete	Medical Equipment	
10440 BULK	Dental Equipment	30025	CTH NMDOH Dental Clinic	Dental Equipment	Dental Equipment	05/01/10	\$	9,918.64	\$	-	None	Unable to Inventory	Medical Equipment	
20081 82228	Dash 5000 Monitor	95700	Clinical Engineering	DASH 5000	S0009047586GR	04/01/11	\$	9,734.33	\$	-	Auction	Replaced	Monitors	Monitor Project
20082 82233	Dash 5000 Monitor	95700	Clinical Engineering	DASH 5000	S0008148506GR	04/01/11	\$	9,734.33	\$	-	Auction	Replaced	Monitors	Monitor Project
20084 82229	Dash 5000 Monitor	95700	Clinical Engineering	DASH 5000	S00009047736GR	04/01/11	\$	9,734.33	\$	-	Auction	Replaced	Monitors	Monitor Project
20085 82231	Dash 5000 Monitor	95700	Clinical Engineering	DASH 5000	S0008419661GR	04/01/11	\$	9,734.33	\$	-	Auction	Replaced	Monitors	Monitor Project
20086 82232	Dash 5000 Monitor	95700	Clinical Engineering	DASH 5000	S0008077060GR	04/01/11	\$	9,734.33	\$	-	Auction	Replaced	Monitors	Monitor Project
20087 82235	Dash 5000 Monitor	12430	General Pediatrics Unit	DASH 5000	S0008505497GR	04/01/11	\$	9,734.33	\$	-	None	Unable to Inventory	Monitors	
5251 SW	Software - Upgrade Reporting S	70020	Endoscopy Center	SW	SW	04/01/06	\$	9,600.00	\$	-	None	Obsolete	SW/Electronics	
5694 52314	Solar 8000M	15055	Anesthesia	SOLAR 8000M	R3505240517GA	11/01/05	\$	9,516.42	\$	-	Auction	Replaced	Monitors	Monitor Project
5697 52322	Solar 8000M	15055	Anesthesia	SOLAR 8000M	R3505240490GA	11/01/05	\$	9,516.41	\$	-	Auction	Replaced	Monitors	Monitor Project
5698 52324	Solar 8000M	15055	Anesthesia	SOLAR 8000M	R3505230484GA	11/01/05	\$	9,516.41	\$	-	Auction	Replaced	Monitors	Monitor Project
4346 51345	Physiological Monitoring Syste	70020	Endoscopy Center	DASH 4000	AAB04469748GA	12/01/04	\$	9,503.25	\$	-	Auction	Replaced	Monitors	Monitor Project
2081 41881	Ventilator, Portable	70060	Fixed Wing Transport	S10A1401-MRI	0111371	04/01/02	\$	9,489.91	\$	-	None	Obsolete	Medical Equipment	
5244 SW	Software - Upgrade Fileserver	70020	Endoscopy Center	SW	SW	04/01/06	\$	9,450.00	\$	-	None	Obsolete	SW/Electronics	
19826 67154	Dash 3000	12410	Pediatric Specialty Care	DASH 3000	S0008199246GA	06/01/08	\$	8,757.00	\$	-	Auction	Replaced	Monitors	Monitor Project
5877 55802	BiPap Vision Ventilatory Suppo	71510	Pulmonary Services	BiPAP VISION	124901	10/01/06	\$	8,643.04	\$	-	Auction	Not Repairable	Medical Equipment	
8022 68582	Totalift II Transfer Chair	12220	Med/Surg Subacute (4-E)	TOTALIFT II	TL-7394	10/01/08	\$	8,560.35	\$	-	None	Obsolete	Furniture/Fixtures	
4685 52595	M-Series, Hospital ACLS, Bipla	12320	General Medicine (S-W)	M-SERIES	T05F71905	06/01/05	\$	8,521.25	\$	-	Auction	Not Repairable	Medical Equipment	
8049 None	Bloodtrack Courier Kiosk	74070	Lab - Blood Bank	BLOODTRACK	I30720210	08/01/08	\$	8,450.00	\$	-	Auction	Not Repairable	Medical Equipment	
9508 74886	PowerEdge R710	96140	IT - Customer Service	R710	9XX1FQ1	05/01/11	\$	8,395.19	\$	-	Electronics Recycling	Obsolete	SW/Electronics	
26138 STERILE	Transducer, L25X	12120	Medical/Cardiac ICU	L25X	03TJHB	01/01/13	\$	8,280.00	\$	-	None	Obsolete	Medical Equipment	
7328 60024	Tram 451N Capitalize CIP 1630	95700	Clinical Engineering	451N	S8B06442718GA	07/01/07	\$	8,236.14	\$	-	Auction	Replaced	Monitors	Monitor Project
8028 MOD	EW7 Registration Workstation	70020	Endoscopy Center	EW7	0080370	10/01/08	\$	7,809.05	\$	-	None	Obsolete	Furniture/Fixtures	
8029 MOD	EW7 Registration Workstation	70020	Endoscopy Center	EW7	0080371	10/01/08	\$	7,809.05	\$	-	None	Obsolete	Furniture/Fixtures	
8030 MOD	EW7 Registration Workstation	70020	Endoscopy Center	EW7	0080372	10/01/08	\$	7,809.05	\$	-	None	Obsolete	Furniture/Fixtures	
19839 67395	Maxi Move 2008 w/Scale	12360	Neuroscience	MAXI MOVE 2008	KMC-00493	07/01/08	\$	7,791.17	\$	-	Auction	Not Repairable	Medical Equipment	
2610 43799	Tracheal Intubation Fiberscope	71520	Pulmonary Diagnostics	LF-TP	1222910	11/01/02	\$	7,760.00	\$	-	Repurposed/Education	Obsolete	Medical Equipment	
16527 33906	Zoll M Series Basic Defibrilla	21015	ED-North	M SERIES	T99801531	05/01/99	\$	7,624.11	\$	-	None	Obsolete	Medical Equipment	

4521	None	Dedicated Micros 1.2 TB DVR Ca	32040	NE Heights Clinic	Dedicated Micros 1.2 TEDedicated Micros 1.2 TB DVR Ca	04/01/05	\$	7,587.25	\$	-	None	Obsolete	Medical Equipment	
3422	None	Kit 300W Xenon LS #201331-20	15500	OSIS Operating Room	Kit 300W Xenon LS #201Kit 300W Xenon LS #201331-20	06/01/04	\$	7,406.15	\$	-	None	Obsolete	Medical Equipment	
6934	56895	Pizza Oven - F&N IP Equipment	84010	Food and Nutrition - BBRP	UN1854NAT 00276	07/01/07	\$	7,190.72	\$	-	Auction	Obsolete	Non Medical Equipment	HUD Asset
6365	58025	Vigilance II Monitor	12130	Trauma/Surgical ICU	VIG2 VG003018	07/01/07	\$	7,000.00	\$	-	Auction	Obsolete	Monitors	
20536	88635	Prelude Shower Cabinet	12030	UPC Inpatient/Geriatrics	Prelude Shower CabinetPrelude Shower Cabinet	07/01/07	\$	6,958.66	\$	-	None	Obsolete	Furniture/Fixtures	
9040	70206	VTS-20-D003 Monitor - OR #E	15000	Operating Room	VTS-20-D003 240-000588	03/01/10	\$	6,764.03	\$	-	None	Obsolete	Medical Equipment	
9426	74881	PowerEdge R710	96140	IT - Customer Service	R710 4RSRBP1	03/01/11	\$	6,568.80	\$	-	Electronics Recycling	Obsolete	SW/Electronics	
21099	80302	SAM Module Multigas	15055	Anesthesia	SAM RC910536012GA	07/01/11	\$	6,545.00	\$	-	Auction	Replaced	Monitors	Monitor Project
21255	80203	Solar 8000i	15055	Anesthesia	SOLAR 8000i SE410529414GA	07/01/11	\$	6,488.70	\$	-	Auction	Replaced	Monitors	Monitor Project
19303	46904	Dash 2000 Portable Monitor	34150	Pediatrics Clinic	DASH 2000 70004049	01/01/04	\$	6,308.23	\$	-	Auction	Replaced	Monitors	Monitor Project
21429	82394	CIC	12240	General Surgery (6-S)	CIC PRO SDY11077891GA	11/01/11	\$	6,212.50	\$	-	Auction	Replaced	Monitors	Monitor Project
21434	82778	CIC	12430	General Pediatrics Unit	CIC PRO SDY111148732GA	05/01/12	\$	6,212.50	\$	-	Auction	Replaced	Monitors	Monitor Project
21431	82445	CIC	95700	Clinical Engineering	CIC PRO SDY11148735GA	02/01/12	\$	6,212.50	\$	-	Auction	Replaced	Monitors	Monitor Project
17728	MOD	Workstations	34540	Sports Medicine	Workstations	03/01/00	\$	6,198.50	\$	-	None	Obsolete	Furniture/Fixtures	
7405	60736	B/W Video Printer Capitalize C	15005	Operating Room - BBRP	UP-55MD-R 81358	07/01/07	\$	6,109.46	\$	-	None	Obsolete	Medical Equipment	HUD Asset
7406	60732	B/W Video Printer Capitalize C	15005	Operating Room - BBRP	UP-55MD-R 81630	07/01/07	\$	6,109.46	\$	-	None	Obsolete	Medical Equipment	HUD Asset
5643	52401	Transport Pro V2	12130	Trauma/Surgical ICU	PRO V2 AAD05240240GA	11/01/05	\$	6,105.00	\$	-	Auction	Replaced	Monitors	Monitor Project
7299	60860	Transport Pro Capitalize CIP 1	15060	Anesthesia - BBRP	TRANSPORT PRO SCS06440439GA	07/01/07	\$	5,775.00	\$	-	Auction	Replaced	Monitors	Monitor Project
5253	SW	Software - Upgrade Endoworks H	70020	Endoscopy Center	SW SW	04/01/06	\$	5,625.00	\$	-	None	Obsolete	SW/Electronics	
5815	None	19" LCD HD TV Flat Panel	70020	Endoscopy Center	7617048 7617048	02/01/07	\$	5,400.00	\$	-	None	Unable to Inventory	SW/Electronics	
7873	58033	Dash 3000	70020	Endoscopy Center	DASH 3000 SBG06504503GA	07/01/07	\$	5,172.76	\$	-	None	Unable to Inventory	Monitors	
8849	74176	5MP Monochrome P Series LCD Du	90020	Radiology - Admin	IF2105MP PN21PGD750020	03/01/10	\$	8,372.50	\$	-	Electronics Recycling	Obsolete	SW/Electronics	
8848	74177	5MP Monochrome P Series LCD Du	90020	Radiology - Admin	IF2105MP PN21PGD750017	03/01/10	\$	8,372.50	\$	-	Electronics Recycling	Obsolete	SW/Electronics	
21541	87976	Reading Station - Radiology	90020	Radiology - Admin	WIDE-COLO SP21PGGS59116	10/01/11	\$	7,110.81	\$	-	Electronics Recycling	Obsolete	SW/Electronics	

University Services
Marcos Roybal
Associate Director

Business Operations
1128 University Blvd NE
505.277.2366

CRLS
Clark Hall
505.277.5109

Copy Center
Dane Smith Hall
505.277.8267

Mailing Systems
1128 University Blvd NE
505.277.4124

Records Management
1128 University Blvd NE
505.277.1136

Shipping & Receiving
915 Camino de Salud
505.272.6302

Surplus Property
1128 University Blvd NE
505.277.2923

Disposition of Surplus Property Approval – January 2019

Date: January 23, 2019

To: Bruce Cherrin
Chief Procurement Officer
Purchasing Department

From: Marcos Roybal
Associate Director
University Services

Attached for your review and submission to the Board of Regents is the Surplus Property Disposition detail list for the month of January 2019.

Consistent with UNM Board of Regents Policy 7.9 and the NM Disposition of Surplus Property Act, 13-6-1, NMSA 1978, and based upon documentation submitted by the UNM departments responsible for the equipment, I certify that the equipment identified on the monthly list is worn-out, unusable or obsolete to the extent that the items are no longer economical or safe for continued use by the University. I recommend that the items be deleted from UNM's inventory and disposed of in accordance with the above noted Regents Policy and NM Surplus Property Act.



UNIVERSITY SERVICES – DISPOSITION OF SURPLUS PROPERTY
JANUARY 2019



Surplus Property Disposition - January FY19

Memo	Asset Tag	Department	Description	Manufacturer	Purchased	Total Cost (\$)	NBV (\$)	Disposal Method
4	N00008240	Physics Astronomy Faculty #108	Long Pulse Laser System	AlexLrsys	06/30/2006	\$27,950.51	\$0.00	Obsolete
2	266126	Parking Transportation Services	COMMUNICATION SYSTEM	SpecComm	05/20/2004	\$18,670.00	\$0.00	Obsolete
5	236023	Health Exercise & Sports Science	ERGOMETER BICYCLE	Physio	04/08/1999	\$16,600.00	\$0.00	Beyond Repair
1	N00005270	KNME PI #5	Audio Test System	AudioPrec	08/29/2005	\$14,459.90	\$0.00	Obsolete
3	N00038387	UME-ETS Educational Tech Support	Server/PowerEdge R620	Dell	10/02/2012	\$10,923.50	\$0.00	Cannibalized
	N00031613	Nursing Development	Billirubin Meter	MedexSup	06/29/2011	\$8,070.85	\$0.00	Obsolete
	N00033195	Taos Executive Director Gen Admin	Copier	Xerox	10/12/2011	\$7,850.00	\$0.00	Obsolete
	251678	Student Health and Counseling	COMPUTER FILE SERVER	Swintec	08/03/2001	\$6,795.00	\$0.00	Obsolete
	N00032435	Ctr for Micro Engineering Materials	MultiEchem Test System	Gamry	08/01/2011	\$6,383.70	\$0.00	Beyond Repair
	N00015544	UME-ETS Educational Tech Support	Presentation Bundle	Epson	04/01/2008	\$6,271.35	\$0.00	Obsolete
	258965	UME-ETS Educational Tech Support	PROJECTOR	VideoTech	11/25/2002	\$6,189.00	\$0.00	Obsolete
	N00001629	VPRED EPSCOR PI #1	Computer Workstation	HP	11/24/2004	\$5,229.09	\$0.00	Obsolete
Total Asset Disposition (#)								12
Total Capitalization (\$)								\$135,392.90
Total Net Book Value (\$)								\$0.00



Board of Regents' Finance & Facilities Committee

Memo

To: University Services

From: Karen Allen, Sr. Fiscal Services Tech – KNME-TV 

CC: Susan Rhymer, Director of Finance and Administration – KNME-TV 

Date: December 6, 2018

Re: Surplus of items over \$10,000 – Tag N00005270

This memo serves as a request to remove the item below from our inventory list.

Asset #N00005270 (\$14,400/NBV \$-0-) Audio Precision Audio Test System. It was purchased in 2005. The equipment is 13 years past its useful life of 5 years and is obsolete.

Contract and Grant Accounting approval is attached.

Thank you for your attention to this matter. If you should have any further questions please feel free to contact Karen Allen at 177-1215 or kallen@nmpbs.org.

Asset#	Description	Acq.Cost	NBV	Date
N00005270	Audio Precision Test System	\$7,663.75	\$0	2005

August 21, 2018


Ms. Alisha Lopez

Business Manager, UNM Inventory Control

Ms. Lopez,

Please accept this signed memo as delegation of signature authority for all inventory control documents pertaining to organization 247A (KNME Operations) and all subsidiary orgs to Susan Rhymer, Director of Finance and Administration.

Respectfully,



Franz Joachim

General Manager and CEO, New Mexico PBS/KNME-TV

fjoachim@nmpbs.org

Karen Meitz Allen

From: Contract Grants Accounting
Sent: Thursday, December 6, 2018 1:42 PM
To: University Services; Karen Meitz Allen
Cc: John Tiesi; Steven Campbell; Daniel Zillich; Susan Rhymer
Subject: RE: 12/5/18 - Request for Disposal of Surplus Property

Hello,

I approve the disposal request for 2R638.

Thank you,
Michelle

Michelle N. Sitter
Accountant III
Office Hours: 7:00am - 4:00pm
Contracts & Grant Accounting, Main
The University of New Mexico
505-277-6086

From: University Services <univserv@unm.edu>
Sent: Thursday, December 6, 2018 8:49 AM
To: Karen Meitz Allen <KAllen@nmpbs.org>; Contract Grants Accounting <cgacctng@unm.edu>
Cc: John Tiesi <jtiesi@nmpbs.org>; Steven Campbell <scampbell@nmpbs.org>; Daniel Zillich <DZillich@nmpbs.org>; Susan Rhymer <srhymer@nmpbs.org>
Subject: RE: 12/5/18 - Request for Disposal of Surplus Property

Good morning,

#N00005270 has a Cost of \$14,440.00 and has a Grant (2R638) Public Tele Fac.

We will need a memo/signature from KNME stating why you want to dispose of the item. Any item over \$10,000 requires a memo.

We also need Contract and Grants approval before disposal of the item. C&G are Cc'd in this email.

Thank You.

From: Karen Meitz Allen
Sent: Wednesday, December 5, 2018 10:35 AM
To: University Services <univserv@unm.edu>
Cc: John Tiesi <jtiesi@nmpbs.org>; Steven Campbell <scampbell@nmpbs.org>; Daniel Zillich <DZillich@nmpbs.org>; Susan Rhymer <srhymer@nmpbs.org>; Karen Meitz Allen <KAllen@nmpbs.org>
Subject: 12/5/18 - Request for Disposal of Surplus Property

Good Morning-

Attached are the forms referenced above.

Please note:

It would be best if you pull in through the North Gate to the loading dock as the items will be easier to access.

Please do not schedule pick up on Friday 12/7 or Tuesday 12/11.

Any questions on this, please let me know.

Thank you.

Karen

Karen M. Allen
Sr. Fiscal Services Tech
New Mexico PBS
1130 University Blvd NE
Albuquerque NM 87102
505.277.1215
kallen@nmpbs.org



This email and any attachments transmitted with it are confidential and intended solely for use by the intended recipient. Any review, reliance or distribution of such material by others, or forwarding of such material without express permission, is strictly prohibited. If you are not the intended recipient, please notify the sender and destroy all copies.



PARKING &
TRANSPORTATION
SERVICES

Memo-#2

Date: December 6, 2018

To: UNM Inventory

CC: Christine Calderon, Fiscal Services Tech, UNM PATS

From: Barbara Morck, Director UNM PATS

RE: Surplus of 2-way radios

UNM Parking & Transportation Services (UNM PATS) intends to surplus the following 2-way radio equipment:

- 1 base station
- 20 handheld radios
- All associated charging docks

This equipment group is under UNM Tag # 266126. The 2-way radios and associated equipment are all in working condition. The 2-way radios do not digital communication capabilities; they have been replaced with newer models that meet this need.

Sincerely,

Barbara Morck, Director
UNM PATS
(505) 277-1969
bmorck@unm.edu

Asset	Description	Acq. Cost	NBV	Date
266126	2 Way Radio	\$18,670.00	0.00	2004



Office of Undergraduate Medical Education
Paul McGuire, PhD
Associate Dean

TO: UNM Surplus Property

FROM: Ricky Roybal, Undergraduate Medical Education – ETS

RE: Obsolete Asset

Undergraduate Medical Education – ETS is requesting the disposal of the following obsolete items:

Asset# N00038387

Serial# 7T1CVV1


Description- Dell PowerEdge Server

Purchase Date- 10-12-2012

The item has been deemed obsolete due to its age and the fact that HSC IT has Virtualized a Server to serve in its place.

Please dispose of this asset and remove it from our list of inventory. If you should have any further questions or are in need of further information, please contact Ricky Roybal at 292-1992.

Sincerely,


Paul McGuire, PhD
Associate Dean, UME
MSC08 4710

Asset#	Description	Acq.Cost	NBV	Date
N00038387	PowerEdge Server	\$10,923.50	\$0	2012

NM DEPARTMENT OF
PHYSICS & ASTRONOMY

January 14, 2019

To: Inventory Control;
Peggy Sedillo, Mgr, Purchasing

Re: RDA for Physics & Astronomy Dept. Asset: N00008240
Dear Peggy Sedillo,

Item with UNM Tag # N00008240/Serial# ASSEMBLY# 57 (7006) and is on 'Grant' 2R67R. This asset also shows that the acquisition method is a Build Project. The item we are surplussing is the most expensive item in the build. I have included a spreadsheet with the items purchased for this assembly. There are no computers or items over \$5000 in the rest of the assembly and the remaining assembly items will continue to be used in the department. I am requesting this item be removed from our inventory.

Sincerely,



Dr. Richard Rand
Dept. Chair
Physics & Astronomy Dept.
277-1517

Asset ID	Description	Acq. Cost	NBV	Date
N00008240	Alexandrite Laser System	\$14,783.69	\$0	07/13/06



Memo- #5

Department of Health, Exercise and Sports Sciences
Exercise Physiology Laboratories

January 14, 2019

To: Surplus Property

From: HESS exercise Physiology Lab

Subject: Cycle Ergometer (Testing bike)

Dear Surplus Property,

UNM Tag #236023 Cycle Ergometer was purchased in 1999 by the Exercise Physiology lab for \$16,600. This equipment was used as a testing bike for clients for fitness testing and research purposes. The testing bike is no longer in working condition and the parts are no longer available for this unit. It is therefore no longer needed in the lab.

We believe our decision to send this equipment to surplus property will be beneficial to lab as we will not incur any costs for repair and maintenance. The equipment is also approximately ten years old and has completed its life span. Thank you for your consideration.

Sincerely,

A handwritten signature in black ink, appearing to read "Christine Mermier", with a long horizontal line extending to the right.

Christine Mermier PHD
Exercise Physiology Lab Director

Asset#	Description	Acq.Cost	NBV	Date
236023	Ergometer Bicycle	\$16,600.00	\$0	04/08/1999

Memo

To: University Services

From: Karen Allen, Sr. Fiscal Services Tech – KNME-TV 

CC: Susan Rhymer, Director of Finance and Administration – KNME-TV 

Date: December 6, 2018

Re: Surplus of items over \$10,000 – Tag N00005270

This memo serves as a request to remove the item below from our inventory list.

Asset #N00005270 (\$14,400/NBV \$-0-) Audio Precision Audio Test System. It was purchased in 2005. The equipment is 13 years past its useful life of 5 years and is obsolete.

Contract and Grant Accounting approval is attached.

Thank you for your attention to this matter. If you should have any further questions please feel free to contact Karen Allen at 177-1215 or kallen@nmpbs.org.

Asset#	Description	Acq.Cost	NBV	Date
N00005270	Audio Precision Test System	\$7,663.75	\$0	2005

New Mexico Compilation Commission

13-6-1 . Disposition of obsolete, worn-out or unusable tangible personal property.

A. The governing authority of each state agency, local public body, school district and state educational institution may dispose of any item of tangible personal property belonging to that authority and delete the item from its public inventory upon a specific finding by the authority that the item of property is:

- (1) of a current resale value of five thousand dollars (\$5,000) or less; and
- (2) worn out, unusable or obsolete to the extent that the item is no longer economical or safe for continued use by the body.

B. The governing authority shall, as a prerequisite to the disposition of any items of tangible personal property:

- (1) designate a committee of at least three officials of the governing authority to approve and oversee the disposition; and
- (2) give notification at least thirty days prior to its action making the deletion by sending a copy of its official finding and the proposed disposition of the property to the state auditor and the appropriate approval authority designated in Section 13-6-2 NMSA 1978, duly sworn and subscribed under oath by each member of the authority approving the action.

C. A copy of the official finding and proposed disposition of the property sought to be disposed of shall be made a permanent part of the official minutes of the governing authority and maintained as a public record subject to the Inspection of Public Records Act [Chapter 14, Article 2 NMSA 1978].

D. The governing authority shall dispose of the tangible personal property by negotiated sale to any governmental unit of an Indian nation, tribe or pueblo in New Mexico or by negotiated sale or donation to other state agencies, local public bodies, school districts, state educational institutions or municipalities or through the central purchasing office of the governing authority by means of competitive sealed bid or public auction or, if a state agency, through the surplus property bureau of the transportation services division of the general services department.

E. A state agency shall give the surplus property bureau of the transportation services division of the general services department the right of first refusal when disposing of obsolete, worn-out or unusable tangible personal property of the state agency.

F. If the governing authority is unable to dispose of the tangible personal property pursuant to Subsection D or E of this section, the governing authority may sell or, if the property has no value, donate the property to any organization described in Section 501(c)(3) of the Internal Revenue Code of 1986.

G. If the governing authority is unable to dispose of the tangible personal property pursuant to Subsection D, E or F of this section, it may order that the property be destroyed or otherwise permanently disposed of in accordance with applicable laws.

H. If the governing authority determines that the tangible personal property is hazardous or contains hazardous materials and may not be used safely under any circumstances, the property shall be destroyed and disposed of pursuant to Subsection G of this section.

I. No tangible personal property shall be donated to an employee or relative of an employee of a state agency, local public body, school district or state educational institution; provided that nothing in this subsection precludes an employee from participating and bidding for public property at a public auction.

J. This section shall not apply to any property acquired by a museum through abandonment procedures pursuant to the Abandoned Cultural Properties Act [18-10-1 to 18-10-5 NMSA 1978].

K. Notwithstanding the provisions of Subsection A of this section, the department of transportation may sell through public auction or dispose of surplus tangible personal property used to manage, maintain or build roads that exceeds five thousand dollars (\$5,000) in value. Proceeds from sales shall be credited to the state road fund. The department of transportation shall notify the department of finance and administration regarding the disposition of all property.

L. If the secretary of public safety finds that the K-9 dog presents no threat to public safety, the K-9 dog shall be released from public ownership as provided in this subsection. The K-9 dog shall first be offered to its trainer or handler free of charge. If the trainer or handler does not want to accept ownership of the K-9 dog, then the K-9 dog shall be offered to an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986 free of charge. If both of the above fail, the K-9 dog shall only be sold to a qualified individual found capable of providing a good home to the animal.

History: 1953 Comp., § 6-1-7.1, enacted by Laws 1961, ch. 100, § 1; 1979, ch. 195, § 2; 1984, ch. 47, § 1; 1987, ch. 15, § 1; 1989, ch. 211, § 6; 1995, ch. 181, § 1; 1998, ch. 16, § 1; 2001, ch. 317, § 1; 2007, ch. 57, § 4; 2012, ch. 10, § 1; 2013, ch. 9, § 1.




University Controller
Financial Services, Main Campus
Phone: (505) 277-5111
FAX: (505) 277-7662

MEMORANDUM

DATE: January 22, 2019

TO: Dr. Craig White
Interim Senior Vice President for Finance & Administration

FROM: Elizabeth Metzger, CPA
University Controller 

RE: Two (2) Items: One (1) Action Item and One (1) Information Item for Board of Regents' Finance & Facilities Committee Meeting

Action Items.

The New Mexico Higher Education Department, Institutional Finance Division, Quarterly Financial Actions Report and Certification through December 31, 2018 needs to be approved at the February 5, 2019 Finance & Facilities Committee meeting.

Information Items.

The Monthly Consolidated Financial Reports for the month ended December 31, 2018 will be presented at the February 5, 2019 Finance & Facilities Committee meeting.

New Mexico Higher Education Department
Institutional Finance Division
Quarterly Financial Certification Report Template

Please complete and sign the following Financial Certification Report and submit with the Quarterly Financial Actions Report.

To the best of my knowledge, I certify that the information provided in the attached Financial Actions Report for the:

1st _____ 2nd X 3rd _____ 4th _____ Quarter, FY 2019

is correct as of the signature dates noted below, and that

The University of New Mexico

has a functioning financial accounting system that captures assets, liabilities, revenues, and expenditures on a timely basis, and the Governing Board receives timely notification of any significant actual or projected variances between budgeted and actual revenues and expenditures.

Marron Lee, Chair, Board of Regents-F&F	Date
---	------

Garnett S. Stokes, President	Date
------------------------------	------

Dr. Craig White, Interim Senior VP for Finance & Administration	Date
---	------

University of New Mexico

Quarterly Financial Actions Report

Fiscal year 2019

Date 1/23/2019

Period (check one)

Quarter 1

Quarter 2

X

Quarter 3

Quarter 4

During the period of time covered by this report; did your institution:

(1) Request an advance of state subsidy?

Yes

No

X

(2) Fail to make its required payments, as scheduled, to appropriate retirement system(s)?

Yes

No

X

(3) Fail to make its payroll payments, as scheduled?

Yes

No

X

(4) Fail to make its scheduled debt service payments?

Yes

No

X

(5) Fail to make payments to vendors, as scheduled, due to a cash deficiency or a substantial deficiency in the payment processing system?

Yes

No

X

(6) Relative to the original fiscal year budget, experience any significant actual or anticipated financial changes that are not reflected in a submitted Budget Adjustment Request (BAR). Significant financial changes refers to fiscal activity that will result in a substantially reduced year-end fund balance or any increase in a fund balance deficit.

Yes

X

No

If the answer to any of the above questions is "Yes," please describe in a separate document:

- (i) the reason for the occurrence,
- (ii) the actions taken by your institution to resolve this particular occurrence, and
- (iii) the actions taken by your institution to prevent events such as this from occurring again.

In addition, if the answer to number 6 is "Yes," please describe in a separate document the nature of the financial changes and describe and assess the impact that the changes will have on your institution's planned year-end financial position. (See attached.)

University of New Mexico
Quarterly Financial Actions Report
Fiscal Year 2019, End of Quarter 2

Updated Additional information for “Yes” answer to Question (6)

Nature of Financial Changes not yet reflected in a BAR:

The enrollment for Fall 2018 is down 7.86% in student credit hours and 7.17% in student headcount. Tuition and fees are expected to come under budget by \$9.7m or 5.7%. The original budget included an adjustment for enrollment fluctuation but current projections exceeded it.

Previously reported for Quarter 1: The current plan to balance the budget, which was presented to the Regents in October, used one-time funding of \$3M in discretionary central reserves and \$1M of uncommitted prior year BR&R funding. The remainder of the shortfall will include a combination of reduction of expenditures and use of department reserves of approximately \$2.6M in Academic Affairs, \$2M in Administration, and \$1.1M in units that receive mandatory student fees.

Current plan as of end of Quarter 2: The current plan to balance the budget is to use one-time funding of \$3M in discretionary central reserves and \$1M of uncommitted prior year BR&R funding. Since the end of Quarter 1, an additional \$2M of unbudgeted permanent and land income has been identified. Therefore, the updated plan is to cover the remainder of the shortfall with a reduction of expenditures and use of department reserves of approximately \$1.7M in Academic Affairs, \$1.3M in Administration, and \$700K in units that receive mandatory student fees.

The tuition and fee projections and plan outlined above are preliminary. Tuition and fee projections and unit reductions will be finalized at the end of February after 21 day census for Spring Term and mid-year reviews. UNM's consolidated BAR, including Main Campus, HSC, Branches and UNMH, will be prepared and submitted in the spring, consistent with our historical practices.



Monthly Financial Report

Consolidated Total Operations Current Funds

Fiscal Year to Date as of December 31, 2018

Contents

Charts

Consolidated Total Operations – 3-Year Net Revenue	4
YTD I&G Consolidated Revenues / Expenses (3 Year)	5

Executive Budget Summary	6
---------------------------------	---

Financial Reports

Consolidated - Total Operations Current Funds	8
Main Campus - Athletics and Auxiliary Operations	11
Main Campus – Total Operations Current Funds	14
Branch Campuses – Total Operations Current Funds	17
HSC Campus – Total Operations Current Funds	19

Appropriations Schedules

Consolidated – Total Operations Current Funds	22
Main Campus – Total Operations Current Funds	23
Branch Campuses – Total Operations Current Funds	24
HSC – Total Operations Current Funds	25

Debt Service


Schedule of Debt Service	26
Source of Funds	27



Summary of Items in the Consolidated Financial Report As of December 31, 2018

- Instruction and General (Consolidated page 8, Main Campus page 14): Tuition and Fees - The graph below indicates the portion of Main Campuses I&G Tuition and Fee revenue that is pooled and allocated to the departments. The remainder of I&G Tuition and Fee revenue distributed directly to the units, EX: tuition differential, course fees.


**Main Campus Tuition and Fees
as of December 31, 2018**






CONSOLIDATED TOTAL OPERATIONS - 3 YEAR NET REVENUE / (EXPENSE) **FISCAL YEAR TO DATE AS OF DECEMBER 31, 2018**

■ CONSOLIDATED ■ MAIN ■ BRANCHES ■ HSC





YTD I&G Consolidated Revenues / Expenses (3 Year) Fiscal Year to Date as of December 31, 2018



Executive Budget Summary

University of New Mexico Consolidated Financial Report

FY 2019 UNM Operating Budget

This report covers current fund operations for the University, including Main Campus, Branch Campuses, and HSC Campus.

Instruction and General operations projects a use of reserves of \$5.7M for the FY 2019 UNM Operating Budget. The use of reserves of \$5.7M is comprised of \$3.9M use of reserves at the Main Campus, a \$1.2M use of reserves at the Branch Campuses, and a \$641K use of reserves at the HSC Campus. The \$641K use of reserves at the HSC Campus is primarily due to budgeting small portions of the hiring packages for two new Deans during FY 2019.

The next block of information shows the **Unrestricted Research** operations. The FY 2019 UNM Operating Budget projects a use of reserves of \$3.0M, of which Main Campus is projecting a \$1.9M use of reserves and HSC is projecting a \$1.1M use of reserves. At the HSC Campus, the \$1.1M use of reserves for non-recurring expenditures includes CTSC Scholar startup packages, equipment purchases and research supplies.

The third business category shown on the first page of this report is **Unrestricted Public Service**. The operations in this category include special projects funded by State Appropriations, for example Newborn Intensive Care, and non-endowed gifts flowing from the UNM Foundation to departments and many small events funded by user fees. The FY 2019 UNM Operating Budget projects a use of reserves of \$1.5M. This use of reserves is comprised of a combined use of reserves of \$1.9M at the Main and Branch Campuses and a \$420K favorable net margin at the HSC Campus. At the HSC Campus, the \$420K favorable net margin includes increased revenue due to an increase in unrestricted contracts.

Page 2 of this report begins with the **Student Aid** function. The FY 2019 UNM Operating Budget projects a use of reserves of \$5.6M. These reserves are comprised of \$5.5M use of reserves at the Main and Branch Campuses and a use of reserves of \$105K at the HSC Campus.

Student Activities are the operations of Student Government and Student organizations. The FY 2019 UNM Operating Budget shows a use of reserves of \$74K.

Auxiliaries and Athletics

The FY 2019 UNM Operating Budget for Auxiliaries and Athletics projects a use of reserves of \$618K.

Sponsored programs operations are our contract and grant research and public service projects funded by outside agencies and companies. These operations will always record a zero net revenue over expense by the nature of their funding. The agency pays for a service or research project, and normally any unspent funds must be returned to the agency.

The next block of numbers on the third page is a summary of our **Clinical Operations**. These operations are essentially all the patient care activities of the HSC Campus, including the UNM Hospitals, SOM physician professional services, Cancer Center operations and Housestaff/Medical Residents who are being trained in the UNM and VA hospitals. The FY 2019 UNM Operating Budget projects a favorable net margin of \$1.5M. UNM Hospitals budgeted a favorable net margin of \$3K. The School of Medicine budgeted a favorable net margin of \$1.5M, which is primarily due to increased outpatient clinical volume.

Statements of Revenues, Expenses and Changes in Net Position - UNM Regents Format
For the six month ended December 31, 2018
Preliminary and Unaudited

University of New Mexico - Consolidated Total Operations Current Funds

	FY 2019 Full Year Operating Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrbtl/(Unfavrbtl) Budget	Actual to Budget Benchmark Rate 50%	FY 2018 Year-to-Date Actual	FY 2019 YTD Actual Change From FY 2018 YTD Actual
Instruction and General						
Tuition and Fees Revenues						
Main Campus	155,623,993	80,147,012	(75,476,981)	52%	82,734,797	(2,587,785)
Branch Campuses	7,465,244	3,556,292	(3,908,952)	48%	3,711,671	(155,379)
HSC Campus	18,634,587	8,529,184	(10,105,403)	46%	8,655,825	(126,641)
Total Tuition and Fees Revenues	181,723,824	92,232,488	(89,491,336)	51%	95,102,293	(2,869,805)
State/Local Appropriations	272,166,725	136,071,119	(136,095,606)	50%	131,892,375	4,178,744
F & A Revenues	45,050,000	22,869,663	(22,180,337)	51%	22,988,471	(118,808)
Transfers	(51,411,147)	(27,952,354)	23,458,793	54%	(29,443,887)	1,491,533
Other Revenues	20,116,165	14,636,199	(5,479,966)	73%	10,201,298	4,434,901
Total Instruction and General Revenues	467,645,567	237,857,115	(229,788,452)	51%	230,740,550	7,116,565
Salaries	290,619,454	140,597,145	150,022,309	48%	139,986,658	(610,487)
Benefits	94,783,627	45,627,845	49,155,782	48%	45,672,094	44,249
Other Expenses	87,939,541	38,309,364	49,630,177	44%	37,376,088	(933,276)
Total Instruction and General Expenses	473,342,622	224,534,354	248,808,268	47%	223,034,840	(1,499,514)
Net Instruction and General Revenue/(Expense)	(5,697,055)	13,322,761	19,019,816		7,705,710	5,617,051
Research						
State/Local Appropriations	11,377,925	5,822,070	(5,555,855)	51%	5,972,385	(150,315)
Transfers	32,236,404	9,522,250	(22,714,154)	30%	10,686,305	(1,164,055)
Other Revenues	1,770,565	2,877,317	1,106,752	163%	1,196,751	1,680,566
Total Research Revenues	45,384,894	18,221,637	(27,163,257)	40%	17,855,441	366,196
Salaries and Benefits	24,927,090	11,821,254	13,105,836	47%	12,192,905	371,651
Other Expenses	23,463,317	8,286,342	15,176,975	35%	7,924,982	(361,360)
Total Research Expenses	48,390,407	20,107,596	28,282,811	42%	20,117,887	10,291
Net Research Revenue/(Expense)	(3,005,513)	(1,885,959)	1,119,554		(2,262,446)	376,487
Public Service						
State/Local Appropriations	3,484,050	1,742,025	(1,742,025)	50%	1,717,625	24,400
Sales and Services Revenues	23,999,169	11,269,373	(12,729,796)	47%	12,246,849	(977,476)
Gifts	9,892,354	6,512,380	(3,379,974)	66%	7,120,357	(607,977)
Transfers	(4,399,967)	(4,527,531)	(127,564)	103%	(394,778)	(4,132,753)
Other Revenues	6,221,094	3,287,952	(2,933,142)	53%	2,078,800	1,209,152
Total Public Service Revenues	39,196,700	18,284,199	(20,912,501)	47%	22,768,853	(4,484,654)
Salaries and Benefits	19,225,538	7,601,895	11,623,643	40%	10,723,229	3,121,334
Other Expenses	21,451,256	9,381,644	12,069,612	44%	8,919,581	(462,063)
Total Public Service Expenses	40,676,794	16,983,539	23,693,255	42%	19,642,810	2,659,271
Net Public Service Revenue/(Expense)	(1,480,094)	1,300,660	2,780,754		3,126,043	(1,825,383)

Statements of Revenues, Expenses and Changes in Net Position - UNM Regents Format
For the six month ended December 31, 2018
Preliminary and Unaudited

University of New Mexico - Consolidated Total Operations Current Funds

	FY 2019 Full Year Operating Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%	FY 2018 Year-to-Date Actual	FY 2019 YTD Actual Change From FY 2018 YTD Actual
Student Aid						
Gifts	6,895,139	4,123,140	(2,771,999)	60%	4,118,381	4,759
State Lottery Scholarship	18,200,000	9,100,000	(9,100,000)	50%	9,331,937	(231,937)
Transfers	20,145,621	10,414,359	(9,731,262)	52%	9,133,884	1,280,475
Other Revenues	417,929	223,143	(194,786)	53%	140,869	82,274
Total Student Aid Revenues	45,658,689	23,860,642	(21,798,047)	52%	22,725,071	1,135,571
Salaries and Benefits	2,908,416	2,025,669	882,747	70%	2,152,276	126,607
Other Expenses	48,354,193	21,737,473	26,616,720	45%	24,060,599	2,323,126
Total Student Aid Expenses	51,262,609	23,763,142	27,499,467	46%	26,212,875	2,449,733
Net Student Aid Revenue/(Expense)	(5,603,920)	97,500	5,701,420		(3,487,804)	3,585,304
Student Social & Cultural Programs						
Fee Revenues	8,487,388	4,289,659	(4,197,729)	51%	4,590,719	(301,060)
Sales and Services Revenues	989,452	541,705	(447,747)	55%	583,591	(41,886)
Transfers	292,425	394,099	101,674	135%	286,753	107,346
Other Revenues	244,154	65,295	(178,859)	27%	82,568	(17,273)
Total Student Social & Cultural Programs Revenues	10,013,419	5,290,758	(4,722,661)	53%	5,543,631	(252,873)
Salaries and Benefits	5,902,790	2,555,223	3,347,567	43%	2,947,589	392,366
Other Expenses	4,184,442	1,918,075	2,266,367	46%	2,190,498	272,423
Total Student Social & Cultural Programs Expenses	10,087,232	4,473,298	5,613,934	44%	5,138,087	664,789
Net Student Social & Cultural Programs Revenue/(Expense)	(73,813)	817,460	891,273		405,544	411,916
Auxiliaries and Athletics						
Branch Campuses Auxiliary Revenues	1,971,989	795,923	(1,176,066)	40%	1,457,319	(661,396)
Main Campus Auxiliaries Revenues	48,446,165	25,945,962	(22,500,203)	54%	26,097,525	(151,563)
Athletics Revenues	33,641,963	16,105,534	(17,536,429)	48%	18,168,770	(2,063,236)
Total Auxiliaries and Athletics Revenues	84,060,117	42,847,419	(41,212,698)	51%	45,723,614	(2,876,195)
Branch Campuses Auxiliary Expenses	2,040,826	920,293	1,120,533	45%	772,912	(147,381)
Main Campus Auxiliaries Expenses	48,995,269	24,119,007	24,876,262	49%	23,527,714	(591,293)
Athletics Expenses	33,641,963	17,350,909	16,291,054	52%	18,407,272	1,056,363
Total Auxiliaries and Athletics Expenses	84,678,058	42,390,209	42,287,849	50%	42,707,898	317,689
Net Auxiliaries and Athletics Revenue/(Expense)	(617,941)	457,210	1,075,151		3,015,716	(2,558,506)

Statements of Revenues, Expenses and Changes in Net Position - UNM Regents Format
For the six month ended December 31, 2018
Preliminary and Unaudited

University of New Mexico - Consolidated Total Operations Current Funds

	FY 2019 Full Year Operating Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrbtl/(Unfavrbtl) Budget	Actual to Budget Benchmark Rate 50%	FY 2018 Year-to-Date Actual	FY 2019 YTD Actual Change From FY 2018 YTD Actual
Sponsored Programs						
Federal Grants and Contracts Revenues	280,121,447	114,436,922	(165,684,525)	41%	118,258,349	(3,821,427)
State and Local Grants and Contracts Revenues	37,652,140	15,463,491	(22,188,649)	41%	13,385,593	2,077,898
Non-Governmental Grants and Contracts Revenues	39,652,565	16,674,657	(22,977,908)	42%	17,942,094	(1,267,437)
Gifts	-	-	-	N/A	-	-
Transfers	1,964,504	3,085,017	1,120,513	157%	3,782,115	(697,098)
Other Revenues	-	1,058	1,058	N/A	-	1,058
Total Sponsored Programs Revenues	359,390,656	149,661,145	(209,729,511)	42%	153,368,151	(3,707,006)
Salaries and Benefits	169,228,822	68,842,653	100,386,169	41%	69,267,689	425,036
Other Expenses	190,161,834	80,818,492	109,343,342	42%	84,100,462	3,281,970
Total Sponsored Programs Expenses	359,390,656	149,661,145	209,729,511	42%	153,368,151	3,707,006
Net Sponsored Programs Revenue/(Expense)	-	-	-		-	-
Clinical Operations						
State/Local Appropriations	26,530,000	13,264,104	(13,265,896)	50%	12,528,746	735,358
Physician Professional Fee Revenues	133,242,851	63,561,813	(69,681,038)	48%	61,711,612	1,850,201
Hospital Facility Revenues	939,105,744	477,571,591	(461,534,153)	51%	462,644,392	14,927,199
Other Patient Revenues, net of Allowance	173,015,985	86,410,496	(86,605,489)	50%	78,599,112	7,811,384
Mil Levy	100,269,401	50,134,700	(50,134,701)	50%	49,138,317	996,383
Investment Income	(82,916)	880,090	963,006	-1061%	96,328	783,762
Gifts	3,138,141	1,239,432	(1,898,709)	39%	1,026,852	212,580
Housestaff Revenues	37,950,860	19,766,533	(18,184,327)	52%	18,764,519	1,002,014
Transfers	(6,525,332)	(373,702)	6,151,630	6%	(3,543,709)	3,170,007
Other Revenues	44,586,523	31,404,823	(13,181,700)	70%	19,679,203	11,725,620
Total Clinical Operations Revenues	1,451,231,257	743,859,880	(707,371,377)	51%	700,645,372	43,214,508
Salaries and Benefits	809,851,210	410,796,065	399,055,145	51%	384,718,875	(26,077,190)
Interest Expense	3,799,848	1,899,924	1,899,924	50%	1,897,124	(2,800)
Housestaff Expenses	37,950,860	19,180,299	18,770,561	51%	18,659,385	(520,914)
Other Expenses	598,128,166	309,726,830	288,401,336	52%	294,715,187	(15,011,643)
Total Clinical Operations Expenses	1,449,730,084	741,603,118	708,126,966	51%	699,990,571	(41,612,547)
Net Clinical Operations Revenue/(Expense)	1,501,173	2,256,762	755,589		654,801	1,601,961
Contingencies						
Total Contingency Revenues	-	-	-	N/A	-	-
Total Contingency Expenses	-	-	-	N/A	-	-
Net Contingencies Revenue/(Expense)	-	-	-		-	-
Net Current Revenue/(Expense)	(14,977,163)	16,366,394	31,343,557		9,157,564	7,208,830

(1) **OPERATING BUDGET** - Clinical Operations include the SOM Clinical Departments which have a budgeted consolidated net margin of \$1,498,537 and UNM Hospital operations which has a budgeted net margin of \$2,636

(2) **ACTUAL** - Clinical Operations include the SOM Clinical Departments which currently have a consolidated net margin of \$(30,282) and UNM Hospitals operations currently has a net margin of \$2,287,044

Statements of Revenues, Expenses and Changes in Net Position - UNM Regents Format
For the six month ended December 31, 2018
Preliminary and Unaudited

University of New Mexico - Main Campus Athletics & Auxiliary Operations

	FY 2019 Full Year Operating Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%	FY 2018 Year-to-Date Actual	FY 2019 YTD Actual Change From FY 2018 YTD Actual
Results of Athletics Operations:						
Athletics Revenues	32,790,628	15,607,791	(17,182,837)	48%	18,206,647	(2,598,856)
Athletics Transfers	851,335	497,743	(353,592)	58%	(37,877)	535,620
Total Athletics Revenues	33,641,963	16,105,534	(17,536,429)	48%	18,168,770	(2,063,236)
Athletics Expenses						
Salaries and Benefits	14,609,246	6,804,612	7,804,634	47%	7,252,977	448,365
Grant-in-Aid	4,862,032	2,360,714	2,501,318	49%	2,510,077	149,363
Other Expenses	14,170,685	8,185,583	5,985,102	58%	8,644,218	458,635
Total Athletics Expenses	33,641,963	17,350,909	16,291,054	52%	18,407,272	1,056,363
Total Net Athletics Revenue/(Expense)	-	(1,245,375)	(1,245,375)		(238,502)	(1,006,873)
Operations		(398,893)			835,929	1,234,822
Debt Service		(740,897)			(855,238)	(114,341)
Endowed Spending Accounts		(105,585)			(219,193)	(113,608)
		(1,245,375)			(238,502)	1,006,873
Results of Auxiliary Operations:						
VP for Institutional Support Services						
Bookstore Revenues	12,045,193	5,868,214	(6,176,979)	49%	6,832,819	(964,605)
Bookstore Transfers	(410,000)	(175,000)	235,000	43%	(175,000)	-
Total Bookstore Revenues	11,635,193	5,693,214	(5,941,979)	49%	6,657,819	(964,605)
Total Bookstore Expenses	11,820,193	5,756,789	6,063,404	49%	6,613,442	856,653
Net Bookstore Revenue/(Expense)	(185,000)	(63,575)	121,425		44,377	(107,952)
University Club Revenues	50,000	23,093	(26,907)	46%	25,781	(2,688)
University Club Expenses	50,000	4,759	45,241	10%	30,017	25,258
Net Faculty & Staff Club Revenue/(Expense)	-	18,334	18,334		(4,236)	22,570
Food Service/Dining Revenues	2,333,989	1,331,311	(1,002,678)	57%	1,291,070	40,241
Food Service/Dining Transfers	(841,901)	(23,000)	818,901	3%	(30,000)	7,000
Total Food Service/Dining Revenues	1,492,088	1,308,311	(183,777)	88%	1,261,070	47,241
Total Food Service/Dining Expenses	1,492,088	721,340	770,748	48%	699,385	(21,955)
Net Food Service/Dining Revenue/(Expense)	-	586,971	586,971		561,685	25,286
Golf Courses Revenues	2,459,490	1,023,143	(1,436,347)	42%	928,671	94,472
Golf Courses Transfers	(39,252)	(9,737)	29,515	25%	(9,553)	(184)
Total Golf Courses Revenues	2,420,238	1,013,406	(1,406,832)	42%	919,118	94,288
Total Golf Courses Expenses	2,420,238	1,175,453	1,244,785	49%	1,196,811	21,358
Net Golf Courses Revenue/(Expense)	-	(162,047)	(162,047)		(277,693)	115,646
Housing Revenues	10,811,376	5,362,380	(5,448,996)	50%	6,028,954	(666,574)
Housing Transfers	(2,798,271)	(1,399,136)	1,399,135	50%	(1,659,500)	260,364
Total Housing Revenues	8,013,105	3,963,244	(4,049,861)	49%	4,369,454	(406,210)
Total Housing Expense	8,013,105	4,187,020	3,826,085	52%	3,963,097	(223,923)
Net Housing Revenue/(Expense)	-	(223,776)	(223,776)		406,357	(630,133)

Statements of Revenues, Expenses and Changes in Net Position - UNM Regents Format
For the six month ended December 31, 2018
Preliminary and Unaudited

University of New Mexico - Main Campus Athletics & Auxiliary Operations

	FY 2019 Full Year Operating Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%	FY 2018 Year-to-Date Actual	FY 2019 YTD Actual Change From FY 2018 YTD Actual
Lobo Cash Revenues	82,500	53,600	(28,900)	65%	62,353	(8,753)
Lobo Cash Expenses	82,500	55,029	(27,471)	67%	18,645	(36,384)
Net Lobo Cash Revenue/(Expense)	-	(1,429)	(1,429)		43,708	(45,137)
Other Revenues	1,974,000	435,750	(1,538,250)	22%	547,666	(111,916)
Other Transfers	(2,077,000)	(920,000)	1,157,000	44%	(915,000)	(5,000)
Total Other Revenues	(103,000)	(484,250)	(381,250)	470%	(367,334)	(116,916)
Total Other Expense	1,216	-	1,216	0%	-	-
Net Other Revenue/(Expense)	(104,216)	(484,250)	(380,034)		(367,334)	(116,916)
Parking and Transportation Revenues	8,009,664	5,426,045	(2,583,619)	68%	5,562,220	(136,175)
Parking and Trans Transfers	(1,688,823)	(911,911)	776,912	54%	(967,117)	55,206
Total Parking and Trans Revenues	6,320,841	4,514,134	(1,806,707)	71%	4,595,103	(80,969)
Total Parking and Trans Expenses	6,580,729	2,914,597	3,666,132	44%	3,093,388	178,791
Net Parking and Trans Revenue/(Expense)	(259,888)	1,599,537	1,859,425		1,501,715	97,822
Popejoy Events Revenues	6,601,930	3,465,199	(3,136,731)	52%	2,074,079	1,391,120
Popejoy Events Transfers	-	-	-	N/A	12,121	(12,121)
Total Popejoy Events Revenues	6,601,930	3,465,199	(3,136,731)	52%	2,086,200	1,378,999
Total Popejoy Events Expenses	6,601,930	3,612,136	2,989,794	55%	2,234,812	(1,377,324)
Net Popejoy Events Revenue/(Expense)	-	(146,937)	(146,937)		(148,612)	1,675
Taos & Lawrence Ranch Revenues	55,000	55,000	-	100%	62,000	(7,000)
Taos & Lawrence Ranch Expenses	55,000	21,987	33,013	40%	25,585	3,598
Net Taos & Lawrence Ranch Revenue/(Expense)	-	33,013	33,013		36,415	(3,402)
Ticketing Services Revenues	1,018,098	676,108	(341,990)	66%	700,146	(24,038)
Ticketing Services Transfers	-	-	-	N/A	-	-
Total Ticketing Services Revenues	1,018,098	676,108	(341,990)	66%	700,146	(24,038)
Total Ticketing Services Expenses	1,018,098	438,149	579,949	43%	520,288	82,139
Net Ticketing Services Revenue/(Expense)	-	237,959	237,959		179,858	58,101
Total VP for Institutional Support Services Revenues	37,585,993	20,281,059	(17,304,934)	54%	20,371,710	(90,651)
Total VP for Institutional Support Services Expenses	38,135,097	18,887,259	19,247,838	50%	18,395,470	(491,789)
Net VP for Institutional Support Services Revenue/(Expense)	(549,104)	1,393,800	1,942,904		1,976,240	(582,440)

Statements of Revenues, Expenses and Changes in Net Position - UNM Regents Format
For the six month ended December 31, 2018
Preliminary and Unaudited

University of New Mexico - Main Campus Athletics & Auxiliary Operations

	FY 2019 Full Year Operating Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrbtl/(Unfavrbtl) Budget	Actual to Budget Benchmark Rate 50%	FY 2018 Year-to-Date Actual	FY 2019 YTD Actual Change From FY 2018 YTD Actual
VP for Student Affairs						
Student Health Center Revenues	7,742,062	3,878,887	(3,863,175)	50%	3,967,995	(89,108)
Student Health Center Expenses	7,742,062	3,718,406	4,023,656	48%	3,646,859	(71,547)
Net Student Health Center Revenue/(Expense)	-	160,481	160,481		321,136	(160,655)
Student Union Revenues	2,910,751	1,555,778	(1,354,973)	53%	1,618,200	(62,422)
Student Union Expenses	2,910,751	1,424,813	1,485,938	49%	1,367,720	(57,093)
Net Student Union Revenue/(Expense)	-	130,965	130,965		250,480	(119,515)
Total VP for Student Affairs Revenues	10,652,813	5,434,665	(5,218,148)	51%	5,586,195	(151,530)
Total VP for Student Affairs Expenses	10,652,813	5,143,219	5,509,594	48%	5,014,579	(128,640)
Net VP for Student Affairs Revenue/(Expense)	-	291,446	291,446		571,616	(280,170)
Provost and Other Units						
Art Museum Revenues	300	-	(300)	0%	305	(305)
Art Museum Expenses	300	-	300	0%	3,216	3,216
Net Art Museum Revenue/(Expense)	-	-	-		(2,911)	2,911
CE Conference Ctr Revenues	100,000	135,935	35,935	136%	47,348	88,587
CE Conference Ctr Transfers	(8,202)	29,249	37,451	-357%	36,787	(7,538)
Total CE Conference Ctr Revenues	91,798	165,184	73,386	180%	84,135	81,049
Total CE Conference Ctr Expenses	91,798	39,317	52,481	43%	71,942	32,625
Net CE Conference Ctr Revenue/(Expense)	-	125,867	125,867		12,193	113,674
Maxwell Museum Revenues	40,261	23,638	(16,623)	59%	25,778	(2,140)
Maxwell Museum Expenses	40,261	7,095	33,166	18%	7,448	353
Net Maxwell Museum Revenue/(Expense)	-	16,543	16,543		18,330	(1,787)
Other Revenues	75,000	41,416	(33,584)	55%	29,402	12,014
Other Expenses	75,000	42,117	32,883	56%	35,059	(7,058)
Net Other Revenue/(Expense)	-	(701)	(701)		(5,657)	4,956
Total Provost and Other Units Revenues	207,359	230,238	22,879	111%	139,620	90,618
Total Provost and Other Units Expenses	207,359	88,529	118,830	43%	117,665	29,136
Net Provost and Other Units Revenue/(Expense)	-	141,709	141,709		21,955	119,754
Auxiliary Totals						
Total Auxiliary Revenues	48,446,165	25,945,962	(22,500,203)	54%	26,097,525	(151,563)
Total Auxiliary Expenses	48,995,269	24,119,007	24,876,262	49%	23,527,714	(591,293)
Net Auxiliary Revenue/(Expense)	(549,104)	1,826,955	2,376,059		2,569,811	(742,856)
Net Athletics Revenue/(Expense)	-	(1,245,375)	(1,245,375)		(238,502)	(1,006,873)
Net Auxiliary and Athletics Revenue/(Expense)	(549,104)	581,580	1,130,684		2,331,309	(1,749,729)
Net Branch Campuses Aux Revenue/(Expense)	(68,837)	(124,370)	(55,533)		684,407	(808,777)
Net All Auxiliary and Athletics Revenue/(Expense)	(617,941)	457,210	1,075,151		3,015,716	(2,558,506)

Statements of Revenues, Expenses and Changes in Net Position - UNM Regents Format
For the six month ended December 31, 2018
Preliminary and Unaudited

Main Campus - Total Operations Current Funds

	FY 2019 Full Year Operating Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%	FY 2018 Year-to-Date Actual	FY 2019 YTD Actual Change From FY 2018 YTD Actual
Instruction and General						
Tuition and Fees Revenues	155,623,993	80,147,012	(75,476,981)	52%	82,734,797	(2,587,785)
State/Local Appropriations	183,436,200	91,718,100	(91,718,100)	50%	88,478,800	3,239,300
F & A Revenues	20,050,000	10,168,990	(9,881,010)	51%	10,046,945	122,045
Transfers	(59,733,262)	(30,970,352)	28,762,910	52%	(32,382,168)	1,411,816
Other Revenues	15,253,985	12,053,644	(3,200,341)	79%	7,696,464	4,357,180
Total Instruction and General Revenues	314,630,916	163,117,394	(151,513,522)	52%	156,574,838	6,542,556
Salaries	193,398,164	93,829,262	99,568,902	49%	93,481,267	(347,995)
Benefits	65,071,028	31,212,130	33,858,898	48%	31,154,052	(58,078)
Other Expenses	60,060,705	26,443,090	33,617,615	44%	25,396,219	(1,046,871)
Total Instruction and General Expenses	318,529,897	151,484,482	167,045,415	48%	150,031,538	(1,452,944)
Net Instruction and General Revenue/(Expense)	(3,898,981)	11,632,912	15,531,893		6,543,300	5,089,612
Research						
State/Local Appropriations	1,931,450	965,725	(965,725)	50%	922,225	43,500
Transfers	16,442,906	5,448,118	(10,994,788)	33%	5,778,330	(330,212)
Other Revenues	348,237	399,487	51,250	115%	712,656	(313,169)
Total Research Revenues	18,722,593	6,813,330	(11,909,263)	36%	7,413,211	(599,881)
Salaries and Benefits	9,695,747	5,444,384	4,251,363	56%	5,370,387	(73,997)
Other Expenses	10,903,450	3,919,448	6,984,002	36%	3,652,100	(267,348)
Total Research Expenses	20,599,197	9,363,832	11,235,365	45%	9,022,487	(341,345)
Net Research Revenue/(Expense)	(1,876,604)	(2,550,502)	(673,898)		(1,609,276)	(941,226)
Public Service						
State/Local Appropriations	3,228,350	1,614,175	(1,614,175)	50%	1,591,625	22,550
Sales and Services Revenues	7,675,467	3,496,381	(4,179,086)	46%	4,127,271	(630,890)
Gifts	6,936,798	3,806,596	(3,130,202)	55%	3,482,870	323,726
Transfers	167,361	(1,126,387)	(1,293,748)	-673%	1,046,631	(2,173,018)
Other Revenues	4,040,515	2,837,992	(1,202,523)	70%	1,672,288	1,165,704
Total Public Service Revenues	22,048,491	10,628,757	(11,419,734)	48%	11,920,685	(1,291,928)
Salaries and Benefits	11,076,126	5,175,213	5,900,913	47%	5,744,403	569,190
Other Expenses	12,851,447	6,258,029	6,593,418	49%	5,672,800	(585,229)
Total Public Service Expenses	23,927,573	11,433,242	12,494,331	48%	11,417,203	(16,039)
Net Public Service Revenue/(Expense)	(1,879,082)	(804,485)	1,074,597		503,482	(1,307,967)

Statements of Revenues, Expenses and Changes in Net Position - UNM Regents Format
For the six month ended December 31, 2018
Preliminary and Unaudited

Main Campus - Total Operations Current Funds

	FY 2019 Full Year Operating Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%	FY 2018 Year-to-Date Actual	FY 2019 YTD Actual Change From FY 2018 YTD Actual
Student Aid						
Private Grants/Gifts	4,793,850	3,079,206	(1,714,644)	64%	3,067,198	12,008
State Lottery Scholarships	18,200,000	9,100,000	(9,100,000)	50%	9,331,937	(231,937)
Transfers	17,648,989	9,029,130	(8,619,859)	51%	8,372,031	657,099
Other Revenues	400,929	215,301	(185,628)	54%	132,889	82,412
Total Student Aid Revenues	41,043,768	21,423,637	(19,620,131)	52%	20,904,055	519,582
Salaries and Benefits	1,375,334	1,184,627	190,707	86%	1,375,745	191,118
Other Expenses	45,144,059	20,722,764	24,421,295	46%	23,197,853	2,475,089
Total Student Aid Expenses	46,519,393	21,907,391	24,612,002	47%	24,573,598	2,666,207
Net Student Aid Revenue/(Expense)	(5,475,625)	(483,754)	4,991,871		(3,669,543)	3,185,789
Student Social & Cultural Programs						
Fee Revenues	8,267,768	4,186,824	(4,080,944)	51%	4,480,159	(293,335)
Sales and Services Revenues	926,109	503,490	(422,619)	54%	546,809	(43,319)
Transfers	331,003	432,677	101,674	131%	276,989	155,688
Other Revenues	243,654	65,245	(178,409)	27%	82,013	(16,768)
Total Student Social & Cultural Programs Revenues	9,768,534	5,188,236	(4,580,298)	53%	5,385,970	(197,734)
Salaries and Benefits	5,894,950	2,555,115	3,339,835	43%	2,947,589	392,474
Other Expenses	3,943,276	1,854,413	2,088,863	47%	2,116,935	262,522
Total Student Social & Cultural Programs Expenses	9,838,226	4,409,528	5,428,698	45%	5,064,524	654,996
Net Student Social & Cultural Programs Revenue/(Expense)	(69,692)	778,708	848,400		321,446	457,262
Auxiliaries						
Auxiliaries Revenues	48,446,165	25,945,962	(22,500,203)	54%	26,097,525	(151,563)
Athletics Revenues	33,641,963	16,105,534	(17,536,429)	48%	18,168,770	(2,063,236)
Total Auxiliaries Revenues	82,088,128	42,051,496	(40,036,632)	51%	44,266,295	(2,214,799)
Auxiliaries Expenses	48,995,269	24,119,007	24,876,262	49%	23,527,714	(591,293)
Athletics Expenses	33,641,963	17,350,909	16,291,054	52%	18,407,272	1,056,363
Total Auxiliaries Expenses	82,637,232	41,469,916	41,167,316	50%	41,934,986	465,070
Net Auxiliaries and Athletics Revenue/(Expense)	(549,104)	581,580	1,130,684		2,331,309	(1,749,729)

Statements of Revenues, Expenses and Changes in Net Position - UNM Regents Format
For the six month ended December 31, 2018
Preliminary and Unaudited

Main Campus - Total Operations Current Funds

	FY 2019 Full Year Operating Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%	FY 2018 Year-to-Date Actual	FY 2019 YTD Actual Change From FY 2018 YTD Actual
Sponsored Programs						
Federal Grants and Contracts Revenues	147,158,888	61,930,901	(85,227,987)	42%	63,319,562	(1,388,661)
State and Local Grants and Contracts Revenues	17,087,338	7,520,206	(9,567,132)	44%	5,078,710	2,441,496
Non-Governmental Grants and Contracts Revenues	12,600,000	5,774,742	(6,825,258)	46%	6,604,106	(829,364)
Gifts	-	-	-	N/A	-	-
Transfers	-	1,438,302	1,438,302	N/A	1,290,651	147,651
Other Revenues	-	-	-	N/A	-	-
Total Sponsored Programs Revenues	176,846,226	76,664,151	(100,182,075)	43%	76,293,029	371,122
Salaries and Benefits	67,960,226	26,617,943	41,342,283	39%	25,782,034	(835,909)
Other Expenses	108,886,000	50,046,208	58,839,792	46%	50,510,995	464,787
Total Sponsored Programs Expenses	176,846,226	76,664,151	100,182,075	43%	76,293,029	(371,122)
Net Sponsored Programs Revenue/(Expense)	-	-	-		-	-
Contingencies						
Total Contingency Revenues	-	-	-	N/A	-	-
Total Contingency Expenses	-	-	-	N/A	-	-
Net Contingencies Revenue/(Expense)	-	-	-		-	-
Net Current Revenue/(Expense)	(13,749,088)	9,154,459	22,903,547		4,420,718	4,733,741

Statements of Revenues, Expenses and Changes in Net Position - UNM Regents Format
For the six month ended December 31, 2018
Preliminary and Unaudited

Branch Campuses - Total Operations Current Funds

	FY 2019 Full Year Operating Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%	FY 2018 Year-to-Date Actual	FY 2019 YTD Actual Change From FY 2018 YTD Actual
Instruction and General						
Tuition and Fees Revenues	7,465,244	3,556,292	(3,908,952)	48%	3,711,671	(155,379)
State/Local Appropriations	28,473,625	14,236,813	(14,236,812)	50%	13,807,521	429,292
Transfers	(1,111,551)	(972,835)	138,716	88%	(717,953)	(254,882)
Other Revenues	663,755	509,530	(154,225)	77%	478,330	31,200
Total Instruction and General Revenues	35,491,073	17,329,800	(18,161,273)	49%	17,279,569	50,231
Salaries	21,287,258	9,737,879	11,549,379	46%	9,771,088	33,209
Benefits	6,847,511	3,122,345	3,725,166	46%	3,114,331	(8,014)
Other Expenses	8,513,804	3,388,594	5,125,210	40%	3,158,460	(230,134)
Total Instruction and General Expenses	36,648,573	16,248,818	20,399,755	44%	16,043,879	(204,939)
Net Instruction and General Revenue/(Expense)	(1,157,500)	1,080,982	2,238,482		1,235,690	(154,708)
Public Service						
State/Local Appropriations	-	-	-	N/A	-	-
Sales and Services Revenues	397,098	230,375	(166,723)	58%	206,305	24,070
Gifts	84,808	169,589	84,781	200%	95,371	74,218
Transfers	-	(1,000)	(1,000)	N/A	35,711	(36,711)
Other Revenues	-	67,747	67,747	N/A	100,426	(32,679)
Total Public Service Revenues	481,906	466,711	(15,195)	97%	437,813	28,898
Salaries and Benefits	300,640	211,333	89,307	70%	296,256	84,923
Other Expenses	202,033	84,569	117,464	42%	91,492	6,923
Total Public Service Expenses	502,673	295,902	206,771	59%	387,748	91,846
Net Public Service Revenue/(Expense)	(20,767)	170,809	191,576		50,065	120,744
Student Aid						
Private Grants/Gifts	103,900	48,261	(55,639)	46%	41,182	7,079
Transfers	370,610	188,045	(182,565)	51%	293,393	(105,348)
Other Revenues	17,000	7,802	(9,198)	46%	7,980	(178)
Total Student Aid Revenues	491,510	244,108	(247,402)	50%	342,555	(98,447)
Salaries and Benefits	-	-	-	N/A	7,536	7,536
Other Expenses	514,510	269,048	245,462	52%	198,552	(70,496)
Total Student Aid Expenses	514,510	269,048	245,462	52%	206,088	(62,960)
Net Student Aid Revenue/(Expense)	(23,000)	(24,940)	(1,940)		136,467	(161,407)

Statements of Revenues, Expenses and Changes in Net Position - UNM Regents Format
For the six month ended December 31, 2018
Preliminary and Unaudited

Branch Campuses - Total Operations Current Funds

	FY 2019 Full Year Operating Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%	FY 2018 Year-to-Date Actual	FY 2019 YTD Actual Change From FY 2018 YTD Actual
Student Social & Cultural Programs						
Fee Revenues	219,620	102,835	(116,785)	47%	110,560	(7,725)
Sales and Services Revenues	7,400	3,587	(3,813)	48%	5,419	(1,832)
Transfers	(40,000)	(40,000)	-	100%	9,500	(49,500)
Other Revenues	500	-	(500)	0%	555	(555)
Total Student Social & Cultural Programs Revenues	187,520	66,422	(121,098)	35%	126,034	(59,612)
Salaries and Benefits	7,840	108	7,732	1%	-	(108)
Other Expenses	179,980	38,912	141,068	22%	53,375	14,463
Total Student Social & Cultural Programs Expenses	187,820	39,020	148,800	21%	53,375	14,355
Net Student Social & Cultural Programs Revenue/(Expense)	(300)	27,402	27,702		72,659	(45,257)
Auxiliaries						
Bookstore Revenues	1,839,389	742,349	(1,097,040)	40%	781,857	(39,508)
Housing and Food Service Revenues	153,000	68,269	(84,731)	45%	66,805	1,464
Transfers	(40,000)	(20,414)	19,586	51%	-	(20,414)
Other Auxiliaries Revenues	19,600	5,719	(13,881)	29%	608,657	(602,938)
Total Auxiliaries Revenues	1,971,989	795,923	(1,176,066)	40%	1,457,319	(661,396)
Bookstore Expenses	1,818,226	853,303	964,923	47%	668,540	(184,763)
Housing and Food Service Expenses	209,600	62,809	146,791	30%	57,944	(4,865)
Other Auxiliaries Expenses	13,000	4,181	8,819	32%	46,428	42,247
Total Auxiliaries Expenses	2,040,826	920,293	1,120,533	45%	772,912	(147,381)
Net Auxiliaries Revenue/(Expense)	(68,837)	(124,370)	(55,533)		684,407	(808,777)
Sponsored Programs						
Federal Grants and Contracts Revenues	10,447,731	3,540,431	(6,907,300)	34%	4,032,740	(492,309)
State and Local Grants and Contracts Revenues	2,103,664	388,199	(1,715,465)	18%	433,932	(45,733)
Non-Governmental Grants and Contracts Revenues	200,000	190,098	(9,902)	95%	265,225	(75,127)
Gifts	-	-	-	N/A	-	-
Transfers	-	-	-	N/A	-	-
Other Revenues	-	1,058	1,058	N/A	-	1,058
Total Sponsored Programs Revenues	12,751,395	4,119,786	(8,631,609)	32%	4,731,897	(612,111)
Salaries and Benefits	7,882,427	2,476,151	5,406,276	31%	2,651,495	175,344
Other Expenses	4,868,968	1,643,635	3,225,333	34%	2,080,402	436,767
Total Sponsored Programs Expenses	12,751,395	4,119,786	8,631,609	32%	4,731,897	612,111
Net Sponsored Programs Revenue/(Expense)	-	-	-		-	-
Net Current Revenue/(Expense)	(1,270,404)	1,129,883	2,400,287		2,179,288	(1,049,405)

Statements of Revenues, Expenses and Changes in Net Position - UNM Regents Format
For the six month ended December 31, 2018
Preliminary and Unaudited

Health Sciences Center - Total Operations Current Funds

	FY 2019 Full Year Operating Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%	FY 2018 Year-to-Date Actual	FY 2019 YTD Actual Change From FY 2018 YTD Actual
Instruction and General						
Tuition and Fees Revenues	18,634,587	8,529,184	(10,105,403)	46%	8,655,825	(126,641)
State/Local Appropriations	60,256,900	30,116,206	(30,140,694)	50%	29,606,054	510,152
F & A Revenues	25,000,000	12,700,673	(12,299,327)	51%	12,941,526	(240,853)
Transfers	9,433,666	3,990,833	(5,442,833)	42%	3,656,234	334,599
Other Revenues	4,198,425	2,073,025	(2,125,400)	49%	2,026,504	46,521
Total Instruction and General Revenues	117,523,578	57,409,921	(60,113,657)	49%	56,886,143	523,778
Salaries	75,934,032	37,030,004	38,904,028	49%	36,734,303	(295,701)
Benefits	22,865,088	11,293,370	11,571,718	49%	11,403,711	110,341
Other Expenses	19,365,032	8,477,680	10,887,352	44%	8,821,409	343,729
Total Instruction and General Expenses	118,164,152	56,801,054	61,363,098	48%	56,959,423	158,369
Net Instruction and General Revenue/(Expense)	(640,574)	608,867	1,249,441		(73,280)	682,147
Research						
State/Local Appropriations	9,446,475	4,856,345	(4,590,130)	51%	5,050,160	(193,815)
Generated Revenues	388,221	73,489	(314,732)	19%	212,243	(138,754)
Transfers	15,793,498	4,074,132	(11,719,366)	26%	4,907,975	(833,843)
Other Revenues	1,034,107	2,404,341	1,370,234	233%	271,852	2,132,489
Total Research Revenues	26,662,301	11,408,307	(15,253,994)	43%	10,442,230	966,077
Salaries and Benefits	15,231,343	6,376,870	8,854,473	42%	6,822,518	445,648
Other Expenses	12,559,867	4,366,894	8,192,973	35%	4,272,882	(94,012)
Total Research Expenses	27,791,210	10,743,764	17,047,446	39%	11,095,400	351,636
Net Research Revenue/(Expense)	(1,128,909)	664,543	1,793,452		(653,170)	1,317,713
Public Service						
State/Local Appropriations	255,700	127,850	(127,850)	50%	126,000	1,850
Sales and Services Revenues	15,926,604	7,542,617	(8,383,987)	47%	7,913,273	(370,656)
Gifts	2,870,748	2,536,195	(334,553)	88%	3,542,116	(1,005,921)
Transfers	(4,567,328)	(3,400,144)	1,167,184	74%	(1,477,120)	(1,923,024)
Other Revenues	2,180,579	382,213	(1,798,366)	18%	306,086	76,127
Total Public Service Revenues	16,666,303	7,188,731	(9,477,572)	43%	10,410,355	(3,221,624)
Salaries and Benefits	7,848,772	2,215,349	5,633,423	28%	4,682,570	2,467,221
Other Expenses	8,397,776	3,039,046	5,358,730	36%	3,155,289	116,243
Total Public Service Expenses	16,246,548	5,254,395	10,992,153	32%	7,837,859	2,583,464
Net Public Service Revenue/(Expense)	419,755	1,934,336	1,514,581		2,572,496	(638,160)

Statements of Revenues, Expenses and Changes in Net Position - UNM Regents Format
For the six month ended December 31, 2018
Preliminary and Unaudited

Health Sciences Center - Total Operations Current Funds

	FY 2019 Full Year Operating Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%	FY 2018 Year-to-Date Actual	FY 2019 YTD Actual Change From FY 2018 YTD Actual
Student Aid						
Gifts	1,997,389	995,673	(1,001,716)	50%	1,010,001	(14,328)
Investment Income	-	-	-	N/A	-	-
Transfers	2,126,022	1,197,184	(928,838)	56%	468,460	728,724
Other Revenues	-	40	40	N/A	-	40
Total Student Aid Revenues	4,123,411	2,192,897	(1,930,514)	53%	1,478,461	714,436
Salaries and Benefits	1,533,082	841,042	692,040	55%	768,995	(72,047)
Other Expenses	2,695,624	745,661	1,949,963	28%	664,194	(81,467)
Total Student Aid Expenses	4,228,706	1,586,703	2,642,003	38%	1,433,189	(153,514)
Net Student Aid Revenue/(Expense)	(105,295)	606,194	711,489		45,272	560,922
Student Social & Cultural Programs						
Fee Revenues	-	-	-	N/A	-	-
Sales and Services Revenues	55,943	34,628	(21,315)	62%	31,363	3,265
Transfers	1,422	1,422	-	100%	264	1,158
Other Revenues	-	50	50	N/A	-	50
Total Student Social & Cultural Programs Revenues	57,365	36,100	(21,265)	63%	31,627	4,473
Salaries and Benefits	-	-	-	N/A	-	-
Other Expenses	61,186	24,750	36,436	40%	20,188	(4,562)
Total Student Social & Cultural Programs Expenses	61,186	24,750	36,436	40%	20,188	(4,562)
Net Student Social & Cultural Programs Revenue/(Expense)	(3,821)	11,350	15,171		11,439	(89)
Sponsored Programs						
Federal Grants and Contracts Revenues	122,514,828	48,965,590	(73,549,238)	40%	50,906,047	(1,940,457)
State and Local Grants and Contracts Revenues	18,461,138	7,555,086	(10,906,052)	41%	7,872,951	(317,865)
Non-Governmental Grants and Contracts Revenues	26,852,565	10,709,817	(16,142,748)	40%	11,072,763	(362,946)
Gifts	-	-	-	N/A	-	-
Other Revenues	-	-	-	N/A	-	-
Transfers	1,964,504	1,646,715	(317,789)	84%	2,491,464	(844,749)
Total Sponsored Programs Revenues	169,793,035	68,877,208	(100,915,827)	41%	72,343,225	(3,466,017)
Salaries and Benefits	93,386,169	39,748,559	53,637,610	43%	40,834,160	1,085,601
Other Expenses	76,406,866	29,128,649	47,278,217	38%	31,509,065	2,380,416
Total Sponsored Programs Expenses	169,793,035	68,877,208	100,915,827	41%	72,343,225	3,466,017
Net Sponsored Programs Revenue/(Expense)	-	-	-		-	-

Statements of Revenues, Expenses and Changes in Net Position - UNM Regents Format
For the six month ended December 31, 2018
Preliminary and Unaudited

Health Sciences Center - Total Operations Current Funds

	FY 2019 Full Year Operating Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%	FY 2018 Year-to-Date Actual	FY 2019 YTD Actual Change From FY 2018 YTD Actual
Clinical Operations						
State/Local Appropriations	26,530,000	13,264,104	(13,265,896)	50%	12,528,746	735,358
Physician Professional Fee Revenues	133,242,851	63,561,813	(69,681,038)	48%	61,711,612	1,850,201
Hospital Facility Revenues	939,105,744	477,571,591	(461,534,153)	51%	462,644,392	14,927,199
Other Patient Revenues, net of Allowance	173,015,985	86,410,496	(86,605,489)	50%	78,599,112	7,811,384
Mil Levy	100,269,401	50,134,700	(50,134,701)	50%	49,138,317	996,383
Investment Income	(82,916)	880,090	963,006	-1061%	96,328	783,762
Gifts	3,138,141	1,239,432	(1,898,709)	39%	1,026,852	212,580
Housestaff Revenues	37,950,860	19,766,533	(18,184,327)	52%	18,764,519	1,002,014
Transfers	(6,525,332)	(373,702)	6,151,630	6%	(3,543,709)	3,170,007
Other Revenues	44,586,523	31,404,823	(13,181,700)	70%	19,679,203	11,725,620
Total Clinical Operations Revenues	1,451,231,257	743,859,880	(707,371,377)	51%	700,645,372	43,214,508
Salaries and Benefits	809,851,210	410,796,065	399,055,145	51%	384,718,875	(26,077,190)
Interest Expense	3,799,848	1,899,924	1,899,924	50%	1,897,124	(2,800)
Housestaff Expenses	37,950,860	19,180,299	18,770,561	51%	18,659,385	(520,914)
Other Expenses	598,128,166	309,726,830	288,401,336	52%	294,715,187	(15,011,643)
Total Clinical Operations Expenses	1,449,730,084	741,603,118	708,126,966	51%	699,990,571	(41,612,547)
Net Clinical Operations Revenue/(Expense)	1,501,173 (1)	2,256,762 (2)	755,589		654,801	1,601,961
Contingencies						
Total Contingency Revenues	-	-	-	N/A	-	-
Total Contingency Expenses	-	-	-	N/A	-	-
Net Contingencies Revenue/(Expense)	-	-	-		-	-
Net Current Revenue/(Expense)	42,329	6,082,052	6,039,723		2,557,558	3,524,494

(1) **OPERATING BUDGET** - Clinical Operations include the SOM Clinical Departments which have a budgeted consolidated net margin of \$1,498,537 and UNM Hospital operations which has a budgeted net margin of \$2,636

(2) **ACTUAL** - Clinical Operations include the SOM Clinical Departments which currently have a consolidated net margin of \$(30,282) and UNM Hospitals operations currently has a net margin of \$2,287,044

Statements of Revenues, Expenses and Changes in Net Assets - UNM Regents Format
For the six month period ended December 31 , 2018
Preliminary and Unaudited

Detail of State/Local Appropriations
Consolidated - Total Operations Current Funds

	FY 2019 Full Year Adopted Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%
Instruction and General				
Instruction & General Appropriations	261,197,400	130,586,450	(130,610,950)	50%
State Special Project Appropriations	1,149,400	574,700	(574,700)	50%
Tobacco Settlement Appropriations	1,081,500	540,756	(540,744)	50%
Mill Levy	8,738,425	4,369,213	(4,369,212)	50%
Total Instruction and General Appropriations	<u>272,166,725</u>	<u>136,071,119</u>	<u>(136,095,606)</u>	<u>50%</u>
Research				
State Special Project Appropriations	6,526,550	3,263,225	(3,263,325)	50%
Tobacco Settlement Appropriations	937,400	468,693	(468,707)	50%
Cigarette Tax Appropriations	3,913,975	2,090,152	(1,823,823)	53%
Total Research Appropriations	<u>11,377,925</u>	<u>5,822,070</u>	<u>(5,555,855)</u>	<u>51%</u>
Public Service				
State Special Project Appropriations	3,484,050	1,742,025	(1,742,025)	50%
Total Public Service Appropriations	<u>3,484,050</u>	<u>1,742,025</u>	<u>(1,742,025)</u>	<u>50%</u>
Clinical Operations				
State Special Project Appropriations	25,689,800	12,844,000	(12,845,800)	50%
Tobacco Settlement Appropriations	840,200	420,104	(420,096)	50%
Total Clinical Operations Appropriations	<u>26,530,000</u>	<u>13,264,104</u>	<u>(13,265,896)</u>	<u>50%</u>

Statements of Revenues, Expenses and Changes in Net Assets - UNM Regents Format
For the six month period ended December 31 , 2018
Preliminary and Unaudited

Detail of State/Local Appropriations
Main Campus - Total Operations Current Funds

	FY 2019 Full Year Adopted Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%
Instruction and General				
Instruction & General Appropriations	182,286,800	91,143,400	(91,143,400)	50%
State Special Project Appropriations				
African American Student Services	67,700	33,850	(33,850)	50%
Degree Mapping	70,400	35,200	(35,200)	50%
Disabled Student Services	178,700	89,350	(89,350)	50%
ENLACE	59,600	29,800	(29,800)	50%
Hispanic Student Center	146,300	73,150	(73,150)	50%
Minority Graduate Recruitment	110,100	55,050	(55,050)	50%
Native American Studies Intervention	332,700	166,350	(166,350)	50%
Pre-College Minority Student Math &Science	183,900	91,950	(91,950)	50%
Total State Special Project Appropriations	1,149,400	574,700	(574,700)	50%
Total Instruction and General Appropriations	183,436,200	91,718,100	(91,718,100)	50%
Research				
State Special Project Appropriations				
Center for Regional Studies (SW Research Ctr)	921,150	460,575	(460,575)	50%
Manufacturing Engineering	523,100	261,550	(261,550)	50%
Morrissey Hall	103,600	51,800	(51,800)	50%
Resource Geographic Information System	61,700	30,850	(30,850)	50%
Utton Transboundary Resource Center	321,900	160,950	(160,950)	50%
Total State Special Project Appropriations	1,931,450	965,725	(965,725)	50%
Total Research Appropriations	1,931,450	965,725	(965,725)	50%
Public Service				
State Special Project Appropriations				
Bureau of Business Research (Census)	360,200	180,100	(180,100)	50%
College Prep Mentoring/School of Law	112,800	56,400	(56,400)	50%
College Preparatory Mentoring	160,400	80,200	(80,200)	50%
Corrine Wolfe Law Center/Child Abuse Training	160,000	80,000	(80,000)	50%
Family Development Program	530,200	265,100	(265,100)	50%
ISTEC	44,900	22,450	(22,450)	50%
Judicial Selection	21,400	10,700	(10,700)	50%
KNME-TV	1,092,300	546,150	(546,150)	50%
Land Grant Studies Program	122,100	61,050	(61,050)	50%
N. M. Historical Review	44,600	22,300	(22,300)	50%
SFAO / Student Activities Administration	50,000	25,000	(25,000)	50%
Southwest Indian Law Clinic	193,000	96,500	(96,500)	50%
Spanish Colonial Research Center (SW Research Ctr)	138,650	69,325	(69,325)	50%
Spanish Resource Center	38,800	19,400	(19,400)	50%
Substance Abuse Program	69,000	34,500	(34,500)	50%
Wildlife Law Education	90,000	45,000	(45,000)	50%
Total State Special Project Appropriations	3,228,350	1,614,175	(1,614,175)	50%
Total Public Service Appropriations	3,228,350	1,614,175	(1,614,175)	50%

Statements of Revenues, Expenses and Changes in Net Assets - UNM Regents Format
For the six month period ended December 31 , 2018
Preliminary and Unaudited

Detail of State/Local Appropriations

Branch Campuses - Total Operations Current Funds

	FY 2019 Full Year Adopted Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%
Instruction and General				
Instruction & General Appropriations				
Gallup	8,878,300	4,439,150	(4,439,150)	50%
Los Alamos	1,757,000	878,500	(878,500)	50%
Valencia	5,465,500	2,732,750	(2,732,750)	50%
Taos	3,634,400	1,817,200	(1,817,200)	50%
Total Instruction & General Appropriations	19,735,200	9,867,600	(9,867,600)	50%
Mill Levy				
McKinley County	2,488,400	1,244,200	(1,244,200)	50%
Los Alamos County	1,424,000	712,000	(712,000)	50%
Valencia County	2,818,183	1,409,092	(1,409,091)	50%
Taos County	2,007,842	1,003,921	(1,003,921)	50%
Total Mill Levy	8,738,425	4,369,213	(4,369,212)	50%
Total Branch Appropriations	28,473,625	14,236,813	(14,236,812)	50%

Statements of Revenues, Expenses and Changes in Net Assets - UNM Regents Format
For the six month period ended December 31 , 2018
Preliminary and Unaudited

Detail of State/Local Appropriations

Health Sciences Center - Total Operations Current Funds

	FY 2019 Full Year Adopted Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%
Instruction and General				
Instruction & General Appropriations	59,175,400	29,575,450	(29,599,950)	50%
Tobacco Settlement Appropriations				
Instruction & General	581,500	290,756	(290,744)	50%
Pediatric Specialty Education	250,000	125,000	(125,000)	50%
Trauma Specialty Education	250,000	125,000	(125,000)	50%
Total Tobacco Settlement Appropriations	1,081,500	540,756	(540,744)	50%
Total Instruction and General Appropriations	60,256,900	30,116,206	(30,140,694)	50%
Research				
State Special Project Appropriations				
Cancer Center	2,549,000	1,274,450	(1,274,550)	50%
Hepatitis C, Project ECHO	2,046,100	1,023,050	(1,023,050)	50%
Total State Special Project Appropriations	4,595,100	2,297,500	(2,297,600)	50%
Tobacco Settlement Appropriations				
Genomics, Biocomputing, Environmental Health	937,400	468,693	(468,707)	50%
Total Tobacco Settlement Appropriations	937,400	468,693	(468,707)	50%
Cigarette Tax Revenues	3,913,975	2,090,152	(1,823,823)	53%
Total Research Appropriations	9,446,475	4,856,345	(4,590,130)	51%
Public Service				
State Special Project Appropriations				
Center for Native American Health	255,700	127,850	(127,850)	50%
Total State Special Project Appropriations	255,700	127,850	(127,850)	50%
Total Public Service Appropriations	255,700	127,850	(127,850)	50%
Clinical Operations				
State Special Project Appropriations				
Newborn Intensive Care Unit	3,145,800	1,572,250	(1,573,550)	50%
Office of the Medical Investigator	5,313,400	2,656,900	(2,656,500)	50%
Pediatric Oncology	1,220,900	610,300	(610,600)	50%
Poison and Drug Info Center	1,493,000	746,200	(746,800)	50%
Native American Suicide Prevention	92,800	46,500	(46,300)	50%
GME Residencies	1,690,700	845,250	(845,450)	50%
UNM Hospitals	12,733,200	6,366,600	(6,366,600)	50%
Total State Special Project Appropriations	25,689,800	12,844,000	(12,845,800)	50%
Tobacco Settlement Appropriations				
Pediatric Oncology	250,000	125,002	(124,998)	50%
Poison and Drug Info Center	590,200	295,102	(295,098)	50%
Total Tobacco Settlement Appropriations	840,200	420,104	(420,096)	50%
Total Clinical Operations Appropriations	26,530,000	13,264,104	(13,265,896)	50%

FY19 UNM Debt Service Schedule

As of December 31, 2018

*UNMH/SRMC Debt

UNM Bond Issue	Original Issue Amount	Outstanding Principal Balance on June 30, 2018	Principal Payment due on June 1, 2019	Interest Payment paid on December 1, 2018	Interest Payment due on June 1, 2019	FY 2019 Principal & Interest
Sub Lien System Improvement Revenue Bonds, Series 2017 ⁽⁷⁾ Series 2017: Interest Range 3.25% to 5.0% Final Maturity Year 2047	\$40,900,000	\$40,585,000	\$875,000	\$991,644	\$991,644	\$2,658,288
Sub Lien System Rfdg Revenue & Improvement Bonds ⁽⁷⁾ Series 2016 A: Interest Range 2.0% to 4.5% Final Maturity Year 2046	\$160,290,000	\$156,445,000	\$1,030,000	\$3,089,950	\$3,089,950	\$7,209,900
Sub Lien System Rfdg Revenue Bonds ⁽⁸⁾ Series 2016 B: Interest Range .72% to 2.48% Final Maturity Year 2024	\$8,215,000	\$6,955,000	\$925,000	\$71,017	\$71,017	\$1,067,033
⁽¹⁾ FHA Insured Hopsital Mortgage Revenue Bonds* Series 2015: Interest Range .484% to 3.532% Final Maturity Year 2032	\$115,000,000	\$97,820,000	\$5,700,000 (due 6/20/2019)	\$1,520,012 (due 12/20/2018)	\$1,520,012 (due 6/20/2019)	\$8,740,023
Sub Lien System Imp Revenue Bonds ⁽⁴⁾ Series 2014 A: Interest Range 3.0% to 5.0% Final Maturity Year 2033	\$10,980,000	\$3,695,000	\$0	\$126,813	\$126,813	\$253,625
Sub Lien System Rfdg Revenue Bonds ⁽⁵⁾ Series 2014 B: Interest Range 0.496% to 3.280% Final Maturity Year 2024	\$3,710,000	\$2,265,000	\$380,000	\$31,402	\$31,402	\$442,803
Sub Lien System Rfdg Revenue Bonds ⁽⁶⁾ Series 2014 C: Interest Range 1.5% to 5.0% Final Maturity Year 2035	\$100,085,000	\$92,265,000	\$2,830,000	\$2,306,625	\$2,306,625	\$7,443,250
Sub Lien System Imp Revenue Bonds ⁽³⁾ Series 2012: Interest Range 2.0% to 5.0% Final Maturity Year 2032	\$35,215,000	\$26,190,000	\$1,600,000	\$620,650	\$620,650	\$2,841,300
Taxable Revenue Build America Bonds* Series 2010A: w/ fixed-interest rate of 4.5% Final Maturity Year 2036	\$133,425,000	\$111,505,000	\$3,890,000 (due in July & Jan)	\$2,487,262 (due in July & Jan)	\$2,487,263 (due in July & Jan)	\$8,864,525
Taxable Revenue Recovery Zone Economic Development Bonds* Series 2010B: w/ fixed-interest rate of 5.0% Final Maturity Year 2037	\$10,000,000	\$9,740,000	\$0	\$243,500 (due in July & Jan)	\$243,500 (due in July & Jan)	\$487,000
Sub Lien System Imp Revenue Bonds (portion refunded 03/08/2016) Series 2007 A&B: Interest Range 4.096% to 5.302% Final Maturity Year 2036	\$7,010,000	\$1,490,000	\$1,490,000	\$29,800	\$29,800	\$1,549,600
Sub Lien Sys Rfdg Revenue Bonds ⁽²⁾ Series 2002 B: Variable Rate Demand Bonds - rates reset weekly Weekly rate as of June 30, 2014 was 0.05% Final Maturity Year 2026	\$25,475,000	\$14,805,000	\$1,400,000	\$283,516	\$283,516	\$1,967,032
Sub Lien System Rfdg Revenue Bonds ⁽²⁾ Series 2002 C: Variable Rate Demand Bonds - rates reset weekly Weekly rate as of June 30, 2014 was 0.05% Final Maturity Year 2030	\$37,840,000	\$30,445,000	\$1,600,000	\$599,767	\$599,767	\$2,799,533
Sub Lien System Imp Revenue Bonds ⁽²⁾ Series 2001: Variable Rate Demand Bonds - rates reset weekly Weekly rate as of June 30, 2014 was 0.07% Ceiling of 12% Final Maturity Year 2026	\$52,625,000	\$23,925,000	\$2,570,000	\$478,500	\$478,500	\$3,527,000
System Revenue Bonds Series 2000 B: Interest Range 5.50% to 6.35% Final Maturity Year 2019	\$6,621,671	\$181,811	\$181,811	\$0	\$428,190	\$610,001
System Revenue Rfdg Bonds Series 1992 A: Interest Range 6.0% to 6.25% Final Maturity Year 2021	\$36,790,000	\$7,090,000	\$3,970,000	\$212,700	\$212,700	\$4,395,400
Grand Total	\$784,181,671	\$625,401,811	\$28,241,811	\$13,093,155	\$13,521,346	\$54,856,312

Note: See attached matrix for funding sources.

(1) Source: UNM Hospital - UNM Hospital Principal payment is due on June 20; interest payments are due on December 20 and June 20.

(2) Variable Rate bonds reflect the actual synthetically fixed interest rate that UNM pays. It is noted that all ranges of interest rates and final maturity dates are reflective of Serial bonds.

(3) Series 2012 bonds refunded 2002A bonds.

(4) Series 2014A bonds refunded 2003A, 2003B bonds.

(5) Series 2014B bonds refunded 2003C bonds.

(6) Series 2014C bonds refunded 2005A bonds.

(7) Series 2016A bonds refunded a portion of 2007A bonds, March 2016

(8) Series 2016B bonds refunded a portion of 2007B bonds, March 2016

FY19 UNM Debt Service - Source of Funds

As of December 31, 2018

	Series 2017	Series 2016A	Series 2016B	Series 2015 (UNMH Bond)	Series 2014A	Series 2014B	Series 2014C	Series 2012	Series 2010A	Series 2010B	Series 2007A&B	Series 2002B	Series 2002C	Series 2001	Series 2000B	Series 1992
Student Fees- Facility	X	X		X		X	X			X	X	X		X	X	
Student Fees - IT						X	X									
Parking Services		X				X	X			X						X
UNM Hospital			X								X					X
SRMC Teaching Hospital Project								X	X							
Bookstore				X												X
Housing & Dining Services				X			X					X		X		
Building R&R				X							X					X
Real Estate Department		X		X	X					X	X					
Physical Plant Department		X				X	X			X	X		X			
Information Technologies						X	X									
Athletics		X	X							X						
KNME																X
Opto Bldg (CHTM Res Park)											X					
CRTC											X					
Continuing Education											X					
Golf Course - North & South												X		X		
HSC		X					X			X						
Interest on Reserve Funds				X			X				X	X				
Student Health and Counseling (SHAC)	X															

UNM Health Sciences Center

Monthly Financial Report

Total Operations – Current Funds

Fiscal Year to Date as of December 31, 2018



HEALTH
SCIENCES

TABLE OF CONTENTS

Executive Summary – BUDGETARY BASIS Format	1-2
Total Operations Current Funds	3-5
State Appropriations Schedule	6
Other Revenue and Expense Analysis	7-12
Executive Summary – GASB Format	13-14
Integrated Financial Statements	15-20
Integrated Financial Statements – Glossary of Report Terms	21-23
Metrics	24-33



HEALTH
SCIENCES

UNM Health Sciences Center

Executive Summary – BUDGETARY BASIS FORMAT

The following financial statements for the UNM Health Sciences Center are presented in accordance with the Budgetary Basis of Reporting as submitted to the New Mexico Higher Education Department. The Statements of Revenues, Expenses and Changes in Net Position are presented for two (2) entities: UNM HSC Academic Enterprise and UNM Hospitals in a consolidated format.

The total UNM Health Sciences Center net margin was \$6.1M as of December 31, 2018 compared to \$2.6M as of December 31, 2017. The UNM HSC Academic Enterprise net margin is \$3.8M as of December 31, 2018. The net margin for UNM Hospitals through December 31, 2018 is \$2.287M.

Instruction & General (I&G)

The net margin for I&G for FY 2019 year to date is \$609K. There is a lag in non-salary expenses year to date versus the budget and F&A Revenues are up as compared to budget.

Research

The HSC Research operation has a net margin of \$665K as of 12/31/18. The UNM Comprehensive Cancer Center has received some large gifts to be used for research. A full year of Cost Share transfers have already been booked for the year. The Operating Budget reflects a use of reserves for non-recurring expenditures that includes CTSC Scholar startup packages, equipment purchases and research supplies.

UNM Health Sciences Center

Executive Summary – BUDGETARY BASIS FORMAT cont...

Public Service

Public Service had a net margin of \$1.9M as of December 31, 2018. There was \$1.4M of gift revenue from DCi (Dialysis Clinic Inc.) recorded in November.

Student Aid

The net margin is \$606K as of December 2018.

Clinical Operations

The School of Medicine (SOM) Clinical Departments have an unfavorable net margin of \$(30K) as of December 31, 2018 and UNM Hospitals currently has a net margin of \$2.287M for a combined net margin of \$2.3M. At UNM Hospitals, in December, there were 2 fewer clinic days as compared to November. The fewer days during the month, along with a tendency for patients to avoid elective procedures during the Holidays, led to lower outpatient volumes. These lower volumes were offset by adjustments made as a result of cash collections on aged accounts that had previously been written down. December expenses were consistent with expectations for the month and the Hospital was able to increase the positive margin for the month and year to date.

Statements of Revenues, Expenses and Changes in Net Position Format for Regents
For the six month period ended December 31, 2018
Preliminary and Unaudited

Health Sciences Center - Total Operations Current Funds

	FY 2019 Full Year Operating Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%	FY 2018 Year-to-Date Actual	FY 2019 YTD Actual Change From FY 2018 YTD Actual
Instruction and General						
Tuition and Fees Revenues	18,634,587	8,529,184	(10,105,403)	46%	8,655,825	(126,641)
State/Local Appropriations	60,256,900	30,116,206	(30,140,694)	50%	29,606,054	510,152
F & A Revenues	25,000,000	12,700,673	(12,299,327)	51%	12,941,526	(240,853)
Transfers	9,433,666	3,990,833	(5,442,833)	42%	3,656,234	334,599
Other Revenues	4,198,425	2,073,025	(2,125,400)	49%	2,026,504	46,521
Total Instruction and General Revenues	117,523,578	57,409,921	(60,113,657)	49%	56,886,143	523,778
Salaries	75,934,032	37,030,004	(38,904,028)	49%	36,734,303	(295,701)
Benefits	22,865,088	11,293,370	(11,571,718)	49%	11,403,711	110,341
Other Expenses	19,365,032	8,477,680	(10,887,352)	44%	8,821,409	343,729
Total Instruction and General Expenses	118,164,152	56,801,054	(61,363,098)	48%	56,959,423	158,369
Net Instruction and General Revenue/(Expense)	(640,574)	608,867	1,249,441		(73,280)	682,147
Research						
State/Local Appropriations	9,446,475	4,856,345	(4,590,130)	51%	5,050,160	(193,815)
Generated Revenues	388,221	73,489	(314,732)	19%	212,243	(138,754)
Transfers	15,793,498	4,074,132	(11,719,366)	26%	4,907,975	(833,843)
Other Revenues	1,034,107	2,404,341	1,370,234	233%	271,852	2,132,489
Total Research Revenues	26,662,301	11,408,307	(15,253,994)	43%	10,442,230	966,077
Salaries and Benefits	15,231,343	6,376,870	(8,854,473)	42%	6,822,518	445,648
Other Expenses	12,559,867	4,366,894	(8,192,973)	35%	4,272,882	(94,012)
Total Research Expenses	27,791,210	10,743,764	(17,047,446)	39%	11,095,400	351,636
Net Research Revenue/(Expense)	(1,128,909)	664,543	1,793,452		(653,170)	1,317,713
Public Service						
State/Local Appropriations	255,700	127,850	(127,850)	50%	126,000	1,850
Sales and Services Revenues	15,926,604	7,542,617	(8,383,987)	47%	7,913,273	(370,656)
Gifts	2,870,748	2,536,195	(334,553)	88%	3,542,116	(1,005,921)
Transfers	(4,567,328)	(3,400,144)	1,167,184	74%	(1,477,120)	(1,923,024)
Other Revenues	2,180,579	382,213	(1,798,366)	18%	306,086	76,127
Total Public Service Revenues	16,666,303	7,188,731	(9,477,572)	43%	10,410,355	(3,221,624)
Salaries and Benefits	7,848,772	2,215,349	(5,633,423)	28%	4,682,570	2,467,221
Other Expenses	8,397,776	3,039,046	(5,358,730)	36%	3,155,289	116,243
Total Public Service Expenses	16,246,548	5,254,395	(10,992,153)	32%	7,837,859	2,583,464
Net Public Service Revenue/(Expense)	419,755	1,934,336	1,514,581		2,572,496	(638,160)

Statements of Revenues, Expenses and Changes in Net Position Format for Regents
For the six month period ended December 31, 2018
Preliminary and Unaudited

Health Sciences Center - Total Operations Current Funds

	FY 2019 Full Year Operating Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%	FY 2018 Year-to-Date Actual	FY 2019 YTD Actual Change From FY 2018 YTD Actual
Student Aid						
Gifts	1,997,389	995,673	(1,001,716)	50%	1,010,001	(14,328)
Investment Income	-	-	-	N/A	-	-
Transfers	2,126,022	1,197,184	(928,838)	56%	468,460	728,724
Other Revenues	-	40	40	N/A	-	40
Total Student Aid Revenues	4,123,411	2,192,897	(1,930,514)	53%	1,478,461	714,436
Salaries and Benefits	1,533,082	841,042	(692,040)	55%	768,995	(72,047)
Other Expenses	2,695,624	745,661	(1,949,963)	28%	664,194	(81,467)
Total Student Aid Expenses	4,228,706	1,586,703	(2,642,003)	38%	1,433,189	(153,514)
Net Student Aid Revenue/(Expense)	(105,295)	606,194	711,489		45,272	560,922
Student Activities						
Fee Revenues	-	-	-	N/A	-	-
Sales and Services Revenues	55,943	34,628	(21,315)	62%	31,363	3,265
Transfers	1,422	1,422	-	100%	264	1,158
Other Revenues	-	50	50	N/A	-	50
Total Student Activities Revenues	57,365	36,100	(21,265)	63%	31,627	4,473
Salaries and Benefits	-	-	-	N/A	-	-
Other Expenses	61,186	24,750	(36,436)	40%	20,188	(4,562)
Total Student Activities Expenses	61,186	24,750	(36,436)	40%	20,188	(4,562)
Net Student Activities Revenue/(Expense)	(3,821)	11,350	15,171		11,439	(89)
Sponsored Programs						
Federal Grants and Contracts Revenues	122,514,828	48,965,590	(73,549,238)	40%	50,906,047	(1,940,457)
State and Local Grants and Contracts Revenues	18,461,138	7,555,086	(10,906,052)	41%	7,872,951	(317,865)
Non-Governmental Grants and Contracts Revenues	26,852,565	10,709,817	(16,142,748)	40%	11,072,763	(362,946)
Gifts	-	-	-	N/A	-	-
Other Revenues	-	-	-	N/A	-	-
Transfers	1,964,504	1,646,715	(317,789)	84%	2,491,464	(844,749)
Total Sponsored Programs Revenues	169,793,035	68,877,208	(100,915,827)	41%	72,343,225	(3,466,017)
Salaries and Benefits	93,386,169	39,748,559	(53,637,610)	43%	40,834,160	1,085,601
Other Expenses	76,406,866	29,128,649	(47,278,217)	38%	31,509,065	2,380,416
Total Sponsored Programs Expenses	169,793,035	68,877,208	(100,915,827)	41%	72,343,225	3,466,017
Net Sponsored Programs Revenue/(Expense)	-	-	-		-	-

Statements of Revenues, Expenses and Changes in Net Position Format for Regents
For the six month period ended December 31, 2018
Preliminary and Unaudited

Health Sciences Center - Total Operations Current Funds

	FY 2019 Full Year Operating Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%	FY 2018 Year-to-Date Actual	FY 2019 YTD Actual Change From FY 2018 YTD Actual
Clinical Operations						
State/Local Appropriations	26,530,000	13,264,104	(13,265,896)	50%	12,528,746	735,358
Physician Professional Fee Revenues	133,242,851	63,561,813	(69,681,038)	48%	61,711,612	1,850,201
Hospital Facility Revenues	939,105,744	477,571,591	(461,534,153)	51%	462,644,392	14,927,199
Other Patient Revenues, net of Allowance	173,015,985	86,410,496	(86,605,489)	50%	78,599,112	7,811,384
Mil Levy	100,269,401	50,134,700	(50,134,701)	50%	49,138,317	996,383
Investment Income	(82,916)	880,090	963,006	-1061%	96,328	783,762
Gifts	3,138,141	1,239,432	(1,898,709)	39%	1,026,852	212,580
Housestaff Revenues	37,950,860	19,766,533	(18,184,327)	52%	18,764,519	1,002,014
Transfers	(6,525,332)	(373,702)	6,151,630	6%	(3,543,709)	3,170,007
Other Revenues	44,586,523	31,404,823	(13,181,700)	70%	19,679,203	11,725,620
Total Clinical Operations Revenues	1,451,231,257	743,859,880	(707,371,377)	51%	700,645,372	43,214,508
Salaries and Benefits	809,851,210	410,796,065	(399,055,145)	51%	384,718,875	(26,077,190)
Interest Expense	3,799,848	1,899,924	(1,899,924)	50%	1,897,124	(2,800)
Housestaff Expenses	37,950,860	19,180,299	(18,770,561)	51%	18,659,385	(520,914)
Other Expenses	598,128,166	309,726,830	(288,401,336)	52%	294,715,187	(15,011,643)
Total Clinical Operations Expenses	1,449,730,084	741,603,118	(708,126,966)	51%	699,990,571	(41,612,547)
Net Clinical Operations Revenue/(Expense)	1,501,173 (1)	2,256,762 (2)	755,589		654,801	1,601,961
Contingencies						
Total Contingency Revenues	-	-	-	N/A	-	-
Total Contingency Expenses	-	-	-	N/A	-	-
Net Contingencies Revenue/(Expense)	-	-	-		-	-
Net Current Revenue/(Expense)	42,329	6,082,052	6,039,723		2,557,558	3,524,494

(1) **OPERATING BUDGET** - Clinical Operations include the SOM Clinical Departments which have a budgeted consolidated net margin of \$1,498,537 and UNM Hospitals operations which has a budgeted net margin of \$2,636

(2) **ACTUAL** - Clinical Operations include the SOM Clinical Departments which currently have a consolidated net margin of \$(30,282) and UNM Hospitals operations which currently has a net margin of \$2,287,044

Statements of Revenues, Expenses and Changes in Net Position Format for Regents
For the six month ended period December 31, 2018
Preliminary and Unaudited

Detail of State/Local Appropriations
Health Sciences Center - Total Operations Current Funds

	FY 2019 Full Year Operating Budget	FY 2019 Year-to-Date Actual	Fiscal YTD Favrb/(Unfavrb) Budget	Actual to Budget Benchmark Rate 50%
Instruction and General				
Instruction & General Appropriations	59,175,400	29,575,450	(29,599,950)	50%
Tobacco Settlement Appropriations				
Instruction & General	581,500	290,756	(290,744)	50%
Pediatric Specialty Education	250,000	125,000	(125,000)	50%
Trauma Specialty Education	250,000	125,000	(125,000)	50%
Total Tobacco Settlement Appropriations	1,081,500	540,756	(540,744)	50%
Total Instruction and General Appropriations	60,256,900	30,116,206	(30,140,694)	50%
Research				
State Special Project Appropriations				
Cancer Center	2,549,000	1,274,450	(1,274,550)	50%
Hepatitis C, Project ECHO	2,046,100	1,023,050	(1,023,050)	50%
Total State Special Project Appropriations	4,595,100	2,297,500	(2,297,600)	50%
Tobacco Settlement Appropriations				
Genomics, Biocomputing, Environmental Health	937,400	468,693	(468,707)	50%
Total Tobacco Settlement Appropriations	937,400	468,693	(468,707)	50%
Cigarette Tax Revenues	3,913,975	2,090,152	(1,823,823)	53%
Total Research Appropriations	9,446,475	4,856,345	(4,590,130)	51%
Public Service				
State Special Project Appropriations				
Center for Native American Health	255,700	127,850	(127,850)	50%
Total State Special Project Appropriations	255,700	127,850	(127,850)	50%
Total Public Service Appropriations	255,700	127,850	(127,850)	50%
Clinical Operations				
State Special Project Appropriations				
Newborn Intensive Care Unit	3,145,800	1,572,250	(1,573,550)	50%
Office of the Medical Investigator	5,313,400	2,656,900	(2,656,500)	50%
Pediatric Oncology	1,220,900	610,300	(610,600)	50%
Poison and Drug Info Center	1,493,000	746,200	(746,800)	50%
Native American Suicide Prevention	92,800	46,500	(46,300)	50%
GME Residencies	1,690,700	845,250	(845,450)	50%
UNM Hospitals	12,733,200	6,366,600	(6,366,600)	50%
Total State Special Project Appropriations	25,689,800	12,844,000	(12,845,800)	50%
Tobacco Settlement Appropriations				
Pediatric Oncology	250,000	125,002	(124,998)	50%
Poison and Drug Info Center	590,200	295,102	(295,098)	50%
Total Tobacco Settlement Appropriations	840,200	420,104	(420,096)	50%
Total Clinical Operations Appropriations	26,530,000	13,264,104	(13,265,896)	50%

Regent's Report Analysis for Ava Lovell			
December 31, 2018			
* I&G Other Revenue Actuals Detail	12/31/2018	12/31/2017	Variance
Misc. Revenue	29,627.50	4,970.57	24,656.93
Faculty Practice Income	1,644,294.00	1,644,294.00	-
Billings to UH - Custodial & Nursing Deans Teaching Support	101,016.55	80,951.90	20,064.65
Billings to SRMC	-	-	-
Billings to UNMMG (Library Collections, Legal Counsel, etc.)	75,750.00	75,000.00	750.00
Sales & Services (Custodial Services, PPD Lock Shop, PPD Landscaping, etc.)	222,336.45	221,287.56	1,048.89
TOTAL	2,073,024.50	2,026,504.03	46,520.47
* I&G Other Expense Actuals Detail	12/31/2018	12/31/2017	Variance
Capital Expenditures	519,027.76	622,723.45	(103,695.69)
Communication Charges	180,788.74	179,356.47	1,432.27
Bad Debt Expense	7,833.06	4,513.02	3,320.04
Other Expenses	(527,584.91)	(783,998.19)	256,413.28
Patient Care Costs	41,380.42	29,790.55	11,589.87
Plant Maintenance	635,846.53	434,124.66	201,721.87
Research Costs	83,536.50	69,904.21	13,632.29
Purchased Services	2,673,587.92	3,026,192.01	(352,604.09)
Special Grant & Contract Expense	71,806.81	70,663.57	1,143.24
Student Costs	892,320.06	899,581.79	(7,261.73)
Supplies	1,052,638.88	1,168,539.42	(115,900.54)
Travel	200,832.27	192,331.27	8,501.00
Utilities	2,645,665.17	2,907,687.11	(262,021.94)
TOTAL	8,477,679.21	8,821,409.34	(343,730.13)
* I&G Other Expense Actuals Detail - by Org Level 5	12/31/2018	12/31/2017	Variance
Continuing Medical Educ Department	-	686.80	(686.80)
VP Health Sciences Office	51,228.79	21,534.50	29,694.29
Poison Control	-	410.04	(410.04)
HSC Office of Community Affairs	-	-	-
School of Medicine Deans Office	285.74	33,643.38	(33,357.64)
VP HSC Monitoring (General Liability Insurance)	849,730.01	531,707.93	318,022.08
AS BA/MD Program (Scholarships/Fellowships)	499,845.22	420,645.76	79,199.46
SOM Faculty Affairs	191.30	276.25	(84.95)
Family Community Medicine Dept.	115,254.28	100,828.56	14,425.72
Interprofessional Education	1,924.22	275.45	1,648.77
Office of Emergency Management	1,670.62	806.81	863.81
VP for Community Health	10,681.43	21,027.56	(10,346.13)
Batcave	-	199.06	(199.06)
HSC Academic Affairs	(26,254.13)	34,633.93	(60,888.06)
HSC Registrar	7,311.90	3,576.65	3,735.25
Senior Assoc. Dean Office of Educ.	9,588.12	14,119.63	(4,531.51)
Pathology Dept.	34,711.00	7,840.58	26,870.42
HSC Wellness	42,157.23	63,879.05	(21,721.82)
Unrestricted Accounting HSC Office	7,391.77	6,151.96	1,239.81
HSC Professionalism Office	876.08	1,788.14	(912.06)
HSC Financial Aid	-	-	-
CNAH	-	-	-
HSC Faculty Contracts	4,096.59	3,047.52	1,049.07
HSC Faculty Council	-	622.13	(622.13)
HSC Development Office	24,155.80	20,199.98	3,955.82
Inst Indigenous Knowledge & Devl	-	-	-
COP Clinical Affairs	-	3,482.35	(3,482.35)
COP Radiopharmacy	-	-	-
Vice Chancellor for Diversity	148,584.18	86,317.35	62,266.83
COPH Deans Office	77,965.01	52,477.32	25,487.69
HSC Budget Office Monitoring	(690,700.00)	-	(690,700.00)
Exec Vice Chancellor -Operations	127,383.76	-	127,383.76
UNNM HSC West Operations	212,824.02	204,930.71	7,893.31
Exec Vice Chancellor -IT	203,672.18	287,023.29	(83,351.11)
HSC Education Space Scheduling	5,178.79	-	5,178.79

Pharmacy Deans Office (Supplies, Scholarship/Fellowships, Professional Services, etc.)	317,230.62	277,191.69	40,038.93
HSC Financial Services	556.55	801.05	(244.50)
Psychiatry Psych	41.71	934.41	(892.70)
HS Library and Informatics Ctr. (Electronic Journals & Perpetuals)	769,475.85	879,792.18	(110,316.33)
Neurology	77.96	-	77.96
Orthopaedics	155,842.79	108,002.39	47,840.40
Radiology Dept.	2,408.04	7,740.29	(5,332.25)
COP Pharmacy Practice & Admin.	41,752.94	46,588.15	(4,835.21)
SOM Surgery	-	-	-
Undergrad Med Educ Dept. (Curriculum fees, supplies, student costs, etc.)	265,330.69	250,222.64	15,108.05
SOM BA/MD Program	52,090.53	44,555.33	7,535.20
Department of Dental Medicine	93,061.28	78,784.65	14,276.63
COP Pharmaceutical Sciences	15,481.29	55,857.87	(40,376.58)
Emergency Medicine Dept.	13,418.11	1,487.38	11,930.73
Molecular Genetics Microbiology	20,353.14	8,756.63	11,596.51
HSC Facility Planning	439.68	1,013.39	(573.71)
Cell Biology	8,160.12	15,036.38	(6,876.26)
Dermatology	157.35	-	157.35
Nursing Deans Office (Computers, instructional materials, foundation surcharge, etc.)	1,010,149.34	1,035,848.79	(25,699.45)
CTSC Administration	-	-	-
HSC Budget Office	6,653.81	1,956.78	4,697.03
HSC Operation Plant Maintenance (Custodial services & supplies, property insurance, utilities, etc.)	3,541,200.03	3,767,720.99	(226,520.96)
HSC Human Resources	12,229.18	13,497.99	(1,268.81)
Anesthesiology Dept.	-	-	-
HSC Communications (Promotional expenses, etc.)	71,842.80	4.33	71,838.47
Obstetrics Gynecology OB GYN	-	-	-
Biochemistry Molecular Biology	66,222.48	37,195.73	29,026.75
HSC Compliance	20,239.29	6,393.01	13,846.28
Internal Medicine IM	2,198.37	190.49	2,007.88
Sr Exec Officer - Finance & Admin	94,198.51	96,205.86	(2,007.35)
SOM Student Services	11,077.11	6,271.39	4,805.72
HSC Legal Counsel Office	61,354.02	41,188.43	20,165.59
Pre Award Services HSC	7,868.31	7,564.11	304.20
Contract Grant Accounting HSC	10,005.98	11,389.09	(1,383.11)
Neurosciences	29,078.78	40,108.12	(11,029.34)
Biomedical Rsrch Edu Prog	201.61	-	201.61
Pediatrics	57,527.03	56,977.11	549.92
TOTAL	8,477,679.21	8,821,409.34	(343,730.13)
* Research Other Revenue Actuals Detail	12/31/2018	12/31/2017	Variance
Misc. Revenue	17,062.50	51.51	17,010.99
Gifts	1,776,440.22	-	1,776,440.22
Gain on Sponsored Projects	405,293.09	101,218.48	304,074.61
Gain on Unrestricted Projects	-	1,714.10	(1,714.10)
Billings to UH (CRTC Faculty Research Support, CTSC Rent, HSC Radiation Safety, etc.)	201,320.03	160,097.46	41,222.57
Billings to SRMC (HSC Radiation Safety)	4,225.02	4,674.92	(449.90)
Billings to UNMMG (HSC Radiation Safety)	-	4,095.38	(4,095.38)
TOTAL	2,404,340.86	271,851.85	2,132,489.01
* Research Other Expense Actuals Detail	12/31/2018	12/31/2017	Variance
Capital Expenditures	44,423.24	8,075.00	36,348.24
Communication Charges	109,004.29	110,004.70	(1,000.41)
Bad Debt Expense	21,422.00	26,786.00	(5,364.00)
Debt Service	518,750.82	518,417.94	332.88
Other Expenses	299,404.65	298,956.60	448.05
Patient Care Costs	(115.43)	5,723.42	(5,838.85)
Plant Maintenance	497,105.68	626,147.76	(129,042.08)
Research Costs	87,596.65	95,594.95	(7,998.30)
Purchased Services	1,428,818.26	1,399,968.39	28,849.87
Special Grant & Contract Expense	38,192.11	13,236.90	24,955.21
Student Costs	(15,064.12)	31,085.30	(46,149.42)
Supplies	779,679.26	586,856.18	192,823.08

Travel	231,407.76	206,598.98	24,808.78
Utilities	326,268.49	345,429.68	(19,161.19)
TOTAL	4,366,893.66	4,272,881.80	94,011.86
* Research Other Expense Actuals Detail - by Org Level 5	12/31/2018	12/31/2017	Variance
VP Health Sciences Office	663.60	796.92	(133.32)
Poison Control	5,017.19	2,418.08	2,599.11
School of Medicine Deans Office	74,010.78	74,010.78	-
Cancer Research Treatment Center CRTC (Lab supplies, travel, equipment warranties & maint., debt service, etc.)	709,530.18	857,867.73	(148,337.55)
SOM Faculty Affairs	35,166.97	22,234.01	12,932.96
Family Community Medicine Dept.	-	-	-
HSC O/R Administration (Equipment, supplies, etc.)	86,969.13	73,151.17	13,817.96
HSC Radiation Safety	66,473.61	40,903.33	25,570.28
VP for Community Health	-	-	-
Batcave	39,328.21	29,279.90	10,048.31
Senior Assoc. Dean Office of Educ.	904.55	10,436.98	(9,532.43)
Pathology Dept.	67,210.42	34,229.05	32,981.37
The ECHO Institute (Computers, travel, supplies, professional services, etc.)	214,349.50	256,384.03	(42,034.53)
Vice Chancellor for Diversity	-	-	-
COPH Deans Office	16,333.45	11,842.96	4,490.49
Unrestricted Acctg HSC Monitoring	51,442.63	52,078.08	(635.45)
Exec Vice Chancellor-Operations	39,081.63	23,597.52	15,484.11
Brain and Behavioral Hlth Inst	4,231.74	8,656.24	(4,424.50)
Pharmacy Deans Office	31,496.86	16,092.57	15,404.29
AVP FA Monitoring (Top Slice, Plant Repairs, debt service, utilities, etc.)	2,253,970.07	2,218,936.87	35,033.20
Psychiatry Psych	16,157.78	18,327.71	(2,169.93)
HS Library and Informatics Ctr	299.88	1,835.67	(1,535.79)
Neurology	26,634.26	17,804.60	8,829.66
Orthopaedics	32,945.68	55,220.79	(22,275.11)
Radiology Department	-	-	-
COP Pharmacy Practice & Admin Scien	72,433.63	35,553.43	36,880.20
SOM Surgery	-	4,847.78	(4,847.78)
SOM Neurosurgery	2,045.25	-	2,045.25
Undergrad Med Educ Department	31,312.60	19,871.02	11,441.58
COP Pharmaceutical Sciences	124,104.87	66,872.47	57,232.40
Emergency Medicine Dept.	1,051.43	1,525.10	(473.67)
Molecular Genetics Microbiology	42,012.52	17,529.47	24,483.05
Nursing Academic Affairs	-	-	-
Cell Biology	52,718.51	34,162.47	18,556.04
Dermatology	7,222.38	-	7,222.38
Nursing Deans Office	16,174.17	19,981.97	(3,807.80)
CTSC Administration (Lab supplies, office supplies, equipment, etc.)	156,634.99	109,580.45	47,054.54
SR Assoc Deans Office	5,165.13	6,325.97	(1,160.84)
Psychology Dept.	-	-	-
Anesthesiology Department	-	3,158.60	(3,158.60)
Obstetrics Gynecology OB GYN	3,347.30	3,517.41	(170.11)
Biochemistry Molecular Biology	4,064.68	6,863.75	(2,799.07)
Internal Medicine IM	23,355.79	45,105.15	(21,749.36)
Center for Infectious Disease	4,498.90	8,007.11	(3,508.21)
Neurosciences	3,000.00	1,561.28	1,438.72
Biomedical Rsrch Edu Prog	20,823.41	33,751.87	(12,928.46)
Pediatrics	24,709.98	28,561.51	(3,851.53)
TOTAL	4,366,893.66	4,272,881.80	94,011.86
* Public Service Other Revenue Actuals Detail	12/31/2018	12/31/2017	Variance
Student Fees	43,602.84	43,396.68	206.16
Allocations	321,330.35	238,386.24	82,944.11
Gain on Sponsored Projects	30,921.06	38,132.46	(7,211.40)
Gain on Unrestricted Projects	(20,275.48)	(33,753.75)	13,478.27
Misc. Revenue	6,000.00	19,391.00	(13,391.00)
Investment Income	634.10	533.19	100.91
TOTAL	382,212.87	306,085.82	76,127.05

* Public Service Other Expense Actuals Detail	12/31/2018	12/31/2017	Variance
Capital Expenditures	12,996.70	7,499.00	5,497.70
Communication Charges	28,745.00	48,141.39	(19,396.39)
Bad Debt Expense	38,504.50	38,885.56	(381.06)
Debt Service	343,262.52	343,641.48	(378.96)
Other Expenses	114,977.24	25,447.39	89,529.85
Patient Care Costs	65,882.87	49,297.23	16,585.64
Plant Maintenance	85,120.73	134,797.97	(49,677.24)
Research Costs	9,021.95	16,410.38	(7,388.43)
Purchased Services	1,257,630.28	1,124,223.48	133,406.80
Special Grant & Contract Expense	33,346.46	21,210.93	12,135.53
Student Costs	288,179.14	245,362.77	42,816.37
Supplies	560,237.07	833,439.47	(273,202.40)
Travel	105,702.62	164,437.47	(58,734.85)
Utilities	95,439.56	102,495.11	(7,055.55)
TOTAL	3,039,046.64	3,155,289.63	(116,242.99)
* Public Service Other Expenses Actuals Detail - By Org Level 5	12/31/2018	12/31/2017	Variance
HSC Clinical Contracting	1,247.34	323.20	924.14
Continuing Medical Educ Dept. (Various courses & conferences costs, etc.)	134,767.22	470,360.11	(335,592.89)
VP Health Sciences Office	424.53	2,098.79	(1,674.26)
College of Pharmacy Continuing Educ.	5,980.04	4,042.78	1,937.26
Poison Control	-	-	-
School of Medicine Deans Office	83,935.50	27,476.52	56,458.98
VP HSC Monitoring	-	-	-
Cancer Research Treatment Ctr CRTC	131,210.01	150,805.88	(19,595.87)
Family Community Medicine Dept.	1,578.80	1,336.51	242.29
BBI Administration	-	-	-
HSC O/R Administration	7,331.38	3,846.89	3,484.49
VP for Community Health (Pathways - UHP, Care NM, etc.)	461,840.28	321,465.67	140,374.61
HSC Capital Projects	379.02	-	379.02
Senior Assoc. Dean Office of Educ.	3,314.50	4,836.59	(1,522.09)
Pathology Dept.	(1,431.26)	1,387.43	(2,818.69)
The ECHO Institute	339,101.53	140,595.19	198,506.34
CNAH	-	39,192.26	(39,192.26)
Inst Indigenous Knowledge & Devl	-	-	-
COP Clinical Affairs	-	-	-
Vice Chancellor for Diversity	70,318.12	63,908.72	6,409.40
EVC Education	-	-	-
COPH Deans Office	4,367.27	4,346.64	20.63
Unrestricted Acctg HSC Monitoring	2.32	325,767.33	(325,765.01)
Office of the Medical Investigator	-	-	-
Exec Vice Chancellor-Operations	170,244.76	19,547.11	150,697.65
Exec Vice Chancellor-IT	259.86	1,816.24	(1,556.38)
Pharmacy Deans Office	97,573.15	77,617.28	19,955.87
Psychiatry Psych	8,831.09	5,224.23	3,606.86
HS Library and Informatics Ctr.	4,266.19	1,320.91	2,945.28
Neurology	14,213.83	2,945.43	11,268.40
Orthopaedics	10,929.87	14,275.23	(3,345.36)
COP Pharmacy Practice & Admin.	-	30,183.03	(30,183.03)
Radiology	3,742.39	-	3,742.39
SOM Surgery	9,212.59	10,228.35	(1,015.76)
SOM Neurosurgery	12,441.73	14,571.47	(2,129.74)
Undergrad Med Educ Dept.	465.52	4,720.54	(4,255.02)
Department of Dental Medicine	18,784.33	24,900.83	(6,116.50)
COP Pharmaceutical Sciences	46,222.46	1,579.29	44,643.17
Molecular Genetics Microbiology	-	50,000.00	(50,000.00)
Emergency Medicine Dept.	138,481.83	135,990.26	2,491.57
Cell Biology	6,633.83	14,959.87	(8,326.04)
Dermatology	13,111.07	1,038.80	12,072.27
Nursing Deans Office	81,922.76	98,506.66	(16,583.90)
HSC Budget Office (1650 Utilities, Debt Service for 1650 University & Elks Lodge)	455,321.08	457,925.13	(2,604.05)
SR Assoc Deans Office	-	-	-
SOM Institute for Ethics	-	109.11	(109.11)
Anesthesiology Dept.	1,106.68	2,603.43	(1,496.75)

HSC Communications (HSC Radio/TV Promotions, HSC Cancer Center Promotions, etc.)	514,169.38	218,776.95	295,392.43
Obstetrics Gynecology OB/GYN	2,029.15	442.25	1,586.90
Biochemistry Molecular Biology	-	70,000.00	(70,000.00)
Internal Medicine IM	5,632.68	14,556.11	(8,923.43)
Sr Exec Officer - Finance & Admin	77,616.16	5,018.76	72,597.40
SOM Student Services	57,337.44	151,462.08	(94,124.64)
Neurosciences	918.57	43.34	875.23
Pediatrics	43,211.64	163,136.43	(119,924.79)
TOTAL	3,039,046.64	3,155,289.63	(116,242.99)
* Student Aid Other Expense Actuals Detail	12/31/2018	12/31/2017	Variance
Capital Expenditures	128.90	484.09	(355.19)
Communication Charges	775.00	951.34	(176.34)
Other Expenses	61,850.89	64,855.19	(3,004.30)
Patient Care Costs	80.00	6,379.00	(6,299.00)
Plant Maintenance	11,088.22	11,077.37	10.85
Research Costs	67,484.47	78,484.68	(11,000.21)
Purchased Services	31,009.20	31,593.17	(583.97)
Special Grant Contract Expense	-	-	-
Student Costs	407,879.49	292,007.33	115,872.16
Supplies	141,929.08	168,438.18	(26,509.10)
Travel	23,435.58	9,923.57	13,512.01
TOTAL	745,660.83	664,193.92	81,466.91
* Student Aid Other Expenses Actuals Detail - By Org Level 5	12/31/2018	12/31/2017	Variance
School of Medicine Dean's Office	22,190.00	27,717.03	(5,527.03)
VP HSC Monitoring	127,038.00	86,059.37	40,978.63
Cancer Research Treatment Ctr CRTC	114,869.92	141,538.28	(26,668.36)
SOM Monitoring	-	-	-
Family Community Medicine Dept.	6,684.80	1,012.82	5,671.98
HSC O/R Administration	1,906.76	-	1,906.76
VP for Community Health	-	-	-
Pathology Department	10,632.75	21,766.68	(11,133.93)
Vice Chancellor for Diversity	10,000.00	5,692.48	4,307.52
Unrestricted Acctg HSC Monitoring	53,232.84	58,574.39	(5,341.55)
General Clinical Research Ctr GCRC	1,278.54	1,316.16	(37.62)
Pharmacy Deans Office	17,382.88	9,500.00	7,882.88
Psychiatry Psych	10,079.30	5,082.32	4,996.98
Scholarships Foundation Funds	-	-	-
HS Library and Informatics Ctr	130.18	488.91	(358.73)
Neurology	(13,932.77)	4.85	(13,937.62)
Orthopaedics	-	-	-
SOM Surgery	-	-	-
SOM Neurosurgery	3,236.52	-	3,236.52
SOM BA/MD Program	-	-	-
Radiology Department	37,967.48	-	37,967.48
Department of Dental Medicine	5,955.99	6,864.09	(908.10)
Emergency Medicine Department	10,203.77	1,241.97	8,961.80
Molecular Genetics Microbiology	5,157.68	5,034.71	122.97
School of Law	125.00	350.00	(225.00)
Cell Biology	872.59	2,467.36	(1,594.77)
Dermatology	12,267.52	3,575.65	8,691.87
Nursing Deans Office	95,618.43	84,272.59	11,345.84
SR ASSOC DEANS OFFICE	-	-	-
SOM Institute for Ethics	-	2,386.75	(2,386.75)
Anesthesiology Department	-	-	-
Obstetrics Gynecology OB GYN	29,327.70	28,405.84	921.86
Biochemistry Molecular Biology	26,226.55	5,523.86	20,702.69
Internal Medicine	9,269.14	8,054.17	1,214.97
SOM Student Services	147,739.15	87,296.00	60,443.15
Neurosciences	171.70	48,986.22	(48,814.52)
Pediatrics	28.41	20,981.42	(20,953.01)
VP Research	-	-	-
TOTAL	745,660.83	664,193.92	81,466.91

* Clinical Operations Other Revenues Actuals Detail	12/31/2018	12/31/2017	Variance
Allocations	(299,315.13)	(222,921.53)	(76,393.60)
Faculty Practice Income	(1,644,294.00)	(1,644,294.00)	-
Grants & Contracts	1,568,312.87	1,188,198.32	380,114.55
Gain on Sponsored Projects	1,051,263.33	790,765.58	260,497.75
Gain on Unrestricted Projects	20,275.48	32,039.65	(11,764.17)
Misc. Revenue	171,073.68	20,313.00	150,760.68
Sales & Services Revenue (COP Radiopharmacy, OMI, CDD Peds - Fit Medicaid Billing, etc.)	3,370,224.17	3,108,913.72	261,310.45
Student Fees	-	-	-
UH- Grants & Contracts	1,422,763.00	1,355,504.00	67,259.00
UH - Other operating revenues	3,259,799.00	3,152,742.00	107,057.00
UH - 340B Revenues	20,742,146.00	11,156,691.00	9,585,455.00
UH - Equity (Loss) in Tricare Invest	1,157,987.00	293,511.00	864,476.00
UH - Other Non operating Revenues	584,588.00	447,740.00	136,848.00
TOTAL	31,404,823.40	19,679,202.74	11,725,620.66
* Clinical Operations Other Expense Actuals Detail	12/31/2018	12/31/2017	Variance
Capital Expenditures	28,472.84	32,493.21	(4,020.37)
Communication Charges	712,000.85	718,652.58	(6,651.73)
Bad Debt Expense	21,846.81	39,130.60	(17,283.79)
Other Expenses (Foundation Surcharge, Banner Tax, etc.)	1,362,900.71	1,524,059.08	(161,158.37)
Patient Care Costs	608,682.47	669,358.63	(60,676.16)
Plant Maintenance	1,686,554.74	1,522,924.32	163,630.42
Research Costs	146,429.36	150,826.84	(4,397.48)
Purchased Services (FY 2019 Cancer Center \$2.0M, OMI \$706K, Peds \$220K, Neurology \$29K and Health System \$21K/ FY 2018 Cancer Center \$1.4M, OMI \$730K, Peds \$123K, Neurology \$233K and Health System \$120K)	7,344,003.27	4,672,837.07	2,671,166.20
Special Grant & Contract Expense	269,762.50	198,177.73	71,584.77
Student Costs	22,047.63	28,888.06	(6,840.43)
Supplies (FY 2019 Cancer Center \$489K, Internal Medicine \$252K, Peds \$170K, Surgery \$129K/ FY 2018 Cancer Center \$664K, Internal Medicine \$342K, Peds \$207K, Surgery \$178K)	3,220,909.21	2,816,636.17	404,273.04
Travel	1,573,573.41	1,425,889.38	147,684.03
Utilities	454,034.36	482,971.25	(28,936.89)
UH- Supplies/Medical Supplies	102,166,854.00	95,958,380.00	6,208,474.00
UH - UCP	44,698,489.00	45,410,555.00	(712,066.00)
UH - Housestaff	15,953,316.00	15,390,006.00	563,310.00
UH - Travel	382,652.00	369,956.00	12,696.00
UH - Patient Care Costs	23,875,674.00	22,788,486.00	1,087,188.00
UH - Telephone/Communication Costs	2,110,374.00	2,011,957.00	98,417.00
UH - Purchased Services	29,830,651.00	25,123,197.00	4,707,454.00
UH - Other Medical Services	21,962,377.00	21,008,950.00	953,427.00
UH - Sub Awards/Service Contracts	6,213,091.00	6,003,586.00	209,505.00
UH - O&M & Leases	9,449,528.00	9,111,120.00	338,408.00
UH - Utilities	3,581,274.00	3,617,413.00	(36,139.00)
UH - Depreciation	15,907,543.00	15,888,813.00	18,730.00
UH - Other Expenses	16,143,789.00	17,749,923.00	(1,606,134.00)
TOTAL	309,726,830.16	294,715,186.92	15,011,643.24

UNM Health Sciences Center

Executive Summary - GASB FORMAT

The following financial statements for the UNM Health Sciences Center are presented in accordance with the GASB financial reporting model. The Statements of Revenues, Expenses and Changes in Net Position are presented for four (4) entities: UNM HSC Academic Enterprise, UNM Hospitals, UNM Medical Group and Sandoval Regional Medical Center. There are also Consolidated UNM Health Sciences Center statements – one that excludes intercompany eliminations and one including intercompany eliminations.

UNM HSC Academic Enterprise

The net margin is \$3.8M as of December 2018. There were some large gifts recorded in November – \$1.4M from DCi (Dialysis Clinic Inc.) and a \$700K gift at the UNM Comprehensive Cancer Center. There is also a lag in non-salary expenses year to date versus the budget.

UNM Hospitals

The net margin for FY 2019 year to date is \$2.287M. In December, there were 2 fewer clinic days as compared to November. The fewer days during the month, along with a tendency for patients to avoid elective procedures during the Holidays, led to lower outpatient volumes. These lower volumes were offset by adjustments made as a result of cash collections on aged accounts that had previously been written down. December expenses were consistent with expectations for the month and the Hospital was able to increase the positive margin for the month and year to date.

UNM Health Sciences Center

Executive Summary - GASB FORMAT cont...

UNM Medical Group

The net margin as of December 31, 2018 is \$1.8M. While revenues are up over last year, purchased services are up as well, with the net gain of \$1.8M coming from earnings in the Lovelace/UNM joint venture.

Sandoval Regional Medical Center

SRMC operations had a net margin of \$20K through December 31, 2018. Inpatient surgical volumes and inpatient discharges are below budget through December 31, 2018. The decrease in inpatient surgical volume is primarily a result of orthopedic provider ramp up and CMS shifting reimbursement for Total Knee Arthroplasty from inpatient to outpatient.

* UNM HSC ACADEMIC ENTERPRISE ONLY INCLUDES: SOM, CON, COP, HSLIC, ADMIN, RESEARCH, COPH

	University HSC FY 2019 Original Budget 12/31/2018	University HSC FY 2019 YTD 12/31/2018 Actual	University HSC FY 2018 Year End Actual	University HSC FY 2019 YTD Actual to FY 2019 Original Budget Benchmark Rate (50%)	University HSC FY 2019 YTD Actual to FY 2018 Year End Actual Benchmark Rate (50%)
1 UNM MEDICAL GROUP REVENUES	133,243	63,562	127,960	48%	50%
2 UNM HOSPITALS REVENUES	183,078	95,947	181,948	52%	53%
3 SRMC REVENUES	22,171	7,707	11,778	35%	65%
4 DIRECT TUITION AND FEES	18,689	8,573	17,991	46%	48%
5 CIGARETTE TAX REVENUES	3,914	2,090	4,028	53%	52%
6 RPSP APPROPRIATIONS	19,585	9,792	18,648	50%	53%
7 I&G APPROPRIATIONS	60,257	30,208	59,285	50%	51%
8 I&G MAIN CAMPUS TRANSFERS	9,797	5,080	9,759	52%	52%
9 HSC I&G TUITION TRANSFER	11,855	6,077	11,477	51%	53%
10 F&A REVENUES (OH RETURN)	25,000	12,701	27,756	51%	46%
11 HSC/UNM INTERNAL TRANSFERS	(5,762)	(4,510)	(8,727)	78%	52%
12 MILL LEVY	0	0	0	N/A	N/A
13 MEANINGFUL USE REVENUE	0	0	0	N/A	N/A
14 EQUITY IN INCOME OF LOVELACE/UNM JOINT VENTURE	0	0	0	N/A	N/A
15 OTHER REVENUES	32,913	17,917	35,674	54%	50%
16 CONTRACT AND GRANT REVENUES	181,543	73,040	162,334	40%	45%
TOTAL REVENUES	696,284	328,182	659,910	47%	50%
17 TOTAL COMPENSATION EXPENSES	446,201	220,036	419,211	49%	52%
18 SUPPLIES/MEDICAL SUPPLIES	13,670	5,853	12,781	43%	46%
19 UNIVERSITY CLINICIANS PROGRAM	0	0	0	N/A	N/A
20 HOUSESTAFF	0	0	0	N/A	N/A
21 PATIENT CARE COSTS	2,223	766	1,693	34%	45%
22 PURCHASED SERVICES	24,954	13,159	23,864	53%	55%
23 OTHER MEDICAL SERVICES	0	0	0	N/A	N/A
24 SUB AWARDS/SERVICE CONTRACTS	477	413	1,635	87%	25%
25 OCCUPANCY	13,458	6,442	10,943	48%	59%
26 DEPRECIATION	957	2,064	6,443	216%	32%
27 CAPITAL EXPENDITURES	1,592	605	1,637	38%	37%
28 USE OF UNMMG RESERVES	0	0	0	N/A	N/A
29 OTHER EXPENSES	22,919	7,933	18,389	35%	43%
30 CONTRACT AND GRANT EXPENSES	169,793	67,116	151,342	40%	44%
TOTAL EXPENSES	696,244	324,387	647,938	47%	50%
NET INCOME/(USE OF RESERVES)	40	3,795	11,972		

UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER - UNM Hospitals Only
Fiscal Year 2019 Year-to-Date Summary through December 31, 2018 (Preliminary and Unaudited)
(In thousands)

Clinical Operations

	UNM Hospitals FY 2019 Original Budget 12/31/2018	UNM Hospitals FY 2019 YTD 12/31/2018 Actual	UNM Hospitals FY 2018 Year End Actual	UNM Hospitals FY 2019 YTD Actual to FY 2019 Original Budget Benchmark Rate (50%)	UNM Hospitals FY 2019 YTD Actual to FY 2018 Year End Actual Benchmark Rate (50%)
1 UNM MEDICAL GROUP REVENUES	0	0	0	N/A	N/A
2 UNM HOSPITALS REVENUES	939,106	477,572	961,441	51%	50%
3 SRMC REVENUES	0	0	0	N/A	N/A
4 DIRECT TUITION AND FEES	0	0	0	N/A	N/A
5 CIGARETTE TAX REVENUES	0	0	0	N/A	N/A
6 RPSP APPROPRIATIONS	12,733	6,367	12,037	50%	53%
7 I&G APPROPRIATIONS	0	0	0	N/A	N/A
8 I&G MAIN CAMPUS TRANSFERS	0	0	0	N/A	N/A
9 HSC I&G TUITION TRANSFER	0	0	0	N/A	N/A
10 F&A REVENUES (OH RETURN)	0	0	0	N/A	N/A
11 HSC/UNM INTERNAL TRANSFERS	0	0	0	N/A	N/A
12 MILL LEVY	100,269	50,135	101,793	50%	49%
13 MEANINGFUL USE REVENUE	0	0	0	N/A	N/A
14 EQUITY IN INCOME OF LOVELACE/UNM JOINT VENTURE	0	0	0	N/A	N/A
15 OTHER REVENUES	35,911	27,724	37,048	77%	75%
16 CONTRACT AND GRANT REVENUES	2,711	1,423	2,738	52%	52%
TOTAL REVENUES	1,090,730	563,220	1,115,056	52%	51%
17 TOTAL COMPENSATION EXPENSES	523,489	267,097	505,286	51%	53%
18 SUPPLIES/MEDICAL SUPPLIES	198,977	102,167	197,708	51%	52%
19 UNIVERSITY CLINICIANS PROGRAM	91,355	44,698	88,997	49%	50%
20 HOUSESTAFF	31,907	15,953	30,476	50%	52%
21 PATIENT CARE COSTS	45,829	23,876	46,756	52%	51%
22 PURCHASED SERVICES	49,795	29,831	52,481	60%	57%
23 OTHER MEDICAL SERVICES	36,404	21,962	38,653	60%	57%
24 SUB AWARDS/SERVICE CONTRACTS	11,810	6,213	11,863	53%	52%
25 OCCUPANCY	25,092	13,031	29,596	52%	44%
26 DEPRECIATION	31,938	15,908	32,322	50%	49%
27 CAPITAL EXPENDITURES	0	0	0	N/A	N/A
28 USE OF UNMMG RESERVES	0	0	0	N/A	N/A
29 OTHER EXPENSES	44,134	20,197	49,385	46%	41%
30 CONTRACT AND GRANT EXPENSES	0	0	0	N/A	N/A
TOTAL EXPENSES	1,090,728	560,933	1,083,522	51%	52%
NET INCOME/(USE OF RESERVES)	3	2,287	31,534		

Clinical Operations

	UNMMG FY 2019 Original Budget 12/31/2018	UNMMG FY 2019 YTD 12/31/2018 Actual	UNMMG FY 2018 Year End Actual	UNMMG FY 2019 YTD Actual to FY 2019 Original Budget Benchmark Rate (50%)	UNMMG FY 2019 YTD Actual to FY 2018 Year End Actual Benchmark Rate (50%)
1 UNM MEDICAL GROUP REVENUES	209,656	100,912	201,113	48%	50%
2 UNM HOSPITALS REVENUES	0	0	0	N/A	N/A
3 SRMC REVENUES	0	0	0	N/A	N/A
4 DIRECT TUITION AND FEES	0	0	0	N/A	N/A
5 CIGARETTE TAX REVENUES	0	0	0	N/A	N/A
6 RPSP APPROPRIATIONS	1,149	580	1,160	50%	50%
7 I&G APPROPRIATIONS	0	0	0	N/A	N/A
8 I&G MAIN CAMPUS TRANSFERS	0	0	0	N/A	N/A
9 HSC I&G TUITION TRANSFER	0	0	0	N/A	N/A
10 F&A REVENUES (OH RETURN)	0	0	0	N/A	N/A
11 HSC/UNM INTERNAL TRANSFERS	0	0	0	N/A	N/A
12 MILL LEVY	0	0	0	N/A	N/A
13 MEANINGFUL USE REVENUE	69	0	86	0%	0%
14 EQUITY IN INCOME OF LOVELACE/UNM JOINT VENTURE	0	1,789	1,462	N/A	122%
15 OTHER REVENUES	1,080	1,451	1,345	134%	108%
16 CONTRACT AND GRANT REVENUES	0	0	0	N/A	N/A
TOTAL REVENUES	211,954	104,733	205,166	49%	51%
17 TOTAL COMPENSATION EXPENSES	20,612	9,324	17,235	45%	54%
18 SUPPLIES/MEDICAL SUPPLIES	0	0	0	N/A	N/A
19 UNIVERSITY CLINICIANS PROGRAM	0	0	0	N/A	N/A
20 HOUSESTAFF	0	0	0	N/A	N/A
21 PATIENT CARE COSTS	34,401	16,636	32,771	48%	51%
22 PURCHASED SERVICES	148,552	72,330	143,174	49%	51%
23 OTHER MEDICAL SERVICES	0	0	0	N/A	N/A
24 SUB AWARDS/SERVICE CONTRACTS	0	0	0	N/A	N/A
25 OCCUPANCY	535	255	519	48%	49%
26 DEPRECIATION	400	154	354	39%	44%
27 CAPITAL EXPENDITURES	0	0	0	N/A	N/A
28 USE OF UNMMG RESERVES	0	329	2,689	N/A	12%
29 OTHER EXPENSES	7,340	3,910	6,973	53%	56%
30 CONTRACT AND GRANT EXPENSES	0	0	0	N/A	N/A
TOTAL EXPENSES	211,839	102,939	203,715	49%	51%
NET INCOME/(USE OF RESERVES)	115	1,794	1,451		

Clinical Operations

	SRMC FY 2019 Original Budget 12/31/2018	SRMC FY 2019 YTD 12/31/2018 Actual	SRMC FY 2018 Year End Actual	SRMC FY 2019 YTD Actual to FY 2019 Original Budget Benchmark Rate (50%)	SRMC FY 2019 YTD Actual to FY 2018 Year End Actual Benchmark Rate (50%)
1 UNM MEDICAL GROUP REVENUES	0	0	0	N/A	N/A
2 UNM HOSPITALS REVENUES	0	0	0	N/A	N/A
3 SRMC REVENUES	74,926	38,354	83,720	51%	46%
4 DIRECT TUITION AND FEES	0	0	0	N/A	N/A
5 CIGARETTE TAX REVENUES	0	0	0	N/A	N/A
6 RPSP APPROPRIATIONS	0	0	0	N/A	N/A
7 I&G APPROPRIATIONS	0	0	0	N/A	N/A
8 I&G MAIN CAMPUS TRANSFERS	0	0	0	N/A	N/A
9 HSC I&G TUITION TRANSFER	0	0	0	N/A	N/A
10 F&A REVENUES (OH RETURN)	0	0	0	N/A	N/A
11 HSC/UNM INTERNAL TRANSFERS	0	0	0	N/A	N/A
12 MILL LEVY	0	32	183	N/A	17%
13 MEANINGFUL USE REVENUE	101	0	911	0%	0%
14 EQUITY IN INCOME OF LOVELACE/UNM JOINT VENTURE	0	0	0	N/A	N/A
15 OTHER REVENUES	6,132	2,566	1,001	42%	256%
16 CONTRACT AND GRANT REVENUES	432	197	414	46%	48%
TOTAL REVENUES	81,592	41,149	86,229	50%	48%
17 TOTAL COMPENSATION EXPENSES	35,800	20,166	38,852	56%	52%
18 SUPPLIES/MEDICAL SUPPLIES	19,953	8,800	20,510	44%	43%
19 UNIVERSITY CLINICIANS PROGRAM	807	194	419	24%	46%
20 HOUSESTAFF	526	302	502	57%	60%
21 PATIENT CARE COSTS	4,014	2,033	4,371	51%	46%
22 PURCHASED SERVICES	3,304	1,366	3,699	41%	37%
23 OTHER MEDICAL SERVICES	320	91	394	28%	23%
24 SUB AWARDS/SERVICE CONTRACTS	1,914	960	1,963	50%	49%
25 OCCUPANCY	1,857	1,145	1,845	62%	62%
26 DEPRECIATION	6,508	2,988	6,106	46%	49%
27 CAPITAL EXPENDITURES	0	0	0	N/A	N/A
28 USE OF UNMMG RESERVES	0	0	0	N/A	N/A
29 OTHER EXPENSES	6,578	3,083	6,645	47%	46%
30 CONTRACT AND GRANT EXPENSES	0	0	0	N/A	N/A
TOTAL EXPENSES	81,581	41,128	85,305	50%	48%
NET INCOME/(USE OF RESERVES)	11	20	924		

UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER - Consolidated HSC
Fiscal Year 2019 Year-to-Date Summary through December 31, 2018 (Preliminary and Unaudited)
(In thousands)

DOES NOT INCLUDE INTERCOMPANY ELIMINATIONS

Clinical and Academic Operations

	Consolidated HSC FY 2019 Original Budget 12/31/2018	Consolidated HSC FY 2019 YTD 12/31/2018 Actual	Consolidated HSC FY 2018 Year End Actual	Consolidated HSC FY 2019 YTD Actual to FY 2019 Original Budget Benchmark Rate (50%)	Consolidated HSC FY 2019 YTD Actual to FY 2018 Year End Actual Benchmark Rate (50%)
1 UNM MEDICAL GROUP REVENUES	342,899	164,474	329,072	48%	50%
2 UNM HOSPITALS REVENUES	1,122,184	573,519	1,143,389	51%	50%
3 SRMC REVENUES	97,097	46,061	95,498	47%	48%
4 DIRECT TUITION AND FEES	18,689	8,573	17,991	46%	48%
5 CIGARETTE TAX REVENUES	3,914	2,090	4,028	53%	52%
6 RPSP APPROPRIATIONS	33,467	16,738	31,845	50%	53%
7 I&G APPROPRIATIONS	60,257	30,208	59,285	50%	51%
8 I&G MAIN CAMPUS TRANSFERS	9,797	5,080	9,759	52%	52%
9 HSC I&G TUITION TRANSFER	11,855	6,077	11,477	51%	53%
10 F&A REVENUES (OH RETURN)	25,000	12,701	27,756	51%	46%
11 HSC/UNM INTERNAL TRANSFERS	(5,762)	(4,510)	(8,727)	78%	52%
12 MILL LEVY	100,269	50,166	101,975	50%	49%
13 MEANINGFUL USE REVENUE	170	0	997	0%	0%
14 EQUITY IN INCOME OF LOVELACE/UNM JOINT VENTURE	0	1,789	1,462	N/A	122%
15 OTHER REVENUES	76,036	49,659	75,069	65%	66%
16 CONTRACT AND GRANT REVENUES	184,686	74,660	165,486	40%	45%
TOTAL REVENUES	2,080,560	1,037,283	2,066,361	50%	50%
17 TOTAL COMPENSATION EXPENSES	1,026,102	516,623	980,584	50%	53%
18 SUPPLIES/MEDICAL SUPPLIES	232,600	116,820	230,999	50%	51%
19 UNIVERSITY CLINICIANS PROGRAM	92,161	44,893	89,416	49%	50%
20 HOUSESTAFF	32,432	16,256	30,977	50%	52%
21 PATIENT CARE COSTS	86,466	43,311	85,591	50%	51%
22 PURCHASED SERVICES	226,605	116,686	223,218	51%	52%
23 OTHER MEDICAL SERVICES	36,724	22,053	39,047	60%	56%
24 SUB AWARDS/SERVICE CONTRACTS	14,201	7,586	15,460	53%	49%
25 OCCUPANCY	40,942	20,873	42,902	51%	49%
26 DEPRECIATION	39,803	21,114	45,225	53%	47%
27 CAPITAL EXPENDITURES	1,592	605	1,637	38%	37%
28 USE OF UNMMG RESERVES	0	329	2,689	N/A	12%
29 OTHER EXPENSES	80,970	35,123	81,392	43%	43%
30 CONTRACT AND GRANT EXPENSES	169,793	67,116	151,342	40%	44%
TOTAL EXPENSES	2,080,392	1,029,387	2,020,479	49%	51%
NET INCOME/(USE OF RESERVES)	168	7,896	45,882		

UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER - Consolidated HSC
Fiscal Year 2019 Year-to-Date Summary through December 31, 2018 (Preliminary and Unaudited)
(In thousands)

* INCLUDES INTERCOMPANY ELIMINATIONS

Clinical and Academic Operations

	Consolidated HSC FY 2019 Original Budget 12/31/2018	Consolidated HSC FY 2019 YTD 12/31/2018 Actual	Consolidated HSC FY 2018 Year End Actual	Consolidated HSC FY 2019 YTD Actual to FY 2019 Original Budget Benchmark Rate (50%)	Consolidated HSC FY 2019 YTD Actual to FY 2018 Year End Actual Benchmark Rate (50%)
1 UNM MEDICAL GROUP REVENUES *	209,656	100,912	201,113	48%	50%
2 UNM HOSPITALS REVENUES *	942,069	478,450	962,954	51%	50%
3 SRMC REVENUES *	74,926	38,354	83,720	51%	46%
4 DIRECT TUITION AND FEES	18,689	8,573	17,991	46%	48%
5 CIGARETTE TAX REVENUES	3,914	2,090	4,028	53%	52%
6 RPSP APPROPRIATIONS	33,467	16,738	31,845	50%	53%
7 I&G APPROPRIATIONS	60,257	30,208	59,285	50%	51%
8 I&G MAIN CAMPUS TRANSFERS	9,797	5,080	9,759	52%	52%
9 HSC I&G TUITION TRANSFER	11,855	6,077	11,477	51%	53%
10 F&A REVENUES (OH RETURN)	25,000	12,701	27,756	51%	46%
11 HSC/UNM INTERNAL TRANSFERS	(5,762)	(4,510)	(8,727)	78%	52%
12 MILL LEVY	100,269	50,166	101,975	50%	49%
13 MEANINGFUL USE REVENUE	170	0	997	0%	0%
14 EQUITY IN INCOME OF LOVELACE/UNM JOINT VENTURE	0	1,789	1,462	N/A	122%
15 OTHER REVENUES *	63,630	43,728	61,849	69%	71%
16 CONTRACT AND GRANT REVENUES	184,686	74,660	165,486	40%	45%
TOTAL REVENUES	1,732,624	865,014	1,732,969	50%	50%
17 TOTAL COMPENSATION EXPENSES *	701,197	356,442	670,282	51%	53%
18 SUPPLIES/MEDICAL SUPPLIES	232,600	116,820	230,999	50%	51%
19 UNIVERSITY CLINICIANS PROGRAM	92,161	44,893	89,416	49%	50%
20 HOUSESTAFF	32,432	16,256	30,977	50%	52%
21 PATIENT CARE COSTS	86,466	43,311	85,591	50%	51%
22 PURCHASED SERVICES *	203,574	104,599	200,127	51%	52%
23 OTHER MEDICAL SERVICES	36,724	22,053	39,047	60%	56%
24 SUB AWARDS/SERVICE CONTRACTS	14,201	7,586	15,460	53%	49%
25 OCCUPANCY	40,942	20,873	42,902	51%	49%
26 DEPRECIATION	39,803	21,114	45,225	53%	47%
27 CAPITAL EXPENDITURES	1,592	605	1,637	38%	37%
28 USE OF UNMMG RESERVES	0	329	2,689	N/A	12%
29 OTHER EXPENSES	80,970	35,123	81,392	43%	43%
30 CONTRACT AND GRANT EXPENSES	169,793	67,116	151,342	40%	44%
TOTAL EXPENSES	1,732,456	857,118	1,687,087	49%	51%
NET INCOME/(USE OF RESERVES)	168	7,896	45,882		

GLOSSARY OF REPORT CATEGORIES

FINANCIAL STATEMENT CATEGORY		UNM	UNMMG	UNM Hospitals	SRMC
1	UNM MEDICAL GROUP REVENUES	Clinical revenue primarily based on Physician or Provider efforts and collection through UNMMG	Net patient services revenue including SCI & UPL from UNMMG Clinical operations	N/A	N/A
2	UNM HOSPITALS REVENUES	Revenue from University Hospital to the School of Medicine	N/A	Hospital facility revenue based on patient billings by UNMH	N/A
3	SRMC REVENUES	Revenue from SRMC to the School of Medicine	N/A	N/A	Hospital facility revenue based on patient billings by SRMC
4	DIRECT TUITION AND FEES	Tuition & Fees, including tuition differentials	N/A	N/A	N/A
5	CIGARETTE TAX REVENUES	Revenues received from the State as a calculated portion of Tax Revenue on the sale of tobacco products for use in Cancer Research	N/A	N/A	N/A
6	RPSP APPROPRIATIONS	Revenue received for current operations made available to UNM by act of NM State Legislature on an annual basis for Research, Public Service and Independent Operations	Revenue received for current operations made available to UNMMG by act of NM State Legislature on an annual basis	Revenue received for current operations made available to UNMH by act of NM State Legislature on an annual basis	N/A
7	I&G APPROPRIATIONS	Revenue received for current operations made available to UNM by act of NM State Legislature on an annual basis for I&G operations	N/A	N/A	N/A
8	I&G MAIN CAMPUS TRANSFERS	Partial transfer of tuition and formula workload generated by Nursing, Pharmacy and SOM	N/A	N/A	N/A
9	HSC I&G TUITION TRANSFER	Incremental tuition transfer from Main Campus.	N/A	N/A	N/A
10	F & A REVENUES (OH RETURN)	Revenue from recovery of indirect costs (F&A) incurred by a Contract or Grant also known as overhead return	N/A	N/A	N/A
11	HSC/UNM INTERNAL TRANSFERS	All transfers to/from HSC Unrestricted Funds excluding the I&G Main Campus Transfer and Transfers for Debt Service	N/A	N/A	N/A
12	MILL LEVY	N/A	N/A	Mil levy taxes collected on behalf of the Bernalillo County Treasurer and remitted to UNMH as required by the Hospital Funding Act.	Mil levy taxes collected on behalf of the Sandoval County Treasurer and remitted to SRMC as required by the Hospital Funding Act.
13	MEANINGFUL USE REVENUE	N/A	Medicare and Medicaid programs provide incentive payments for hospital and physicians that make meaningful use of certified electronic health record technology.	Medicare and Medicaid programs provide incentive payments for hospital and physicians that make meaningful use of certified electronic health record technology.	Medicare and Medicaid programs provide incentive payments for hospital and physicians that make meaningful use of certified electronic health record technology.
14	EQUITY IN INCOME OF LOVELACE/UNM JOINT VENTURE	NA	Lovelace Health System and UNM Medical Group, Inc., are partnering to deliver enhanced state-of-the-art rehabilitation services to New Mexico patients recovering from health care conditions such as stroke, brain injury and musculoskeletal disorders. Under an agreement, Lovelace and UNM physicians and providers will deliver services at Lovelace Rehabilitation Hospital and its outpatient therapy clinics starting in 2017.	NA	NA

GLOSSARY OF REPORT CATEGORIES

FINANCIAL STATEMENT CATEGORY		UNM	UNMMG	UNM Hospitals	SRMC
15	OTHER REVENUES	All other Revenues - not contained in any other category - Sales & Services (not Internal Service Center P18 sales), Gains on Sponsored Projects, Gifts, Endowment Spending Distributions, Investment Income, etc.	Other operating revenues and revenue received from UNM Hospitals to cover SRMC physician costs.	All other revenues not contained in any other category: Investment income, equity loss in Tricare, donated revenue, gain/loss on sale of assets, food, nutrition, catering & vending revenue, medical records revenue, rent revenue, all other non-operating revenue	All other revenues not contained in any other category: Investment income, donated revenue, gain/loss on sale of assets, food, nutrition, catering & vending revenue, medical records revenue, rent revenue, all other non-operating revenue
16	CONTRACT AND GRANT REVENUES	All Restricted Funds Revenue and Unrestricted Contract Revenue for example VA contracts	N/A	Revenue associated with restricted and unrestricted contracts and grants	N/A
17	TOTAL COMPENSATION EXPENSES	Salary, wages & benefits	Salaries and benefits considered to be operating and certain clinical expenses of UNMMG	Salary, wages & benefits	Salary, wages & benefits
18	SUPPLIES/MEDICAL SUPPLIES	Office supplies, computer supplies, dues & memberships, postage charges, recruitment expenses, non capital equipment, computers, food, lab supplies, uniforms, training materials, etc.	N/A	Medical supplies for: lab, radiology, blood, pharmaceuticals, biologics, implantable devices, office supplies, computer supplies, photocopy expense, forms, linen, food, uniforms, and training materials.	Medical supplies for: lab, radiology, blood, pharmaceuticals, biologics, implantable devices, office supplies, computer supplies, photocopy expense, forms, linen, food, uniforms, and training materials.
19	UNIVERSITY CLINICIANS PROGRAM	N/A	N/A	Special clinician program to support SOM	Special clinician program to support SOM
20	HOUSESTAFF	N/A	N/A	Reimbursement of patient care services provided by residents who are employed by SOM.	Reimbursement of patient care services provided by SOM through UNMMG.
21	PATIENT CARE COSTS	Patient Care costs for inpatient, outpatient care & lab, pharmacy and x-ray services for patients	Patient Care costs for inpatient, outpatient care & lab, pharmacy and x-ray services for patients	Patient Care costs for inpatient, outpatient care including Tricare laboratory expense, OR instruments, NM Insurance pool premiums, kidney acquisition, step down care (snf) for IV dependent patients, radiation oncology and patient assistance	Patient Care costs for inpatient, outpatient care including Tricare laboratory expense, OR instruments, NM Insurance pool premiums, kidney acquisition, step down care (snf) for IV dependent patients, radiation oncology and patient assistance
22	PURCHASED SERVICES	Alarm fees, internet fees, architectural services, auditing services, printing/copying/binding fees, conference/event fees, honoraria, insurance charges (general liability, professional liability), legal services, electronic journals & books, consultant fees, etc.	Includes payment to UNM SOM for physician and other provider services	Recruitment, professional, legal, auditing, consulting fees, promotional/graphics, IT Hosting Center, Siemens and PACS, safety and risk services, equifax, laundry, malpractice and liability insurance, etc.	Recruitment, professional, legal, auditing, consulting fees, promotional/graphics, IT Hosting Center, Siemens and PACS, safety and risk services, equifax, laundry, malpractice and liability insurance, etc.
23	OTHER MEDICAL SERVICES	N/A	N/A	Pathology contract, physician services, Executive Medical Directors, Medical Directors, dialysis services for UNM Care patients, OMI MOU, Adult Infusion net	Physician services
24	SUB AWARDS/SERVICE CONTRACTS	Unrestricted Sub Awards, Gain/Loss on Unrestricted Projects	N/A	All service contracts	All service contracts
25	OCCUPANCY	Plant maintenance and repairs, equipment repairs and maintenance, property insurance, auto insurance, facility rent expense & utilities costs (natural gas, electricity, steam, sewer, water, chilled water)	Building maintenance and repairs, equipment repairs and maintenance, repair parts, equipment rent, property insurance, auto insurance, facility rent expense, and housekeeping supplies	Building maintenance and repairs, equipment repairs and maintenance, repair parts, equipment rent, property insurance, auto insurance, facility rent expense, and housekeeping supplies & utilities costs (natural gas, electricity, steam, sewer, water, chilled water)	Building maintenance and repairs, equipment repairs and maintenance, repair parts, equipment rent, property insurance, auto insurance, facility rent expense, and housekeeping supplies & utilities costs (natural gas, electricity, steam, sewer, water, chilled water)


GLOSSARY OF REPORT CATEGORIES

FINANCIAL STATEMENT CATEGORY		UNM	UNMMG	UNM Hospitals	SRMC
26	DEPRECIATION	The annual amortization for the capital outlay associated with building, building improvement, fixed and moveable equipment which is based on the estimated useful lives of the assets.	The annual amortization for the furniture and equipment.	The annual amortization for the capital outlay associated with building, building improvement, fixed and moveable equipment which is based on the estimated useful lives of the assets as determined by the AHA "Estimated useful lives of Depreciable Hospital Assets".	The annual amortization for the capital outlay associated with building, building improvement, fixed and moveable equipment which is based on the estimated useful lives of the assets as determined by the AHA "Estimated useful lives of Depreciable Hospital Assets".
27	CAPITAL EXPENDITURES	Equipment/furniture >\$5,000, Computer hardware, library acquisitions, etc.	N/A	This is capital initiatives in the case of UNM Hospitals.	N/A
28	USE OF UNMMG RESERVES	N/A	To fund and support the mission of the Health Sciences Center.	N/A	N/A
29	OTHER EXPENSES	Banking fees, cost of goods sold, research costs, royalties, bad debt expense, other operating costs, Banner tax, etc. Travel - in state, out of state, foreign, business meals, rental vehicles, new employee moving expenses, vehicle fuel, etc. Student costs - student tuition/fees, student travel, scholarships/fellowships, housing, insurance for students, student awards, etc. Telephone/communication costs - telephone, voicemail, cellular, long distance, paging and data networking charges. Interest expense (transfers to cover debt service)	Billings & collections expenses and other operating expenses of UNMMG	Programming, application, software and maintenance expenses, non capital equipment (less than \$5k), signs, dues & memberships, freight, postage, subscriptions, licenses/permits, Gap Tax, Intergovernmental Transfers for the SCI and IME, bond issuance costs, capital initiatives and other non-operating expenses. Travel - in state, out of state, etc. Telephone/communication costs - telephone, voicemail, cellular, long distance, paging and data networking charges. Interest expense associated with the Insured Hospital Mortgage Revenue Bonds.	Programming, application, software and maintenance expenses, non capital equipment (less than \$5k), signs, dues & memberships, freight, postage, subscriptions, licenses/permits, Gap Tax, Intergovernmental Transfers for the SCI and IME, bond issuance costs, capital initiatives and other non-operating expenses. Travel - in state, out of state, etc. Telephone/communication costs - telephone, voicemail, cellular, long distance, paging and data networking charges. Interest expense - SRMC receives subsidy payments related to interest payments under the federal Build American Bond program. Under the program SRMC applies for subsidy funds commensurate with each bond payment, so the application for the subsidy is made semiannually. Also includes interest expense on the Series A & B Bonds.
30	CONTRACT AND GRANT EXPENSES	All Restricted Funds Expense and Unrestricted Contract Expense for example VA contracts	N/A	N/A	N/A



UNM Health Sciences Center
Metrics - Preliminary and Unaudited
Uncompensated Care as a Percentage of Total Patient Care

UNM HEALTH SYSTEM



FY 2014

FY 2015

FY 2016

FY 2017

FY 2018

FY 2019
Dec 31st YTD

21%

12%


7%

8%

7%

6%

UNM HOSPITALS



**FY 2014
2nd Quarter**

46.86

**FY 2015
2nd Quarter**

58.43

**FY 2016
2nd Quarter**

56.35

**FY 2017
2nd Quarter**

60.47

**FY 2018
2nd Quarter**


67.56

**FY 2019
2nd Quarter**

78.08

Per S&P Global Ratings, "U.S. Not-for-Profit Health Care System Median Financial Ratios - 2017 vs. 2016" report, the "AA" credit rating group has a benchmark of 341.8 days cash on hand for 2017.

UNM MEDICAL GROUP



FY 2014
2nd Quarter

45.30

FY 2015
2nd Quarter

53.35

FY 2016
2nd Quarter

39.03

FY 2017
2nd Quarter

42.13

FY 2018
2nd Quarter


57.04

FY 2019
2nd Quarter

51.20

Per S&P Global Ratings, "U.S. Not-for-Profit Health Care System Median Financial Ratios - 2017 vs. 2016" report, the "AA" credit rating group has a benchmark of 341.8 days cash on hand for 2017.

SANDOVAL REGIONAL MEDICAL CENTER



FY 2014
2nd Quarter

16.25

FY 2015
2nd Quarter

61.72

FY 2016
2nd Quarter

57.46

FY 2017
2nd Quarter

83.20

FY 2018
2nd Quarter


125.62

FY 2019
2nd Quarter

130.99

Per S&P Global Ratings, "U.S. Not-for-Profit Health Care System Median Financial Ratios - 2017 vs. 2016" report, the "AA" credit rating group has a benchmark of 341.8 days cash on hand for 2017.

UNIVERSITY HSC



FY 2014

FY 2015

FY 2016

FY 2017

FY 2018

**FY 2019
Dec 31st**

45.57

41.40


36.76

49.18

41.17

45.05


UNM HOSPITALS



FY 2014	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019 Dec 31st
51.09	54.52	55.13	46.96	51.00	48.84

Per S&P Global Ratings, "U.S. Not-for-Profit Health Care System Median Financial Ratios - 2017 vs. 2016" report, the "AA" credit rating group has a benchmark of 53.2 days in accounts receivable for 2017.

UNM MEDICAL GROUP



FY 2014

FY 2015

FY 2016

FY 2017

FY 2018

**FY 2019
Dec 31st**

34.60

35.10

37.00


37.00

41.60

38.70

Per S&P Global Ratings, "U.S. Not-for-Profit Health Care System Median Financial Ratios - 2017 vs. 2016" report, the "AA" credit rating group has a benchmark of 53.2 days in accounts receivable for 2017.

SANDOVAL REGIONAL MEDICAL CENTER



FY 2014

FY 2015

FY 2016

FY 2017

FY 2018

**FY 2019
Dec 31st**

48.71

50.50

56.90


46.63

41.24

34.71

Per S&P Global Ratings, "U.S. Not-for-Profit Health Care System Median Financial Ratios - 2017 vs. 2016" report, the "AA" credit rating group has a benchmark of 53.2 days in accounts receivable for 2017.

UNIVERSITY HSC



**FY 2015
2nd Quarter**

\$80,032

**FY 2016
2nd Quarter**

\$79,120

**FY 2017
2nd Quarter**

\$102,842


**FY 2018
2nd Quarter**

\$101,229

**FY 2019
2nd Quarter**

\$73,954

UNIVERSITY HSC



**FY 2015
2nd Quarter**

\$11,175

**FY 2016
2nd Quarter**

\$11,917

**FY 2017
2nd Quarter**

\$11,803

**FY 2018
2nd Quarter**

\$12,942

**FY 2019
2nd Quarter**

\$12,701

MEMORANDUM

To: UNM Regent Health Sciences Center Committee

From: Mike Richards, MD
Vice Chancellor, UNM Health System

Date: February 5, 2019

Subject: Monthly Health System Activity Update

This report represents unaudited year to date December 2018 activity and is compared to audited year to date December 2017 activity.

Quality and Safety: For FY19 thru November 2018, UNM Hospitals have 7/13 metrics are at or better than fiscal year targets set for the UNMH UOP. For non-infection Severe Patient Harm Events, 5/6 remain at or better than target. For infection Severe Patient Harm Events, 2/5 are at or better than target.

For SRMC, 10/13 metrics are at or better than fiscal year targets set for the SRMC UOP. For non-infection Severe Patient Harm Events, 5/6 remain at or better than target. For infection Severe Patient Harm Events, 3/5 are at or better than target at UNMH.

Activity Levels: Health System total inpatient discharges and observation discharges are up 2% as compared to prior year.

Health System total inpatient discharges are down 4% compared to prior year, with discharges down 4% at UNMH and 5% at SRMC. Health System adult length of stay (without obstetrics) is down 4% compared to prior year, with length of stay down 3% at UNMH and down 11% SRMC.

Health System observation discharges are up 15% compared to prior year, with adult observation discharges up 19% at UNMH and up 12% at SRMC. The SRMC increase in observation discharges is predominately driven (>80%) by the CMS reclassification of total knee joint replacement surgery from an inpatient procedure to an outpatient procedure.

Case Mix Index (CMI) is flat compared to prior year and up 2% compared to FY 19 budget.

Births are down 1% year over year and 4% above budget.

Health System total outpatient activity is 3% higher compared to prior year. Primary care clinic visits are up 9% compared to prior year. Specialty clinic visits are up 1% compared to prior year. Emergency visits are 17% lower than prior year.

Surgeries overall are down 5% year over year due to decrease in community physician surgical volume at SRMC. UNM surgical volume is down 4% compared to prior year.

Medical Group RVUs are down 1% FY19 over prior year.

Finances: Health System had total year-to-date operating revenue of \$644.0 million, representing a 4% increase over prior year. Total non-operating revenue was \$55.8 million, representing a 7% increase (\$3.6 million) over prior year. Total operating expenses were \$695.6 million, representing a 4% increase over prior year. Net margin was \$4.2 million as compared to \$1.8 million prior year.

The balance sheet is stable with a current ratio of 1.83 as compared to 2.04 prior year. The cash and cash equivalents for UNM Health System is \$309.7 million as compared to \$289.4 million prior year. Net patient receivables are up 3% and total assets are up 6%. Total liabilities are up 12% over prior year. Total net position is up 1% over prior year.

SRMC Mill Levy: The Trauma and Behavioral Health teams have begun meeting. They are working on the program scope and will soon start detailed proformas. SRMC's Chief Medical Officer and Chief Operating Officer/Chief Nursing Officer are leading these efforts.

Mission Excellence: We continue to hardwire our MISSION: Excellence work. We are currently working on the charter for the newly developed M:E Advisory Committee. The Foundational Team is transitioning to an Operational Oversight group. We are redesigning the Physician Engagement Survey based on feedback received and will be posting an RFP soon. The hardwired version of the Quarterly Forums held following LEADing to Excellence conferences have transitioned to entity Town Halls led by Health System CEOs. SRMC has begun working with the Studer consultants and focusing on hardwiring all of the M:E strategies, systems, and tools.

UNM HS Total Operations - Stats Snapshot

YTD December 31, 2018

	FY 2019	FY 2018	Change		FY 2019	Variance	
	Actual	Actual	Units	%	Budget	Units	%
<i>Patient Days - w/o observation</i>							
HS	82,178	86,719	(4,541)	-5%	86,214	(4,036)	-5%
UNMH-Adult	55,861	58,712	(2,851)	-5%	57,050	(1,189)	-2%
UNMH-Pediatric	20,233	20,754	(521)	-3%	21,631	(1,398)	-6%
SRMC	6,084	7,253	(1,169)	-16%	7,533	(1,449)	-19%
<i>Adult w/o Obstetrics Patient Days</i>							
HS	56,195	60,241	(4,046)	-7%	59,217	(3,022)	-5%
UNMH	50,111	52,988	(2,877)	-5%	51,684	(1,573)	-3%
SRMC	6,084	7,253	(1,169)	-16%	7,533	(1,449)	-19%
<i>Discharges</i>							
HS	13,797	14,345	(548)	-4%	14,393	(596)	-4%
UNMH-Adult	9,139	9,384	(245)	-3%	9,325	(186)	-2%
UNMH-Pediatric	3,179	3,396	(217)	-6%	3,440	(261)	-8%
SRMC	1,479	1,565	(86)	-5%	1,628	(149)	-9%
<i>Adult w/o Obstetrics Discharges</i>							
HS	8,903	9,197	(294)	-3%	9,197	(294)	-3%
UNMH	7,424	7,632	(208)	-3%	7,569	(145)	-2%
SRMC	1,479	1,565	(86)	-5%	1,628	(149)	-9%
<i>Observation Discharges</i>							
HS	6,812	5,919	893	15%	7,032	(220)	-3%
UNMH-Adult	4,717	3,948	769	19%	5,079	(362)	-7%
UNMH-Pediatric	1,102	1,087	15	1%	1,069	33	3%
SRMC	993	884	109	12%	884	109	12%
<i>LOS</i>							
HS	6.0	6.0	(0.1)	-1%	6.0	(0.0)	-1%
UNMH-Adult	6.1	6.3	(0.1)	-2%	6.1	(0.0)	0%
UNMH-Pediatric	6.4	6.1	0.3	4%	6.3	0.1	1%
SRMC	4.1	4.6	(0.5)	-11%	4.6	(0.5)	-11%
<i>Adult w/o Obstetrics LOS</i>							
HS	6.3	6.6	(0.2)	-4%	6.4	(0.1)	-2%
UNMH	6.7	6.9	(0.2)	-3%	6.8	(0.1)	-1%
SRMC	4.1	4.6	(0.5)	-11%	4.6	(0.5)	-11%
<i>CMI w/o Newborn</i>							
HS	1.942	1.950	(0.008)	0%	1.910	0.032	2%
UNMH	1.981	1.974	0.008	0%	1.934	0.047	2%
SRMC	1.626	1.766	(0.140)	-8%	1.710	(0.084)	-5%

UNM HS Total Operations - Stats Snapshot

YTD December 31, 2018

	FY 2019 Actual	FY 2018 Actual	Change		FY 2019 Budget	Variance	
			Units	%		Units	%
Behavioral Patient Days							
HS	11,840	11,761	79	1%	11,822	18	0%
UNMH-Adult Psych	7,207	6,882	325	5%	6,906	301	4%
UNMH-Peds Psych	4,633	4,879	(246)	-5%	4,916	(283)	-6%
Behavioral Discharges							
HS	1,319	1,344	(25)	-2%	1,348	(29)	-2%
UNMH-Adult Psych	872	895	(23)	-3%	878	(6)	-1%
UNMH-Peds Psych	447	449	(2)	0%	470	(23)	-5%
Behavioral LOS							
HS	9.0	8.8	0.2	3%	8.8	0.2	2%
UNMH-Adult Psych	8.3	7.7	0.6	7%	7.9	0.4	5%
UNMH-Peds Psych	10.4	10.9	(1)	-5%	10.5	(0.1)	-1%
Primary Clinics							
HS	91,265	83,691	7,574	9%	89,871	1,394	2%
UNMH	84,197	77,531	6,666	9%	82,381	1,816	2%
SRMC	7,068	6,160	908	15%	7,490	(422)	-6%
Specialty Clinics							
HS	222,643	219,423	3,220	1%	232,267	(9,624)	-4%
UNMH - Adult	146,384	145,614	770	1%	150,936	(4,552)	-3%
UNMH - Pediatric	42,326	40,779	1,547	4%	43,094	(768)	-2%
SRMC	16,157	13,606	2,551	19%	14,255	1,902	13%
UNMMG	17,776	19,424	(1,648)	-8%	23,982	(6,206)	-26%
Other Clinics							
Rad/Onc	15,551	13,561	1,990	15%	15,022	529	4%
Med/Onc	20,773	19,219	1,554	8%	21,166	(393)	-2%
CPC	17,370	13,433	3,937	29%	14,104	3,266	23%
UPC	64,284	59,595	4,689	8%	62,058	2,226	4%
Urgent Care	10,587	9,642	945	10%	10,655	(68)	-1%
Emergency Room							
HS	46,078	55,390	(9,312)	-17%	52,335	(6,257)	-12%
UNMH - Adult	27,213	34,175	(6,962)	-20%	30,196	(2,983)	-10%
UNMH - Pediatric	9,162	11,677	(2,515)	-22%	11,831	(2,669)	-23%
SRMC	9,703	9,538	165	2%	10,308	(605)	-6%

UNM HS Total Operations - Stats Snapshot

YTD December 31, 2018

	FY 2019	FY 2018	Change		FY 2019	Variance	
	Actual	Actual	Units	%	Budget	Units	%
Total Outpatient Visits							
HS	488,551	473,954	14,597	3%	497,478	(8,927)	-2%
UNMH	437,847	425,226	12,621	3%	441,443	(3,597)	-1%
SRMC	32,928	29,304	3,624	12%	32,053	875	3%
UNMMG	17,776	19,424	(1,648)	-8%	23,982	(6,206)	-26%
Total Surgeries							
HS	11,639	12,306	(667)	-5%	12,263	(624)	-5%
UNMH	9,913	10,334	(421)	-4%	10,463	(550)	-5%
SRMC	1,726	1,972	(246)	-12%	1,800	(74)	-4%
Other							
Births	1,511	1,528	(17)	-1%	1,449	62	4%
ECT	769	1,199	(430)	-36%	1,227	(458)	-37%
Derm MOHS	159	-	159		-	159	
CC Procedures	319	-	319		-	319	
Infusion Clinics	9,877	8,671	1,206	14%	10,698	(821)	-8%
Work RVU's							
HS	1,607,233	1,630,985	(23,752)	-1%	1,702,513	(95,280)	-6%
SOM	1,339,565	1,360,279	(20,714)	-2%	1,412,111	(72,546)	-5%
SRMC	177,626	184,388	(6,762)	-4%	184,488	(6,862)	-4%
MG Clinic	27,070	28,923	(1,853)	-6%	37,910	(10,840)	-29%
Cancer Center	62,972	57,395	5,577	10%	68,004	(5,032)	-7%
FTE's							
HS	7,514	7,375	140	2%	7,601	(86)	-1%
UNMH	6,437	6,294	143	2%	6,484	(47)	-1%
SRMC	506	502	4	1%	484	22	5%
UNMMG	571	578	(7)	-1%	632	(61)	-10%

UNM HS Total Operations - Stats
YTD December 31, 2018

	Total HS	Total HS Prior Year	FY 18 vs. FY 19		Total HS FY 19 Budget	FY 19 Actual vs. Budget	
			\$ Change	% Change		\$ Change	% Change
TOTAL PATIENT DAYS	82,178	86,719	(4,541)	-5%	86,214	(4,036)	-5%
TOTAL DISCHARGES	13,797	14,345	(548)	-4%	14,393	(596)	-4%
OBSERVATION DISCHARGES	6,812	5,919	893	15%	7,032	(220)	-3%
TOTAL LENGTH OF STAY	6.0	6.0	(0.1)	-1%	6.0	(0.0)	-1%
<i>Adult w/Obstetrics LOS</i>	<i>5.8</i>	<i>6.0</i>	<i>(0.2)</i>	<i>-3%</i>	<i>5.9</i>	<i>(0.1)</i>	<i>-1%</i>
<i>CMI w/o Newborn</i>	<i>1.942</i>	<i>1.950</i>	<i>(0.0)</i>	<i>0%</i>	<i>1.910</i>	<i>0.0</i>	<i>2%</i>

UNM HS Total Operations - Stats
YTD December 31, 2018

	Total HS	Total HS Prior Year	FY 18 vs. FY 19		Total HS FY 19 Budget	FY 19 Actual vs. Budget	
			\$ Change	% Change		\$ Change	% Change
BEHAVIORAL							
Psychiatric-Adult Days	7,207	6,882	325	5%	6,906	301	4%
Psychiatric-Pediatric Days	4,633	4,879	(246)	-5%	4,916	(283)	-6%
Psychiatric-Adult Discharges	872	895	(23)	-3%	878	(6)	-1%
Psychiatric-Pediatric Discharges	447	449	(2.0)	0%	470	(23)	-5%
Length of Stay - Psychiatric Adult	8.3	7.7	0.6	7%	7.9	0.4	5%
Length of Stay - Psychiatric Pediatric	10.4	10.9	(0.5)	-5%	10.5	(0.1)	-1%
<hr/>							
OUTPATIENT VISITS							
TOTAL OUTPATIENT CLINICS	431,886	408,922	22,964	6%	434,488	(2,602)	-1%
URGENT CARE	10,587	9,642	945	10%	10,655	(68)	-1%
EMERGENCY ROOM	46,078	55,390	(9,312)	-17%	52,335	(6,257)	-12%
TOTAL OUTPATIENT VISITS	488,551	473,954	14,597	3%	497,478	(8,927)	-2%
<hr/>							
TOTAL SURGERIES	11,639	12,306	(667)	-5%	12,263	(624)	-5%
<hr/>							
TOTAL BIRTHS	1,511	1,528	(17)	-1%	1,449	62	4%
ECT Stats	769	1,199	(430)	-36%	1,227	(458)	-37%
DERM MOHS	159	-	159	-	-	159	-
CC PROCEDURES	319	-	319	-	-	319	-
INFUSION CLINIC	9,877	8,671	1,206	14%	10,698	(821)	-8%
Total Work RVU's	1,607,233	1,630,985	(23,752)	-1%	1,702,513	(95,280)	-6%
Total FTE's	7,514	7,375	140	2%	7,601	(86)	-1%
<hr/>							

UNM HS Total Operations Snapshot
YTD December 31, 2018

(in thousands)	FY 2019	FY 2018	Change		FY 2019	Variance	
	Actual	Actual	\$	%	Budget	\$	%
Net Patient Revenue							
HS	617,120	601,504	15,617	3%	611,330	5,790	1%
UNMH	477,571	462,644	14,927	3%	469,553	8,018	2%
SRMC	38,354	40,071	(1,718)	-4%	37,463	891	2%
UNMMG	101,195	98,788	2,407	2%	104,315	(3,120)	-3%
Other Operating Revenue							
HS	26,905	16,859	10,047	60%	18,856	8,049	43%
UNMH	25,425	15,665	9,760	62%	17,646	7,778	44%
SRMC	653	743	(90)	-12%	779	(126)	-16%
UNMMG	828	451	376	83%	431	397	92%
Total Operating Revenue							
HS	644,025	618,362	25,663	4%	630,186	13,839	2%
UNMH	502,996	478,309	24,686	5%	487,199	15,796	3%
SRMC	39,007	40,814	(1,807)	-4%	38,241	765	2%
UNMMG	102,023	99,239	2,784	3%	104,746	(2,723)	-3%
Total Operating Expense							
HS	695,611	668,648	26,963	4%	682,391	13,221	2%
UNMH	553,866	527,692	26,174	5%	538,454	15,412	3%
SRMC	38,917	40,769	(1,851)	-5%	38,663	255	1%
UNMMG	102,828	100,188	2,640	3%	105,275	(2,446)	-2%
Operating (Loss)/Gain							
HS	(51,586)	(50,286)	(1,300)	3%	(52,204)	618	-1%
UNMH	(50,870)	(49,382)	(1,488)	3%	(51,254)	384	-1%
SRMC	90	45	44	97%	(421)	511	-121%
UNMMG	(806)	(949)	143	-15%	(529)	(277)	52%
Non-Operating Revenue							
HS	55,770	52,130	3,640	7%	52,273	3,497	7%
UNMH	53,157	49,601	3,556	7%	51,256	1,901	4%
SRMC	(70)	1,036	(1,105)	-107%	427	(496)	116%
UNMMG	2,682	1,493	1,189	80%	591	2,092	354%
Increase/(Decrease) in Net Position							
HS	4,184	1,844	2,340	127%	69	4,115	5978%
UNMH	2,287	218	2,068	948%	1	2,285	173914%
SRMC	20	1,081	(1,061)	-98%	6	15	261%
UNMMG	1,877	545	1,332	245%	62	1,815	2930%

UNM HS Total Operations
YTD December 31, 2018
(In thousands)

	Total HS	Total HS Prior Year	FY 18 vs. FY 19		Total HS FY 19 Budget	Budget Variance
			Change	% Change		
Total NET Patient Revenue	617,120	601,504	15,617	3%	611,330	5,790
State/Local Contracts/Grants	1,620	1,563	56	4%	1,572	48
Other Operating Revenues	25,286	15,295	9,990	65%	17,284	8,001
Total Operating Revenues	644,025	618,362	25,663	4%	630,186	13,839
Total Operating Expenses	695,611	668,648	26,963	4%	682,391	13,221
Total Operating (Loss) Gain	(51,586)	(50,286)	(1,300)	3%	(52,204)	618
Total Net Non-Operating Revenue	55,770	52,130	3,640	7%	52,273	3,497
Total Increase in Net Position	4,184	1,844	2,340	127%	69	4,115

UNM HS Total Operations - Balance Sheet Snapshot

YTD December 31, 2018

(in thousands)	FY 2019	FY 2018	Change	
	Actual	Actual	\$	%
Cash & Cash Equivalents				
HS	309,669	289,442	20,227	7%
UNMH	257,642	236,375	21,267	9%
SRMC	25,577	26,851	(1,273)	-5%
UNMMG	26,450	26,216	234	1%
Total Assets				
HS	1,008,758	947,876	60,882	6%
UNMH	750,824	695,155	55,669	8%
SRMC	158,882	160,740	(1,858)	-1%
UNMMG	102,776	97,343	5,432	6%
Elimination	(3,723)	(5,362)	1,639	-31%
Total Liabilities				
HS	533,151	476,453	56,699	12%
UNMH	359,270	305,887	53,382	17%
SRMC	138,715	140,593	(1,878)	-1%
UNMMG	38,890	35,334	3,555	10%
Elimination	(3,723)	(5,362)	1,639	-31%
Total Net Position				
HS	475,607	471,423	4,184	1%
UNMH	391,555	389,268	2,287	1%
SRMC	20,166	20,146	20	0%
UNMMG	63,886	62,009	1,877	3%


UNM Health System - Cash Flow
YTD December 31, 2018
(In thousands)

	UNMH	UNMMG	SRMC	Total HS	Total HS FY 2018
Cash flows from operating activities					
Operating Income/(Loss)	\$ (50,870)	\$ (806)	\$ 90	\$ (51,586)	\$ (69,060)
Adjustments to reconcile increase in unrestricted net assets to net cash provided by operating activities:					
Depreciation and amortization	15,908	408	2,988	19,303	39,352
Provision for doubtful accounts	24,802	18,803	3,147	46,752	116,173
Changes in assets and liabilities:					
Net patient receivables	(31,971)	(17,597)	(1,728)	(51,296)	(117,474)
Third-party settlements	22,589	-	(277)	22,313	2,965
Due from affiliates	232	(2,300)	(952)	(3,021)	(521)
Other receivables	(1,782)	(2,448)	33	(4,198)	(4,453)
Prepays & Inventory	3,166	(284)	(130)	2,752	(2,713)
Accounts Payable	(14,963)	4,597	1,188	(9,178)	(21,098)
Due to affiliates	55,309	(1,393)	(1,067)	52,848	4,040
Accrued liabilities	57	352	326	735	7,319
Net cash (used in) provided by operating activities	22,476	(669)	3,617	25,424	(45,470)
Cash flows from noncapital financing activities					
Cash received from county mill levy	23,066	-	32	23,098	102,067
Cash received from appropriations and contributions	7,600	552	10	8,163	14,957
Cash payments for Mission Support	(10,697)	-	850	(9,847)	-
Net cash provided by noncapital financing activities	19,970	552	892	21,413	117,024
Cash flows from capital financing activities					
Purchases of capital assets - net acquisitions & disposals	(17,306)	(377)	(693)	(18,376)	(28,103)
Inflows (outflows) to trustee accounts	(2,866)		52	(2,814)	716
Interest payments on bonds	(1,520)		(2,752)	(4,272)	(8,751)
Principal payments on bonds	-	-	(1,920)	(1,920)	(9,274)
Cash payments for mortgage reserve fund	(142)		(967)	(1,109)	(1,964)
Principal payments on mortgage	(2,758)		(1,932)	(4,690)	(9,098)
Cash payments for mortgage-related activities	(217)	-	(486)	(703)	(1,761)
Net cash (used in) provided by capital financing activities	(24,809)	(377)	(8,697)	(33,883)	(58,235)
Cash flows from investing activities					
Investment income	3,144	341	2,916	6,401	11,462
Net Proceeds from investments -Triwest/TRL/TLSC/Lovelace Reha	-	386	-	386	1,429
Net cash (used in) provided by investing activities	3,144	727	2,916	6,787	12,891
Net increase (decrease) in cash and cash equivalents	20,781	234	(1,273)	19,741	26,211
Cash and cash equivalents, beginning of year	201,784	26,216	26,851	254,851	228,640
Cash and cash equivalents, end of year	\$ 222,565	\$ 26,450	\$ 25,577	\$ 274,592	\$ 254,851


Transfers to UNMH




UNMH - Average Occupancy in Adult Licensed Beds (by Month)



Emergency Room Census with over 20 patients with Admit Status




UNMH Emergency Department Average Wait Hours for a Bed




SRMC - Average Occupancy in Adult Licensed Beds (by Month)


Billed Data based on Midnight Census




Transfers to UNMH




UNMH - Average Patients in Adult Licensed Beds (by Month)




UNMH - Average Occupancy in Adult Licensed Beds (by Month)




UNMH Emergency Department Wait Hours for a Bed




Number of Diverted Patients from UNM



Number of Warm Hand Offs




Transfers to SRMC and Diversions from SRMC




SRMC - Average Patients in Adult Licensed Beds (by Month)

Billed Data based on Midnight Census




SRMC - Average Occupancy in Adult Licensed Beds (by Month)

Billed Data based on Midnight Census



SRMC Emergency Department Wait Hours for a Bed



MEMORANDUM

January 28, 2019

TO: UNM Board of Regents Health Sciences Center Committee

FROM: Rick Holmes, Office of the University Secretary

SUBJECT: Approval of appointments of endowed position holders from the Health Sciences Center

Upon recommendation of the Health Sciences Cancer Center, the University Naming Committee approved the appointment of the endowed position holders listed below:

- Request approval to appoint **Leslie Andritsos, MD**, as the new holder of the Cancer Center's Maralyn S. Budke; Endowed Professorship in Leukemia, Transplantation, and Cell-Based Therapeutics
(3.2.6. Endowed Faculty Positions)
- Request approval to appoint **Diane Lidke, PhD**, as the new holder of the Cancer Center's Victor and Ruby Hansen Surface Endowed Professorship in Cancer Cell Signal Transduction and Cellular Imaging
(3.2.6. Endowed Faculty Positions)
- Request a request approval to appoint **Eric Prossnitz, PhD**, as the new holder of the Cancer Center's Maralyn S. Budke Endowed Chair in Cancer Chemical Biology and Therapeutics.
(3.2.6. Endowed Faculty Positions)


Please place these items on the next Health Sciences Center Committee meeting agenda for consideration.

Thank you.

Attachments

MEMO

To: Cinnamon Blair
Chair, UNM Naming Committee

From: Cheryl Willman, MD  On behalf of Dr. Cheryl Willman, MD
Maurice and Marguerite Liberman Distinguished Chair in Cancer Research
Director & CEO, UNM Comprehensive Cancer Center (UNMCCC)

Date: January 14, 2019

Re: Appointment of the Maralyn S. Budke Endowed Professorship in Leukemia,
Transplantation, and Cell-Based Therapeutics

Leslie Andritsos, M.D.
Professor and Vice-Chief, Division of Hematology & Oncology, Department of
Internal Medicine, UNM School of Medicine
Leader, UNM Comprehensive Cancer Center, Clinical Programs in Hematologic
Malignancies, Transplantation, and Cell Based Therapies

Dear Ms. Blair and Members of the UNM Foundation Naming Committee,

On behalf of the University of New Mexico Comprehensive Cancer Center, we request approval to appoint Leslie Andritsos, MD, as the new holder of the Cancer Center's Maralyn S. Budke Endowed Professorship in Leukemia, Transplantation, and Cell-Based Therapeutics.

This Endowed Professorship was created and approved in October 2010 by the UNM Board of Regents according to Regents Policy 2.11 and University Business Policy 1020. This Professorship was previously held by Dr. Bridget Wilson (and was previously named the Maralyn S. Budke Endowed Professorship in Cancer Cell Signaling) who retired from UNM on 6/30/2018. As prescribed by Faculty Handbook Policy C170 "Endowed Chairs and Named Professorships" we seek approval to appoint Dr. Andritsos as the new holder of this Endowed Professorship.

As an outstanding New Mexican, former director of the Legislative Council Service and Chief of Staff to two New Mexico Governors, Ms. Budke was a notable New Mexican. She was also devoted to UNM, particularly UNM Hospital, School of Medicine, and the Comprehensive Cancer Center. In January 2010, Ms. Budke passed from cancer and was very grateful to the doctors and nurses at the UNM Cancer Center who cared for her through her illnesses. Ms. Budke established a significant endowment fund which was directed to establish endowed chairs and professorships in cancer science and care, consistent with the current needs of the UNM Comprehensive Cancer Center, as determined by the UNMCCC Director & CEO.

Our belief is Dr. Andritsos will carry forward this important legacy and be an outstanding representative of the qualities required of the Endowed Professorship position. Dr. Andritsos is an outstanding accomplished, renowned, and internationally known physician scientist and an expert in the treatment of leukemia, stem cell transplantation, and the new field of cell-based therapies and immunotherapies. We were very fortunate to recruit her to UNM where she will work with a team to continue to build New Mexico's only stem cell transplantation and cell-based therapies program. Dr. Andritsos is also an excellent educator and mentor of medical students, trainees, and young faculty. She also has excellent leadership skills, currently serving as Chief of the Division of Hematology/Oncology in the Department of Internal Medicine, and she holds several leadership roles in the UNMCCC.

Thank you for your time and consideration of this request.

Leslie A. Andritsos, M.D.

Curriculum Vitae

The University of New Mexico
1201 Camino de Salud NE
MSC07 4025
Albuquerque, New Mexico 87102
Phone: 505.925.0405
Fax: 505.925.0408
Mobile: 614.670
Landritsos@salud.unm.edu

CURRENT POSITION

Professor of Internal Medicine
Associate Division Chief
Division of Hematology Oncology and Blood and Marrow Transplantation
Department of Internal Medicine
The University of New Mexico

CHRONOLOGY OF EDUCATION

Aug 1995 – May 1999 University of Texas Medical Branch
Galveston, Texas
Degree: M.D.

May 1990 Texas Tech University
Lubbock, Texas
Degree: B.A.

POSTDOCTORAL TRAINING

June 2004 – July 2005 Fellowship, Stem Cell Transplantation and Leukemia
Barnes-Jewish Hospital, St. Louis, Missouri
Washington University School of Medicine St. Louis, Missouri

July 2001 – June 2004 Fellowship, Hematology/Oncology
Barnes-Jewish Hospital, St. Louis, Missouri
Washington University School of Medicine St. Louis, Missouri

June 1999 - June 2001 Intern and Resident, Internal Medicine
Barnes-Jewish Hospital, St. Louis, Missouri
Washington University School of Medicine St. Louis, Missouri

CHRONOLOGY OF EMPLOYMENT AND ACADEMIC APPOINTMENTS

August 2018 – Present	Professor of Internal Medicine Associate Division Chief
-----------------------	--

Division of Hematology Oncology
Department of Internal Medicine
The University of New Mexico
Albuquerque, New Mexico

Jun 2016 – Sept 2017	Co-Director Division of Hematology, Department of Internal Medicine The Ohio State University Wexner Medical Center Columbus, Ohio
May 2016 – Sept 2017	Section Head, James Cancer Network Division of Hematology, Department of Internal Medicine James Cancer Hospital Columbus, Ohio
Aug 2015 – Sept 2017	Director of Clinical Operations Division of Hematology, Department of Internal Medicine The Ohio State University Wexner Medical Center Columbus, Ohio
Sept 2013 – Jun 2018	Associate Professor of Medicine, Clinical Division of Hematology, Department of Internal Medicine The Ohio State University Wexner Medical Center Columbus, Ohio
Feb 2012 – Aug 2015	Clinical Director, Blood and Marrow Transplant Program Division of Hematology, Department of Internal Medicine The Ohio State University Wexner Medical Center Columbus, Ohio
July 2011 – Aug 2015	Medical Director of Quality, Blood and Marrow Transplant Program Division of Hematology, Department of Internal Medicine The Ohio State University Wexner Medical Center Columbus, Ohio
Sept 2006 – Aug 2013	Assistant Professor of Medicine Division of Hematology, Department of Internal Medicine The Ohio State University Wexner Medical Center Columbus, Ohio
Aug 2005 – July 2006	Assistant Professor of Clinical Medicine Division of Hematology/Oncology, Department of Internal Medicine University of Arizona Arizona Cancer Center University Medical Center Tucson, Arizona

HONORS AND AWARDS

1999	Alpha Omega Alpha
2002	Knowlton Award for Excellence in Medicine
2003	American Society of Hematology Clinical Research Training Institute
2005	Young Investigator Award, American Society for Blood and Marrow Transplantation
2007	CALGB Outstanding Achievement in Clinical Cancer Research
2010	Patient Satisfaction Award, OSUMC

2014 FAME Faculty Leadership Institute, OSUMC
 2014 Teaching Award, Department of Internal Medicine
 2015 Best Doctors Database
 2015 Nominated Chief-of-Staff Elect, Medical Staff Administrative Committee, OSUMC

SERVICE

Intramural

2004-2005	Institutional Review Board New Protocol Committee, Washington University, St. Louis, Missouri
2005-2006	Fellowship Committee, Arizona Cancer Center, Tucson, Arizona
2005-2006	Hematology Fellowship Curriculum and Training
2005-2006	Chair, Hematopathology Case Review Committee, Arizona Cancer Center, Tucson Arizona
2005-2006	Chair, Subcommittee for Apheresis Procedures, Blood and Marrow Transplant Program
2007-2008	Fellowship Review Committee
2009-present	Comprehensive Transplant Center Education Committee
2009-present	Venous Thrombosis Prophylaxis Guidelines in Cancer Patients Committee
2009-2010	OSUCCC James Cancer Hospital & Solove Research Institute Medical Staff Administrative Committee (MSAC)
2009-2010	OSUCCC James Cancer Hospital & Solove Research Institute Patient Satisfaction Taskforce Workgroup
2011-2015	Medical Director, Blood and Marrow Transplant Program Quality Committee
2012-present	Chair, Sentinel Event Committee, Sentinel Event #83156"
2012-present	Leader, James Cancer Hospital Sepsis Detection and Intervention Project Team
2013-present	Health System Infection Prevention Committee
2013-present	Expansion Transition Subcommittee: Inpatient Acute Care
2013-present	Graft vs. Host Disease (GVHD Grading) Committee
2013-present	Bone and Marrow Transplant Clinical Quality Management and Patient Safety (BMT CQM & PS) Committee
2013-present	Leader, Leading Edge Advanced Practice Topics (LEAPT) Sepsis Work Group
2013-present	Leader, Environment of Care and C. Diff Reduction Task Force
2014-present	Hematology Representative, James Service Line Advisory Committee
2014-present	Member, Transfusion and Isoimmunization Committee
2014-present	Antibiotics Committee, Subcommittee of the Pharmacy, Therapeutics and Drug Utilization Committee
2014-present	Ambulatory Experience Steering Committee
2014-present	Finance Committee, Division of Hematology
2014-present	James Cancer Hospital Clinical Operations, Quality and Safety Committee
2014-present	Patient Education Content Review Committee
2015-present	Division of Hematology Leadership Council
2015-Present	Hematology representative, James Medical Staff Advisory Committee
2015-present	Leader, James Cancer Network Tele-Tumor Board
2016-2017	Chair, Clinical Operations Committee, Division of Hematology
2016-present	James Immediate Center Care Steering Committee
2016-present	Sickle Cell Steering Committee

Extramural

2005-2006	Southwest Oncology Group
2009-present	Center for International Blood and Marrow Transplant Research (CIBMTR) Chronic Leukemia Working Committee
2009-present	American Society of Blood and Marrow Transplant, Chronic Leukemia Working Committee
2009-present	Cancer and Leukemia Group B (CALGB) Transplant Core Committee
2010-present	Member, Hairy Cell Leukemia Foundation (Formerly Hairy Cell Leukemia Research Consortium)
2013-present	Center for International Blood and Marrow Transplant Research (CIBMTR) Lymphoma Working Committee
2014-present	Chair, Steering Committee, Hairy Cell Leukemia Foundation Patient Data Registry
2015-present	Scientific Program Committee on the Hematologic Malignancies- Lymphoma and CLL, American Society of Clinical Oncology
2016-present	American Society of Hematology MMSAP Career Development Mentor

Society Memberships

2003 –	American Board of Internal Medicine
2005 –	American College of Physicians
2005 –	American Society of Hematology
2005 –	American Society of Blood and Marrow Transplantation
2014 –	American Association of Cancer Research
2015 –	American Society of Clinical Oncology

Editorial Activities/Grant Reviewer

2011	<i>Blood</i>
2011	Editor-in-Chief – <i>Hem Onc Update</i>
2012	<i>Cancer</i>
2012	<i>Journal of Clinical Oncology</i>
2014	<i>Drugs of Today</i>
2014	<i>Biology of Blood and Marrow Transplantation</i>
2015	<i>Genes, Chromosomes and Cancer</i>
2015	<i>Transplant Infectious Disease</i>
2015	Grant Reviewer - National Science Centre (Narodowe Centrum Nauki – NCN), Poland
2015	<i>Cancer</i>
2015	<i>HemOnc Today</i>
2015	<i>Plos One</i>
2015	<i>Tumori Journal</i>
2016	Bloodwise – United Kingdom
2017	<i>Archiv der Pharmazie</i>
2017	<i>European Journal of Hematology</i>
2017	<i>Expert Opinion on Investigational Drugs</i>
2017	<i>Future Oncology</i>
2017	<i>Leukemia</i>
2017	<i>Oncotarget</i>
2018	<i>Annals of Internal Medicine</i>
2018	<i>Clinical Advances in Hematology and Oncology</i>
2018	<i>Expert Opinion on Biological Therapy</i>

LICENSURE AND CERTIFICATION

2016 Diplomat, American Board of Internal Medicine, Hematology
2003 Diplomat, American Board of Internal Medicine, expires 2013
2005 Board eligible in Oncology

Active Missouri Medical License #2003018899
Active Ohio Medical License # 35088745

TEACHING

Undergraduate, graduate, and professional courses taught

- 2003 - Washington University School of Medicine, Hematology, medical student didactic course in addition to lab exercises and microscopy.
- 2008 – The Ohio State University School of Medicine, Med 1 Integrated Pathway, Hematology/Host Defense, Chronic Lymphocytic Leukemia. Didactic.
- 2009 - The Ohio State University School of Medicine, Med 1 Integrated Pathway, Hematology/Host Defense, Chronic Lymphocytic Leukemia. Didactic.
- 2010 - The Ohio State University, Medical Student Host Defense lecture series. Chronic Lymphocytic Leukemia. Didactic.
- 2011 - Department of Internal Medicine, Division of Hematology, Basic and Clinical Science Core Conference. Stem Cell Transplantation for Treatment of Follicular Lymphoma. Didactic.
- 2014 – The Ohio State University, Medical Student Host Defense. Blood and Marrow Transplantation. Didactic.
- 2015 – The Ohio State University, Medical Student Host Defense. Blood and Marrow Transplantation eLearning module. Didactic.

Precepting

- 2007 – Med I DPR Preceptorship, The Ohio State University.
- 2007 – Med II Hospital Based Preceptorship, The Ohio State University.
- 2008 – Internal Medicine Online Journal Club, The Ohio State University.
- 2009 – Medical Student Host Defense (Chronic Lymphocytic Leukemia), The Ohio State University.
- 2010 – Medical Student Host Defense (Chronic Lymphocytic Leukemia), The Ohio State University.
- 2011 – Med II Hospital Based Preceptorship, The Ohio State University.
- 2012 – Med II Hospital Based Preceptorship, The Ohio State University.
- 2013 – Longitudinal Practice Preceptorship, The Ohio State University
- 2013 – Ambulatory Care Clerkship, The Ohio State University

INVITED PRESENTATIONS

1. Andritsos LA, Lecturer. 2001. "Leukemia Cutis." Presented at Washington University Hematology/Oncology Grand Rounds, to Washington University Hematology/Oncology faculty and staff. St. Louis, MO. (November 9)
2. Andritsos LA, Lecturer. 2002. "Post-Transfusion Purpura." Presented at Washington University Hematology/Oncology Grand Rounds, to Washington University Hematology/Oncology faculty and staff. St. Louis, MO. (January 18) [Peer Reviewed]
3. Andritsos LA, Lecturer. 2002. "Acquired Von-Willebrand Disease." Presented at Washington University Hematology/Oncology Grand Rounds, to Washington University Hematology/Oncology faculty and staff. St. Louis, MO. (March 22) [Peer Reviewed]
4. Andritsos LA, Lecturer. 2002. "Hairy Cell Leukemia." Presented at Washington University Hematology/Oncology Grand Rounds, to Washington University Hematology/Oncology faculty and staff. St. Louis, MO. (May 3) [Peer Reviewed]
5. Andritsos LA, Lecturer. 2002. "Iron Deficiency in Celiac Disease." Presented at Washington University Hematology/Oncology Grand Rounds, to Washington University Hematology/Oncology faculty and staff. St. Louis, MO. (June 7) [Peer Reviewed]
6. Andritsos LA, Lecturer. 2002. "Thymoma." Presented at Washington University Hematology/Oncology Grand Rounds, to Washington University Hematology/Oncology faculty and staff. St. Louis, MO. (October 18) [Peer Reviewed]
7. Andritsos LA, Lecturer. 2003. "MTHFR Gene Mutations and Thrombosis." Presented at Washington University Hematology/Oncology Grand Rounds, to Washington University Hematology/Oncology faculty and staff. St. Louis, MO. (March 28) [Peer Reviewed]
8. Andritsos LA, Lecturer. 2003. "Porphyria Cutanea Tarda." Presented at Washington University Hematology/Oncology Grand Rounds, to Washington University Hematology/Oncology faculty and staff. St. Louis, MO. (May 16) [Peer Reviewed]
9. Andritsos LA, Lecturer. 2004. "Castleman's Disease." Presented at Washington University Hematology/Oncology Grand Rounds, to Washington University Hematology/Oncology faculty and staff. St. Louis, MO. (January 16) [Peer Reviewed]
10. Andritsos LA, Lecturer. 2005. "Stem Cell Mobilization: Current Therapies and Future Directions." Presented at Washington University Hematology/Oncology Grand Rounds, to Washington University Hematology/Oncology faculty and staff. St. Louis, MO. (January 14) [Peer Reviewed]
11. Andritsos LA, Lecturer. 2005. "Clinical Trials of AMD3100 and Stem Cell Mobilization." Presented at Washington University Hematology/Oncology Grand Rounds, to Washington University Hematology/Oncology faculty and staff. St. Louis, MO. (May 27) [Peer Reviewed]
12. Andritsos LA, Presenter. 2009. "Follicular: Non-Hodgkin's lymphoma and T-Cell Non-Hodgkin's lymphoma." Presented at American Society of Hematology Review. Columbus, Ohio. (January) [Peer Reviewed]
13. Andritsos LA, Lecturer. 2009. "T-Cell Non-Hodgkin's lymphoma." Presented to Cancer and

Leukemia Group B. (June 27) [Peer Reviewed]

14. Andritsos LA, Lecturer. 2009. "T-Cell Non-Hodgkin's lymphoma." Presented to Cancer and Leukemia Group B. (September 11)[Peer Reviewed]
15. Andritsos LA, Lecturer. 2009. "Stem Cell Transplantation." Presented to Leukemia Lymphoma Society. (December 1) [Peer Reviewed]
16. Andritsos LA, Presenter. 2010. "Bone Marrow Transplantation." Presented at American Society of Hematology Review. Columbus, Ohio. (January) [Peer Reviewed]
17. Andritsos LA, Lecturer. 2010. "T-Cell Non-Hodgkin's lymphoma." Presented to Cancer and Leukemia Group B. (March 19) [Peer Reviewed]
18. Andritsos LA, Lecturer. 2010. "Autologous Stem Cell Transplantation for Diffuse Large B-cell Lymphoma." Presented at BMT Journal Club, to Division of Hematology. (September) [Peer Reviewed]
19. Andritsos LA, Lecturer. 2010. "Acute Graft vs. Host Disease." Presented at Immunology Journal Club. (September) [Peer Reviewed]
20. Andritsos LA, Lecturer. 2011. "Stem cell transplantation for CLL and Low Grade Lymphoma." Presented at Fellowship Lecture Series, to Division of Hematology. [Peer Reviewed]
21. Andritsos LA, Lecturer. 2011. "T-Cell Non-Hodgkin's lymphoma." Presented to Cancer and Leukemia Group B. (March) [Peer Reviewed]
22. Andritsos LA, Lecturer. 2011. "Allogeneic Transplant for Multiple Myeloma." Presented at BMT Journal Club, to Division of Hematology. (March) [Peer Reviewed]
23. Andritsos LA, Lecturer. 2012. "First and Second Line Treatment of Acute GVHD." Presented at BMT Journal Club, to Division of Hematology (August) [Peer reviewed]
24. Andritsos LA, Presenter. 2013. "Targeting BTK in Relapsed/Refractory Hairy Cell Leukemia." Presented at Hairy Cell Leukemia Consortium Meeting, New York, New York, United States. (May) [Peer reviewed]
25. Andritsos LA, Presenter. 2014. "Early Warning Signs of Sepsis." Presented at BMT Program Clinical Quality Management and Patient Safety Meeting, The Ohio State University, Columbus, Ohio, United States. (April)
26. Andritsos LA. Presenter. 2014 "Concept for an International Patient Data Registry." Presented at Hairy Cell Leukemia Foundation Meeting. Houston, Texas, United States. (May) [Peer Reviewed]
27. Andritsos LA, Presenter. 2015. "Blood and Marrow Transplantation". Presented at American Society of Hematology Review. The Ohio State Medical University, Columbus, Ohio, United States. (January) [Peer Reviewed]
28. Andritsos LA. Presenter. 2015. "Proposed Utilization of Patient Data Registry." Presented at Hairy Cell Leukemia Foundation Meeting, Chicago, Illinois, United States. (May) [Peer reviewed]

29. Andritsos LA. Presenter. 2015. "International Hairy Cell Leukemia Patient Registry." Presented at Hairy Cell Leukemia Foundation Meeting, Chicago, Illinois, United States. (May) [Peer reviewed]
30. "Advanced Early Diagnosis and Early Therapy of Cancer." PCS Global Cancer Conference (GCC-2015.) Warsaw, Poland. (October) *Unable to attend.*
31. Andritsos LA. Presenter. 2015. "Diversity in Medicine." Presented at Department of Internal Medicine Grand Rounds, The Ohio State Medical University, Columbus, OH, United States. (October)
32. Andritsos LA. Presenter. 2016. "The Importance of Philanthropy in the Fight against Cancer." Presented at Phi Beta Psi State Convention, Columbus, Ohio, United States. (April)
33. Andritsos LA. Presenter. 2016. "Breakout Session 1: Living with HCL – Quality of Life Presentation." Presented at Hairy Cell Leukemia Foundation Annual Meeting, Heidelberg University Heidelberg, Germany. (May)
34. Andritsos LA. Presenter. 2016. "Governance and Utilization of Patient Data Registry." Presented at Hairy Cell Leukemia Foundation Annual Meeting, Heidelberg University Heidelberg, Germany. (May)
35. Andritsos LA. Chair. 2016. "Integrating New Diagnostics in Lymphoid Malignancies." American Society of Clinical Oncology Annual Meeting, McCormick Place, Chicago, IL, United States. (June)
36. Andritsos LA, Cole K. Presenter. 2016. "How to create, develop, and retain a diverse faculty and workforce." Presented at Annual Meeting of the Women Faculty of the College of Medicine, The Ohio State Medical University, Columbus, OH, United States. (October)
37. Andritsos LA. Presenter. 2016. "Chronic Lymphocytic Leukemia." Presented at the 2016 Hematology Preceptorship for Sanofi Genzyme, The Ohio State Medical University, Columbus, OH, United States. (November)
38. Andritsos LA. Chair. 2017. "Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia." American Society of Clinical Oncology Annual Meeting, McCormick Place, Chicago, IL, United States. (June)
39. Andritsos LA. Presenter. 2017. "Welcome and Introductions." Presented at 2017 American Society of Clinical Oncology Annual Meeting, McCormick Place, Chicago, IL, United States. (June)
40. Andritsos LA, Angelina M, Omkar L, Heckler C, Johnson K, Jenson K. Lead Discussants. 2017. "Patient Data Registry for Investigators." Presented at Hairy Cell Leukemia Foundation Annual Meeting, The Ohio State University, Columbus, OH. (October)
41. Andritsos LA, Anghelina M, Johnson K, Lele O, Heckler C, Jensen K. Lead Discussants. 2017. "Break Out Session for Clinical Research Coordinators Only." Presented at Hairy Cell Leukemia Foundation Annual Meeting, The Ohio State University, Columbus, OH. (October)
42. Andritsos LA, Jensen K. Presenter. 2017. "HCL Data Registry for Patients – Importance, Purpose & Outcomes." Presented at Hairy Cell Leukemia Foundation Annual Meeting, The

Ohio State University, Columbus, OH. (October)

43. Ho A, Lustberg M, Andritsos LA. Presenter 2017. "Infections, Relapse, & Long-term Side Effects." Presented at Hairy Cell Leukemia Foundation Annual Meeting, The Ohio State University, Columbus, OH. (October)

PEER-REVIEWED PUBLICATIONS

1. Walling DM, **Andritsos LA**, Etienne W, Payne DA, Aronson JF, Flaitz CM, Nichols CM. Molecular Markers of Clonality and Identity in Epstein-Barr Virus-Associated B-Cell Lymphoproliferative Disease. *J Med Virol*. 2004 Sep 7; 74:94-101. PMID: 15258974.
2. Bennett CL, Evens EM, **Andritsos LA**, Balasubramanian L, Mai M, Fisher M, Kuzel TM, Angelotta C, McKoy JM, Vose JM, Bierman PJ, Kuter PJ, Trifilio SM, Devine SM, Tallman MS. Haematological Malignancies Developing in Previously Healthy Individuals Who Received Haematopoietic Growth Factors: Report From the Research on Adverse Drug Events and Reports (RADAR) Project. *Br J Haematol*. 2006 Dec; 135:12. PMID: 17054431.
3. **Andritsos LA**, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, May SE, Raymond CA, Wang D, Knight RD, Ruppert AS, Lehman A, Jarjoura D, Chen C, Byrd JC. Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia. *J Clin Oncol*. 2008 May 20; 26 (15), 2519-25. PMC: 4312490.
4. **Andritsos LA**, Lin TS, Blum W, Kefauver C, Johnson AJ, Byrd JC. Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia – Reply. *J Clin Oncol*. 2008 October; 26(29): 4852-4853.
5. Lapalombella R, Yu B, Triantafillou G, Liu Q, Butcher JP, Lozanski G, Ramanunni A, Smith LL, Blum W, **Andritsos LA**, Wang DS, Lehman A, Chen CS, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC. Lenalidomide Down-Regulates the CD20 Antigen and Antagonizes Direct and Antibody-Dependent Cellular Cytotoxicity of Rituximab on Primary Chronic Lymphocytic Leukemia Cells. *Blood*. 2008 Dec 15; 112 (13) 5180-89. PMID: 18772452. PMC: 2597613.
6. Hamadani M, Blum W, Phillips G, Elder P, **Andritsos LA**, Hofmeister C, O'Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin TS, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM. Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Anthracycline Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic Transplantation for Hematologic Malignancies. *Biol Blood Marrow Transplant*. 2009 Nov; 15(11):1422-30. PMC3953136.
7. Lin T, Ruppert A, Johnson A, Fishcer B, Heerema N, **Andritsos L**, Blum K, Flynn J, Jones J, Hu W, Moran M, Mitchell S, Smith L, Wagner A, Raymond C, Schaaf L, Phelps M, Villalona M, Grever M, Byrd J. A Phase II Study of Flavopiridol (Alvocidib) in Relapsed, Chronic Lymphocytic Leukemia (CLL): High Response Rates in Genetically High-Risk Disease. *J Clin Oncol*. 2009 Dec 10; 27(35): 6012-8. PMC: 2793044.
8. Woyach JA, Heerema NA, Zhao J, McFaddin A, Stark A, Lin TS, **Andritsos LA**, Blum KA, FlynnJM, Jones JA, Byrd JC. Dic (17;18) (p11.2;p11.2) is a Recurring Abnormality in Chronic Lymphocytic Leukaemia Sassociated with Aggressive Disease. *Br J Haematol*. 2010 Mar; 148(5):754. PMID: 20015097. PMC: 2902554.

9. Flynn JM, **Andritsos LA**, Lucas D, Byrd JC. Second malignancies in B-cell chronic lymphocytic leukaemia: possible association with human papilloma virus. *Br J Haematol*. 2010 May; 149(3):388-90. PMC: 4038061.
10. Lapalombella R, **Andritsos LA**, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Chen C, Rader C, Ford R Jr, Muthusamy N, Johnson AJ, Byrd JC. Lenalidomide Treatment Promotes CD154 Expression on CLL Cells and Enhances Production of Antibodies by Normal B Cells Through a PI3-Kinase Dependent Pathway. *Blood*, 2010 Apr 1; 115 (13) 2619-2629. PMC: 2852364.
11. Blum KA, Liu Z, Lucas DM, Chen P, Xie Z, Baiocchi Ra, Benson DM, Devine SM, Jones JA, **Andritsos LA**, Flynn JM, Plass C, Marcucci G, Chan KK, Grever MR, Byrd JC. Phase I Trial of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma: Dose-Limiting Myelosuppression Without Evidence of DNA Hypomethylation. *Br J Haematol*. 2010 Jul; 150(2):189-95. PMC: 2917115.
12. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, **Andritsos L**, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd, JC, Johnson AJ. Phosphatidylinositol 3-Kinase- δ Inhibitor CAL-101 Demonstrates Promising Pre-Clinical Activity in Chronic Lymphocytic Leukemia by Antagonizing Intrinsic and Extrinsic Cellular Survival Signals. *Blood*, 2010 Sep 23; 116(12):2078-88. PMC: 2951855.
13. Muthusamy N, Breidenbach H, **Andritsos L**, Flynn J, Jones J, Ramanunni A, Mo X, Jarjoura D, Byrd JC, Heerema NA. Enhanced Detection of Chromosomal Abnormalities in Chronic Lymphocytic Leukemia by Conventional Cytogenetics Using CpG Oligonucleotide in Combination with Pokeweed Mitogen and Phorbol Myristate Acetate. *Cancer Genet*. 2011 Feb; 204(2):77-83. PMC: 3073597.
14. Hamadani M, Craig M, Phillips, GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, **Andritsos LA**, Garzon, R, Benson, DM, Blum W, Devine SM. Higher Busulfan Dose Intensity Does Not Improve Outcomes of Patients Undergoing Allogeneic Hematopoietic Cell Transplantation Following Fludarabine, Busulfan-based Reduced Toxicity Conditioning. *Hematol Oncol*. 2011 Dec; 29(4):2002-10. PMC: 3557914.
15. Blum KA, Ruppert AS, Woyach JA, Jones JA, **Andritsos L**, Flynn JM, Rovin B, Villalona-Calero M, Ji J, Phelps M, Johnson AJ, Grever MR, Byrd JC. Risk Factors for Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol. *Leukemia*. 2011 Sep; 25(9):1444-51. PMC: 3162125.
16. Troeger A, Johnson AJ, Wood J, Blum W, **Andritsos LA**, Byrd JC, Williams DA. RhoH is Critical for Cell-Microenvironment Interactions in Chronic Lymphocytic Leukemia in Mice and Humans. *Blood*. 2012 May 17; 119(20):4708-18. PMC: 3367874.
17. Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, Staubli J, Lucas DM, Mani R, Herman SE, Johnson AJ, Lozanski A, **Andritsos L**, Jones J, Flynn JM, Lannutti B, Thompson P, Algate P, Stromatt S, Jarjoura D, Mo X, Wang D, Chen CS, Lozanski G, Heerema NA, Tridandapani S, Freitas MA, Muthusamy N, Byrd JC. Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals. *Cancer Cell*. 2012 May 15; 21(5):694-708. PMC: 3360882.

18. Mahoney E, Lucas DM; Gupta S, Wagner Amy, Smith L, Herman S; Yuh-Ying Y, **Andritsos L**, Jones JA, Flynn JM, Blum KA, Zhang X, Lehman A, Kong H, Metlin G, Grever M, Johnson A, Byrd JC. ER Stress and Autophagy: New Players in the Mechanism of Action and Drug Resistance of the Cyclin- Dependent Kinase Inhibitor Flavopiridol. *Blood*. 2012 Aug 9; 120(6):1262-73. PMC: 3418721.
19. Cohen JB, Caveliere R, Byrd JC, **Andritsos LA**. Hearing Loss Due to Infiltration of the Tympanic Membrane by Chronic Lymphocytic Leukemia. *Case Rep Hematol*. 2012; 2012: 589718. PMC: 3502771.
20. Jaglowski SM, Ruppert AS, Heerema NA, Bingman A, Flynn JM, Grever MR , Jones JA, Elder P, Devine SM, Byrd JC, **Andritsos LA**. Complex Karyotype Predicts for Inferior Outcomes Following Reduced-Intensity Conditioning Allogeneic Transplant for Chronic Lymphocytic Leukaemia. *Br J Haematol*. 2012 Oct; 159(1):82-7. PMC: 3719859.
21. Kaffenberger B, Wong H, Jarjour W, **Andritsos LA**. Remission of Psoriasis After Allogeneic, but Not Autologous, Hematopoietic Stem Cell Transplantation. *J Am Acad Dermatol*. 2013 Mar; 68(3):489-92. PMID: 22981608.
22. Cohen JB, Hall NC, Ruppert AS, Jones JA, Porcu P, Baiocchi R, Christian BA, Penza S, Benson DM Jr, Flynn J, **Andritsos LA**, Devine SM, Blum KA. Association of Pre-Transplantation Positron Emission Tomography/Computed Tomography and Outcome in Mantle Cell Lymphoma. *Bone Marrow Transplant*. 2013 Sep; 48(9):1212-7. PMID: 23584442.
23. Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Jacob NK, Lapalombella R, McGourty J, Moledor M, Lowe R, Setter B, Jones J, Flynn JM, **Andritsos L**, Devine S, Mo X, Jarjoura D, Tridandapani S, Algate P, Byrd JC, Muthusamy N. Glycovariant Anti-CD37 Monospecific Protein Therapeutic Exhibits Enhanced Effector Cell-Mediated Cytotoxicity Against Chronic and Acute B Cell Malignancies. *MAbs*. 2013 Sep; 5(5):723-35. PMC: 3851225.
24. Stephens DM, Ruppert AS, Maddocks K, **Andritsos L**, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JM. Cyclophosphamide, Alvocidib (Flavopiridol), and Rituximab, a Novel Feasible Chemotherapy Regimen for Patients with High-Risk Chronic Lymphocytic Leukemia. *Leuk Res*. 2013 Oct; 37(10):1195-9. PMC: 3934299.
25. Hertlein E, Beckwith KA, Lozanski G, Chen TL, Towns WH, Johnson AJ, Lehman A, Ruppert AS, Bolon B, **Andritsos L**, Lozanski A, Rassenti L, Zhao W, Jarvinen TM, Senter L, Croce CM, Symer DE, de la Chapelle A, Heerema NA, Byrd JC. Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease. *PLoS One*. 2013 Oct 9; 8(10):e76607. PMC: 3793922.
26. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frizzera FW, Smith LL, Smucker KA, Flynn JM, Jones JA, **Andritsos LA**, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. Ibrutinib is an Irreversible Molecular Inhibitor of ITK Driving a Th1-Selective Pressure in T Lymphocytes. *Blood*. 2013 Oct 10; 122(15):2539-49. PMC 3795457.
27. Abandeh FI, Lustberg M, Devine S, Elder P, **Andritsos L**, Martin SI. Outcomes of Hematopoietic SCT Recipients with Rhinovirus Infection: A Matched, Case-Control Study. *Bone Marrow Transplant*. 2013 Nov; 48(12):1554-7. PMID: 23872740.

28. Dubovsky JA, Chappell DL, Harrington BK, Agrawal K, **Andritsos LA**, Flynn JM, Jones JA, Paulaitis ME, Bolon B, Johnson AJ, Byrd JC, Muthusamy N. Lymphocyte Cytosolic Protein 1 is a Chronic Lymphocytic Leukemia Membrane-Associated Antigen Critical to Niche Homing. *Blood*. 2013 Nov 7; 122(19):3308-16. PMC: 3953089.
29. Jones JA, Rupert AS, Poi M, Phelps MA, **Andritsos L**, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JC. Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity in Relapsed and Refractory Non-Hodgkin's Lymphoma. *Am J Hematol*. 2014 Jan; 89(1):19-24. PMC: 4150545.
30. Zhong Y, El-Gamal D, Dubovsky JA, Beckwith KA, Harrington BK, Williams KE, Goettl VM, Jha S, Mo X, Jones JA, Flynn JM, Maddocks KJ, **Andritsos LA**, McCauley D, Shacham S, Kauffman M, Byrd JC, Lapalombella R. Selinexor Suppresses Downstream Effectors of B-Cell Activation, Proliferation and Migration in Chronic Lymphocytic Leukemia Cells. *Leukemia*. 2014 May; 28(5): 1158-1163. Epub 2014 Jan 13. PMC: 4013224.
31. Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, Spurgeon SE, **Andritsos LA**, Gopal AK, Leonard JP, Eisenfeld AJ, Bannink JE, Stromatt SC, Furman RR. A Phase I Study Evaluating the Safety and Tolerability of Orlertuzumab, an Anti-CD37 Mono-Specific ADAPTIR Therapeutic Protein in Chronic Lymphocytic Leukemia. *Blood*. 2014 Feb 27; 123(9):1302-8. PMC: 24381226.
32. Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks K, Jaglowski SM, **Andritsos LA**, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC. Impact of Targeted Therapy on Outcome of Chronic Lymphocytic Leukemia Patients with Relapsed del(17p13.1) Karyotype at a Single Center. *Leukemia*. 2014 June; 28(6): 1365-1368. Epub 2014 Jan 23. PMC: 4047185.
33. Beckwith KA, Frizzera FW, Stefanovski MR, Towns WH, Cheney C, Mo X, Deckert J, Croce CM, Flynn JM, **Andritsos LA**, Jones JA, Maddocks KJ, Lozanski G, Byrd JC, Muthusamy N. The CD37- Targeted Antibody-Drug Conjugate IMGN529 is Highly Active Against Human CLL and in a Aovel CD37 Transgenic Murine Leukemia Model. *Leukemia*. 2014 July; 28(7): 1501-1510. Epub 2014. Jan 23. PMC: 4090271.
34. Haverkos BM, McBride A, O'Donnell L, Scholl D, Whittaker B, Vasu S, Penza S, **Andritsos LA**, Devine SM, Jaglowski SM. An Effective Mobilization Strategy For Lymphoma Patients After Failed Upfront Mobilization With Plerixafor. *Bone Marrow Transplant*. 2014 August; 49(8): 1052-1055. Epub 2014 May. PMC: 4125480.
35. Patterson AT, **Andritsos L**, Allen CM, Gru A, Kaffenberger BH. Multifocal Epithelial Hyperplasia (Heck disease) In A Patient With Chronic Lymphocytic Leukemia. *J Cutan Pathol*. 2014 Aug 4; 41(8):694-6. PMID: 24754486.
36. El-Gamal D, Williams K, LaFollette TD, Cannon M, Blachly JS, Zhong Y, Woyach JA, Williams E, Awan FT, Jones J, **Andritsos L**, Maddocks K, Wu CH, Chen CS, Lehman A, Zhang X, Lapalombella R, Byrd JC. PKC- β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. *Blood*. 2014 Aug 28; 124(9):1481-91. Epub 2014 Jul 7. PMC: 4148770.
37. Maddocks K, Ruppert AS, Browning R, Jones J, Flynn J, Kefauver C, Gao Y, Jiang Y, Rozewski DM, Poi M, Phelps MA, Harper E, Johnson AJ, Byrd JC, **Andritsos LA**. A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic

lymphocytic leukemia. *Leuk Res*. 2014 Sep; 38(9):1025-9. Epub 2014 May 29. PMC: 4312491.

38. Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM Jr, Jaglowski S, Penza S, **Andritsos LA**, Devine SM. Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. *Support Care in Cancer*. 2014 Nov; 22(11):2911-6. Epub 2014 May 17. PMID: 24838259.
39. Pierceall WE, Warner SL, Lena RJ, Doykan C, Blake N, Elashoff M, Hoff DV, Bearss DJ, Cardone MH, **Andritsos L**, Byrd JC, Lanasa MC, Grever MR, Johnson AJ. Mitochondrial Priming of Chronic Lymphocytic Leukemia Patients Associates Bcl-xL Dependence With Alvocidib Response. *Leukemia*. 2014 November; 28(11): 2251-4. Epub 2014 Jul 3. PMC: 4221486.
40. Jaglowski S, Ruppert AS, Hofmeister C, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera YA, Benson DM, Devine SM, **Andritsos LA**. The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict For 30 day Readmission Following Autologous Stem Cell Transplant For Lymphoma And Multiple Myeloma. *Bone Marrow Transplantation*. 2014 October; 49(10): 1323-1329. Epub 2014 Jul 28. PMC: 4192086
41. **Andritsos LA**, Dunavin N, Lozanski G, Jones JA, Blachly JS, Lucas DM, Byrd JC, Kraut E, Grever MR. Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective. *Haematologica*. 2015 Jan; 100(1): e18-20. Epub 2014 Oct 31. PMC: 4281329
42. Blachly JS, Lozanski G, Lucas DM, Grever MR, Kendra K, **Andritsos LA**. Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib. *J Natl Compr Can Netw*. 2015 January; 13(1): 9-13. PMID: 25583765.
43. Liu TM, Ling Y, Woyach JA, Beckwith K, Yeh YY, Hertlein E, Zhang X, Lehman A, Awan F, Jones JA, **Andritsos LA**, Maddocks K, MacMurray J, Salunke SB, Chen CS, Phelps MA, Byrd JC, Johnson AJ. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. *Blood*. 2015 Jan 8; 125(2):284-95. PMC: 4287637
44. Mani R, Mao Y, Frizzera FW, Chiang CL, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X, Yu L, Flynn J, Jones J, **Andritsos L**, Baskar S, Rader C, Phelps MA, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N. Tumor Antigen ROR1 Targeted Drug Delivery Mediated Selective Leukemic But Not Normal B Cell Cytotoxicity In Chronic Lymphocytic Leukemia. *Leukemia*. 2015 February; 29(2): 346-355. Epub 2014 Jun 20. PMC: 4272672.
45. Hofmeister CC, Williams N, Geyer S, Hade EM, Bowers MA, Earl CT, Vaughn J, Bingman A, Humphries K, Lozanski G, Baiocchi RA, Jaglowski SM, Blum K, Porcu P, Flynn J, Penza S, Benson DM, **Andritsos LA**, Devine SM. A Phase 1 study of Vorinostat Maintenance after Autologous Transplant in High Risk Lymphoma. *Leuk Lymphoma*. 2015 April; 56(4):1043-1049. Epub 2014 Nov 20. PMID: 25213183.
46. Maddocks K, Wei L, Rozewski D, Jiang Y, Zhao Y, Adusumilli M, Pierceall WE, Doykin C, Cardone MH, Jones JA, Flynn J, **Andritsos LA**, Grever MR, Byrd JC, Johnson AJ, Phelps MA, Blum KA. Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). *AM J Hematol*. 2015 April; 90(4): 327-33. Epub 2015 February. PMID 25639448.

47. Blachly JS, Ruppert AS, Zhao W, Long S, Flynn J, Flinn I, Jones J, Maddocks K, **Andritsos L**, Ghia EM, Rassenti LZ, Kipps TJ, de la Chapelle A, Byrd JC. Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. *Proc Natl Acad Sci U.S.A.* 2015 April; 112(14): 4322-7. Epub 2015 March. PMID: 25787252.
48. Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, **Andritsos L**, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera YA. Lower Dose of Antithymocyte Globulin (ATG) does not increase Graft-vs-Host Disease (GVHD) in Patients Undergoing Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (allo HSCT). *Leuk Lymphoma*. 2015 April; 56(4):18-1065. PMID: 25166008.
49. Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, **Andritsos LA**, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. *Jama oncology*. 2015 April; 1(1): 80-87. PMID: 26182309.
50. Cohen JB, Ruppert AS, Heerema NA, **Andritsos LA**, Jones JA, Porcu P, Baiocchi R, Christian BA, Byrd JC, Flynn J, Penza S, Devine SM, Blum KA. Complex Karyotype is Associated with Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma. *Clin Lymphoma Myeloma Leuk*. 2015 May; 15(5):278-285. PMID: 25660723.
51. Lanasa MC, **Andritsos L**, Brown JR, Gabrilove J, Caligaris-Cappio F, Ghia P, Larson RA, Kipps TJ, Leblond V, Milligan DW, Janssens A, Johnson AJ, Heerema NA, Bühler A, Stilgenbauer S, Devin J, Hallek M, Byrd JC, Grever MR. Final results of EFC6663: a multicenter, international, phase 2 study of alvociclib for patients with fludarabine-refractory chronic lymphocytic leukemia. *Leuk Res*. 2015 May; 39(5): 495-500. Epub 2015 February. PMID: 25804339.
52. Miller CR, Stephens D, Ruppert A, Racke F, McFaddin A, Breidenbach H, Lin HJ, Waller K, Bannerman T, Jones JA, Woyach JA, **Andritsos LA**, Maddocks K, Zhao W, Lozanski G, Flynn JM, Grever M, Byrd JC, Heerema NA. Jumping translocations, a novel finding in chronic lymphocytic leukaemia. *Br J Haematol*. 2015 Jul; 170(2): 200-7. PMID: 25891862.
53. Flynn JM, Jones J, Johnson A, **Andritsos L**, Maddocks K, Jaglowski S, Hessler J, Grever M, Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC. Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia. *Leukemia*. 2015 July; 29(7): 1524-9. Epub 2015 Feb 24. PMID: 25708835.
54. Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA, Flynn J, **Andritsos LA**, Maddocks K, Jaglowski SM, Blum KA, Byrd JC, Dubovsky JA, Johnson AJ. Hypermorphic mutation of phospholipase C, $\gamma 2$ acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. *Blood*. 2015 Jul 2; 126(1): 61-8. PMC4492196.
55. Jaglowski SM, Jones JA, Nagar V, Flynn JM, **Andritsos LA**, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke B, West JS, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. *Blood*. 2015 Aug 13; 126(7): 842-50. Epub 2015 Jun 26. PMC: 4536539.

56. Awan FT, Flynn JM, Jones JA, **Andritsos LA**, Maddocks KJ, Sass EJ, Lucas MS, Chase W, Waymer S, Ling Y, Jiang Y, Phelps MA, Byrd JC, Lucas DM, Woyach JA. Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma. *Leuk Lymphoma*. 2015 Oct; 56(10): 2834-40. Epub 2015 Mar 11. PMID: 25669927.
57. Stephens DM, Ruppert AS, Weir DA WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, **Andritsos LA**, Flynn JM, Grever MR, Lozanski G, Tam C, O'Brien S, Keating MJ, Muthusamy N, Abruzzo LV, Heerema NA, Byrd JC. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. *Am J Hematol*. 2015 Nov; 90(11):967-9. Epub 2015 Oct 12. PMID: 26202978.
58. Efebera YA, Geyer S, **Andritsos L**, Vasu S, Jaglowski S, Bingman A, Blum W, Klisovic R, Hofmeister CC, Benson DM, Penza S, Elder P, Cortright K, Kitzler R, Coombes K, O'Donnell L, Daneault B, Bradbury H, Zhang J, Chen X, Garman S, Ranganathan P, Yu X, Hofstetter J, Yu J, Garzon R, Scrape SR, Lozanski G, Devine SM. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (allo-HTC). *Biol Blood Marrow Transplant*. 2016 Jan; 22(1): 71-9. Epub 2015 Aug 6. PMID: 26256940.
59. Roddy JV, Haverkos BM, McBride A, Leininger KM, Jaglowski S, Penza S, Klisovic R, Blum W, Vasu S, Hofmeister CC, Benson DM, **Andritsos LA**, Devine SM, Efebera YA. Tocilizumab for steroid refractory acute graft-versus-host disease. *Leuk Lymphoma*. 2016 Jan; 57(1): 81-5. Epub 2015 Jul 3. PMC: 4698359.
60. Rogers KA, Ruppert AS, Bingman A, **Andritsos LA**, Awan FT, Blum KA, Flynn JM, Jaglowski SM, Lozanski G, Maddocks KJ, Byrd JC, Woyach JA, Jones JA. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. *Leukemia*. 2016 Feb; 30(2): 346-50. Epub 2015 Oct 7. PMID: 26442611.
61. Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, O'Donnell L, Bradbury H, Kitzler R, **Andritsos L**, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-Versus-Host Disease. *Biol Blood Marrow Transplant*. 2016 Apr; 22(3): 658-68. Epub 2015 Dec 29. PMID: 26743340.
62. Chen TL, Gupta N, Lehman A, Ruppert AS, Yu L, Oakes CC, Claus R, Plass C, Maddocks KJ, **Andritsos L**, Jones JA, Lucas DM, Johnson AJ, Byrd JC, Hertlein E. Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia. *Oncotarget*. 2016 May 10; 7(19): 28684-96. Epub 2016 Apr 16. PMID: 27107422.
63. Awan FT, Jones JA, Maddocks K, Poi M, Grever MR, Johnson A, Byrd JC, **Andritsos LA**. A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy. *Ann Hematol*. 2016 June; 95(7): 1137-43. Epub 2016 Apr 27. PMID: 27118540.
64. Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, O'Donnell LC, Bradbury H, Kitzler R, **Andritsos L**, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM. Erratum to "Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of

Acute and Chronic Graft-versus-Host Disease" [Biol Blood Marrow Transplant 22(2016):658-668]. *Bio Blood Marrow Transplant*. 2016 Jul; 22(7): 1341. Epub 2016 Apr 29. PMID: 27291293.

65. Vasu S, Wu H, Satoskar A, Puto M, Roddy J, Blum W, Klisovic R, **Andritsos L**, Hofmeister C, Benson DM, Efebera Y, Jaglowski S, Penza S, Cohen D, Devine S, Cataland S. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. *Bone Marrow Transplant*. 2016 Sep; 51(9) 1241-5. Epub 2016 Apr 11. PMID: 27064689.
66. Grever MR, Abdel-Wahab O, **Andritsos LA**, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. *Blood*. 2017 Feb 2; 195(5): 553-560. Epub 2016 Nov 30. PMID: 27903528.
67. Haverkos BM, Huang Y, Elder P, O'Donnell L, Scholl D, Whittaker B, Vasu S, Penza S, **Andritsos LA**, Devine SM, Jaglowski SM. A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation. *Bone Marrow Transplant*. 2017 Apr; 52(4): 561-566. Epub 2017 Jan 9. PMID: 28067870.
68. Guinn D, Lehman A, Fabian C, Yu L, Maddocks K, **Andritsos LA**, Jones JA, Flynn JM, Jaglowski SM, Woyach JA, Byrd JC, Johnson AJ. The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia. *Cancer Med*. 2017 Apr; 6(4): 778-787. Epub 2017 Mar 15. PMID: 28299881.
69. Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo L, Gordon A, Mantel R, Smith LL, McWhorter S, Davis M, Doong TJ, Ny F, Lucas M, Chase W, Jones JA, Flynn JM, Maddocks K, Rogers K, Jaglowski S, **Andritsos LA**, Awan FT, Blum KA, Grever MR, Lozanski G, Johnson AJ, Byrd JC. BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. *J Clin Oncol*. 2017 May 1; 35(13): 1437-1443. Epub 2017 Feb 13. PMID: 28418267.
70. Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, **Andritsos L**, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. *Blood*. 2017 Jul 13; 130(2):221-228. Epub 2017 May 3. PMID: 28468799.
71. Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, **Andritsos LA**, Awan F, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, Byrd JC. Ibrutinib treatment improves T cell number and function in CLL patients. *J Clin Invest*. 2017 Aug 1; 127(8):3052-3064. Epub 2017 Jul 17. PMID: 28714866
72. Vaughn JL, Kline D, Denlinger NM, **Andritsos LA**, Exline MC, Walker AR. Predictive performance of early warning scores in acute leukemia patients receiving induction chemotherapy. *Leuk Lymphoma*. [Epub ahead of print.] 2017 Sep 13:1-3. doi: 10.1080/10428194.2017.1376744. PMID: 28901797.

73. Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, Phelps MA, Mortazavi A, **Andritsos L**, Baiocchi RA, Christian BA, Benson DM, Flynn J, Porcu P, Byrd JC, Pichiorri F, Hofmeister CC. A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. *Leuk Lymphoma*. 2017 Oct; 58(10):2310-2318. Epub 2017 Mar 7:1-9. PMID: 28270022.
74. Miller CR, Ruppert AS, Heerema NA, Maddocks KJ, Labanowska J, Breidenbach H, Lozanski G, Zhao W, Gordon AL, Jones JA, Flynn JM, Jaglowski SM, **Andritsos LA**, Blum KA, T Awan F, Rogers KA, Grever MR, Johnson AJ, Abruzzo LV, Hertlein EK, Blachly JS, Woyach JA, Byrd JC. Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. *Blood Adv*. 2017 Aug 21; 1(19):1584-1588. eCollection 2017 Aug 22. PMID: 29296799
75. Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, Rogers K, McCoy A, Mousa L, Guha A, Heerema NA, Maddocks K, Christian B, **Andritsos LA**, Jaglowski S, Devine S, Baiocchi R, Woyach J, Jones J, Grever M, Blum KA, Byrd JC, Awan FT. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. *Blood Adv*. 2017 Sep 8; 1(20):1739-1748. eCollection 2017 Sep 12. PMID: 29296820.
76. Rogers KA, Huang Y, Ruppert AS, Salem G, Stephens DM, Heerema NA, **Andritsos LA**, Awan FT, Byrd JC, Flynn JM, Maddocks KJ, Jones JA. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. *Br J Haematol*. 2018 Jan; 180(2):259-266. Epub 2017 Nov 28. PMID: 29193006.
77. Richardson DR, Huang Y, McGinty HL, Elder P, Newlin J, Kirkendall C, **Andritsos L**, Benson D, Blum W, Efebera Y, Penza S, Hofmeister C, Jaglowski S, Klisovic R, Vasu S, William B, Devine S, Rosko AE. Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients. *Bone Marrow Transplant*. [Epub ahead of print] 2018 Feb 14. doi: 10.1038/s41409-018-0118-4. PMID: 29445123.
78. **Andritsos LA**, Grieselhuber NR, Anghelina M, Rogers KA, Roychowdhury S, Reeser JW, Timmers CD, Freud AG, Blachly JS, Lucas DM, Lozanski G, Jones JA, Williams K, Oakes C, Jones D, Grever MR. Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. *Leuk Lymphoma*. 2018 Apr; 59(4): 1008-1011. Epub 2017 Sep 18. PMID: 28918710.
79. Vela CM, Grate LM, McBride A, Devine S, **Andritsos LA**. A retrospective review of fall risk factors in the bone marrow transplant inpatient service. *J Oncol Pharm Pract*. 2018 Jun; 24(4): 272-280. Epub 2017 Jan 1. PMID: 29284362.
80. Vaughn JL, Balada-Llasat JM, Lamprecht M, Huang Y, Anghelina M, El Boghdadly Z, Bishop-Hill K, Childs R, Pancholi P, **Andritsos LA**. Detection of toxigenic *Clostridium difficile* colonization in patients admitted to the hospital for chemotherapy or haematopoietic cell transplantation. *J Med Microbiol*. 2018 Jun 4. PMID: 29863458
81. Rogers KA, Huang Y, Dotson E, Lundberg J, **Andritsos LA**, Awan FT, Woyach JA, Byrd JC. Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre. *Br J Haematol*. 2018 Jul 20. PMID: 30028000

82. Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, Goettl VM, Tran M, Harrington BK, Rogers KA, Awan FT, Maddocks K, **Andritsos L**, Lehman AM, Sampath D, Lapalombella R, Eathiraj S, Abbadessa G, Schwartz B, Johnson AJ, Byrd JC, Woyach JA. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. *Cancer Discov*. 2018 Aug 9. PMID: 30093506
83. Wang RF, Li D, Kuehn GJ, **Andritsos LA**, Grever MR, Kaffenberger BH. Antibiotic exposure is associated with cutaneous adverse events in hairy cell leukemia patients treated with purine analogs. *J Am Acad Dermatol*. 2018 Sep 8. PMID: 30205132

ONLINE PUBLICATIONS

1. Contributing author to hairycellleukemia.org "Complications."
2. Perspective: Hematologic Malignancies. *HemOnc Today: Clinical News in Oncology and Hematology*. 17(2/25/16): 73. <http://www.healio.com/hematology-oncology/leukemia/news/print/hemonc-today/%7B851b288a-63c5-465e-9670-495248fd5f4c%7D/vemurafenib-effective-in-relapsed-refractory-hairy-cell-leukemia>.
3. Perspective: Hematologic Malignancies. *HemOnc Today: Clinical News in Oncology and Hematology*. 5/14/15. <http://www.healio.com/hematology-oncology/leukemia/news/online/%7Be528ce19-3442-446b-b183-d959bcbbeb89f%7D/salvage-therapies-benefit-patients-with-cll-after-allogeneic-sct-failure>

REVIEW ARTICLES

1. **Andritsos LA**, Khoury H. Chronic Lymphocytic leukemia. *Current Treatment Options Oncology*, 3(3):225-31, 2002.
2. Alinari L, Lapalombella R, **Andritsos LA**, Baiocchi RA, Lin TS, Byrd JC. Alemtuzumab (Campath- 1H) in the Treatment of Chronic Lymphocytic Leukemia. *Oncogene*. 2007 May 28; 26:3644-3653. PMID: 17530018.
3. **Andritsos LA**, Grever MR. Salvage therapy for chronic lymphocytic leukemia. *Expert Rev Hematol*. 2011 Apr; 4(2):199-212. PMID: 21495929.
4. **Andritsos LA**, Jaglowski SM. Ibrutinib Inhibitor of Tyrosine-Protein Kinase BTK Oncolytic. *Drugs of the Future*. 2013 June; 38(6): 359-366.
5. Grever MR, Blachly JS, **Andritsos LA**. Hairy cell leukemia: Update on molecular profiling and therapeutic advances. *Blood Rev*. 2014 Sep; 28(5):197-203. Epub 2014 Jul 11. PMID: 25110197.
6. **Andritsos LA**, Grever MR. Historical overview of hairy cell leukemia. *Best Pract Res Clin Haematol*. 2015 Dec; 28(4): 166-74. Epub 2015 Oct 26. PMID: 26614894.
7. Vela CM, McBride A, Jaglowski SM, **Andritsos LA**. Ibrutinib for treatment of chronic lymphocytic leukemia. *Am J Health Syst Pharm*. 2016 Mar 15; 73(6):367-75. PMID: 26953281.

EDITORIALS

Grieselhuber, NR, Asquith, JM, **Andritsos, LA**. Dealing with complexity: prognostic implications

of karyotype and mutations in chronic lymphocytic leukemia. *Transl Cancer Res* 2016; 5(suppl 6):S1149-S1152. Doi:10.21037/tcr.2016.11.42

BOOK CHAPTERS

1. **Andritsos LA**, Eby C. 2003. Coagulation Disorders. In *Washington Manual of Hematology and Oncology* St. Louis: Lippincott Williams & Wilkins.
1. **Andritsos LA**, Blinder M. 2004. Anemia and Transfusion Therapy. In *Washington Manual of Medical Therapeutics*, ed. Harris I, Lin G. St. Louis: Lippincott Williams & Wilkins.
2. **Andritsos LA**, Yusen RD, Eby C. 2004. Disorders of Hemostasis. In *Washington Manual of Medical Therapeutics*, ed. Harris I, Lin G. St. Louis: Lippincott Williams & Wilkins.
3. **Andritsos LA**, Paprocki C, Yeager, AM. 2008 Collection, Processing, and Infusion of Adult Hematopoietic Stem Cells (Peripheral Blood and Bone Marrow). In *Living Donor Organ Transplantation*, ed. Rainer WG. Tucson, Arizona, USA: McGraw-Hill.
4. Grever MR, **Andritsos LA**, Lozanski G. 2008. Chronic Lymphoid Leukemias. In *Abeloff's Clinical Oncology*, ed. Martin D Abeloff, James O Armitage, John E Niederhuber, Michael B Kastan, W Gillies McKenna. Columbus: Churchill Livingstone Elsevier.
5. **Andritsos LA**, Byrd JC, Devine SM. Hematopoietic Progenitor Cell Transplantation for Treatment of Chronic Lymphocytic Leukemia. In *Allogeneic Stem Cell Transplantation, Clinical Research and Practice*, ed. Mary J. Laughlin, Hillard M. Lazarus. Columbus: Humana Press. 2009

ABSTRACTS

1. Wilson DB, Park J, **Andritsos LA**, Kulkarni S, Savage SA, Chanock SJ, Shannon KM, Bessler M. Monosomy 7 Myelodysplastic-Myeloproliferative Syndrome in an Infant with a Germline Mutation in the Primer Alignment Region of the Telomerase RNA (TERC) Gene. *Blood*. 2003; 102 (11).
2. **Andritsos LA**, Adkins D, Vij R, DiPersio JF, Devine SM. Late Development of Acute Myeloid Leukemia in Two Peripheral Blood Stem Cell Donors Mobilized with G-CSF. *Blood (ASH Annual Meeting Abstracts)*. 2004 Nov; 104(11):1842. Poster Presentation.
3. **Andritsos LA**, Edwards T, Sempek D, Calandra G, Badel K, Vij R, DiPersio JF, Devine SM. A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies. *American Society of Blood and Marrow Transplantation Annual Meeting*. 2005 Oral Presentation.
4. Devine SM, **Andritsos LA**, Todt L, Vig R, Bonde J, Hess D, Nolte J, Link D, Bridger G, Calandra G, DiPersio JF; A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies. *Blood (ASH Annual Meeting Abstracts)*. 2005 Nov; 106 (11). Oral Presentation.

5. **Andritsos LA**, Augustin K, Vij R, DiPersio JF, Devine SM. Acute GVHD May Play a Role in Preventing Relapse Following Reduced Intensity Allografts for Acute Myeloid Leukemia. *Blood (ASH Annual Meeting Abstracts)*. 2005 Nov; 106 (11). Poster Presentation.
6. **Andritsos L**, Suhre W, Nahirny M, Chase E, Carroll M, Christian J, Miller TP, Yeager AM. Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) with High- Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation (HSCT) Using a Novel Mitoxantrone-Containing Preparative Regimen. *Blood (ASH Annual Meeting Abstracts)*, Nov 2006; 108: 5264.
7. **Andritsos LA**, Johnson AJ, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, Wang DS, Knight RD, Chen CS, Byrd JC. Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses. *Blood (ASH Annual Meeting Abstracts)*. 2007 Nov; 110(11):4727.
8. Lin TS, Fischer B, Blum KA, **Andritsos LA**, Jones JA, Moran ME, Broering S, Heerema NA, Lozanski G, Schaaf LJ, Mahoney LS, Johnson AJ, Smith LL, Wagner AJ, Raymond CA, Phelps M, Dalton JT, Grever MR, Byrd JR. Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses. *Blood (ASH Annual Meeting Abstracts)*. 2007 Nov; 110(11): 3104. Poster Presentation.
9. **Andritsos LA**, Fischer B, Lin TS, Blum KA, Jones JA, Moran ME, Byrd JC, Grever MR; Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol. *Blood (ASH Annual Meeting Abstracts)*, 2007 Nov; 110(11): 3128. Poster Presentation.
10. Hamadani M, Elder P, Awan F, Krugh D, Blum W, Lin TS, **Andritsos LA**, Bechtel T, Blum KA, Klisovic R, Devine SM. High Rates of Early Donor Chimerism and Low Risk of Chronic GVHD Can Be Achieved in Poor Risk Patients Undergoing Unrelated Donor Stem Cell Transplantation Using a Reduced Intensity Conditioning Regimen Incorporating Fludarabine, Busulfan, and Rabbit ATG. *Blood (ASH Annual Meeting Abstracts)*. 2007 Nov; 110 (11): 5080.
11. **Andritsos LA**, Jones J, Lozanski G, Lin TS, Blum KA, Grever MR, Jarjoura D, Byrd JC, Heerema N. del (17p13.1) in Chronic Lymphocytic Leukemia Confers Poor Prognosis Even at Low Percentage Involvement and Increases Proportionately with Increase in Clonal Involvement. *Blood (ASH Annual Meeting Abstracts)*. 2007 Nov; 110(11): 2073. Poster Presentation.
12. Heerema NA, Byrd JC, **Andritsos LA**, Lozanski G, Blum KA, Fischer B, Jones JA, Moran ME, Groering S, Schaaf LJ, Maho L, Johnson AJ, Smith LS, Wagner, AJ, Raymond CA, Phelps MA, Dalton JT, Grever M, Lin TS. Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients. *Blood (ASH Annual Meeting Abstracts)*. 2007 Nov; 110 (11): 3107. Poster Presentation.
13. Heerema NA, Lin TS, Fischer B, Lozanski G, Blum KA, **Andritsos LA**, Jones JA, Flynn JM, Moran ME, Mitchell SM, Schaaf LJ, Johnson AJ, Smith LL, Wagner AJ, Raymond CA, Phelps M, Dalton JT, Grever MR, Byrd JC. Chronic lymphocytic leukemia (CLL) patients with high-risk cytogenetics respond to treatment with flavopiridol: Study of 120 patients (pts) with relapsed, genetically high risk CLL. *Cytogenetic and Genome Research*. 2008 Jan; 46.
14. Blum W, **Andritsos L**, Johnson AJ, Klisovic R, Kefauver C, Devine S, Marcucci G, Byrd JC. Preliminary Results of a Phase I Trial with Dose Escalated Lenalidomide (L) in Separate

Cohorts of Relapsed Acute Leukemia (AL) or Chronic Lymphocytic Leukemia (CLL): Evidence of Activity in Acute Myeloid Leukemia (AML) and Toxicity in CLL at Starting Dose. *J Clin Oncol (ASCO Annual Meeting)*. 2008 May; 26(15):7075.

15. Lin TS, **Andritsos LA**, Jones J, Fischer B, Heerema NA, Blum KA, Flynn JM, Moran ME, Phelps MA, Grever MR, Byrd JC. Activity of the Cyclin-Dependent Kinase (CDK) Inhibitor Flavopiridol in Relapsed, Genetically High Risk Chronic Lymphocytic Leukemia (CLL). *J Clin Oncol (ASCO Meeting Abstracts)*. 2008 May; 26(15):7007.
16. Flynn JM, **Andritsos LA**, Lin TS, Byrd JC, Jones JA. Second Primary Malignancies After Chronic Lymphocytic Leukemia. *J Clin Oncol (ASCO Meeting Abstracts)*. 2008 May; 26(15):9632.
17. **Andritsos LA**, Hamadani M, Heerema NA, Benson D, Hofmister CC, Blum W, Flynn J, Jones J, Elder P, Lin TS, Byrd JC, Devine S. Attainment of Minimal Residual Disease Negative State is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL). *Blood (ASH Annual Meeting Abstracts)*. Nov 2008; 112:2170. Poster Presentation.
18. Benson D, **Andritsos L**, Hamadani M, Lin T, Flynn J, Jones J, Blum W, Elder P, Lozanski G, Byrd J, Devine S. Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation. *Blood (ASH Annual Meeting Abstracts)*. 2008 Nov; 112(11): 3300. Poster Presentation.
19. Lin TS, Heerema NA, Lozanski G, Fischer B, Blum KA, **Andritsos LA**, Jones J, Flynn JM, Moran M, Mitchell S, Johnson AJ, Phelps MA, Grever MR, Byrd JC. Flavopiridol (Alvocidib) Induces durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities. *Blood (ASH Annual Meeting Abstracts)*. 2008 Nov; 112 (11): 46. Oral Presentation.
20. Hamadani M, Blum W, Benson D, Blum KA, Porcu P, Elder P, Krugh D, Bechtel T, **Andritsos L**, Garzon R, Penza S, Lin TS, Devine SM. Assessment of Rabbit Antithymocyte Globulin (rATG) Dose- Intensity in Patients with Hematological Malignancies Undergoing Allogeneic Stem Cell Transplantation (ASCT) Following Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and rATG (FBA). *Blood (ASH Annual Meeting Abstracts)*. 2008 Nov; 112(11): 4405.
21. Blum KA, Liu Z, Lucas DM, Baiocchi R, Lin TS, Benson D, Devine SM, Jones JA, **Andritsos LA**, Flynn J, Cheng P, Xie Z, Marcucci G, Chan KK, Grever MR, Byrd JC. A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation. *Blood (ASH Annual Meeting Abstracts)*. 2008 Nov; 112(11): 3169. Poster Presentation.
22. **Andritsos, LA**, Furman R., Flinn IW, Foreno-Torres A., Flynn JM, Stromatt, SC, Byrd JC. A Phase I Trial of TRU-016, An Anti-CD37 Small Modular Immunopharmaceutical (SMIP) in Relapsed and Refractory CLL. *J Clin Oncol (ASCO Meeting Abstracts)*. 2009 May; 27(15): 3017. Poster Presentation.
23. Byrd JC, Lapalombella R, Ramanunni A, **Andritsos, LA**, Flynn JM, Baum P, Thompson P, Muthusamy N. Effect of CD37 Small Modular Immunopharmaceutical (SMIP) on Direct Apoptosis in Chronic Lymphocytic Leukemia Cells Via Transcriptional Up-Regulation of the BH3 Family Member BIM. *J Clin Oncol (ASCO Meeting Abstracts)*. 2009 May; 27(15): 3035.

Poster Presentation.

24. Woyach JA, Byrd JC, Zhao J, McFaddin A, Ruppert AS, Lin TS, **Andritsos L**, Blum K, Flynn JM, Jones JA, Heerema NA. Dic(17;18)(p11.2;p11.2) Is a Recurring Abnormality in Chronic Lymphocytic Leukemia Associated with Aggressive Disease. *Blood (ASH Annual Meeting Abstracts)*. 2009 Nov; 114(22): 1233. Poster Presentation.
25. Maddocks K, Lapalombella R, Blum K, Blum W, Fischer B, Muthusamy N, Moran M, Holtzapfel D, Byrd JC, Johnson AJ, **Andritsos L**. Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia. *Blood (ASH Annual Meeting Abstracts)*. 2009 Nov; 114(22): 3446. Poster Presentation.
26. Jaglowski S, Lin T, Elder P, Scholl D, Byrd JC, Devine S, **Andritsos L**. Barriers to Reduced-Intensity Conditioning (RIC) Transplant in Patients with Chronic Lymphocytic Leukemia. *Blood (ASH Annual Meeting Abstracts)*. 2009 Nov; 114(22): 1374. Poster Presentation.
27. Flynn J, Johnson AJ, **Andritsos L**, Blum K, Jones JA, Wiley E, Hu W, Hessler J, Smith L, Lucas DM, Small K, Statkevich P, Grever M, Bannerji R, Byrd JC. The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia. *Blood (ASH Annual Meeting Abstracts)*. 2009 Nov; 114(22): 886. Oral Presentation.
28. **Andritsos LA**, Furman R, Flinn IW, Foreno-Torres A, Flynn JM, Stromatt, SC, Byrd JC. A Phase I Trial of TRU-016, An Anti-CD37 Small Modular Immunopharmaceutical (SMIP) in Relapsed and Refractory CLL: Early Promising Clinical Activity. *Blood (ASH Annual Meeting Abstracts)*. 2009 Nov; 114(22): 3424. Poster Presentation.
29. **Andritsos L**, Byrd J, Hewes B, Kipps T, Johns D, Burger J. Preliminary Results From A Phase I Dose Escalation Study To Determine The Maximum Tolerated Dose Of Plerixafor In Combination With Rituximab In Patients With Relapsed Chronic Lymphocytic Leukemia. *Haematologica*. 2010 June; 95(18): 321-322
30. Zhao WQ, Tang Y, Li Y, Long S, Jones J, **Andritsos L**, Flynn J, Byrd J, Heerema N, Lozanski G. Mutation Status and Preferred Utilization of IGVH Gene in Chronic Lymphocytic Leukemia and Associations with Common Biologic Abnormalities. *Haematologica*. 2010 June; 95(18): 1274.
31. Mahoney E, Johnson AJ, Wagner AJ, Hessler J, Gupta SV, Herman SEM, **Andritsos L**, Jones JJ, Flynn JM, Lucas DM, Grever MR, Byrd JC. Autophagy Is a Relevant Cellular Process in CLL and Contributes to Drug Resistance of Flavopiridol. *Blood (ASH Annual Meeting Abstracts)*. 2010 Nov; 116(21): 691. Oral Presentation.
32. Blum KA, Ruppert AS, Woyach JA, Jones JJ, **Andritsos L**, Flynn JM, Rovin B, Villalona-Calero M, Ji J, Phelps M, Johnson AJ, Grever MR, Byrd JC. Risk Factors for Tumor Lysis Syndrome (TLS) In Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol. *Blood (ASH Annual Meeting Abstracts)*. 2010 Nov; 116(21): 1386. Poster Presentation.
33. Flynn JM, Jones JA, **Andritsos L**, Blum KA, Johnson JA, Hessler J, Wiley E, Poon J, Small K, Statkevich P, Grever MR, Bannerji R, Byrd JC. Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration. *Blood (ASH Annual Meeting Abstracts)*. 2010 Nov; 116(21): 1396. Poster Presentation.

34. **Andritsos L**, Byrd JC, Jones J, Hewes B, Kipps T, Hsu F, Burger J. Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor in Combination with Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia. *Blood (ASH Annual Meeting Abstracts)*. 2010 Nov; 116(21): 2450. Poster Presentation.
35. Blum KA, Jones JA, **Andritsos L**, Flynn J, Deam D, Heerema NA, Phelps M, Johnson AJ, Grever MR, Byrd JC. Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL). *Blood (ASH Annual Meeting Abstracts)*. 2010 Nov; 116(21): 2472. Poster Presentation.
36. Furman R, **Andritsos L**, Flinn I, Forero-Torres A, Foon K, Pagel J, Singhal A, Stromatt S, Byrd JC. Phase 1 Dose Escalation Study of TRU-016, An Anti-CD37 SMIP™ Protein In Relapsed and Refractory CLL. *Blood (ASH Annual Meeting Abstracts)*. 2010 Nov; 116(21): 56. Oral Presentation.
37. Lanasa M, **Andritsos L**, Brown J, Gabrilove J, Caligaris-Cappio F, Larson R, Kipps TJ, Leblond V, Milligan D, Janssens A, Heerema NA, Stilgenbauer S, Byrd JC, Grever MR. Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL. *Blood (ASH Annual Meeting Abstracts)*. 2010 Nov; 116(21): 58. Oral Presentation.
38. Jones JA, **Andritsos L**, Baiocchi R, Benson DM Jr., Blum KA, Christian B, Deam D, Flynn J, Johnson A, Phelps MA, Porcu P, Byrd JC, Grever MR. Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non- Hodgkin's Lymphoma. *Blood (ASH Annual Meeting Abstracts)*. 2010 Nov; 116(21): 2834. Poster Presentation.
39. Herman S, Lapalombella R, Jones JA, **Andritsos L**, Gordon A, Ramanunni A, Lannutti B, Muthusamy N, Byrd JC, Johnson A. Lenalidomide Dependent Activation of the Phosphatidylinositol 3-kinase- δ Pathway Is Antagonized by CAL-101 In Chronic Lymphocytic Leukemia. *Blood (ASH Annual Meeting Abstracts)*. 2010 Nov; 116(21): 1821. Poster Presentation.
40. Jaglowski SM, Scholl D, Elder P, Lin T, Byrd JC, Devine SM, **Andritsos L**. Conditioning with Fludarabine, Busulfan, and ATG Prior to Reduced-Intensity Allogeneic Stem Cell Transplant for CLL Is Associated with a Low Incidence of Acute Graft-Versus-Host Disease. *Blood (ASH Annual Meeting Abstracts)*. 2010 Nov; 116(21): 4568.
41. Jaglowski S, Flynn J, Jones JA, Lin T, Fischer B, Scholl D, Elder P, Devine SM, Grever MR, Byrd JC, **Andritsos L**. Flavopiridol Is An Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia(CLL) to Reduced Intensity Conditioning Allogeneic Stem Cell Transplant. *Blood (ASH Annual Meeting Abstracts)*. 2010 Nov; 116(21): 2383. Poster Presentation.
42. Hamadani M, Craig M, Abraham J, Tse W, Cumpston A, Gibson LF, Remick SC, Leadmon S, Elder P, Hofmeister C, Penza S, **Andritsos L**, Blum W, Benson DM, Devine SM. Higher Busulfan Dose Intensity Does Not Improve Outcomes Of Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (AHCT) Following Fludarabine/Busulfan/ATG (FBA)-Based Reduced Toxicity Conditioning (RTC). *Biology of Blood and Marrow Transplantation*. 2011 Feb; 17(2): S306.
43. Flynn JM, Jones JA, **Andritsos LA**, Blum KA, Johnson AJ, Hessler J, Wiley E, Heerema N,

Poon J, Small KA, Jou Y, Zhang D, Statkevich P, Grever MR, Bannerji R, Byrd JC. Phase I Study of the CDK Inhibitor Dinaciclib (SCH 727965) in Patients (pts) with Relapsed/Refractory CLL. *J Clin Oncol (ASCO Meeting Abstracts)*. 2011 May; 29(15): 6623. Poster Presentation.

44. Awan FT, Pagel J, **Andritsos LA**, Gopal AK, Furman R, Spurgeon S, Deauna-Limayo D, Stromatt S, Byrd JC. Phase 1 Study of Tru-016, An Anti CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients. *Blood (ASH Annual Meeting Abstracts)*. 2011 Nov; 118(21): 1792. Poster Presentation.
45. Cohen JB, Hall N, Ruppert AS, Jones JA, Porcu P, Baiocchi RA, Penza S, Benson DM, **Andritsos LA**, Flynn JM, Devine SM, Blum KA. The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant In Mantle Cell Lymphoma. *Blood (ASH Annual Meeting Abstracts)*. 2011 Nov; 118(21): 3113. Poster Presentation.
46. Blum KA, Wei L, Jones JA, **Andritsos LA**, Flynn JM, Heerema N, Yang X, Rozewski D, Phelps M, Johnson AJ, Grever MR, Byrd JC. Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial. *Blood (ASH Annual Meeting Abstracts)*. 2011 Nov; 118(21): 3910. Poster Presentation.
47. Lapalombella R, Ramanunni A, Yeh YY, Wang L, Jha S, Staubli J, Herman S, **Andritsos LA**, Jones JA, Flynn JM, Mo X, Johnson AJ, Thompson P, Algate PA, Stromatt S, Freitas MA, Muthusamy N, Byrd JC. Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals. *Blood (ASH Annual Meeting Abstracts)*. 2011 Nov; 118(21): 622. Oral Presentation.
48. Jaglowski SM, Heerema N, Elder P, Byrd JC, Devine SM, **Andritsos LA**. Increasing Genetic Complexity Predicts for Inferior Outcomes Following Reduced-Intensity Conditioning Allogeneic Transplant for Chronic Lymphocytic Leukemia. *Blood (ASH Annual Meeting Abstracts)*. 2011 Nov; 118(21): 3090. Poster Presentation.
49. Cohen JB, Ruppert AS, Kaplan LD, Baiocchi R, Porcu P, Flynn J, Penza S, Jones JA, Blum KA, Devine SM, **Andritsos LA**. Complex Karyotype (CK) Is Associated With Increased Cumulative Incidence Of Relapse (CIR) Following Autologous Stem Cell Transplantation (ASCT) For Mantle Cell Lymphoma (MCL) In First Remission. *Biology of Blood and Marrow Transplantation*. 2012 Feb; 18(2): S205-S206.
50. Salem G, Ruppert AS, Efebera Y, Elder P, Bingman A, Penza S, **Andritsos LA**, Devine SM. Busulfan, Cyclophosphamide, Etoposide (Bucyvp) Or Carmustine, Etoposide, Cytarabine, Melfelan (Beam) For Conditioning Prior To Autologous Stem Cell Transplantation (Asct) In Patients With Hodgkin Lymphoma (HL)? *Biology of Blood and Marrow Transplantation*. 2012 Feb; 18(2): S246.
51. Dubovsky JA, Andritsos LA, Blum W, Johnson A, Muthusamy N, Byrd JC. Immunoglobulin reactivity analysis of chronic lymphocytic leukemia patients unveils Lymphocyte Cytosolic Protein 1 (LCP1) as a novel CLL exosome antigen. *Cancer Res*. 2012 April; 72:509.
52. Salem G, Dunavin N, Wei L, Elder P, Penza S, Blum K, Porcu P, Baiocchi R, Jones J, Flynn J, **Andritsos L**, Devine SM, Christian B, Efebera Y. Busulfan, cyclophosphamide, etoposide is not superior to carmustine, etoposide, cytarabine, melfalan conditioning prior to autologous stem cell transplantation in patients with Hodgkin's lymphoma and is associated with increased toxicity. *Bone Marrow Transplantation*. 2012 April; 47(S1): S84-S85.

53. Troeger A, Johnson AJ, Wood J, Blum W, **Andritsos LA**, Byrd JC, Williams DA. RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans. *Blood*. 2012 May; 119(20): 4708-4718.
54. Mahoney E, Lucas DM, Gupta S, Wagner Amy, Smith L, Herman S, Yuh-Ying Y, **Andritsos L**, Jones JA, Flynn JM, Blum KA, Zhang X, Lehman A, Kong H, Metlin G, Grever M, Johnson A, Byrd JC. "ER stress and autophagy: new players in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol." *Blood*. 2012 Aug; 120(6): 1262-1273.
55. Jaglowski S, Jones JA, Flynn JM, **Andritsos LA**, Maddocks K, Blum KA, Grever MR, Geyer S, Woyach J, Johnson AJ, Heerema N, Molnar E, Stefanos M, Devlin S, Navarro T, James DF, Lowe AM, Hedrick E, Byrd JC. A Phase Ib/II Study Evaluating Activity and Tolerability of BTK Inhibitor PCI- 32765 and Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Related Diseases. *J Clin Oncol (ASCO Meeting Abstracts)*. 2012; 30(15): 6508. Oral Presentation.
56. Jaglowski S, Hofmeister C, Elder P, Penza S, Efebera YA, Benson DM, Devine SM, **Andritsos LA**. The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma. *Blood (ASH Annual Meeting Abstracts)*. 2012 Nov; 120(21): 4286. Poster Presentation.
57. Dubovsky JA, Beckwith KA, Woyach JA, Jaglowski S, Hessler J, Chang BY, Larkin K, Stefanovski MR, Frissora FW, Smith L, Smucker K, Flynn JM, Jones JA, **Andritsos LA**, Maddocks K, Lehman A, Furman R, Sharman J, Mishra A, Caligiuri MA, Buggy J, Muthusamy N, Johnson AJ, Byrd JC. Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells. *Blood (ASH Annual Meeting Abstracts)*. 2012 Nov; 120(21): 775. Oral Presentation.
58. Hofmeister C, Liu Z, Bowers MA, Porcu P, Flynn JM, Christian B, Baiocchi RA, Benson DM, **Andritsos LA**, Greenfield C, Sell M, Geyer S, Byrd JC, Grever MR. Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma. *Blood (ASH Annual Meeting Abstracts)*. 2012 Nov; 120(21): 2955. Poster Presentation.
59. Maddocks K, Hertlein E, Flynn JM, **Andritsos LA**, Wagner AJ, Chen TL, Phelps MA, Grever MR, Johnson AJ, Byrd JC, Jones JA. A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). *Blood (ASH Annual Meeting Abstracts)*. 2012 Nov; 120(21): 1800. Poster Presentation.
60. Chappell DL, Dubovsky JA, **Andritsos LA**, Flynn JM, Jones JA, Byrd JC, Muthusamy N. Lymphocyte Cytosolic Protein 1 (LCP1) Is a Membrane Associated Molecular Target in Chronic Lymphocytic Leukemia and Is Activated in Microenvironment Signaling. *Blood (ASH Annual Meeting Abstracts)*. 2012 Nov; 120(21): 3866. Poster Presentation.
61. Hofmeister C, Bowers MA, Baiocchi RA, Lozanski G, Humphries K, Blum KA, Porcu P, Penza S, Greenfield CN, Sell M, Earl CT, Zitesman J, Quinion C, Lustberg M, **Andritsos LA**, Devine SM. Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance. *Blood (ASH Annual Meeting Abstracts)*. 2012 Nov; 120(21): 2004. Poster Presentation.
62. Jaglowski S, Vasu S, Geyer S, Bingman A, Elder P, Yu J, Blum W, Klisovic R, Penza S,

Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Devine SM, **Andritsos LA**, Lozanski G. Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease. *Blood (ASH Annual Meeting Abstracts)*. 2012 Nov; 120(21): 1949. Poster Presentation.

63. Hamadani M, Craig M, Remick S, Gibson L, Petros W, Abraham J, Cumpston A, Bunner P, Basu S, Tse W, Hennelly C, Vasu S, Klisovic R, Blum W, Jaglowski S, Benson DM, **Andritsos LA**, Penza S, Hofmeister C, Geyer S, Devine SM, Efebera Y. Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT). *Blood (ASH Annual Meeting Abstracts)*. 2012 Nov; 120(21): 1942. Poster Presentation.
64. Cohen JB, Ruppert AS, Heerema N, Jones JA, Porcu P, Baiocchi RA, Christian B, Byrd JC, Flynn JM, Penza S, **Andritsos LA**, Devine SM, Blum KA. Complex Karyotype (CK) Is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL). *Blood (ASH Annual Meeting Abstracts)*. 2012 Nov; 120(21): 2691. Poster Presentation.
65. Vasu S, Jaglowski S, Geyer S, Bingman A, Elder P, Yu J, **Andritsos LA**, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Devine SM, Lozanski G. Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD). *Blood (ASH Annual Meeting Abstracts)*. 2012 Nov; 120(21): 4192. Poster Presentation.
66. Cohen JB, McBride A, Geyer S, Bingman A, Elder P, Blum W, Klisovic R, Penza S, **Andritsos LA**, Benson DM, Efebera Y, Hofmeister CC, Garzon R, Marcucci G, Devine SM. Improved Survival of Patients (Pts) with Acute Graft-Versus-Host Disease (aGVHD) During Recent Years: Impact of Donor and Recipient Characteristics. *Biology of Blood and Marrow Transplantation*. 2013 Feb; 19(2): S320-321.
67. Efebera Y, Geyer S, Bingman A, Kitzler R, Elder P, Hennelly C, **Andritsos LA**, Jaglowski S, Blum W, Klisovic R, Penza S, Vasu S, Hofmeister CC, Benson DM, Devine SM, Lozanski G. Impact of Atorvastatin On Cellular Immune of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT). *Biology of Blood and Marrow Transplantation*. 2013 Feb; 19(2): S202.
68. Pandit A, Wei L, Elder P, Falk W, Sell M, Hofmeister CC, Benson DM, Penza S, **Andritsos LA**, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera Y. Autologous Hematopoietic Stem Cell Transplant (aHSCT) is a Safe and Reasonable Treatment in Patients with Primary Systemic Amyloidosis (AL amyloidosis). *Biology of Blood and Marrow Transplantation*. 2013 Feb; 19(2): S186.
69. Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, **Andritsos LA**, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera Y. Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-Vs-Host Disease (GVHD) and Relapse in Patients Undergoing Reduced-Intensity (RIC) Allogeneic Hematopoietic Stem Cell Transplant (HSCT). *Biology of Blood and Marrow Transplantation*. 2013 Feb; 19(2): S304-305.
70. Chappell DL, Dubovsky JA, **Andritsos LA**, Flynn JM, Jones JA, Paulaitis ME, Agrawal K, Byrd JC, Muthusamy N. Lymphocyte cytosolic protein 1 (LCP1) is a membrane-associated molecular target in chronic lymphocytic leukemia and is activated in microenvironment

signaling. *Cancer Research*. 2013 April; 73(8): 4925. Poster Presentation.

71. Woyach JA, Flynn JM, Jones JA, **Andritsos LA**, Lucas M, Chase W, Yang Y, Lucas DM, Sass E, Waymer S, Ling Y, Jiang Y, Phelps MA, Byrd JC. Results of a Phase I Trial of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL). *J Clin Oncol (ASCO Annual Meeting)*. 2013 May; 31(15):7077. Poster Presentation.
72. Flynn J, **Andritsos L**, Jones J, Johnson A, Maddocks K, Wiley E, Small K, Kyung Im E, Grever M, Bannerji R, Byrd JC, Zhou H. Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL). *Blood (ASH Annual Meeting Abstracts)*. 2013 Nov; 122(21): 871. Oral Presentation.
73. Stephens D, Stark A, Jones J, Woyach J, Maddocks K, Jaglowski S, **Andritsos L**, Flynn J, Grever M, Lozanski G, Johnson A, Muthusamy N, Heerema N, Byrd JC. Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype. *Blood (ASH Annual Meeting Abstracts)*. 2013 Nov; 122(21): 2872. Poster presentation.
74. Stephens D, Stark A, Wierda W, Jones J, Maddocks K, Jaglowski S, **Andritsos L**, Flynn J, Grever M, Lozanski G, Tam C, O'Brien S, Keating M, Muthusamy N, Abruzzo L, Heerema N, Byrd JC. Externally Validated Predictive Clinical Model For Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients. *Blood (ASH Annual Meeting Abstracts)*. 2013 Nov; 122(21): 4128. Poster presentation.
75. **Andritsos L**, Blachly J, Kendra K, Lozanski G, Grever M. Co-Treatment Of Hairy Cell Leukemia and Melanoma With The BRAF Inhibitor Dabrafenib. *Blood (ASH Annual Meeting Abstracts)*. 2013 Nov; 122(21): 5311. Online.
76. Roddy J, Haverkos B, McBride A, Leininger K, **Andritsos L**, Devine S, Efebera Y. Tocilizumab In The Treatment Of Steroid Refractory Graft Versus Host Disease: A Single Institutional Experience. *Blood (ASH Annual Meeting Abstracts)*. 2013 Nov; 122(21): 2067. Poster presentation.
77. Heerema N, Muthusamy N, Ruppert A, **Andritsos L**, Grever M, Jones J, Maddocks K, Byrd JC. Prognostic Significance Of Cytogenetic Complexity and Del(17p) At Diagnosis Of Chronic Lymphocytic Leukemia (CLL). *Blood (ASH Annual Meeting Abstracts)*. 2013 Nov; 122(21): 1321. Poster Presentation.
78. McWilliams E, Cheney C, Jones J, Flynn J, Maddocks K, **Andritsos L**, Huet H, Gram H, Baeck J, Muthusamy N, Byrd JC. B-1239, a Novel Anti-BAFF-R Afucosylated Human Antibody, Promotes Potent Natural Killer Cell- Mediated Antibody Dependent Cellular Cytotoxicity In Chronic Lymphocytic Leukemia Cells In- Vitro and Depletion Of Circulating Leukemic CLL B Cells In-Vivo. *Blood (ASH Annual Meeting Abstracts)*. 2013 Nov; 122(21): 4185. Poster presentation.
79. **Andritsos LA**, Shanafelt T, Blachly J, Grever MR. Outcomes of Melanoma in Patients with Concurrent Hairy Cell Leukemia. *OSUCCC-James 16th Annual Scientific Meeting*. Feb. 2014. Poster presentation.
80. **Andritsos LA**, Payne P, Stephens W, Kelley M, Heckler C, Blachly JS, Grever MR. Hairy Cell Leukemia: An International Clinical Database. *OSUCCC-James 16th Annual Scientific Meeting*. Feb. 2014. Poster presentation.

81. Haverkos BM, Geyer S, McBride A, Penza S, Devine SM, **Andritsos LA**, Jaglowski S. Mobilization for Autologous Stem Cell Transplantation in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma: A Single Institution Experience. *Biology of Blood and Marrow Transplantation*. 2014 Feb; 20(2): S111-112.
82. McBride A, Geyer S, Jaglowski S, Devine SM, **Andritsos LA**. Plerixafor Mobilization in MM Patients and Impact on CD34 Cell Collection and Transplant Outcomes. *Biology of Blood and Marrow Transplantation*. 2014 Feb; 20(2): S293.
83. Woyach JA, Ruppert AS, Lozanski G, Lozanski A, Heerema NA, Zhao W, Abruzzo L, Gordon A, Jones JA, Flynn JM, Jaglowski SM, **Andritsos LA**, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Maddocks KJ. Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: A single-center experience of 267 patients. *ASCO Meeting Abstracts*. 2014 May; 32(15): 7010.
84. Pierceall WE, Maddocks KJ, Wei EN, Chen C, Warner S, Doykan C, Lena R, Blake N, Cardone MH, **Andritsos LA**, Grever MR, Byrd JC, Trudel S, Johnson AJ. Distinct biomarkers as prognostic in chronic lymphocytic leukemia patients treated with alvocidib and lenalidomide as single agents or combination regimens thereof. *ASCO Meeting Abstracts*. 2014 May; 32(15): 7087. Poster presentation.
85. Jaglowski SM, Jones JA, Flynn JM, **Andritsos LA**, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Geyer SM, Heerema NA, Lozanski G, Stefanos M, Hall N, Nagar V, Munneke B, West JS, Neuenburg J, James DF, Johnson AJ, Byrd JC. A phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. *ASCO Meeting Abstracts*. 2014 May; 32(15): 7009.
86. Jones JA, **Andritsos LA**, Lucas DM, Lozanski G, Hutchinson T, Sexton JL, Harris PJ, Grever MR. Preliminary safety and efficacy of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (IBR) in patients (pts) with hairy cell leukemia (HCL). *ASCO Meeting Abstracts*. 2014 May; 32(15): 7063. Poster presentation.
87. **Andritsos LA**, Blum W, Klisovic RB, Vasu S, Penza S, Lee J, Marcucci G, Byrd JC, Devine SM. A phase I dose escalation study of lenalidomide following reduced intensity conditioning allogeneic stem cell transplantation. *Blood (ASH Annual Meeting Abstracts)*. 2014 Dec; 124(21): 3954. Poster presentation.
88. Efebera YA, Geyer S, Bingman A, Kitzler R, Elder P, **Andritsos LA**, Jaglowski SM, Vasu S, Blum W, Klisovic RB, Penza S, Coombes K, Hofmeister CC, Benson D, Devine SM, Lozanski G. Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT). *Blood (ASH Annual Meeting Abstracts)*. 2014 Dec; 124(21): 1166. Poster Presentation.
89. Efebera YA, Geyer S, Bingman A, Elder P, Kitzler R, Coombes K, Hennelly C, Cortright K, **Andritsos LA**, Jaglowski SM, Vasu S, Blum W, Klisovic RB, Penza S, Hofmeister CC, Benson DM, Lozanski G, Devine SM. Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT). *Blood (ASH Annual Meeting Abstracts)*. 2014 Dec; 124(21):3929. Poster presentation.
90. Haverkos BM, Cortright K, **Andritsos LA**, Blum W, Klisovic RB, Vasu S, Goldenberg DM,

Wegener WA, Devine SM, Jaglowski SM. A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies. *Blood (ASH Annual Meeting Abstracts)*. 2014 Dec; 124(21): 1168. Poster presentation.

91. Jones JA, Geyer S, **Andritsos LA**, Awan F, Flynn JM, Maddocks KJ, Bingman A, Johnson AJ, Heerema NA, Brookfield C, Byrd JC, Grever MR. Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study. *Blood (ASH Annual Meeting Abstracts)*. 2014 Dec; 124(21): 329. Oral presentation.
92. Martin P, Maddocks KJ, Noto K, Christian B, Furman RR, **Andritsos LA**, Flynn JM, Jones JA, Ruan J, Chen-Kiang S, Di Liberto M, Leonard JP, Blum KA. Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell Lymphoma. *Blood (ASH Annual Meeting Abstracts)*. 2014 Dec; 124(21): 3047. Poster presentation.
93. Rogers KA, Woyach JA, **Andritsos LA**, Awan F, Blum KA, Flynn JM, Jaglowski S, Lozanski G, Maddocks KJ, Byrd JC, Jones JA. Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with Ibrutinib. *Blood (ASH Annual Meeting Abstracts)*. 2014 Dec; 124(21): 1997. Poster presentation.
94. Vasu S, Bingman A, Geyer S, Elder P, Kitzler R, Bradbury H, Odonnell L, Blum W, Jaglowski SM, **Andritsos LA**, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Lozanski G, Devine SM. Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation. *Blood (ASH Annual Meeting Abstracts)*. 2014 Dec; 124(21): 2494. Poster presentation.
95. Haverkos B, Cortright K, **Andritsos LA**, Blum W, Klisovic R, Vasu S, Goldenberg DM, Wegener W, Devine SM, Jaglowski S. A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies. *Biology of Blood And Marrow Transplantation*. 2014 Feb; 21(2): S331-332.
96. Efebera YA, Geyer S, Bingman A, Elder P, Kitzler R, Coombes K, Hennelly C, Cortright K, **Andritsos L**, Jaglowski S, Vasu S, Blum W, Klisovic R, Penza S, Hofmeister C, Benson DM, Lozanski G, Devine SM. Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-SCT). *Bone Marrow Transplantation*. 2015 March; 50(S1): S397-398.
97. Efebera YA, Geyer S, **Andritsos L**, Vasu S, Jaglowski S, Bingman A, Blum W, Klisovic R, Hofmeister CC, Benson DM, Penza S, Elder P, Cortright K, Kitzler R, Coombes K, O'Donnell L, Daneault B, Bradbury H, Zhang J, Chen X, Garman S, Ranganathan P, Yu X, Hofstetter J, Yu J, Garzon R, Scrape SR, Devine SM, Lozanski G. Impact of Atorvastatin on Immune Reconstitution and cytokines of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). *Bone Marrow Transplantation*. 2015 March; 50(S1): S398.
98. Jones JA, **Andritsos L**, Ravandi F, Kreitman RJ, Schiffer C, Call T, Lozanski G, Sexton J, Harris P, Grever MR. Safety And Efficacy Of The Bruton Tyrosine Kinase Inhibitor Ibrutinib In Patients With Hairy Cell Leukemia: Interim Results Of A Phase 2 Study. *Haematologica*. 2015 June; 100(s1): 313.

99. Jaglowski SM, Jones JA, Flynn JM, **Andritsos LA**, Maddocks KJ, Woyach JA, Blum KA, Greyer MR, Geyer SM, Heerema NA, Lozanski G, Stefanos M, Hall N, Nagar V, Munneke B, West JS, Neuenburg JK, James DF, Johnson AJ, Byrd JC. Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). *Clinical Lymphoma Myeloma & Leukemia*. 2015 June; 15(s1): S206-207.
100. El-Gamal D, Hing ZA, Mitchell S, LaFollette TD, Brennan PJ, Flynn JM, Jones JA, Awan F, Andritsos LA, Blachly JS, Williams K, Harrington BK, Goettl VM, Woyach JA, Lehman AM, Yu L, Byrd JC, Lapalombella R. A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and In Vitro Potency in B-Cell Malignancies. *Blood*. 2015 Dec; 126(23): 318.
101. Rogers KA, Salem G, Stephens DM, **Andritsos LA**, Awan FT, Byrd JC, Flynn JM, Maddocks KJ, Huang Y, Ruppert AS, Jones JA. A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia. *Blood*. 2015 Dec; 126(23): 2951.
102. Issa H, Ruppert AS, Elder P, Hofmeister C, Benson DM, Penza S, **Andritsos LA**, Klisovic RB, Vasu S, Blum W, Jaglowski SM, Devine SM, Efebera YA. Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT). *Blood*. 2015 Dec; 126(23): 1328.
103. Anwar MA, Johnston J, Reed E, Lustberg M, Stevenson K, **Andritsos LA**, Devine SM, Martin SL. Antimicrobial Use for Febrile Neutropenia in Patients with Hematologic Malignancies Undergoing Autologous Hematopoietic Stem Cell Transplant and Clinical Outcome. *Biology of Blood and Marrow Transplantation*. 2016 Mar; 22(3): S158.
104. Issa H, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, **Andritsos LA**, Klisovic R, Vasu S, Blum W, Jaglowski S, Devine SM, Efebera YA. Antithymocyte Globulin (ATG) 4.5 Vs. 6.0 Mg/Kg in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT). *Biology of Blood and Marrow Transplantation*. 2016 March; 22(3): S316-317.
105. Rotta M, Wei L, Kitzler R, Bradbury H, Bingman A, Vasu S, Jaglowski S, Blum W, Klisovic R, Penza S, **Andritsos LA**, Efebera YA, Lozanski G, Devine SM. Significant Impact of Mobilization Strategy on the Cellular Composition of Donor Allografts. *Biology of Blood and Marrow Transplantation*. 2016 March; 22(3): S351-352.
106. Roddy J, Puto M, McDonald M, Montgomery P, Phillips, O'Connor M, Griffith N, **Andritsos LA**. Development of a Transition of Care Medication Education Program for Hematopoietic Stem-Cell Transplantation Patients. *Biology of Blood and Marrow Transplantation*. 2016 March; 22(3): S478-479.
107. Eulitt P, Zhao Q, Ruppert AS, Abruzzo L, Coombes C, Gordon A, Jones JA, Awan FT, Blachly JS, **Andritsos LA**, Byrd JC, Heerema NA, Woyach JA. The significance of BCL6 abnormalities on fluorescence in situ hybridization (FISH) in chronic lymphocytic leukemia (CLL). *J Clin Oncol (Meeting Abstracts)*. 2016 May; 34(15s): e19005.
108. Eulitt P, Zhao Q, Ruppert A, Abruzzo L, Coombes C, Gordon A, Jones J, Awan F, Blachly J, **Andritsos L**, Byrd J, Heerema N, Woyach J. Bcl6 Abnormalities On Fluorescence In Situ Hybridization Are Associated With Early Age At Diagnosis, Karyotypic Complexity, And Aggressive Disease In Chronic Lymphocytic Leukemia. *Haematologica (21st Congress of the European-Hematology-Association)*. 2016 June; 101(s1): 434-435.

109. Singer S, Efebera YA, Zhao Q, Abounader D, Elder P, Hofmeister CC, Benson DM, Penza S, **Andritsos L**, Klisovic R, Vasu S, Blum W, Jaglowski S, William BM, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Majhail N, Devine SM, Dean R. A two-center retrospective comparison of beam vs bucyvp16 conditioning prior to autologous hematopoietic stem cell transplantation in patients with Hodgkin's lymphoma. *Haematologica (21st Congress of the European-Hematology-Association)*. 2016 June; 101(s1): 625-625.
110. Singer S, Efebera YA, Zhao Q, Abounader D, Elder P, Hofmeister CC, Benson DM, Penza S, **Andritsos L**, Klisovic R, Vasu S, Blum W, Jaglowski S, William BM, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Majhail N, Devine SM, Dean R. A Two-Center Retrospective Comparison Of Beam Vs Bucyvp16 Conditioning Prior To Autologous Hematopoietic Stem Cell Transplantation In Patients With Non-Hodgkin's Lymphoma. *Haematologica (21st Congress of the European-Hematology-Association)*. 2016 June; 101(s1): 625-626s.
111. **Andritsos LA**, Grever MR, Anghelina M, Dearden CE, Else M, Blachly JS, Lele O, Ravandi F, Zent CS, Johnston JB, Banerji V, Forconi F, Ho AD, Zenz T, Dietrich S, Demeter J, Barrientos JC, Burger JA, Call TG, Chiorazzi N, DeAngelo DJ, Delgado J, Fagarasanu A, Falini B, Gozzetti A, Jones J, Juliusson G, Kraut EH, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Robak T, Saven A, Tadmor T, Tallman MS, Tam CS, Tiacci E, Troussard X, Abdel-Wahab O, Zinzani PL, Heckler C, Payne PRO. A Distributed International Patient Data Registry for Hairy Cell Leukemia. *Blood (ASH Annual Meeting Abstracts)*. 2016 Dec; 128(22): 5986.
112. **Andritsos LA**, Ying H, Tao F, Huff K, Drea E, McBride A. A Retrospective Evaluation of the Impact of Pre-Emptive Plerixafor Administration on Collection Efficiency in Patients with Myeloma Undergoing Stem Cell Mobilization. *Blood (ASH Annual Meeting Abstracts)*. 2016 Dec; 128(22): 5740.
113. **Andritsos LA**, Anghelina M, Grieselhuber NR, Roychowdhury S, Reeser J, Timmers C, Freud AG, Blachly JS, Lucas DM, Lozanski G, Jones J, Rogers KA, Zhao W, Grever MR. Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia. *Blood (ASH Annual Meeting Abstracts)*. 2016 Dec; 128(22): 5598.
114. Auletta JJ, Ardura MI, Vasu S, Zhao Q, Huang Y, Ruppert AS, Shoben A, Elder P, Bingman A, Kitzler R, Lozanski G, Abu-Arja R, Rangarajan HG, Bajwa R, Horwitz E, O'Donnell L, Jaglowski S, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Rosko AE, Benson DM, **Andritsos LA**, Blum W, Devine S. Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation. *Blood (ASH Annual Meeting Abstracts)*. 2016 Dec; 128(22):3409.
115. Auletta JJ, Ardura MI, Vasu S, Huang Y, Zhao Q, Ruppert AS, Shoben A, Elder P, Bingman A, Kitzler R, Lozanski G, Abu-Arja R, Rangarajan HG, Bajwa R, Horwitz E, O'Donnell L, Jaglowski S, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Rosko AE, Benson DM, **Andritsos LA**, Blum W, Devine S. Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation. *Blood (ASH Annual Meeting Abstracts)*. 2016 Dec; 128(22):3410.
116. Haverkos BM, Schowinsky J, Kaplan J, Kamdar, Kanate AS, Saad A, Mehta A, Ganguly S, Flowers MED, Fenske TS, Hari P, Hamadani M, Lowsky R, **Andritsos LA**, Jagasia

MH, Brown S, Armand P, Merryman RW, Bachanova V, Stephens DM, Nakamura R, Gutman JA, Devine SM. Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease. *Blood (ASH Annual Meeting Abstracts)*. 2016 Dec; 128(22):1163.

117. Heerema NA, Zhao Q, Ruppert AS, Breidenbach H, Jones J, **Andritsos LA**, Woyach JA, Awan FT, Long M, Gordon A, Coombes C, Byrd JC, Muthusamy N. Presence of a Translocation Is Associated with Short Time to Treatment from Diagnosis in IGHV Mutated Chronic Lymphocytic Leukemia (CLL) Patients. *Blood (ASH Annual Meeting Abstracts)*. 2016 Dec; 128(22): 4372.
118. Jones J, **Andritsos L**, Kreitman RJ, Ravandi F, Schiffer C, Call TG, Lozanski G, Harris P, Sexton J, Ruppert AS, Grever MR. Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study. *Blood (ASH Annual Meeting Abstracts)*. 2016 Dec; 128(22): 1215.
119. Jones JA, Johnson AJ, Awan FT, Zhao Q, Muthusamy R, Maddocks KJ, **Andritsos LA**, Rogers KA, Woyach JA, Lozanski B, Heerema NA, Brookfield C, Ruppert AS, Byrd JC. A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features. *Blood (ASH Annual Meeting Abstracts)*. 2016 Dec; 128(22):4388
120. Long M, Beckwith KA, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks K, Cheney C, Jones J, **Andritsos LA**, Awan FT, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, Byrd JC. Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism. *Blood (ASH Annual Meeting Abstracts)*. 2016 Dec; 128(22): 3238.
121. Miller CR, Ruppert AS, Heerema NA, Maddocks KJ, Labanowska J, Breidenbach H, Lozanski G, Zhao W, Gordon J, Flynn FM, Jaglowski S, **Andritsos LA**, Awan FT, Blum KA, Grever MR, Johnson AJ, Abruzzo LV, Hertlein EK, Woyach JA, Byrd JC. Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. *(ASH Annual Meeting Abstracts)*. 2016 Dec; 128(22): 3198.
122. Richardson D, Zhao Q, Kitzler R, Elder P, Lozanski G, **Andritsos LA**, Benson DM, Blum W, Efebera YA, Jaglowski S, Klisovic RB, Penza S, Vasu S, Devine SM. Doses of Total Nucleated Cells and Activated T-Cells Transplanted Influence Survival and Graft Versus Host Disease Among AML and MDS Recipients of Reduced-Intensity Mobilized Peripheral Blood Allografts. *Blood (ASH Annual Meeting Abstracts)*. 2016 Dec; 128(22): 4598.
123. Richardson DR, Huang Y, Elder P, Newlin J, Kirkendall C, Devine SM, **Andritsos LA**, Benson DM, Blum W, Efebera YA, Hofmeister CC, Jaglowski S, Klisovic RB, McGinty HL, Penza S, Vasu S, William BM, Rosko AE. Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation. *Blood (ASH Annual Meeting Abstracts)*. 2016 Dec; 128(22): 1241.
124. Shindiapina P, Khountham S, Rogers KA, Jones J, **Andritsos L**, Maddocks KJ, Flynn JM, Woyach JA, Byrd JC, Awan FT. Natural History of Non-Infectious, Ibrutinib-

Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL. *Blood (ASH Annual Meeting Abstracts)*. 2016 Dec; 128 (22): 4385.

125. Vaughn J, Kline D, Denlinger N, **Andritsos L**, Walker AR. Performance of Quick Sepsis-Related Organ Failure Assessment (qSOFA) in Predicting Adverse Outcomes in Acute Leukemia Patients Receiving Induction Chemotherapy. *Blood (ASH Annual Meeting Abstracts)*. 2016 Dec; 128(22): 241.
126. Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, McCoy A, Maddocks KJ, Christian BA, Rogers KA, **Andritsos L**, Jaglowski S, Devine SM, Porcu P, Woyach JA, Jones J, Grever MR, Byrd JC, Awan FT. Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center. *Blood (ASH Annual Meeting Abstracts)*. 2016 Dec; 128(22): 2040.
127. Woyach JA, Guinn D, Ruppert AS, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo LV, Gordon A, Mantel, Smith LL, McWorter S, Davis M, Doong TJ, Ny F, Lucas MS, Chase W, Jones J, Flynn JM, Maddocks KJ, Jaglowski S, **Andritsos LA**, Awan FT, Blum K, Grever MR, Lozanski G, Byrd JC, Johnson AJ. The Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL. *Blood (ASH Annual Meeting Abstracts)*. 2016 Dec; 128(22): 55.
128. Woyach JA, Ruppert AS, Awan FT, Jones J, **Andritsos LA**, Waymer S, Lozanski G, Muthusamy N, Byrd JC. Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones. *Blood (ASH Annual Meeting Abstracts)*. 2016 Dec; 128(22): 4386.
129. Alsaid N, McBride A, Oh M, Persky D, Anwer F, **Andritsos L**, Kumar A, Yun S, Abraham I. Economic Evaluation for the US of Venetoclax Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. *Blood (ASH Annual Meeting Abstract)*. 2017 Dec; 130(Suppl 1): 4678.
130. Alsaid N, McBride A, Oh M, Kim H, Oh K, **Andritsos L**, Anwer F, Persky D, Kumar A, Yun S, Abraham I. Economic Evaluation for the US of Ibrutinib Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. *Blood (ASH Annual Meeting Abstract)*. 2017 Dec; 130(Suppl 1): 4679.
131. Awan FT, Thangavadivel S, Weiss D, Wei L, Woyach JA, Rogers KA, Jones J, **Andritsos L**, Muthusamy N, Andersen B, Byrd JC. A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL. *Blood (ASH Annual Meeting Abstract)*. 2017 Dec; 130(Suppl 1): 1748.
132. Rogers KA, Huang Y, Dotson E, Lundberg J, **Andritsos L**, Awan FT, Jones JA, Woyach JA, Byrd JC. Ingle-Institutional Experience with the Use of PD-1 Inhibitors for the Treatment of Richter's Syndrome. *Blood (ASH Annual Meeting Abstract)*. 2017 Dec; 130(Suppl 1): 5345.
133. Vaughn JL, Zhao Q, Ranganathan P, Elder P, William BM, Puto M, Julianna Roddy J, Klisovic R, Blum W, Benson DM Jr, Jaglowski SM, Mims AS, Brammer JE, Bhatnagar B, Efebera YA, Hofmeister CC, **Andritsos LA**, Penza S, Walker AR, Devine, SM, Cataland

SR, Vasu S. Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab. *Blood (ASH Annual Meeting Abstract)*. 2017 Dec; 130(Suppl 1): 1932.

134. Vaughn JL, Lamprecht M, Huang Y, Angelina M, Balada-Llasat J-M, El Boghdady Z, Childs R, Pancholi P, **Andritsos LA**. Toxigenic Clostridium Difficile Colonization in Patients with Hematologic Malignancies Admitted to the Hospital for Chemotherapy or Hematopoietic Cell Transplantation. *Blood (ASH Annual Meeting Abstract)*. 2017 Dec; 130(Suppl 1): 3211.
135. Wall SA, Zhao Q, Ranganathan P, Elder P, William BM, Puto M, Roddy J, Klisovic RB, Blum W, Benson DM Jr, Jaglowski S, Mims AS, Brammer JE, Efebera YA, Hofmeister CC, **Andritsos L**, Penza S, Walker AR, Devine SM, Cataland SR, Vasu S. Transplant Associated Thrombotic Microangiopathy (TA-TMA) Commonly Occurs after Steroid-Refractory or Dependent Gastrointestinal (GI) Graft Versus Host Disease (GVHD) and Contributes to Post-Transplant Morbidity. *Blood (ASH Annual Meeting Abstract)*. 2017 Dec; 130(Suppl 1): 4483.

RESEARCH SUPPORT

Ongoing Research Support

- Hairy Cell Leukemia Foundation (PI: **Andritsos**) 11/2/16 – 1/2/18
Quality of Life and Clinical Outcomes of Hairy Cell Leukemia Patients: A Longitudinal Study
Objective: This is a planned multicenter quality of life survey which will be performed at Centers of Excellence which are participating in the Hairy Cell Leukemia Patient Data Registry.
Funding Amount: \$ 44,326
- Hairy Cell Leukemia Foundation (CO PI: **Andritsos**) 6/15/2013 - Present
Protocol ID: OSU-121941 Hairy Cell Leukemia Research Data Registry
Objective: To deploy and manage a Hairy Cell Leukemia Research Data Registry (HCL- RDR) to at least three sites for use by the Hairy Cell Leukemia Foundation. Clinical research in hairy cell leukemia: surveillance and documentation of clinical outcomes in a rare form of adult leukemia.
Funding Amount: \$1,069,067
- Hairy Cell Leukemia Foundation (PI: **Andritsos**) 2/16/2016 – Present
Student funds for HCL patient data registry supplement
Funding amount: \$9,360
- Patient Safety Advancement Grant (PI: **Andritsos**) 7/1/2015
A Pilot Study for Evaluation of Clostridium Difficile Colonization in Patients with Hematologic Malignancies Admitted to the Hospital for Chemotherapy or Stem Cell Transplantation
Objective: To Assess the prevalence of C. diff colonization, the subsequent development of C. diff colitis, species identification, and impact on patient outcomes with a goal of preventing Clostridium difficile infection and improving patient outcomes during the transplant procedure
Funding Amount: \$75,000
- Sanofi (PI: **Andritsos**) 7/1/2016
Evaluation of the clinical and economic impact of plerixafor dosing schedules in stem cell mobilization for autologous transplant.
Objective: To perform a value-based care analysis in stem cell mobilization for patients with multiple myeloma

Funding Amount: \$35,000

Completed Research Support

1 K12 CA133250-01 (PI: Byrd) 9/9/2008 -7/31/2013 NIH
Translational Training Grant in Experimental Therapeutics
Objective: To perform Phase 1 and Phase 2 studies in experimental therapeutics for
Chronic Lymphocytic Leukemia
Role: Paul Calabresi Scholar

CALGB Foundation Award (PI: Andritsos) 8/1/2007 – 7/31/2008
Cancer and Leukemia Group B/Career development grant Flavopiridol for Treatment of Minimal
Residual Disease in Patients with Chronic Lymphocytic Leukemia.
Goal: To perform a phase I study of flavopiridol in CLL patients with minimal residual disease
Funding Amount: \$35,000

CLINICAL TRIALS

Principal Investigator

2001 – 2001. Minimal Ablation & Cellular Immune Therapy of Chronic Lymphocytic Leuk, Prolymphocytic Leuk, Low-Grade Non-Hodgkin's Lymphoma & Mantle Cell Lymphoma w/Allogeneic Donor Stem Cells. Andritsos, LA. Clinical Trials.
Protocol ID: CALGB-109901, 2001C0195.

2006 - 2010. A Phase I Dose-Escalating Study of Flavopiridol Administered as a 30 Minute Loading Dose Followed by a 4 hour infusion in patients with B-Cell Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) following cytoreduction with chemotherapy. Andritsos, LA. Clinical Trial.
Protocol ID: OSU-05116
Secondary ID: 2006C0031; 7368

2006 – 2016. Phase I Study of Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia. Andritsos, LA. Celgene. Clinical Trial. Columbus, Ohio, USA.
Summary: Co-Principal Investigator of phase I clinical trial evaluating lenalidomide for treatment of chronic lymphocytic leukemia. Andritsos, LA. Clinical Trial.
Protocol ID: OSU-06003
Funding Amount: \$354,840

2007 - 2009. A multi-center, open-label, single arm study of weekly alvocidib in patients with previously treated B-cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) arriving from CLL. Andritsos, LA. Clinical Trial.
Protocol ID: OSU-06124
Secondary ID: 2007C0055; EFC6663

2008 – 2012. Phase I/II Study of AMD3100 (Mozobil) and Rituximab in Patients with CLL or SLL. Andritsos, LA. Genzyme. Clinical Trial. Columbus, Ohio, USA.
Protocol ID: OSU-07117
Secondary ID: 2008C0014; MOZ00207

2010 - 2011. Embedded Protocol to CALGB-100701. Andritsos, LA. Clinical Trial.

Secondary ID: CALGB-20802

2010 - 2011. A Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High- Risk Chronic Lymphocytic Leukemia (CLL). Andritsos, LA. Clinical Trial.

Protocol ID: CALGB-100701

Secondary ID: 100701(20802); 2010C0077

2010 - present. A Phase I Study of Lenalidomide Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Patients with Select High Risk Hematological Malignancies. Andritsos, LA. Clinical Trial.

Protocol ID: OSU-10079

Secondary ID: 2010C0069; 8305

09/2010 - present. A Phase III Multi-center Randomized Trial Comparing Tacrolimus/Sirolimus/Methotrexate versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis after Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation for Patients with Lymphoma. Devine, Steven. Clinical Trial.

Protocol ID: OSU-09143

Secondary ID: 09-073; 2010C005

2011 - present. A Retrospective Analysis of Outcomes following Autologous Stem Cell Transplant for Multiple Myeloma and Lymphoma. Andritsos, LA. Clinical Trial.

Protocol ID: OSU-11098

2011 - present. A retrospective analysis of factors contributing to outcomes following reduced- intensity conditioning allogeneic stem cell transplant for chronic lymphocytic leukemia. Andritsos, LA. Clinical Trial.

Protocol ID: OSU-11068

2012 – present. Compassionate use: safety and efficacy of varicella zoster immune globulin(Human) (VariZIG™) in patients at-risk of varicella infection. Andritsos, LA. Clinical Trials.

Protocol ID: OSU-12076


2013 – present: Development of a transition of care medication education program for hematopoietic stem cell transplantation recipients.

Protocol ID: OSU-13068



MEMO

To: Cinnamon Blair
Chair, UNM Naming Committee

From: Cheryl Willman, MD  On behalf of Dr. Cheryl Willman, MD
Maurice and Marguerite Liberman Distinguished Chair in Cancer Research
Director & CEO, UNM Comprehensive Cancer Center (UNMCCC)

Date: January 14, 2019

Re: Appointment of the Victor and Ruby Hansen Surface Endowed Professorship in
Cancer Cell Signal Transduction and Cellular Imaging

Diane Lidke, PhD.
Professor and Vice-Chair for Research, Department of Pathology, UNM School of
Medicine Leader, UNM Comprehensive Cancer Center Shared Resource in
Microscopy and Cellular Imaging

Dear Ms. Blair and Members of the UNM Foundation Naming Committee,

On behalf of the University of New Mexico Comprehensive Cancer Center, we request approval to appoint Diane Lidke, PhD, as the new holder of the Cancer Center's Victor and Ruby Hansen Surface Endowed Professorship in Cancer Cell Signal Transduction and Cellular Imaging.

This Endowed Professorship was created and approved in October 2010 by the UNM Board of Regents according to Regents Policy 2.11 and University Business Policy 1020. This Professorship was previously held by Dr. Eric Prossnitz (and was previously named the Victor and Ruby Hansen Surface Endowed Professorship in Cancer Chemical Biology). As prescribed by Faculty Handbook Policy C170 "Endowed Chairs and Named Professorships" we seek approval to appoint Dr. Lidke as the new holder of this Endowed Professorship.

During his life, Mr. Victor Surface was very generous to the UNM Comprehensive Cancer Center, providing one of UNM's largest gifts from an individual donor (exceeding \$11 million) for the establishment of Endowed Professorships and Chairs and to advance cancer research. He intended for his gift to have a transformational impact on the Cancer Center and on cancer research and ultimately clinical care in New Mexico. His desire was to honor his deceased wife, Ruby Hanson Surface, who had died of colorectal cancer, as had her mother and his father. The Surface Family Trust gift seeks to support the world-class, cutting-edge cancer research that so interested Mr. Surface, and will, to quote Mr. Surface, "go where it counts" and "where it will make a difference to everyone." Of note, Mr. Surface's daughter, Carolyn Surface, has in addition established an Endowment Fund at the UNM Comprehensive Cancer Center (of approximately \$7 million), which also provides funds to support Endowed Chairs and cancer research.

Our belief is Dr. Lidke will carry forward this Surface Family legacy and be an outstanding representative of the qualities required of the endowed professorships. Dr. Lidke is an accomplished, internationally known scientist who is an expert in the development and application of advanced methods for live cell imaging and she particularly applies her work to imaging and modeling of the aberrant behavior of cancer cells and tissues. She recently received a NIGMS MIRA (R35) award and is a well-funded and well published scientist, who has brought great renown to the Department of Pathology, the Cancer Center, and UNM. She serves as an outstanding educator and mentor to many students, trainees, and junior faculty and she holds important leadership roles in the UNM Department of Pathology and the Cancer Center.

Thank you for your time and consideration of this request.

Diane S. Lidke

University of New Mexico
Department of Pathology
Cancer Research Facility, Room 203A
2325 Camino de Salud NE
Albuquerque, NM 87131
Phone: 505-272-8375 FAX: 505-272-1435
dlidke@salud.unm.edu

Education

- 2002 - **Ph.D. Biophysical Sciences and Medical Physics**, University of Minnesota, Minneapolis
Thesis advisor: Dr. David D. Thomas
Thesis title: "Coordination of The Two Heads of Myosin during Muscle Contraction"
- 1994 - **B.S. Physics**, Nebraska Wesleyan University, Lincoln
Graduated with High Distinction

Academic Appointments

- 2018-present **Professor**
2011 - 2018 **Associate Professor**
2006 - 2011 **Assistant Professor**
2005 - 2006 **Research Assistant Professor**
University of New Mexico, Department of Pathology
My research interests involve development and application of new techniques in fluorescence microscopy that combine the spatial, temporal and spectroscopic properties of a sample for use in live cell imaging. Current research involves the application of fluorescence microscopy and biophysical techniques to the study of protein dynamics and interactions during signal transduction in living cells. This involves the study of the spatial-temporal organization of membrane proteins, such as FcεRI and the erbB family members, and how these are altered in disease.

Research Experience

- 2002 - 2005 **Postdoctoral Research Fellow** (Dr. Thomas M. Jovin)
Max Planck Institute for Biophysical Chemistry, Department of Molecular Biology
Research involved the use of fluorescence microscopy to study the mechanisms of erbB and MAPK signaling in live cells. The main focus was the study of protein interactions necessary for signal transduction.
- 1997-2002 **Graduate Research Assistant** (Dr. David D. Thomas)
University of Minnesota, Minneapolis
Used optical spectroscopy to study the structure of the muscle motor protein, myosin. Measured resonance energy transfer between the two light chain domains of the myosin dimer to determine the structural changes that produce muscle contraction.
- 1995 **Graduate Research Assistant**, Department of Physics (Dr. Timothy Gay)
University of Nebraska-Lincoln
Project involved the integration of dye laser hardware for atomic spectroscopy.
- 1992-1994 **Research Assistant**, Department of Physics (Dr. David W. Duquette)
University of Nebraska-Lincoln
Measurement of relative and absolute photoionization cross-section of excited states of atoms.

Teaching

2007-present **Co-instructor**, BIOM 508 Biomedical Sciences Graduate Course, Cell Biology, UNM
2018-present **Co-instructor**, BIOM 252 Biomedical Sciences Graduate Course, Foundations of Molecular and Cellular Biology, UNM
2014-2018 **Co-director**, BIOM 555, Responsible Conduct of Research
2006-2013 **Tutorial Group Leader**, Genetics & Neoplasia Block first year medical students, UNM
2007-2014 **Co-instructor**, Biology 547 Advanced Techniques in Light Microscopy, UNM
2011-2018 **Co-instructor**, BIOM 522 Biomedical Sciences Graduate Course, Experimental Design and Methods in Molecular and Cellular Biosciences, UNM
2010-2012 **Co-instructor**, BIOM 514 Biomedical Sciences Graduate Course, Immunobiology, UNM
2002-2004 **Teaching Assistant**, Molecular Biology PhD Program, University of Goettingen, Germany
1995-1997 **Graduate Teaching Assistant**, Department of Physics, University of Minnesota
1994-1995 **Graduate Teaching Assistant**, Department of Physics, University of Nebraska-Lincoln

Invited Educational Lectures

2015 Cancer Biology Course Symposium
Radboud University, Nijmegen, The Netherlands
“Enhanced Dimerization Drives Ligand-independent Activity of Mutant EGFR in Lung Cancer.”

2015 Computational Image Analysis in Cellular and Developmental Biology
Woods Hole Marine Biological Lab
“Biochemistry in motion: Single molecule imaging to quantify protein interactions during signaling”

2014 Special seminar
University of Pennsylvania
“Dissecting signal transduction, one molecule at a time; single particle tracking for cell biology.”

2014-2107 Qbio Summer School
UNM campus
“Imaging protein dynamics during signal transduction.”

2011 Cellular & Molecular Pharmacology and Physiology “Neuroeffector Signaling”
University of Nevada Reno School of Medicine
“Fluorescence microscopy to quantify protein behavior in living cells”

2011 Special Topics in Computational Biology,
UNM
“Fluorescence microscopy for studying biological processes Or How I learned to stop blotting and love the microscope”

2007-2008 UNM Chemical & Nuclear Engineering “Biomolecular Engineering”
UNM
“Live Cell Imaging with Quantum Dot Probes”

2008 “Biology: Discovery and Innovation”
UNM
“Live Cell Imaging and Quantification of Signal Transduction”

Postdoctoral Fellow Mentoring

Amanda Carroll-Portillo, PhD (Biology & Immunology) 2009-2011
Christopher Valley, PhD (Biomedical Sciences) 2012-2015
Marta Cooperstein, PhD (Biomedical Sciences) 2014-2016

Samantha Schwartz, PhD (NSMS) 2016

Carolina Franco Nitta, PhD (Biomedical Sciences) 2016 - present

Graduate Student Mentoring – Thesis Advisor

Nicholas Andrews, BSGP, MD/PhD. PhD received 2008. (INCBN IGERT Fellow)

Shalini Low-Nam, BSGP, PhD received 2011. Co-advisor with Bridget Wilson (NSMS IGERT Fellow)

Patrick Cutler, BSGP, PhD received 2013. (INCBN IGERT Fellow)

Mario Paz, NSMS, MS received 2015 (AMP-BD Fellow)

Samantha Schwartz, NSMS, PhD received 2017 (NSMS IGERT & CNTC Fellow)

Genevieve Phillips, BSGP, MS received 2017

Ellen Hatch, MD/PhD student, PhD defended 2017 (CNTC Fellow)

Emanuel Salazar-Cavazos, BSGP graduate student, PhD received 2018

William Kanagy, BSGP graduate student

Derek Rinaldi, BSGP graduate student

Cristina Flores Cadengo, BME graduate student

Graduate Student Mentoring - Doctoral Thesis Committee (COS)

Kristy Nowak-Lovato, PhD received 2008, BSGP, Advisor: Kirk Rector (LANL)

Shujie Yang, PhD received 2008, BSGP, Pathology, Advisor: Bridget Wilson

Fang Huang, PhD received 2011, Physics, Advisor: Keith Lidke

Megan Brady, BSGP, Neuroscience, PhD received, Advisor: Kevin Caldwell

Soumik Basuray, BSGP, Pathology, PhD received, Advisor: Angela Wandinger-Ness

Michael Malik, Physics, PhD received 2012, Advisor: Keith Lidke

Kathrin Spendier, Physics, PhD received 2013, Advisor: James Thomas

Kristin Wilde, Chemical Engineering, PhD received 2013, Advisor: Heather Canavan

Erin Zekas, BSGP, PhD received 2015, Advisor: Eric Prossnitz

Stephanie Jerman, BSGP, PhD received 2015, Advisor: Angela Wandinger-Ness

Marta Cooperstein, Biomedical Engineering, PhD received 2014 Advisor: Heather Canavan

Meghan Pryor, Chemical Engineering, PhD received 2014, Advisor: Jeremy Edwards

Patricia Langan, BSGP, PhD received 2014, Advisor: Andrew Bradury/James Freyer

Peter Relich, Physics, PhD received 2016, Advisor: Keith Lidke

Joshua Sheak, BSGP (MD/PhD), PhD defended 2017, Advisor: Tom Resta

Nathaniel Weist, BSGP (MD/PhD), PhD defended 2017, Advisor: Allan Tomkinson

Frank Erasmus, BSGP, PhD received 2017, Advisor: Bridget Wilson

Romika Kerketta, Chemistry, PhD received 2017, Advisor: Jeremy Edwards

Annikka Jenssen, BSPG, PhD received 2018, Advisor: Jeff Brinker

Jacqueline De Lora, BSGP, PhD received 2018, Advisor: James Freyer

Christina Hanson, NSMS, PhD received 2018, Advisor: John Grey

Farzin Farzam, Physics, PhD received 2018, Advisor: Keith Lidke

Camden Bair, BSGP, Advisor: Adriana Kajon

Muskan Floren, BSGP, Advisor: Jennifer Gillette

Eduardo Anaya, BSGP; Advisor: Aaron Neumann

Jessie Young, BSGP; Advisor: Michelle Ozbun

Akram Amin, Physics; Advisor: Aaron Neumann

Stephanie Kehl, BSGP; Advisor: Michael Mandel

Graduate Student Mentoring - Master's Thesis Committee

Laura Konopka, Masters of Science for Teachers (M.S.T) 2011, New Mexico Institute of Mining and Technology, Advisor: Rebecca Reiss.

**Mrs. Konopka performed her Master's thesis research in my lab.

Richard Pepermans, Masters 2013, Utrecht University, Advisor: Paul van Bergen en Henegowen

**Mr. Pepermans performed part of his Master's thesis research in my lab.

Pamela Langer, BSGP, MS received, Neuroscience, Advisor: Elaine Bearer
Sonya Flores, BSGP, MS received, Molecular Genetics & Microbiology, Advisor: Michelle Ozbun

Pre-baccalaureate Student Mentoring

Guilliana DiPiazza 2007-2008, IMSD (Initiative to Maximize Student Diversity) fellowship student, UNM Biology major
Hannah Johnson Summer 2011, University of Puget Sound, Biology major
Brad Dimos, Summer 2014 UPN student, Baylor College Biology major
Luis Vidal, Summer 2015, Santa Fe Community College Physics major
Cheyenne Martin, 2014-2016, UNM biology major
Troy Ramos, June 2015-August 2017, UPN student, UNM Chemical Engineering major
Paula Martin Gonzalez, Feb-May 2016, Biomedical Engineering student, Universidad Carlos III de Madrid (Non-European Exchange Program for Undergraduate Students)
Justine Keth, Oct 2016-present, MARK fellow, 2017 UPN student, UNM Biochemistry major
Aubrey Gibson, Sep 2018-present, UNM Biochemistry major

High School students

Carlos Villarreal, Fall 2014, Spring & Summer 2015, Summer 2016; South Valley Academy
Zuly Fornelli, Summer 2016; South Valley Academy

High School Teachers

Laura Konopka, 2010-2011, Early College Academy, Biology teacher
Andres Plaza, Summer 2014, South Valley Academy, Physics/Chemistry Teacher

Honors and Awards

UNM "Apple for the teacher" Educational Excellence Award 2016
UNM-BSGP Outstanding Mentor Award 2016
Margaret Oakley Dayhoff Award from the Biophysical Society; 2011
UNM-HSC Jr. Faculty Excellence in Research Award; 2010
NSF Faculty Early Career Development (CAREER) Award; 2009
Human Frontiers Science Program Young Investigator Award; 2008
Selected participant in the UK-Germany Frontiers of Science Symposium; 2006
Max-Planck-Gesellschaft Fortbildungsstipendium, Post-doctoral Fellowship; 2002-2005
NSF Research Training Grant; 1999-2000
NIH Molecular Biophysics Training Grant; 1997-1999, 2000-2001
Block Research Fellowship (University of Minnesota – Physics Department); 1997
Selected participant in the Science and Engineering Research Semester (Argonne National Lab); 1994
Schock scholarship (Nebraska Wesleyan University – Physics Department); 1993
Selected participant in the NASA Space Life Science Training Program (Kennedy Space Center); 1993
Howard Hughes Medical Institute Fellowship; summer 1992, 1993
Captain Nebraska Wesleyan University women's varsity basketball team; 1992-1993
Lemmon Endowed Scholarship for athletic and academic achievement; 1992
Honor Societies: Phi Kappa Phi, Cardinal Key, Sigma Pi Sigma, Kappa Mu Epsilon; selected 1992-93

Professional Activities

Guest editor for Quantitative Biology Special issue, *Molecular Biology of the Cell* (2016-present)
Monitoring Editor, *Molecular Biology of the Cell* (2014-present)
Associate Editor, *Journal of Membrane Biology* (2015-2018)
Member of the External Advisory committee for "Computer Integrated Systems for Microscopy and Manipulation (CISMM)", an NIH-funded P41 Center at UNC Chapel Hill (2016-present)
Reviewer for *Nature Nanotechnology*, *Molecular Biology of the Cell*, *Biophysical Journal*, *Nano Letters*, *Journal of Microscopy*, *Journal of Molecular Medicine*, *Current Nanoscience*, *Journal of Biological*

Chemistry, Journal of Cell Science, Analytical Biochemistry

NIH Study Sections: EBIT Panel (2013); Physical Sciences of Oncology Panel (2014); 4D Nucleosome Review Panel (2015); F Awards Biological Chemistry and Macromolecular Biophysics (BCMB) Panel (2015); IMAT Panel (2015); EBIT-J Panel (June & Oct 2016); MIRA Panel (Nov 2016); 4D Nucleome Phase I reviewer (Mar 2017); Special Emphasis Panel/Scientific Review Group BCMB (June 2017; Mar 2018)

NSF Review Panels: Cellular Organization Program (2010), NSF Membrane Trafficking and Biogenesis review panel (2011, 2012); Council for Earth and Life Sciences (NOW-ALW Dutch funding agency, 2007)

Member of the Euro-Bioimaging Centers of Excellence Review Panel (2013)

Human Frontiers Science Program Review Panel (2018-present)

DFG Centers of Excellence Review Panel (2018)

Volunteer in the Portal to the Public program, an NSF-funded science outreach program (2008-present)

Member of the Biophysical Society (1998-present), American Society for Cell Biology (2010-present), American Association for the Advancement of Science (2010-present).

Meeting Organization and Sessions Chaired

2012-present, program committee of the *Annual Quantitative BioImaging Conference*

2018-2019, Chair-elect, *Biological Fluorescence Subgroup* (Biophysical Society subgroup)

2018-2020; Chair-elect, *FASEB Immunoreceptors and Immunotherapy Conference*

2016, session chair, *Annual Biophysical Society Meeting* in Los Angeles, CA

2016, program committee for "Förster Resonance Energy Transfer in Life Sciences" at the Max Planck Institute for Biophysical Chemistry, Goettingen, Germany

2013, co-organizer of the ICREA international Symposium on "Visualizing signaling nanoplateforms at a higher spatiotemporal resolution." Barcelona, Spain

2013 & 2014, co-organizer of "Understanding Cell Behavior through Single Cell and Single Molecule Biology" at the University of New Mexico

2008-2012, program committee for the q-bio Conference on Cellular Information Processing in Santa Fe, NM

2012, co-organizer of a symposium at Microscopy & Microanalysis Annual Conference, Phoenix, AZ

2011, co-organized a session for the SNL/UNM Symposium on Nanoparticle/Human Interactions

2007, chaired session at SPIE Photonics West: Colloidal Quantum Dots for Biomedical Applications II, Applications of Colloidal Quantum Dots in Neuroscience, Drug Delivery and Biomechanics

2006, chaired session at SPIE Photonics West: Colloidal Quantum Dots for Biomedical Applications, Applications of Quantum Dots in Cell Biology

Books Edited

Cell Membrane Nanodomains: from Biochemistry to Nanoscopy. CRC Press. A. Cambi and D.S. Lidke, eds. (2014)

Publications

1. A.M. Brandsma*, S.L. Schwartz*, C.C. Valley, G.L.A. Blezer, G. Vidarsson, K.A. Lidke, T. ten Broeke, **D.S. Lidke**[^], J.H.W. Leusen[^]. "Mechanisms of inside-out signaling of the high affinity IgG-receptor FcγRI." *Science Signaling*. 11: eaaq0891 (2018) [^]Contributed equally.

2. E.W. Hatch, M. Geeze, C. Martin, S. Perkins, H. Ward, K. Hartmann, P. Valent, J. Gotlib, **D.S. Lidke**, T.I. George. "Variability of PD-L1 expression in mastocytosis." *Blood Advances*. 2: 189-199 (2018) PMID: 29378725 (Cover)
3. S.A. Freeman, A. Vega, M. Riedl, R.F. Collins, C.R. Bertozzi, M.I. Tammi, **D.S. Lidke**, P. Johnson, S. Mayor, K. Jaqaman, S. Grinstein. "Transmembrane pickets connect cyto- and pericellular-skeletons forming barriers to receptor engagement." *Cell*. 172:305-317 (2018) PMC5929997
4. D.M. Freed, N.J. Bessman, A. Kiyatkin, E. Salazar Cavazos, P.O. Byrne, J.O. Moore, C.C. Valley, D.J. Leahy, **D.S. Lidke**, M.A. Lemmon. "Ligand discrimination by EGFR through altered stability of receptor dimers." *Cell*. 171: 683–695 (2017) PMC5650921
5. S.L. Schwartz, C. Cleyrat, M. Olah, P. Relich, G. Phillips, W.S. Hlavacek, K.A. Lidke, B.S. Wilson and **D.S. Lidke**. "Differential mast cell outcomes are sensitive to FcεRI-Syk binding kinetics." *Molecular Biology of the Cell – Quantitative Biology Special Issue*. 28: 3397-3414 (2017) PMCID: PMC5687039 **MBoC Highlight article
6. M.F. Erasmus, K. Matlawaska-Wasowska, I. Kinjyo, A. Mahajan, S.S. Winter, L. Xu, M. Horowitz, **D.S. Lidke**, B.S. Wilson. "Dynamic pre-BCR homodimers fine-tune autonomous survival signals in B cell precursor acute lymphoblastic leukemia." *Science Signaling*. 9: ra116 (2016)
7. C.C. Valley, D.J. Arndt-Jovin, N. Karedla, M.P. Steinkamp, A. Chizhik, W.S. Hlavachk, B.S. Wilson, K.A. Lidke, **D.S. Lidke**. "Enhanced dimerization drives ligand-independent activity of mutant EGFR in lung cancer." *Molecular Biology of the Cell*. 26: 4087-99 (2015)
8. M. Pryor, M.P. Steinkamp, A.M. Halasz, Y. Chen, S. Yang, M.S. Smith, G. Zahoransky-Kohalmi, M. Swift, X. Xu, D. Hanien, N. Volkmann, **D.S. Lidke**, J.S. Edwards and B.S. Wilson. "Orchestration of ErbB3 signaling through hetero and homo-interactions." *Molecular Biology of the Cell*. 26: 4109-23 (2015)
9. Carroll-Portillo, J.L. Cannon, J. te Riet, A. Holmes, Y. Kawakami, T. Kawakami, A. Cambi, **D.S. Lidke**. "Mast cells and dendritic cells form synapses that facilitate antigen transfer for T cell activation." *Journal of Cell Biology*. 210: 851-864 (2015)
10. G. Wan, C. Pehlke, R. Pepermans, J.L. Cannon, **D.S. Lidke**, A. Rajput. "The H1047R point mutation in p110a changes the morphology of human colon HCT116 cancer cells. *Cell Death and Discovery*, 1: 15044 (2015).
11. T.Q. Vu, W.Y. Lam, E.W. Hatch, **D.S. Lidke**. "Quantum dots for quantitative imaging: from single molecules to tissue." An invited review for *Cell & Tissue Research*. 360:71-86 (2015)
12. C.C. Valley, Liu, **D.S. Lidke**, K.A. Lidke. "Sequential Superresolution Imaging of Multiple Targets Using a Single Fluorophore" *PLoS ONE*, v.10, p.e0123941 (2015)
13. J. Broeken, H. Johnson, **D.S. Lidke**, S. Liu, R.P.J. Nieuwenhuizen, S. Stalling, K.A. Lidke B. Rieger. "Resolution improvement by 3D particle averaging in localization microscopy" *Methods and Applications in Fluorescence*, 3: 014003 (2015)
14. O. Coban, L.C. Zanetti-Dominguez, D.R. Matthews, D.J. Rolfe, G. Weitsman, P.R. Barber, J. Barbeau, V. Devaughes, F. Kampmeier, M. Winn, B. Vojnovic, P.J. Parker, K.A. Lidke, **D.S. Lidke**, S.M. Ameer-Beg, M.L. Martin-Fernandez, T. Ng. "Effect of phosphorylation on EGFR dimer

- stability probed by single-molecule dynamics and FRET/FLIM." *Biophysical Journal*. **108**: 1013-1026 (2015)
15. S.L. Schwartz, Q. Yan, C.A. Telmer, K.A. Lidke, M.P. Bruchez, **D.S. Lidke**. "Fluorogen-Activating Proteins Provide Tunable Labeling Densities for Tracking FcεRI Independent of IgE." *ACS Chemical Biology*. **10**:539-546 (2015)
 16. M.S. DeVore, D.G. Stich, A.M. Keller, Y. Gosh, P.M. Goodwin, M.E. Phipps, M.H. Stewart, C. Cleyrat, B.S. Wilson, **D.S. Lidke**, J.A. Hollingsworth, J.H. Werner. "Three dimensional time-gated tracking of non-blinking quantum dots in live cells." *Proceedings of SPIE*. 12:933812 (2015)
 17. A.M. Keller, Y. Ghosh, M.S. DeVore, M.E. Phipps, M.H. Stewart, B.S. Wilson, **D.S. Lidke**, J.A. Hollingsworth, J.H. Werner. "3-Dimensional Tracking of Non-blinking 'Giant' Quantum Dots in Live Cells." *Advanced Functional Material*. **24**:4796-4803 (2014)
 18. Q. Yan*, S.L. Schwartz*, S. Maji, F. Huang, C. Szent-Gyorgyi, **D.S. Lidke**, K.A. Lidke and M.P. Bruchez. Localization Microscopy using Noncovalent Fluorogen Activation by Genetically Encoded Fluorogen-Activating Proteins. *Chemphyschem*. **15**:687-695 (2014)
 19. M.P. Steinkamp, S.T. Low-Nam, S. Yang, K.A. Lidke, **D.S. Lidke**, B.S. Wilson. "ErbB3 is an active tyrosine kinase capable of homo- and hetero-interactions." *Molecular and Cellular Biology*. **34**:965-77 (2014)
 20. C.C. Valley, K.A. Lidke, **D.S. Lidke**. "The Spatiotemporal Organization of ErbB Receptors: Insights from Microscopy." An invited chapter for *Signaling by Receptor Tyrosine Kinases*. Cold Spring Harbor Perspectives in Biology. J Schlessinger and MA Lemmon, eds. pp. 179-192 (2014)
 21. T.C. Lund, X. Patrinostro, A.C. Kramer, P. Stadem, L.A. Higgins, T.W. Markowski, M.S. Wroblewski, **D.S. Lidke**, J. Tolar, B.R. Blazar. "sdf1 Expression reveals a source of perivascular-derived mesenchymal stem cells in zebrafish." *Stem Cells*. **32**:2767-2779 (2014)
 22. Mahajan, D. Barua, P.J. Cutler, **D.S. Lidke**, F.A. Espinoza, C. Pehlke, R. Grattan, Y. Kawakami, C.S. Tung, A.R. Bradbury, W.S. Hlavacek, B.W. Wilson. "Optimal aggregation of FcεRI with a structurally defined trivalent ligand overrides negative regulation driven by phosphatases." *ACS Chemical Biology*. **9**:1508-1519 (2014)
 23. Cleyrat, A. Darehshouri, K.L. Anderson, C. Page, **D.S. Lidke**, N. Volkmann, D. Hanein, and B.S. Wilson. "The architectural relationship of components controlling mast cell endocytosis." *Journal of Cell Science*. **126**: 4913-4925 (2013)
 24. Cambi, M. Lakadamyali, **D.S. Lidke**, M.F. Garcia-Parajo. "Meeting report--Visualizing signaling nanoplatfoms at a higher spatiotemporal resolution." *Journal of Cell Science*. 126:3817-21 (2013)
 25. P.J. Cutler, M.D. Malik, S. Liu, J.M. Byars, **D.S. Lidke** and K.A. Lidke. "Multi-color quantum dot tracking using a high-speed hyperspectral line-scanning microscope." *PLoS One*. **8**: e64320 (2013)
 26. M.M. Pryor, S.T. Low-Nam*, A.M. Halasz, **D.S. Lidke**, B.S. Wilson and J.S. Edwards. "Dynamic Transition States of ErbB1 Phosphorylation Predicted by Spatial Stochastic Modeling." *Biophysical Journal*, **105**:1533-1543 (2013)

27. TC Lund, AJ Kobs, A Kramer, M Nyquist, MT Kuroki, J Osborn, **DS Lidke**, ST Low-Nam, BR Blazar and J Tolar. Bone marrow stromal and vascular smooth muscle cells have chemosensory capacity via bitter taste receptor expression. *PLoS One*. **8**: e58945 (2013)
28. K van den Dries, SL Schwartz, J Byars, MB Meddens, M Bolomini-Vittori, **DS Lidke**, CG Figdor, KA Lidke and A Cambi. Dual-color superresolution microscopy reveals nanoscale organization of mechanosensory podosomes. *Molecular Biology of the Cell*. **24**: 2112-2123 (2013)
29. Cambi and **D.S. Lidke**. "Nanoscale Membrane Organization: Where Biochemistry Meets Advanced Microscopy." An invited review for *ACS Chemical Biology*. **7**: 139-149 (2012)
30. **D.S. Lidke** and K.A. Lidke. "Advances in high-resolution imaging - techniques for three-dimensional imaging of cellular structures." An invited review for *Journal of Cell Science*. **125**:2571-2580 (2012).
31. Carroll-Portillo, Z. Surviladze, A. Cambi, **D.S. Lidke**, and B.S. Wilson. "Mast cell synapses and exosomes: membrane contacts for information exchange." *Frontiers in Immunology*. **3**:46 (2012)
32. K. Spendier, K.A. Lidke, **D.S. Lidke**, and J.L. Thomas. "Single-particle tracking of immunoglobulin E receptors (Fc epsilon RI) in micron-sized clusters and receptor patches." *FEBS Letters*. **586**: 426-421 (2012)
33. F.A. Espinoza, M.J. Wester, J.M. Oliver, B.S. Wilson, N.L. Andrews, **D.S. Lidke**, and S.L. Steinberg. "Insights into Cell Membrane Microdomain Organization from Live Cell Single Particle Tracking of the IgE High Affinity Receptor Fc epsilon RI of Mast Cells." *Bulletin of Mathematical Biology*. **74**:1857-1911 (2012)
34. S.T. Low-Nam, K.A. Lidke, P.J. Cutler, R.C. Roovers, P.M.P. van Bergen en Henegouwen, B.S. Wilson, **D.S. Lidke**. "ErbB1 dimerization is promoted by domain co-confinement and stabilized by ligand." *Nature Structural & Molecular Biology*. **18**: 1244-1249 (2011)
35. S. de Keijzer, M. Meddens, D. Kilic, B. Joosten, I. Reinieren-Beeren, **D.S. Lidke**, S. Grinstein and A. Cambi. "Interleukin-4 alters early phagosome phenotype by modulating class I PI3K dependent lipid remodeling and protein recruitment." *PLoS ONE*. **6**(7): e22328. doi:10.1371/journal.pone.0022328 (2011)
36. **D.S. Lidke**, S.T. Low-Nam, P.J. Cutler, K.A. Lidke. "Determining FcεRI diffusional dynamics via single quantum dot tracking." *Methods in Molecular Biology*. Vol 748: Immune Receptors. J.P. Rast and J.W.D. Booth, Eds. Humana Press pp. 121-132 (2011)
37. B.S. Wilson, J.M. Oliver, **D.S. Lidke**. "Spatio-temporal signaling in mast cells." A chapter for *Mast Cell Biology: Contemporary and Emerging Topics*. Vol. 716, D. Metcalfe and A. Gilfillan, Eds.. Landes BioScience and Spring Science. pp. 91-106 (2011)
38. **D.S. Lidke**, F. Huang, J.N. Post, B. Rieger, J. Wilsbacher, J.L. Thomas, J. Pouysségur, T.M. Jovin and P. Lenormand. "ERK nuclear translocation is dimerization-independent but controlled by the rate of phosphorylation." *Journal of Biological Chemistry*. **285**:3092-3102 (2010) PMC2823437
**Selected as "Paper of the Week."
39. N.P. Wells, G.A. Lessard, P.M. Goodwin, M.E. Phipps, P.J. Cutler, D.S. Lidke, B.S. Wilson, J.H. Werner. "Time-Resolved Three-Dimensional Molecular Tracking in Live Cells." *Nano Letters*. **10**: 4732-4737 (2010) PMC3061257

40. Carroll-Portillo, K. Spendier, J. Pfeiffer, G. Griffiths, H. Li, K.A. Lidke, J.M. Oliver, **D.S. Lidke**, J.L. Thomas, B.S. Wilson, J.A. Timlin. "Formation of a mast cell synapse: FcεRI membrane dynamics upon binding mobile or immobilized ligands on surfaces." *Journal of Immunology*. **184**: 1328-1338 (2010)
41. N.L. Andrews, J.R. Pfeiffer, A.M. Martinez, D.M. Haaland, R.W. Davis, T. Kawakami, J.M. Oliver, B.S. Wilson and **D.S. Lidke**. "Small, mobile FcεRI aggregates are signaling competent." *Immunity*, **31**: 469-479 (2009)
42. **D.S. Lidke** and B.S. Wilson. "Caught in the act: quantifying protein behaviour in living cells." An invited review for *Trends in Cell Biology*, **19**: 566-574 (2009) (cover)
43. K. Radhakrishnan, J.S. Edwards, **D.S. Lidke**, T.M. Jovin, B.S. Wilson and J.M. Oliver. "Sensitivity analysis predicts that the ERK-pMEK interaction regulates ERK nuclear translocation." *IET Systems Biology*, **3**: 329-341 (2009)
44. D.M. Haaland, H.D.T. Jones, M.H. Van Benthem, M.B. Sinclair, D.K. Melgaard, C.L. Stork, M.C. Pedroso, P. Liu, A.R. Brasier, N.L. Andrews, and **D.S. Lidke**. "Hyperspectral confocal fluorescence imaging: Exploring alternative multivariate curve resolution approaches." *Applied Spectroscopy*. **63**: 271-279 (2009)
45. N.P. Wells, G.A. Lessard, M.E. Phipps, P.M. Goodwin, **D.S. Lidke**, B.S. Wilson, J.H. Werner. "Going beyond 2D: following membrane diffusion and topography in the IgE-FcεRI system using 3-dimensional tracking microscopy." *Proceedings of SPIE*, **7185**: 71850Z (2009)
46. J.L. Smith, D.S. Lidke, M. Ozbun. "Virus activated filopodia promote human papillomavirus type 31 uptake from the extracellular matrix." *Virology*, **381**:16-21 (2008) (cover)
47. N.L. Andrews, K.A. Lidke, J.R. Pfeiffer, A.R. Burns, B.S. Wilson, J.M. Oliver and **D.S. Lidke**. "Actin restricts FcεRI diffusion and facilitates antigen induced immobilization." *Nature Cell Biology*, **10**:955-963 (2008)
48. G.M. Hagen, K.A. Lidke, B. Rieger, **D.S. Lidke**, W. Caarls, D.J. Arndt-Jovin and T.M. Jovin. "Dynamics of membrane receptors: single molecule tracking of quantum dot liganded epidermal growth factor." A chapter for *Single Molecule Dynamics*, Wiley-VCH: Weinheim (2008)
49. **D.S. Lidke**, N.L. Andrews, J.R. Pfeiffer, H.D.T. Jones M.B. Sinclair, D.M. Haaland, A.R. Burns, B.S. Wilson, J.M. Oliver and K.A. Lidke. "Exploring membrane protein dynamics by multicolor single quantum dot imaging using wide field, TIRF, and hyperspectral microscopy." *Proceedings of SPIE*, **6448**:6448Y1-8 (2007)
50. **D.S. Lidke**, P. Nagy and D.J. Arndt-Jovin. "In vivo imaging using quantum dot conjugated probes." A chapter for *Current Protocols in Cell Biology*, Wiley Press. **25.1**:1-18 (2007)
51. **D.S. Lidke**, P. Nagy, T.M. Jovin and D.J. Arndt-Jovin. "Biotin-Ligand Complexes with Streptavidin Quantum Dots for in vivo Cell Labeling of Membrane Receptors." *Methods in Molecular Biology*, **374**: 69-80 (2007)
52. S. Yang, M. Raymond-Stintz, W. Ying, J. Zhang, **D.S. Lidke**, S.L. Steinberg, J.M. Oliver, B. S. Wilson. "Mapping erbB receptors on breast cancer cell membranes during signal transduction." *Journal of Cell Science*, **120**:2763-2773 (2007)

53. M. Xue, G. Hsieh, M. Raymond-Stintz, J. Pfeiffer, D. Roberts, S.L. Steinberg, J.M. Oliver, E.R. Prossnitz, **D.S. Lidke**, and B.S. Wilson. "Activated FPR and FcεRI Occupy Common Domains for Signaling and Internalization." *Molecular Biology of the Cell*, **18**:1410-1420 (2007)
54. B.S. Wilson, J.R. Pfeiffer, M.A. Raymond-Stintz, **D.S. Lidke**, N.L. Andrews, J.A. Zhang, W. Yin, S. Steinberg and J.M. Oliver. "Exploring membrane domains using native membrane sheets and transmission electron microscopy." *Methods in Molecular Biology*. Vol 398: Lipid Rafts. T. McIntosh, Ed. Humana Press pp. 247-263 (2007)
55. Cambi, **D.S. Lidke**, D.J. Arndt-Jovin, C.G. Figdor and T.M. Jovin. "Ligand-conjugated quantum dots monitor antigen uptake and processing by dendritic cells." *Nano Letters*, **7**:970-977 (2007)
56. Arndt-Jovin, D.J., M.A. Lopez-Quintela, **D.S. Lidke**, M.J. Rodríguez, F.M. Santos, K.A. Lidke, G.M. Hagen, and T.M. Jovin, "In vivo cell imaging with semiconductor quantum dots and noble-metal nanodots." *Proceedings of SPIE*, 2006. **6096**:60960P1-10 (2006)
57. B.A. Hernandez-Sanchez, T.J. Boyle, T.N. Lambert, S. Daniel-Taylor, J.M. Oliver, B.S. Wilson, **D.S. Lidke**, N.L. Andrews. "Synthesizing biofunctionalized nanoparticles to image cell signaling pathways." *IEEE Transactions in Nanobioscience*, **5**:222-230 (2006)
58. D.J. Arndt-Jovin, T.M. Jovin and **D.S. Lidke**. "Quantum dots, a new tool for real-time in vivo imaging." In: From cells to proteins: Imaging nature across dimensions, In: *From cells to proteins: Imaging nature across dimensions*, (Proc. of NATO ASI 2004, Pisa. Italy). V. Evangelista, L. Barsanti, V. Passarelli and P. Gualteri, Eds. Springer, Dordrecht, The Netherlands, pp. 217-225 (2005)
59. T.M. Jovin, **D.S. Lidke** and E.A. Jares-Erijman, "Fluorescence Resonance Energy Transfer (FRET) and Fluorescence Lifetime Imaging Microscopy (FLIM)." In: *From cells to proteins: Imaging nature across dimensions*, (Proc. of NATO ASI 2004, Pisa. Italy). V. Evangelista, L. Barsanti, V. Passarelli and P. Gualteri, Eds. Springer, Dordrecht, The Netherlands, pp. 209-216 (2005)
60. **D.S. Lidke**, K.A. Lidke, B. Rieger, T.M. Jovin and D.J. Arndt-Jovin. "Reaching out for signals: filopodia sense EGF and respond by retrograde transport of activated EGF receptors." *Journal of Cell Biology*, **170**: 619-626 (2005)
61. K.A. Lidke, B. Reiger, **D.S. Lidke** and T.M. Jovin. "The role of photon statistics in fluorescence anisotropy imaging." *IEEE Journal for Image Processing*, **14**: 1237-1245 (2005)
62. F. Rooms, W. Philips and **D.S. Lidke**. "Simultaneous estimation and restoration of confocal images and its evaluation by colocalization analysis." *Journal of Microscopy*, **218**: 22-36 (2005) (cover)
63. H.E. Grecco, K.A. Lidke, R. Heintzmann, **D.S. Lidke**, C. Spagnuolo, O.E. Martinez, E.A. Jares-Erijman and T.M. Jovin. "Ensemble and single particle photophysical properties (two-photon excitation, anisotropy, FRET, lifetime, spectral conversion) of commercial quantum dots in solution and in live cells." *Microscopy Research and Technique*, **65**: 169-179 (2004)
64. **D.S. Lidke** and D.J. Arndt-Jovin. "Imaging takes a quantum leap." An invited review for *Physiology*, **19**: 322-325 (2004)

65. E. Jares-Erijman, C. Spagnuolo, L. Giordano, M. Etchehon, J. Kawior, M. Mañalich-Arana, M. Bossi, **D.S. Lidke**, J.N. Post, R. Vermeij, R. Heintzmann, K.A. Lidke, D.J. Arndt-Jovin and T.M. Jovin. "Novel (bio)chemical and (photo)physical probes for imaging live cells." In: *Supramolecular structure and function*, Vol 8, G. Pifat-Mrzljak (ed.), Kluwer-Plenum Publishers, Amsterdam, pp. 99-118 (2004)
66. T.M. Jovin, **D.S. Lidke** and J.N. Post. "Dynamic and static anisotropy in biological microscopy (rFLIM and emFRET)." *Proceedings of SPIE*, **5323**: 1-12 (2004)
67. **D.S. Lidke**, P. Nagy, R. Heintzmann, D.J. Arndt-Jovin, J.N. Post, H. Grecco, E.A. Jares-Erijman and T.M. Jovin. "Quantum Dot ligands provide new insights into receptor-mediated signal transduction." *Nature Biotechnology*, **22**: 198-203 (2004)
68. **D.S. Lidke**, P. Nagy, B.G. Barisas, R. Heintzmann, J.N. Post, K.A. Lidke, A.H.A. Clayton, D.J. Arndt-Jovin and T.M. Jovin. "Imaging molecular interactions in cells by dynamic and static fluorescence anisotropy (rFLIM and emFRET)." *Biochemical Society Transactions*, **31**: 1020-1027 (2003)
69. **D.S. Lidke** and D.D. Thomas. "Coordination of the two heads of myosin during muscle contraction." *Proceedings of the National Academy of Sciences of the United States of America*, **99**: 14801-14806 (2002)
70. K.W. McLaughlin, **D.S. Eschliman (Lidke)**, O.P. Francis and D.W. Duquette. "Near-threshold photoionization spectrum of aligned Ca 4s5p 1P1." *Physical Review A*, **49**: 240-245 (1994)

Invited Talks / Platform Presentations

1. **D.S. Lidke**. "Quantifying the protein-protein interactions that regulate FcεRI/ITAM signaling." Department of Cell Biology, Radboud University, Nijmegen, Netherlands (October 2018)
2. **D.S. Lidke**. "Imaging the Early Events in EGFR Signaling." *Annual Dutch Biophysical Society Meeting*, Veldhoven, Netherlands (Oct 2018)
3. **D.S. Lidke**. "Molecular mechanisms of membrane-associated signaling revealed by fluorescence nanoscopy." *Genmab*, Utrecht, Netherlands (June 2018)
4. **D.S. Lidke**. "Dissecting the Structural Requirements of FcεRI ITAM Interactions with Syk." *FASEB Immunoreceptors Conference*, Snowmass, CO (June 2018)
5. **D.S. Lidke**. "Integrating Multiplex Single-Molecule Pull-down Data and Computational Modeling to Understand EGFR Signaling." *Qbio Conference*, Houston, TX (June 2018)
6. **D.S. Lidke**. "Optimized Single Molecule Pulldown Reveals Heterogeneity in EGFR Phosphorylation." *Quantitative Bioimaging Conference*, Göttingen, Germany (Jan 2018)
7. **D.S. Lidke**. "Imaging the Early Events of Signaling." *American Society of Cell Biology - Advanced Imaging for Quantitative Cell Biology Subgroup*, Philadelphia, PA (Dec 2017)
8. **D.S. Lidke**. "Quantifying the protein-protein interactions that regulate FcεRI and pre-BCR signaling" *Center for Immunology Seminar Series*, University of Minnesota, Minneapolis, MN (Nov 2017)

9. **D.S. Lidke** "Imaging the Early Events of Signaling." *EMBO/EMBL Symposia: Seeing is Believing - Imaging the Processes of Life* in Heidelberg, Germany (Oct 2017)
10. **D.S. Lidke** "Imaging the Early Events of Signaling." *The 10th International Weber Symposium on Innovative Fluorescence Methodologies in Biochemistry and Medicine*, Búzios, Brazil (May 2017)
11. **D.S. Lidke** "Optimizing multiplex single molecule pull-down (SiMPull) to Quantify protein phosphorylation patterns." Selected oral presentation at the *Focus on Microscopy Annual Meeting*, Bordeaux, France (March 2017)
12. **D.S. Lidke** "Fluorescence Nanoscopy for Studies of Cell Signaling" Optical Science & Engineering Seminar Series, University of New Mexico, *Optical Science & Engineering Seminar Series* (Aug 2017)
13. **D.S. Lidke** "Imaging mast cell activation: from single molecules to synapses." *FASEB conference: IgE and Allergy, 50 Years & Onward*, West Palm Beach, FL (2016)
14. **D.S. Lidke** "Single molecule imaging of Syk binding events reveals the critical role for dynamics in the efficiency of FcεRI signal propagation." *FASEB Immunoreceptors Conference* in Snomass, CO (2016)
15. **D.S. Lidke** "Imaging the early events in membrane receptor signaling." *BioNanoVision of cellular architecture: from the nucleus to the cell membrane* at the Institute of Photonic Sciences, Barcelona, Spain (2016)
16. **D.S. Lidke** "Enhanced dimerization of oncogenic EGFR mutants revealed by single molecule imaging and FRET microscopy." *International Discussion Meeting FRET 2* at the Max Planck Institute for Biophysical Chemistry, Gottingen, Germany (2016)
17. **D.S. Lidke** "Molecular mechanisms of EGFR signaling revealed by fluorescence nanoscopy." *Symposium on Biotechnology*, New Mexico Institute of Mining and Technology, Socorro, NM (2016)
18. **D.S. Lidke** "Imaging the early events in membrane receptor signaling." Invited talk in the Biological Fluorescence Subgroup, *Annual Biophysical Society Meeting*, Los Angeles, CA (2016)
19. **D.S. Lidke** "Imaging Mast Cell Activation: from Single Molecules to Synapses." *Easton Seminar*, Department of Immunology, University of Toronto, Canada (2106)
20. **D.S. Lidke** "Molecular mechanisms of EGFR signaling revealed by fluorescence nanoscopy." *Quantitative Bioimaging Conference*, Delft, The Netherlands (2016)
21. **D.S. Lidke** "Enhanced Dimerization Drives Ligand-independent Activity of Mutant EGFR in Lung Cancer." *Imaging Cancer: from Molecule to Man*, Symposium at the Institute for Molecular Life Sciences, Nijmegen, The Netherlands (2015)
22. **D.S. Lidke** "Imaging Mast Cell Activation: from Single Molecules to Synapses." Department of Immunology, Utrecht University, The Netherlands (2015)
23. **D.S. Lidke** "Biochemistry in motion: Single molecule imaging to quantify protein interactions during signaling." Invited lecture for the special topics course: *Computational Image Analysis in*

Cellular and Developmental Biology, Marine Biological Lab, Woodshole, MA (2015)

24. **D.S. Lidke** "Imaging Mast Cell Activation: from Single Molecules to Synapses." Department of Biophysics, University of Michigan, Ann Arbor, MI (2015)
25. **D.S. Lidke** "Biochemistry in motion: Single molecule imaging to quantify protein interactions during signaling." Keynote speaker for the *Mexican Biochemistry Society Meeting*, Oaxaca, Mexico (2015)
26. **D.S. Lidke** "Fluorescence microscopy to quantify protein behavior in living cells." Lecture for the *Q-bio Summer School*, Albuquerque, NM (2015)
27. **D.S. Lidke** "Enhanced dimerization of oncogenic EGFR mutants revealed by single molecule imaging and FRET microscopy." *European Light Microscopy Initiative*, Stiges, Spain (2015)
28. **D.S. Lidke** "Spatiotemporal remodeling of membrane nanoplateforms under mechanical forces." Presentation at the annual *Human Frontiers Science Program Awardee Meeting*, San Diego, CA (2015)
29. **D.S. Lidke** "Measuring membrane receptor dynamics, interactions and lateral organization on live cells." *Mechanistic Studies in Membrane Biophysics*, Telluride Science Workshop, Telluride, CO (2015)
30. **D.S. Lidke** "Single molecule imaging of Syk dynamics during FcεRI signaling." *Quantitative Bioimaging Conference*, Institute Pasteur, Paris, France (2015)
31. **D.S. Lidke** "Measuring EGFR dynamics, dimerization and conformation on live cells." University of California San Diego (2014)
32. **D.S. Lidke** "FcεRI dynamics and clustering during signal transduction." NIH Systems Biology All Centers Meeting, San Diego, CA (2014)
33. **D.S. Lidke** "Quantum Dot-based Immunohistochemistry." UNM Breast Cancer Working Group, (2014)
34. **D.S. Lidke** "Imaging Mast Cell Activation: from Single Molecules to Synapses." University of Colorado Denver (2014)
35. **D.S. Lidke** "Biochemistry in motion: Single molecule imaging to quantify protein interactions." UNM Biochemistry Department (2014)
36. **D.S. Lidke** "Measuring EGFR dynamics, dimerization and conformation on live cells." AMOLF, Amsterdam, The Netherlands (2014)
37. **D.S. Lidke** "Single molecule imaging of EGFR" *Pathology 50th Anniversary Event* (2014)
38. **D.S. Lidke** "Mast Cell Communication: Synapses and Single Molecules." *FASEB Immunoreceptors* Conference in Steamboat Springs, CO (2014)
39. **D.S. Lidke** "Measuring EGFR dynamics, dimerization and conformation on live cells." *FASEB Membrane Biophysics* Conference in Big Sky, MT (2014)

40. **D.S. Lidke** "Understanding how ErbB/HER receptor dynamics, dimerization and conformation regulate signaling." Children's Hospital of Philadelphia, Philadelphia, PA (2014)
41. **D.S. Lidke** "Dissecting signal transduction, one molecule at a time: single particle tracking for cell biology." *University of Pennsylvania*, Philadelphia, PA (2014)
42. **D.S. Lidke** "Imaging protein dynamics during signal transduction." *Qbio Summer School*, (2014)
43. **D.S. Lidke** "Dynamic conformational transitions of the EGFR in living mammalian cells determined by FRET and FLIM." *Annual Biophysical Society Meeting*, San Francisco, CA (2014)
44. **D.S. Lidke** "Single molecule dynamics of early events in FcεRI signaling." University of Texas Southwestern, Dallas, TX (2014)
45. **D.S. Lidke** "Single molecule dynamics of FcεRI signaling." *Symposium on Single Cell and Single Molecule Biology*, University of New Mexico, Albuquerque, NM (2014)
46. **D.S. Lidke** "Imaging ErbB Receptor Dynamics and Dimerization at the Single Molecule Level." *Epidermal Growth Factor Receptor – Future Directions*, Jerusalem University, Jerusalem, Israel (2013)
47. **D.S. Lidke** "Dissecting Signal Transduction, One Molecule at a Time: Using Single Molecule Imaging to Correlate Protein Behavior and Signaling." Max Planck Institute for Biophysical Chemistry, Goettingen, Germany (2013)
48. **D.S. Lidke** "Imaging protein dynamics during signal transduction." *Qbio Summer School Symposium*, Santa Fe, NM (2013)
49. **D.S. Lidke** "Single particle tracking to determine the role of membrane receptor diffusion in cell signaling." UNM Physics (2013)
50. **D.S. Lidke** "Dissecting signal transduction, one molecule at a time: Using single particle tracking to correlate membrane protein behavior and signaling." UNM Pharmacotoxicology (2013)
51. **D.S. Lidke** "Dissecting Signal Transduction, One Molecule at a Time: Using Single Particle Tracking to Correlate Membrane Protein Behavior and Signaling." University of Minnesota, Minneapolis, MN (2013)
52. **D.S. Lidke** "Diffusion, dimerization and domains: single quantum dot tracking to correlate membrane receptor dynamics with signaling." *Physiology and dynamics of cellular microcompartments*, University of Osnabruck, Germany (2012)
53. **D.S. Lidke** "Measuring Membrane Receptor Interactions Using Single Quantum Dot Tracking." *Microscopy & Microanalysis* in Phoenix, AZ (2012)
54. **D.S. Lidke** "Single molecule imaging to quantify FcεRI signaling dynamics" *FASEB Immunoreceptors Conference* in Snowmass, CO (2012)
55. **D.S. Lidke** "Capturing EGFR dimerization." *Imaging the EGFR bio-system; from molecules to man* at Kings College, London, UK. (2012)
56. **D.S. Lidke** "Diffusion, dimerization and domains: single quantum dot tracking to correlate

membrane receptor dynamics with signaling." *Linz Winter Workshop* in Linz, Austria (2012)

57. **D.S. Lidke** "Capturing and quantifying erbB receptor dimerization reveals receptor- and membrane- mediated interactions." *Utrecht University, The Netherlands*. (2011)
58. **D.S. Lidke** "Imaging mast cell activation: single molecule dynamics of FcεRI during signaling and formation of the mast cell synapse." *Utrecht University, The Netherlands*. (2011)
59. **D.S. Lidke** "Single molecule dynamics of FcεRI during signaling." *Immunanmap Symposium* in Nijmegen, The Netherlands. (2011)
60. **D.S. Lidke**, "Caught in the Act: Imaging membrane protein dynamics and interactions on living cells." Oral presentation as acceptance of the Margaret Oakley Dayhoff Award at the annual meeting of the Biophysical Society, Baltimore, MD. (2011).
61. **D.S. Lidke** "Capturing and quantifying erbB receptor dimerization reveals receptor- and membrane mediated interactions." Max Plank Institute for Biophysical Chemistry, Goettingen, Germany. (2011)
62. **D.S. Lidke** "Single quantum dot tracking to correlate membrane receptor dynamics with signaling." *EMBO/EMBL Symposia: Seeing is Believing - Imaging the Processes of Life* in Heidelberg, Germany. (2011)
63. **D.S. Lidke** "Single molecule dynamics of FcεRI during signaling." *Canadian Society for Immunology* in Lake Louis, Canada. (2011)
64. **D.S. Lidke** "Single molecule dynamics of Fc receptors during signaling." *FASEB Immunoreceptors Conference* in Snowmass, CO. (2010)
65. **D.S. Lidke**, "Correlating FcεRI signaling with dynamics via single quantum dot imaging." *Midwest Microscopy and Microanalysis Symposium: Super-resolution microscopy and live cell imaging* at Northwestern University, Evanston, IL. (2010)
66. **D.S. Lidke**, "Correlating FcεRI signaling with dynamics via single quantum dot imaging." *Gordon Research Conference on Antibody Biology and Engineering* in Ventura, CA. (2010)
67. **D.S. Lidke**, "Correlating FcεRI signaling with dynamics and microdomains using single quantum dot imaging." Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands. (2009)
68. **D.S. Lidke**, "Using single quantum dot tracking to examine how diffusion, oligomerization and microdomains regulate membrane protein activation." Max Planck Institute for Biophysical Chemistry in Goettingen, Germany. (2009)
69. N.L. Andrews, R. Davis, D. Haaland, J.M. Oliver, B.S. Wilson, and **D.S. Lidke**, "Correlating FcεRI Signaling with Dynamics using Single Quantum Dot Imaging." *Qbio Conference* in Santa Fe, NM. (2009)
70. **D.S. Lidke**, "Correlating FcεRI signaling with receptor dynamics using single quantum dot tracking." CINT, Los Alamos, NM (2009)
71. **D.S. Lidke**, "Single molecule studies of FcεRI dynamics using quantum dot probes." *UNM INCBN IGERT seminar series*. University of New Mexico, Albuquerque, NM. (2009)

72. **D.S. Lidke** "FcεRI immobilization is not required for signal initiation." *FASEB Immunoreceptors Conference* in New Haven, CT. (2008)
73. **D.S. Lidke** "Correlating FcεRI signaling with dynamics, topography and microdomains via single quantum dot imaging." Max Planck Institute for Biophysical Chemistry in Goettingen, Germany. (2008)
74. **D.S. Lidke**. "Correlating FcεRI signaling with dynamics, topography and microdomains via single quantum dot imaging." Cleveland Clinic in Cleveland, OH. (2008)
75. N.L. Andrews, K. Radhakrishnan, K.A. Lidke, J.R. Pfeiffer, B.S. Wilson, J.M. Oliver, and **D.S. Lidke**. "Live cell imaging methods to quantify signaling molecule dynamics." *Qbio Conference* in Santa Fe, NM. (2007)
76. **D.S. Lidke**, N.L. Andrews, K.A. Lidke, J.R. Pfeiffer, A.R. Burns, B.S. Wilson, J.M. Oliver. "Correlating FcεRI signaling with dynamics, topography and microdomains via single quantum dot imaging." *FASEB Signal Transduction and the Immune System* in Snowmass, CO. (2007)
77. **D.S. Lidke**, N.L. Andrews, J.R. Pfeiffer, H.D.T. Jones M.B. Sinclair, David M. Haaland, Alan R. Burns, Bridget S. Wilson, J.M. Oliver and K.A. Lidke. "Exploring membrane protein dynamics by multicolor single quantum dot imaging using wide field, TIRF, and hyperspectral microscopy." *SPIE Photonics West Meeting* in San Jose, CA. (2007)
78. **D.S. Lidke**. "Quantum dot enabled exploration of the roles of diffusion and topography in FcεRI signal transduction" University of Twente, Twente, The Netherlands. (2007)
79. **D.S. Lidke**. "Quantum dot enabled exploration of the roles of diffusion and topography in FcεRI signal transduction" Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands. (2007)
80. **D.S. Lidke**. "Correlating FcεRI signaling with dynamics, topography and microdomains via single quantum dot imaging" Carnegie Mellon University. Pittsburgh, PA. (2007)
81. **D.S. Lidke**. "Real-time Visualization of ErbB Dynamics using Quantum Dot-labeled Ligands" The LRRRI seminar series, Lovelace Respiratory Research Institute. Albuquerque, NM. (2007)
82. **D.S. Lidke**. "Correlating FcεRI signaling with dynamics, topography and microdomains via single quantum dot imaging" Los Alamos National Laboratory. Los Alamos, NM. (2007)
83. **D.S. Lidke**. "Single Particle Tracking using the Microscope Facility's new Olympus Microscope." *Cancer Center Microscopy Facility Open House*. University of New Mexico, Albuquerque, NM. (2006)
84. **D.S. Lidke**. "Using Quantum Dots to Track Membrane Protein Dynamics in Living Cells." *UNM INCBN IGERT seminar series*. University of New Mexico, Albuquerque, NM. (2006)
85. **D.S. Lidke**. "Using Quantum Dots to Explore Membrane Protein Dynamics: EGFR and FCεRI." *UNM Toxicology Departmental Seminar*. University of New Mexico, Albuquerque, NM (2006)
86. **D.S. Lidke**. "Tracking membrane receptor dynamics using Quantum Dot-labeled ligands." *British-German Frontiers of Science* in Wyboston, United Kingdom. (2006)

87. **D.S. Lidke.** "Using Quantum Dots and Quantitative Fluorescence Microscopy to Track ErbB Family Dynamics in Live Cells." *Department of Mathematics and Statistics Colloquium*, University of New Mexico, Albuquerque, NM. (2006)
88. **D.S. Lidke.** "Live cell imaging and quantification of signal transduction." *Pathology Grand Rounds*, University of New Mexico, Albuquerque, NM. (2006)
89. **D.S. Lidke.** "Real-time visualization of membrane receptor dynamics using Quantum Dot-labeled ligands." *American Society of Cell Biology* in San Francisco, CA. (2005)
90. **D.S. Lidke, K.A. Lidke, B. Rieger, T.M. Jovin and D.J. Arndt-Jovin.** "Tracking erbB1 retrograde transport using quantum dot-labeled ligands." *Biophysical Society Meeting* in Long Beach, CA. (2005)
91. **D. S. Lidke.** "Surfing and signaling: ErbB dynamics tracked by quantum dots and fluorescent proteins." *Focus on Fluorescence* in Amsterdam, The Netherlands. (2004)
92. **D.S. Lidke, H. Grecco, E.A. Jares-Erijman, O. Martinez, D. Arndt-Jovin and T. M. Jovin.** "Real-time visualization of transmembrane receptor tyrosine kinase (erbB) oligomerization and trafficking: quantum dots and emFRET microscopy." *Real Time Signaling and Imaging Workshop* in Glasgow, Scotland. (2003)
93. **D.S. Lidke, R. Heintzmann, D.J. Arndt-Jovin, B.G. Barisas and T.M. Jovin.** "Detection of membrane protein association using homotransfer RET (emFRET) imaging" *Biophysical Journal*, **84(2)**: 486a. *Biophysical Society Meeting* in San Antonio, TX. (2003)
94. **D.S. Eschliman (Lidke) and D.D. Thomas.** "Dynamics of the myosin dimer in intact muscle." *Biophysical Journal*, **80**: A509. *Biophysical Society Meeting* in Boston, MA. (2001)

Poster Presentations

S.T. Low-Nam, K.A. Lidke, P.J. Cutler, R.C. Roovers, P.M.P. van Bergen en Henegouwen, B.S. Wilson, **D.S. Lidke.** Single Quantum Dot Tracking Coupled to a Three-state HMM Provides New Mechanistic Insight into ErbB1 Homodimerization." *Biophysical Society Annual Meeting* in San Baltimore, MD. (2011)

P.J. Cutler, M. Malik, S. Liu, F. Huang, J. Byars, **D.S. Lidke, K.A. Lidke.** "Single Particle Tracking of QD-IgE in Hyperspectral Fluorescent Images." *Biophysical Society Annual Meeting* in San Baltimore, MD. (2011)

** P.J. Cutler received the Student Achievement poster award.

S.L. Schwartz, Q. Yan, F. Huang, M.P. Bruchez, **D.S. Lidke, K.A. Lidke.** "Fluorogen Activating Peptides for Single Particle Tracking and Single Molecule Localization-based Superresolution of FcεRI Subunits." *Biophysical Society Annual Meeting* in San Baltimore, MD. (2011)

M. Malik, P.J. Cutler, S. Liu, J. Byars, **D.S. Lidke, K.A. Lidke.** "Hyperspectral Line Scanning Microscopy for High-speed Multicolor Quantum Dot Tracking." *Biophysical Society Annual Meeting* in San Baltimore, MD. (2011)

P.J. Cutler, B.S. Wilson, J.M. Oliver, K.A. Lidke, **D.S. Lidke.** "Multi-color Quantum Dot Tracking to Correlate FcεRI Aggregate Size with Mobility." *Biophysical Society Annual Meeting* in San Francisco, CA. (2010)

S.T. Low-Nam, K.A. Lidke, P.J. Cutler, R.C. Roovers, P.M.P. van Bergen en Henegouwen, B.S. Wilson, **D.S. Lidke**. "Determination of Single Molecule ErbB1 Homodimer Lifetimes Using Single Quantum Dot Tracking and a Diffusive Hidden Markov Model." *Biophysical Society Annual Meeting* in San Francisco, CA. (2010)

M.D. Malik, P. Cutler, M. Sinclair, **D.S. Lidke**, K.A. Lidke. "Hyperspectral Line Scanning Microscopy for High-speed Multicolor Quantum Dot Tracking." *Biophysical Society Annual Meeting* in San Francisco, CA. (2010)

S.L. Schwartz, Q. Yan, S. Maji, J.A.J. Fitzpatrick, K.A. Lidke, M.P. Bruchez, **D.S. Lidke**. "Fluorogen Activating Peptides for Single Molecule Localization-based Super-resolution and Single Particle Tracking of FcεRI Subunits." *Biophysical Society Annual Meeting* in San Francisco, CA. (2010)

N.L. Andrews, K.A. Lidke, J.R. Pfeiffer, A.R. Burns, B.S. Wilson, J.M. Oliver and **D.S. Lidke**. "Single Molecule Studies of FcεRI Dynamics Link Mobile Receptors with Signaling." *Biophysical Society Meeting* in Boston, MA. (2009)

S. Low-Nam, K.A. Lidke, R. Roovers, P. van Bergen en Henegouwen, B.S. Wilson and **D.S. Lidke**. "Multi-color Single Quantum Dot Tracking To Characterize Membrane Receptor Interactions On Living Cells." *Biophysical Society Meeting* in Boston, MA. (2009)

D.S. Lidke and A. Cambi. "Integrating single molecule imaging techniques to unravel mast-dendritic cell interplay." Human Frontiers Science Program 8th Annual Awardees Meeting in Berlin, Germany. (2008)

N.L. Andrews, K.A. Lidke, J.R. Pfeiffer, A.R. Burns, B.S. Wilson, J.M. Oliver and **D.S. Lidke**. "Single quantum dot tracking of IgE receptors reveals actin corralling and crosslinker induced immobilization kinetics." *Biophysical Society Meeting* in Long Beach, CA. (2008)

D.S. Lidke, P. Lenormand, K. Radhakrishnan, F. Huang, J.L. Thomas, T.M. Jovin. "Dimerization is not required for nuclear translocation of hERK1." *Biophysical Society Meeting* in Long Beach, CA. (2008)

N.L. Andrews, K.A. Lidke, J.R. Pfeiffer, A.R. Burns, B.S. Wilson, J.M. Oliver and **D.S. Lidke**. "FcεRI diffusional dynamics measured by single quantum dot tracking in resting and activated cells." *Biophysical Society Meeting* in Baltimore, MD. (2007)

K.A. Lidke, N.L. Andrews, **D.S. Lidke**, J.P. Pfeiffer, B.S. Wilson, J.M. Oliver, A.R. Burns. "Direct Observation of Confined Motion of Membrane Proteins Associated with Actin Corrals." *Biophysical Society Meeting* in Baltimore, MD. (2007)

D.S. Lidke, K.A. Lidke, A. Cambi, D.J. Arndt-Jovin, T.M. Jovin. "Determining protein homoassociation by emFRET imaging in the confocal microscope." *Biophysical Journal*, **90**. *Biophysical Society Meeting* in Salt Lake City, UT. (2006)

K.A. Lidke, **D. S. Lidke**, B. Rieger, D.J. Arndt-Jovin, T.M. Jovin. "Measuring erbB1 diffusion on the cell body and filopodial membranes by tracking EGF-Quantum Dots and by FRAP analysis of erbB1-EGFP." *Biophysical Journal*, **90**. *Biophysical Society Meeting* in Salt Lake City, UT. (2006)

D.S. Lidke, J.N. Post, M. Vučković, R. Heintzmann, P. Lenormand, J. Pouyssegur and T.M. Jovin. "Imaging intracellular ERK1 dynamics upon stimulation of the MAPK signaling pathway." *Biophysical Society Meeting* in Long Beach, CA. (2005)

D.S. Lidke, J.N. Post, M. Vučković, M. Schmidt, P. Lenormand and T.M. Jovin. "Intracellular protein dynamics in the MAPK signaling cascade: hERK1 translocation." *Biophysical Journal*, **86** (1): 228a. *Biophysical Society Meeting* in Baltimore, MD. (2004)

D.S. Lidke, P. Nagy, R. Heintzmann, D.J. Arndt-Jovin, J.N. Post, H. Grecco, E.A. Jares-Erijman and T.M. Jovin. "Real-time visualization of receptor tyrosine kinase (erbB) dynamics using quantum dot ligands." *Biophysical Journal*, **86** (1): 446a. *Biophysical Society Meeting* in Baltimore, MD. (2004)

D.S. Lidke, J.N. Post, R. Rivera-Pomar and T.M. Jovin. "Dynamic studies of protein interactions along the MAPK signaling pathway." *Biophysical Journal*, **84**(2): 396a. *Biophysical Society Meeting* in San Antonio, TX. (2003)

D.S. Lidke, V. Subramaniam and T.M. Jovin. "Energy homotransfer and association properties of the family of yellow fluorescent proteins." *Biophysical Journal*, **84**(2): 499a. *Biophysical Society Meeting* in San Antonio, TX. (2003)

D.S. Eschliman (Lidke), W.D. Nelson and D.D. Thomas. "Detecting structural changes of the myosin dimer within intact muscle." *Biophysical Journal*, **80**: A267. *Biophysical Society Meeting* in Boston, MA. (2001)

D.S. Eschliman (Lidke) and D.D. Thomas. "A novel method for exploring the structure of the myosin dimer in muscle." *Biophysical Journal*, **78**: A117. *Biophysical Society Meeting* in New Orleans, LA. (2000)

D.S. Eschliman (Lidke), D.W. Hayden and D.D. Thomas. "Underlying similarities in disparate spectroscopies: application of EPR and fluorescence polarization to muscle contraction." *Biophysical Journal*, **74**: A363. *Biophysical Society Meeting* in Kansas City, MO. (1998)

Current Active Support

1R35GM126934 (Lidke, PI) 9/15/2018-8/31/2023
NIH/NIGMS

"Imaging the Early Events in Membrane Receptor Signaling"

The major goals of this project are to quantify the protein interactions and dynamics at the molecular level that regulate signal transduction using innovative imaging techniques.

Role: PI

5P50GM085273 (Wilson, PI; D. Lidke, Project 2 PI) 8/1/14-7/31/19
NIH/NIGMS

Center for Spatiotemporal Modeling of Cell Signaling

"Project 2: Elucidating the mechanisms and consequences of erbB/Met family crosstalk" *Sub-Project ID: 6521*

This Center grant supports three complementary projects and several technical cores all focused around the integration of quantitative biochemical measurement, novel imaging technologies and computational modeling to better understand membrane microdomain organization and the role of membrane protein mobility in the regulation of complex signaling pathways in immune and cancer cells. Project 2 focuses on the molecular mechanisms and physiological consequences of crosstalk between the ErbB and Met families and how these are co-opted in the oncogenic process.

Role: Co-director and Program Project 2 Leader

5R01GM114075 (Bruchez, D. Lidke MPI) 4/1/15-1/31/19
NIH/NIGMS

“Fluorogen Activating Peptide-Based FRET to Quantify FcεRI Activation Mechanisms”

This proposal develops a single molecule FRET based method using Fluorogen Activating Proteins and various fluorescent donor proteins and dyes to explore the order of interactions in high-affinity IgE receptor activation.

Role: MPI

1R01CA207368-01A1 (Ozbun)

6/9/17-5/31/22

NIH/NCI

“Mechanisms of Infection by Oncogenic HPV’s”

The major goals are to determine the roles of EGFR and annexin A2 tetramers in infectious entry of HPVs into human keratinocytes using *in vitro* and *in vivo* models of HPV infection.

Role: co-investigator

Previous Support (completed)

NIH/NIGMS 1R01GM100114 (Lidke, PI)

5/1/12-2/28/18

“Single Molecule Imaging to Quantify FcεRI Signaling Dynamics”

Human Frontiers Science Program RGY Program Grant (Garcia-Parajo, Lidke MPI) 9/1/12-8/31/16

“Nano-Mechano-Biology: spatiotemporal remodeling of membrane nanoplateforms under mechanical forces”

NIH/NIGMS 1R21EB019589-01 (K. Lidke, PI; D. Lidke, co-I)

9/1/15-8/31/16

“Multi-target super-resolution imaging using sequential labeling”

NIH/NIGMS R01GM081685 (Boehning, PI; Lidke, co-I)

11/1/13-12/31/16

“Mechanisms of apoptotic calcium signaling”

NSF CAREER Award (Lidke, PI)

1/1/09-12/31/15

“Elucidating the regulation mechanisms of erbB signaling using quantitative imaging”

NIH/ NCRR R21 (K. Lidke, PI; D. Lidke, co-I)

1/1/09–12/31/12

“A hyperspectral microscope optimized for spectrally multiplexed live cell imaging”

NIH (Halasz PI, Lidke, co-I)

1/1/08-12/31/12

“Spatial Monte Carlo models for VEGF binding on the cell membrane”

NIH 5R01AI051575-05 (Wilson, PI; Lidke, co-I)

2/15/09 - 1/31/12

“Mapping for Special Domains for FcεRI Signaling & Internalization”

NIH NCI RO1 (Wilson, PI; Lidke, co-I)

7/1/09 – 6/30/13

“MSM Mapping & Modeling ErbB Receptor Membrane Topography”

NIH 1R01CA132136-01 (Ozbun, PI; Lidke, co-I)

12/1/08–11/30/12

“Entry of oncogenic HPVs into human keratinocytes”

Human Frontiers Science Program Young Investigator Award (Lidke, PI)

9/1/08 - 8/31/11

“Integrating Single Molecule Imaging Techniques to Unravel Mast-Dendritic Cell Interplay”

NIH/NCTNP/Grant 1-U54-RR022241-01

8/01/08- 7/31/10

CMU-Pitt Fluorescent Probes & Imaging Tech Ctr: Driving Biol Project (D. Lidke, K. Lidke, co-PIs)


“The influence of subunit integrity and TLR4 crosstalk on IgE receptor signaling.”

Oxnard Foundation Award (Lidke PI) "Understanding ErbB Signaling in Cancer"	2/1/07-1/31/09
American Cancer Society Institutional Research Grant (Lidke PI) "Real-time imaging of erbB behavior in primary cancer cells"	4/1/08-3/31/09
Sandia-University Research Program (Lidke PI) Hyperspectral Imaging and Multi-color Single Particle Quantum Dot Tracking	10/1/06 -9/31/08
UNM Cross-campus Collaboration in Life Sciences (Lidke PI , Thomas Co-PI) "Measuring Spatial Correlations of Uncrosslinked IgE Receptors using Quantum Dot Probes"	1/1/06-12/31/07
NIH-NCI 5 R01CA119232-03 (Wilson PI, Lidke co-I) Mapping and Modeling ErbB Receptor Membrane Topography	7/1/05-6/31/08
NIH/NIGMS R01 GM49814 (Oliver PI; Lidke, co-I) "Signaling Activity of IgE Receptor Subunits"	9/1/05-8/31/09
NIH R21 EB005365 (Boyle, PI; Lidke, co-I) "Fluorescent Ceramic Nanoprobes"	10/1/05-9/31/09
NIH-Los Alamos National Laboratory (Werner, PI; Lidke, co-I) "Tracking the 3D Intracellular Special Trajectory of an Individual IgE Molecules"	12/15/07-11/30/09



MEMO

To: Cinnamon Blair
Chair, UNM Naming Committee

From: Cheryl Willman, MD  On behalf of Dr. Cheryl Willman, MD
Maurice and Marguerite Liberman Distinguished Chair in Cancer Research
Director & CEO, UNM Comprehensive Cancer Center (UNMCCC)

Date: January 14, 2019

Re: Appointment of the Maralyn S. Budke Endowed Chair in Cancer Chemical Biology
and Therapeutics
Eric Prossnitz, PhD
Professor and Chief, Division of Molecular Medicine, Department of Internal
Medicine, UNM School of Medicine
Co-Leader, Cancer Biology, Genetics, and Genomics Research Program, UNM
Comprehensive Cancer Center

Dear Ms. Blair and members of the UNM Foundation Naming Committee,

On behalf of the University of New Mexico Comprehensive Cancer Center, we request approval to appoint Eric Prossnitz, PhD, as the new holder of the Cancer Center's Maralyn S. Budke Endowed Chair in Cancer Chemical Biology and Therapeutics. Currently, Dr. Prossnitz's holds a UNM Cancer Center Endowed Professorship: The Victor and Ruby Hansen Surface Professorship in Cancer Chemical Biology.

This Endowed Chair was created and approved in October 2010 by the UNM Board of Regents according to Regents Policy 2.11 and University Business Policy 1020. The Chair was previously held by Dr. Renata Pasqualini who has left the institution. As prescribed by Faculty Handbook Policy C170 "Endowed Chairs and Named Professorships" we seek approval to appoint Dr. Prossnitz as the new holder of this Endowed Chair.

As an outstanding New Mexican, former director of the Legislative Council Service and Chief of Staff to two New Mexico Governors, Ms. Budke was a notable New Mexican. She was also devoted to UNM, particularly UNM Hospital, School of Medicine, and the Comprehensive Cancer Center. In January 2010, Ms. Budke passed from cancer and was very grateful to the doctors and nurses at the UNM Cancer Center who cared for her through her illnesses. Ms. Budke established a significant endowment fund which was directed to establish endowed chairs and professorships in cancer science and care, consistent with the current needs of the UNM Comprehensive Cancer Center, as determined by the UNMCCC Director & CEO.

Our belief is Dr. Prossnitz will carry forward this important legacy and be an outstanding representative of the qualities required of the Endowed Chair position. He is an outstanding accomplished, renowned, and internationally known scientist whose discoveries are being translated into new therapeutic agents for melanoma, breast, and pancreatic cancer; he is an excellent educator and mentor to trainees and young faculty; and he is an excellent institutional leader, leading the Division of Molecular Medicine, and playing key leadership roles in the UNM Comprehensive Cancer Center and the Clinical and Translational Science Center.

Thank you for your time and consideration of this request.

CURRICULUM VITAE

Eric R. Prossnitz, Ph.D.

January 2019

Current position

Professor of Internal Medicine
Chief, Division of Molecular Medicine
Victor and Ruby Hansen Surface Professor of Cancer Chemical Biology
University of New Mexico Health Sciences Center

Address

2705 Rio Orilla Ln. NW
Albuquerque, NM 87131

Professional Address

Department of Internal Medicine
University of New Mexico Health Science Center
Albuquerque NM 87131

Tel: (505) 272-5647
email: eprossnitz@salud.unm.edu

Personal

Date of Birth: December 21, 1965
Place of Birth: Victoria, B.C. Canada
Marital Status: Married, 2 Children

Educational History

Ph.D. Biochemistry, 1989
University of California, Berkeley, California

B.Sc. Biochemistry, 1985 (First class honors)
University of Victoria, B.C. Canada

Employment History

Present Appointments

2018-pres. Chief, Division of Molecular Medicine, University of New Mexico Health Science Center, Albuquerque, NM
2015-pres. Professor of Internal Medicine, University of New Mexico Health Science Center, Albuquerque, NM
2018-pres. Academic Lead, ASCEND: Accelerating Solutions for Commercialization and Entrepreneurial Development in the Mountain-West IDeA States

- 2017-pres. Associate Director, Autophagy, Inflammation and Metabolism (AIM) Center of Biomedical Research Excellence (CoBRE)
- 2015-pres. Associate Director, Professional Development, Mentoring Unit, Mountain West (MW) Clinical and Translational Research - Infrastructure Network (CTR-IN)
- 2015 - pres. Board Member, UNM.STC, Science and Technology Corporation, University of New Mexico
- 2014-pres. UNM PI, New Mexico IDeA Network of Biomedical Research Excellence (NM-INBRE)
- 2013-pres. Director, Translational Cancer Biology and Signaling Program, UNM Comprehensive Cancer Center
- 2011-pres. Leader, Team Science & Commercialization, UNM Clinical and Translational Science Center

Previous Appointments

- 2005-2015 Professor of Cell Biology and Physiology, University of New Mexico Health Science Center, Albuquerque, NM
- 2008-2013 Co-Director, Women's Cancers Program, UNM Cancer Center
- 2008-2012 Chair, UNM HSC Conflict of Interest Committee
- 2000-2005 Associate Professor of Cell Biology and Physiology, University of New Mexico Health Science Center, Albuquerque, NM
- 1997-2000 Assistant Professor of Cell Biology and Physiology, University of New Mexico Health Science Center, Albuquerque, NM
- 1994-1997 Assistant Professor, Department of Immunology, The Scripps Research Institute, La Jolla, CA
- 1993-1994 Senior Research Associate, Department of Immunology, The Scripps Research Institute, La Jolla, CA
- 1989-1993 Research Associate, Department of Immunology, Scripps Clinic and Research Foundation, La Jolla, CA
- 1985-1989 Graduate Student, Department of Biochemistry, University of California at Berkeley, CA.

Honors

- 2013 Victor and Ruby Hansen Surface Endowed Professor of Cancer Chemical Biology
- 2009 Excellence in Basic Research Award, UNM
- 2009 Best Manuscript Award, Circulation Research
- 2008-2010 Top Cited Article, Prostaglandins and Other Lipid Mediators
- 2006-2014 UNM Science and Technology Creative Awards (6)
- 2004 HHMI 2004-2005 UNM Investigator Competition Nominee
- 2002 Dean's Award of Distinction
- 1999 Human Frontiers of Science Program Organization Career Development Finalist
- 1994 NIH FIRST Award
- 1991-1993 Human Frontiers of Science Program Organization Long Term Fellowship
- 1985-1988 Comparative Biochemistry Graduate Fellowship, U.C. Berkeley, CA

- 1985-1989 The 1967 Science and Engineering Scholarship, Natural Sciences and Engineering Research Council of Canada
 1983-1985 Presidents Scholarship, University of Victoria, B.C. Canada

Professional Society Memberships

American Society for Cell Biology
 American Association for the Advancement of Science
 Society for Leukocyte Biology
 Endocrine Society
 American Society for Pharmacology and Experimental Therapeutics

Editorial Boards

Journal of Steroid Biochemistry and Molecular Biology (Guest Editor for special issue, 2017-2018)
 Nuclear Receptor Research (Board Member, 2013-present)
 Obstetrics and Gynecology International (Guest Editor for special issue, 2013-2014)
 Journal of Steroid Biochemistry and Molecular Biology (Board Member, 2011-present)
 Molecular and Cellular Endocrinology (Guest Editor for special issue, 2009)

Journal Reviewer

Biochemistry
 BMC Cancer
 Cancer Research
 Cell
 Cytometry
 Journal of Biological Chemistry
 Journal of Clinical Investigation
 Journal of Leukocyte Biology
 Journal of Steroid Biochemistry and Molecular Biology
 Journal of Immunology
 Molecular Brain Research
 Molecular Pharmacology
 Nature
 Neuroscience Letters
 Proceedings of the National Academy of Sciences U.S.A.
 Science
 Trends in Immunology
 Trends in Pharmacology

Grant Reviewer

2018 Department of Defense Breast Cancer Research Program Study Section, Full Member
 2017 NIDDK SEP: 2017/07 ZRG1-EMNR-F (50) R
 2016 NCI SEP IMST11: 2016/01 ZCA1 SRB-L (J1) S

2015 NCI SEP IMST11: 2015/10 ZCA1 SRB-L (O1) S
 2014 NCI P30 CCSG Site Visit Review Panel (Duke Cancer Institute)
 2013 Basic Mechanisms of Cancer Therapeutics Study Section, ad hoc member
 2012, 2013 NIH Small Business: Biological Chemistry, Biophysics, and Drug
 Discovery, ad hoc member
 2011 NIH NCI Drug Discovery and Molecular Pharmacology Study Section, ad
 hoc member
 2010-2014 Department of Defense Breast Cancer Research Program Study Section,
 Full Member
 2009 NIH NHLBI, Special Emphasis Review Panel, ad hoc member
 2007 NCI Tumor Cell Biology Study Section, NIH
 2005-2009 NCI Training and Manpower Study Section, NIH, Full Member
 2005-2009 American Cancer Society (Leukemia, Immunology and Red Blood Cell),
 Full Member
 2004-2008 Susan G. Komen Foundations Tumor Cell Biology II Study Section, Full Member
 2004 NIH, Molecular Neuropharmacology and Signaling Study Section
 2004 French Ministry for Research
 2002 VA Merit Awards
 2001, 2002 Montana State NSF/EPSCoR program

Publications (>200, h-index 72, >17,500 citations)

Original Peer-reviewed Articles

1. Sharma G, Hu C, Staquicini DI, Brigman JL, Liu M, Arap W, Pasqualini R, Arterburn JB, Hathaway HJ, Prossnitz ER: Preclinical efficacy of a first-in-class selective GPER agonist in mouse models of obesity and diabetes. *Sci Trans Med* 2018: (under revision).
2. Revankar CM, Bologna CG, Pepermans R, Sharma G, Petrie WK, Alcon SN, Field AS, Ramesh C, Parker MA, Savchuck NP, Sklar LA, Hathaway HJ, Arterburn JB, Oprea TI, and Prossnitz ER: A Selective Ligand for Estrogen Receptor Proteins Discriminates Rapid and Genomic Signaling. *Cell Chem Biol* 2018: (submitted).
3. Sharma G, Mauvais-Jarvis F, Prossnitz ER: Roles of G protein-coupled estrogen receptor GPER in metabolic regulation. *J Steroid Biochem Mol Biol* 2018, 176:31-37.
4. Prossnitz ER: New developments in the rapid actions of steroids and their receptors. *J Steroid Biochem Mol Biol* 2018, 176:1-3.
5. Prossnitz ER: GPER modulators: Opportunity Nox on the heels of a class Akt. *J Steroid Biochem Mol Biol* 2018, 176:73-81.
6. Peretti AS, Dominguez D, Grimes MM, Hathaway HJ, Prossnitz ER, Rivera MR, Wandinger-Ness A, Kusewitt DF, Hudson LG: The R-Enantiomer of Ketorolac Delays Mammary Tumor Development in Mouse Mammary Tumor Virus-Polyoma Middle T Antigen (MMTV-PyMT) Mice. *Am J Pathol* 2018, 188(2):515-524.
7. Marcus JZ, Klobocista M, Karabakhtsian RG, Prossnitz E, Goldberg GL, Huang GS: Female Sex Hormone Receptor Profiling in Uterine Adenosarcomas. *Int J Gynecol Cancer* 2018, 28(3):500-504.

8. Hill DA, Friend S, Lomo L, Wiggins C, Barry M, Prossnitz E, Royce M: Breast cancer survival, survival disparities, and guideline-based treatment. *Breast Cancer Res Treat* 2018, 170(2):405-414.
9. Fredette NC, Meyer MR, Prossnitz ER: Role of GPER in estrogen-dependent nitric oxide formation and vasodilation. *J Steroid Biochem Mol Biol* 2018, 176:65-72.
10. Deretic V, Prossnitz E, Burge M, Campen MJ, Cannon J, Liu KJ, Sklar LA, Allers L, Garcia SA, Baehrecke EH *et al*: Autophagy, Inflammation, and Metabolism (AIM) Center of Biomedical Research Excellence: supporting the next generation of autophagy researchers and fostering international collaborations. *Autophagy* 2018.
11. Castleman MJ, Pokhrel S, Triplett KD, Kusewitt DF, Elmore BO, Joyner JA, Femling JK, Sharma G, Hathaway HJ, Prossnitz ER *et al*: Innate Sex Bias of *Staphylococcus aureus* Skin Infection Is Driven by alpha-Hemolysin. *J Immunol* 2018, 200(2):657-668.
12. Barton M, Filardo EJ, Lolait SJ, Thomas P, Maggiolini M, Prossnitz ER: Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives. *J Steroid Biochem Mol Biol* 2018, 176:4-15.
13. Arias-Pulido H, Cimino-Mathews A, Chaher N, Qualls C, Joste N, Colpaert C, Marotti JD, Foisey M, Prossnitz ER, Emens LA *et al*: The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. *Breast Cancer Res Treat* 2018, 171(2):273-282.
14. Sharma G, Prossnitz ER: G-Protein-Coupled Estrogen Receptor (GPER) and Sex-Specific Metabolic Homeostasis. *Adv Exp Med Biol* 2017, 1043:427-453.
15. Meyer MR, Rosemann T, Barton M, Prossnitz ER: GPER mediates functional endothelial aging in renal arteries. *Pharmacology* 2017, 100(3-4):188-193.
16. Hill DA, Barry M, Wiggins C, Nibbe A, Royce M, Prossnitz E, Lomo L: Estrogen receptor quantitative measures and breast cancer survival. *Breast Cancer Res Treat* 2017, 166(3):855-864.
17. Barton M, Prossnitz ER: Rapid vasodilation to raloxifene: role of oestrogen receptors and off-target effects. *Br J Pharmacol* 2017, 174(22):4201-4202.
18. Alexander SP, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Buneman OP *et al*: The Concise Guide to Pharmacology 2017/18: Overview. *Br J Pharmacol* 2017, 174 Suppl 1: S1-S16.
19. Wagener BM, Marjon NA, Prossnitz ER: Regulation of N-Formyl Peptide Receptor Signaling and Trafficking by Arrestin-Src Kinase Interaction. *PLoS One* 2016, 11(1): e0147442.
20. Sharma G, Prossnitz ER: GPER/GPR30 Knockout Mice: Effects of GPER on Metabolism. *Methods Mol Biol* 2016, 1366:489-502.
21. Meyer MR, Fredette NC, Sharma G, Barton M, Prossnitz ER: GPER is required for the age-dependent upregulation of the myocardial endothelin system. *Life Sci* 2016.
22. Meyer MR, Fredette NC, Daniel C, Sharma G, Amann K, Arterburn JB, Barton M, Prossnitz ER: Obligatory role for GPER in cardiovascular aging and disease. *Sci Signal* 2016, 9(452):ra105.

23. Dobroff AS, D'Angelo S, Eckhardt BL, Ferrara F, Staquicini DI, Cardo-Vila M, Staquicini FI, Nunes DN, Kim K, Driessen WH *et al*: Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. *Proc Natl Acad Sci U S A* 2016.
24. Zekas E, Prossnitz ER: Estrogen-mediated inactivation of FOXO3a by the G protein-coupled estrogen receptor GPER. *BMC Cancer* 2015, 15:702.
25. Prossnitz ER, Hathaway HJ: What have we learned about GPER function in physiology and disease from knockout mice? *J Steroid Biochem Mol Biol* 2015, 153:114-126.
26. Prossnitz ER, Arterburn JB: International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators. *Pharmacol Rev* 2015, 67(3):505-540.
27. Meyer MR, Fredette NC, Barton M, Prossnitz ER: G protein-coupled estrogen receptor inhibits vascular prostanoid production and activity. *J Endocrinol* 2015, 227(1):61-69.
28. Meyer MR, Fredette NC, Barton M, Prossnitz ER: Prostanoid-mediated contractions of the carotid artery become Nox2-independent with aging. *Age* 2015, 37(4):9806.
29. Barton M, Prossnitz ER: Emerging roles of GPER in diabetes and atherosclerosis. *Trends Endocrinol Metab* 2015, 26(4):185-192.
30. Alexander SP, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Buneman OP *et al*: The Concise Guide to PHARMACOLOGY 2015/16: Overview. *Br J Pharmacol* 2015, 172(24):5729-5743.
31. Albanito L, Lappano R, Madeo A, Chimento A, Prossnitz ER, Cappello AR, Dolce V, Abonante S, Pezzi V, Maggiolini M: Effects of atrazine on estrogen receptor alpha- and G protein-coupled receptor 30-mediated signaling and proliferation in cancer cells and cancer-associated fibroblasts. *Environ Health Perspect* 2015, 123(5):493-499.
32. Vaucher L, Funaro MG, Mehta A, Mielnik A, Bolyakov A, Prossnitz ER, Schlegel PN, Paduch DA: Activation of GPER-1 estradiol receptor downregulates production of testosterone in isolated rat Leydig cells and adult human testis. *PLoS One* 2014, 9(4):e92425. F91000Prime Recommended.
33. Scaling AL, Prossnitz ER, Hathaway HJ: GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast. *Horm Cancer* 2014, 5(3):146-160.
34. Prossnitz ER, Barton M: Estrogen biology: new insights into GPER function and clinical opportunities. *Mol Cell Endocrinol* 2014, 389(1-2):71-83.
35. Nayak TK, Ramesh C, Hathaway HJ, Norenberg JP, Arterburn JB, Prossnitz ER: GPER-targeted, 99mTc-labeled, nonsteroidal ligands demonstrate selective tumor imaging and in vivo estrogen binding. *Mol Cancer Res* 2014, 12(11):1635-1643.
36. Meyer MR, Fredette NC, Howard TA, Hu C, Ramesh C, Daniel C, Amann K, Arterburn JB, Barton M, Prossnitz ER: G Protein-coupled Estrogen Receptor protects from atherosclerosis. *Sci Rep* 2014, 4:7564.

37. Meyer MR, Fredette NC, Barton M, Prossnitz ER: Endothelin-1 but not angiotensin II contributes to functional aging in murine carotid arteries. *Life Sci* 2014, 118:213-216.
38. Meyer MR, Barton M, Prossnitz ER: Functional heterogeneity of NADPH oxidase-mediated contractions to endothelin with vascular aging. *Life Sci* 2014, 118:226-231.
39. Marjon NA, Hu C, Hathaway HJ, Prossnitz ER: G protein-coupled estrogen receptor regulates mammary tumorigenesis and metastasis. *Mol Cancer Res* 2014, 12(11):1644-1654.
40. Lu J, Hathaway HJ, Royce ME, Prossnitz ER, Miao Y: Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides. *Bioorg Med Chem Lett* 2014, 24(3):725-730.
41. Bielecka E, Scavenius C, Kantyka T, Jusko M, Mizgalska D, Szmigielski B, Potempa B, Enghild JJ, Prossnitz ER, Blom AM *et al*: Peptidyl arginine deiminase from *Porphyromonas gingivalis* abolishes anaphylatoxin C5a activity. *J Biol Chem* 2014, 289(47):32481-32487.
42. Sharma G, Hu C, Brigman JL, Zhu G, Hathaway HJ, Prossnitz ER: GPER deficiency in male mice results in insulin resistance, dyslipidemia, and a proinflammatory state. *Endocrinology* 2013, 154(11):4136-4145.
43. Prossnitz ER, Sklar LA: Chemotactic Peptide/Complement Receptors. In: *Encyclopedia of Biological Chemistry. Volume 1*, edn. Edited by Lennarz WJ, Lane MD. Waltham, MA: Academic Press: Elsevier; 2013: 493-497.
44. Petrie WK, Dennis MK, Hu C, Dai D, Arterburn JB, Smith HO, Hathaway HJ, Prossnitz ER: G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth. *Obstet Gynecol Int* 2013, 2013:472720.
45. Meyer MR, Fredette NC, Barton M, Prossnitz ER: Regulation of vascular smooth muscle tone by adipose-derived contracting factor. *PLoS One* 2013, 8(11):e79245.
46. Guo H, Hathaway H, Royce ME, Prossnitz ER, Miao Y: Influences of hydrocarbon linkers on the receptor binding affinities of gonadotropin-releasing hormone peptides. *Bioorg Med Chem Lett* 2013, 23(20):5484-5487.
47. Brunsing RL, Owens KS, Prossnitz ER: The G protein-coupled estrogen receptor (GPER) agonist G-1 expands the regulatory T-cell population under TH17-polarizing conditions. *J Immunother* 2013, 36(3):190-196.
48. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, Harmar AJ *et al*: The Concise Guide to PHARMACOLOGY 2013/14: overview. *Br J Pharmacol* 2013, 170(8):1449-1458.
49. Prossnitz ER: G protein-coupled estrogen receptor: A new therapeutic target in stroke and traumatic brain/spinal cord injury? *Crit Care Med* 2012, 40(12):3323-3325.
50. Meyer MR, Field AS, Kanagy NL, Barton M, Prossnitz ER: GPER regulates endothelin-dependent vascular tone and intracellular calcium. *Life Sci* 2012, 91(13-14):623-627.
51. Meyer MR, Amann K, Field AS, Hu C, Hathaway HJ, Kanagy NL, Walker MK, Barton M, Prossnitz ER: Deletion of G protein-coupled estrogen receptor increases endothelial vasoconstriction. *Hypertension* 2012, 59(2):507-512.

52. Burai R, Ramesh C, Nayak TK, Dennis MK, Bryant BK, Prossnitz ER, Arterburn JB: Synthesis and characterization of tricarbonyl-Re/Tc(I) chelate probes targeting the G protein-coupled estrogen receptor GPER/GPR30. *PLoS One* 2012, 7(10):e46861.
53. Barton M, Prossnitz ER, Meyer MR: Testosterone and secondary hypertension: new pieces to the puzzle. *Hypertension* 2012, 59(6):1101-1103.
54. Yu X, Ma H, Barman SA, Liu AT, Sellers M, Stallone JN, Prossnitz ER, White RE, Han G: Activation of G protein-coupled estrogen receptor induces endothelium-independent relaxation of coronary artery smooth muscle. *Am J Physiol Endocrinol Metab* 2011, 301(5):E882-888.
55. Sharma G, Prossnitz ER: Mechanisms of estradiol-induced insulin secretion by the G protein-coupled estrogen receptor GPR30/GPER in pancreatic beta-cells. *Endocrinology* 2011, 152(8):3030-3039.
56. Prossnitz ER, Barton M: The G-protein-coupled estrogen receptor GPER in health and disease. *Nat Rev Endocrinol* 2011, 7(12):715-726.
57. Meyer MR, Prossnitz ER, Barton M: GPER/GPR30 and Regulation of Vascular Tone and Blood Pressure. *Immunol Endocr Metab Agents Med Chem* 2011, 11(4):255-261.
58. Meyer MR, Prossnitz ER, Barton M: The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. *Vascul Pharmacol* 2011, 55(1-3):17-25.
59. Meyer MR, Clegg DJ, Prossnitz ER, Barton M: Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors. *Acta Physiol (Oxf)* 2011, 203(1):259-269.
60. Lindsey SH, Carver KA, Prossnitz ER, Chappell MC: Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mRen2.Lewis female rat. *J Cardiovasc Pharmacol* 2011, 57(5):598-603.
61. Kasai RS, Suzuki KG, Prossnitz ER, Koyama-Honda I, Nakada C, Fujiwara TK, Kusumi A: Full characterization of GPCR monomer-dimer dynamic equilibrium by single molecule imaging. *J Cell Biol* 2011, 192(3):463-480.
62. Guo H, Lu J, Hathaway H, Royce ME, Prossnitz ER, Miao Y: Synthesis and evaluation of novel gonadotropin-releasing hormone receptor-targeting peptides. *Bioconjug Chem* 2011, 22(8):1682-1689.
63. Gros R, Ding Q, Sklar LA, Prossnitz EE, Arterburn JB, Chorzyczewski J, Feldman RD: GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. *Hypertension* 2011, 57(3):442-451.
64. Glass JP, Parasher G, Arias-Pulido H, Donohue R, Prossnitz ER, Cerilli LA: Mesothelin and GPR30 staining among a spectrum of pancreatic epithelial neoplasms. *Int J Surg Pathol* 2011, 19(5):588-596.
65. Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologna CG, Oprea TI, Yamaguchi Y, Hayashi S, Sklar LA *et al*: Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. *J Steroid Biochem Mol Biol* 2011, 127(3-5):358-366.

66. Brunsing RL, Prossnitz ER: Induction of interleukin-10 in the T helper type 17 effector population by the G protein coupled estrogen receptor (GPER) agonist G-1. *Immunology* 2011, 134(1):93-106.
67. Barton M, Meyer MR, Prossnitz ER: Estrogen-independent activation of estrogen receptors. *Hypertension* 2011, 57(6):1056-1057.
68. Takanami K, Sakamoto H, Matsuda K, Hosokawa K, Nishi M, Prossnitz ER, Kawata M: Expression of G protein-coupled receptor 30 in the spinal somatosensory system. *Brain Res* 2010, 1310:17-28.
69. Ramesh C, Nayak TK, Burai R, Dennis MK, Hathaway HJ, Sklar LA, Prossnitz ER, Arterburn JB: Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30. *J Med Chem* 2010, 53(3):1004-1014.
70. Prossnitz ER: GPER (G protein-coupled estrogen receptor 1). *Atlas Genet Cytogenet Oncol Haematol* 2010, 14(2):114-116.
71. Nayak TK, Dennis MK, Ramesh C, Burai R, Atcher RW, Sklar LA, Norenberg JP, Hathaway HJ, Arterburn JB, Prossnitz ER: Influence of charge on cell permeability and tumor imaging of GPR30-targeted ¹¹¹In-labeled nonsteroidal imaging agents. *ACS Chem Biol* 2010, 5(7):681-690.
72. Meyer MR, Baretella O, Prossnitz ER, Barton M: Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780. *Pharmacology* 2010, 86(1):58-64.
73. Kuo J, Hamid N, Bondar G, Prossnitz ER, Micevych P: Membrane estrogen receptors stimulate intracellular calcium release and progesterone synthesis in hypothalamic astrocytes. *J Neurosci* 2010, 30(39):12950-12957.
74. Huang GS, Gunter MJ, Arend RC, Li M, Arias-Pulido H, Prossnitz ER, Goldberg GL, Smith HO: Co-expression of GPR30 and ERbeta and their association with disease progression in uterine carcinosarcoma. *Am J Obstet Gynecol* 2010, 203(3):242 e241-245.
75. Huang GS, Brouwer-Visser J, Ramirez MJ, Kim CH, Hebert TM, Lin J, Arias-Pulido H, Qualls CR, Prossnitz ER, Goldberg GL *et al*: Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. *Clin Cancer Res* 2010, 16(11):2999-3010.
76. Burai R, Ramesh C, Shorty M, Curpan R, Bologna C, Sklar LA, Oprea T, Prossnitz ER, Arterburn JB: Highly efficient synthesis and characterization of the GPR30-selective agonist G-1 and related tetrahydroquinoline analogs. *Org Biomol Chem* 2010, 8(9):2252-2259.
77. Barton M, Meyer MR, Bolton JL, Prossnitz ER: Lung cancer and hormone replacement therapy. *Lancet* 2010, 375(9709):117-118; author reply 118-119.
78. Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, Black MA, Donato AL, Arterburn JB, Oprea TI *et al*: The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. *Cancer Res* 2010, 70(3):1184-1194.
79. Arias-Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee SJ, Chaher N, Verschraegen C, Lara J, Prossnitz ER *et al*: GPR30 and estrogen receptor expression:

- new insights into hormone dependence of inflammatory breast cancer. *Breast Cancer Res Treat* 2010, 123(1):51-58.
80. Young SM, Bologna CM, Fara D, Bryant BK, Strouse JJ, Arterburn JB, Ye RD, Oprea TI, Prossnitz ER, Sklar LA *et al*: Duplex high-throughput flow cytometry screen identifies two novel formylpeptide receptor family probes. *Cytometry A* 2009, 75(3):253-263.
 81. Xu H, Qin S, Carrasco GA, Dai Y, Filardo EJ, Prossnitz ER, Battaglia G, Doncarlos LL, Muma NA: Extra-nuclear estrogen receptor GPR30 regulates serotonin function in rat hypothalamus. *Neuroscience* 2009, 158(4):1599-1607.
 82. Wagener BM, Marjon NA, Revankar CM, Prossnitz ER: Adaptor protein-2 interaction with arrestin regulates GPCR recycling and apoptosis. *Traffic* 2009, 10(9):1286-1300.
 83. Strouse JJ, Young SM, Mitchell HD, Ye RD, Prossnitz ER, Sklar LA, Edwards BS: A novel fluorescent cross-reactive formylpeptide receptor/formylpeptide receptor-like 1 hexapeptide ligand. *Cytometry A* 2009, 75(3):264-270.
 84. Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER: GPR30 predicts poor survival for ovarian cancer. *Gynecol Oncol* 2009, 114(3):465-471.
 85. Prossnitz ER, Maggiolini M: Mechanisms of estrogen signaling and gene expression via GPR30. *Mol Cell Endocrinol* 2009, 308(1-2):32-38.
 86. Prossnitz ER, Maggiolini M: Non-genomic signaling by steroids. *Mol Cell Endocrinol* 2009, 308(1-2):1-2.
 87. Prossnitz ER, Barton M: Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER. *Prostaglandins Other Lipid Mediat* 2009, 89(3-4):89-97.
 88. Prossnitz ER: Guide to Receptors and Channels (GRAC), 4th edition: GPE Receptor. *Br J Pharmacol* 2009, 1((Suppl.)):S000.
 89. Meyer MR, Haas E, Prossnitz ER, Barton M: Non-genomic regulation of vascular cell function and growth by estrogen. *Mol Cell Endocrinol* 2009, 308(1-2):9-16.
 90. Hazell GG, Yao ST, Roper JA, Prossnitz ER, O'Carroll AM, Lolait SJ: Localisation of GPR30, a novel G protein-coupled oestrogen receptor, suggests multiple functions in rodent brain and peripheral tissues. *J Endocrinol* 2009, 202(2):223-236.
 91. Haynes MK, Strouse JJ, Waller A, Leitao A, Curpan RF, Bologna C, Oprea TI, Prossnitz ER, Edwards BS, Sklar LA *et al*: Detection of intracellular granularity induction in prostate cancer cell lines by small molecules using the HyperCyt high-throughput flow cytometry system. *J Biomol Screen* 2009, 14(6):596-609.
 92. Haas E, Bhattacharya I, Brailoiu E, Damjanovic M, Brailoiu GC, Gao X, Mueller-Guerre L, Marjon NA, Gut A, Minotti R *et al*: Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. *Circ Res* 2009, 104(3):288-291.
 93. Guo H, Yang J, Gallazzi F, Prossnitz ER, Sklar LA, Miao Y: Effect of DOTA position on melanoma targeting and pharmacokinetic properties of ¹¹¹In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide. *Bioconjug Chem* 2009, 20(11):2162-2168.

94. Edwards BS, Young SM, Ivnitsky-Steele I, Ye RD, Prossnitz ER, Sklar LA: High-content screening: flow cytometry analysis. *Methods Mol Biol* 2009, 486:151-165.
95. Dun SL, Brailoiu GC, Gao X, Brailoiu E, Arterburn JB, Prossnitz ER, Oprea TI, Dun NJ: Expression of estrogen receptor GPR30 in the rat spinal cord and in autonomic and sensory ganglia. *J Neurosci Res* 2009, 87(7):1610-1619.
96. Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK, Bologna CG, Leitao A, Brailoiu E, Deliu E *et al*: In vivo effects of a GPR30 antagonist. *Nat Chem Biol* 2009, 5(6):421-427.
97. Blasko E, Haskell CA, Leung S, Gualtieri G, Halks-Miller M, Mahmoudi M, Dennis MK, Prossnitz ER, Karpus WJ, Horuk R: Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. *J Neuroimmunol* 2009, 214(1-2):67-77.
98. Arterburn JB, Oprea TI, Prossnitz ER, Edwards BS, Sklar LA: Discovery of selective probes and antagonists for G-protein-coupled receptors FPR/FPRL1 and GPR30. *Curr Top Med Chem* 2009, 9(13):1227-1236.
99. Arias-Pulido H, Smith HO, Joste NE, Bocklage T, Qualls CR, Chavez A, Prossnitz ER, Verschraegen CF: Estrogen and progesterone receptor status and outcome of epithelial ovarian cancer. *Gynecol Oncol* 2009, 114(3):480-485.
100. Wang C, Prossnitz ER, Roy SK: G protein-coupled receptor 30 expression is required for estrogen stimulation of primordial follicle formation in the hamster ovary. *Endocrinology* 2008, 149(9):4452-4461.
101. Teng J, Wang ZY, Prossnitz ER, Bjorling DE: The G protein-coupled receptor GPR30 inhibits human urothelial cell proliferation. *Endocrinology* 2008, 149(8):4024-4034.
102. Prossnitz ER, Sklar LA, Oprea TI, Arterburn JB: GPR30: a novel therapeutic target in estrogen-related disease. *Trends Pharmacol Sci* 2008, 29(3):116-123.
103. Prossnitz ER, Oprea TI, Sklar LA, Arterburn JB: The ins and outs of GPR30: A transmembrane estrogen receptor. *J Steroid Biochem Mol Biol* 2008, 109(3-5):350-353.
104. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ: Estrogen action via the transmembrane receptor GPR30. *Annu Rev Physiol* 2008, 70:165-190.
105. Nayak TK, Hathaway HJ, Ramesh C, Arterburn JB, Dai D, Sklar LA, Norenberg JP, Prossnitz ER: Preclinical development of a neutral, estrogen receptor-targeted, tridentate ^{99m}Tc(I) estradiol pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers. *J Nuc Med* 2008, 49(6):978-986.
106. Nayak TK, Atcher RW, Prossnitz ER, Norenberg JP: Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation. *Nucl Med Biol* 2008, 35(6):673-678.
107. Matsuda K, Sakamoto H, Mori H, Hosokawa K, Kawamura A, Itose M, Nishi M, Prossnitz ER, Kawata M: Expression and intracellular distribution of the G protein-coupled receptor 30 in rat hippocampal formation. *Neurosci Lett* 2008, 441(1):94-99.
108. Dennis MK, Bowles HJ, MacKenzie DA, Burchiel SW, Edwards BS, Sklar LA, Prossnitz ER, Thompson TA: A multifunctional androgen receptor screening assay using the high-throughput Hypercyt flow cytometry system. *Cytometry A* 2008, 73(5):390-399.

109. Xue M, Hsieh G, Raymond-Stintz MA, Pfeiffer J, Roberts D, Steinberg SL, Oliver JM, Prossnitz ER, Lidke DS, Wilson BS: Activated N-formyl peptide receptor and high-affinity IgE receptor occupy common domains for signaling and internalization. *Mol Biol Cell* 2007, 18(4):1410-1420.
110. Wu Y, Buranda T, Simons PC, Lopez GP, McIntire WE, Garrison JC, Prossnitz ER, Sklar LA: Rapid-mix flow cytometry measurements of subsecond regulation of G protein-coupled receptor ternary complex dynamics by guanine nucleotides. *Anal Biochem* 2007, 371(1):10-20.
111. Wang C, Prossnitz ER, Roy SK: Expression of GPR30 in the hamster ovary: differential regulation by gonadotropins and steroids hormones. *Endocrinology* 2007, 148:4853-4864.
112. Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE, Prossnitz ER: GPR30: a novel indicator of poor survival for endometrial carcinoma. *Am J Obstet Gynecol* 2007, 196(4):386 e381-389; discussion 386 e389-311.
113. Sakamoto H, Matsuda K, Hosokawa K, Nishi M, Morris JF, Prossnitz ER, Kawata M: Expression of GPR30, a G protein-coupled membrane estrogen receptor, in oxytocin neurons of the rat paraventricular and supraoptic nuclei. *Endocrinology* 2007, 148:5842-5850.
114. Revankar CM, Mitchell HD, Field AS, Burai R, Corona C, Ramesh C, Sklar LA, Arterburn JB, Prossnitz ER: Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. *ACS Chem Biol* 2007, 2(8):536-544.
115. Prossnitz ER, Sklar LA: Modulation of GPCR conformations by ligands, G proteins and arrestins. In: *GPCRs: from deorphanization to lead structure identification*. edn. Edited by Bourne H, Horuk R, Kuhnke J, Michel H; 2007: 211-228.
116. Prossnitz ER, Arterburn JB, Sklar LA: GPR30: A G protein-coupled receptor for estrogen. *Mol Cell Endocrinol* 2007, 265-266:138-142.
117. Nayak TK, Norenberg JP, Anderson TL, Prossnitz ER, Stabin MG, Atcher RW: Somatostatin-receptor-targeted alpha-emitting ²¹³Bi is therapeutically more effective than beta(-)-emitting ¹⁷⁷Lu in human pancreatic adenocarcinoma cells. *Nucl Med Biol* 2007, 34(2):185-193.
118. Buranda T, Waller A, Wu Y, Simons PC, Biggs S, Prossnitz ER, Sklar LA: Some mechanistic insights into GPCR activation from detergent-solubilized ternary complexes on beads. In: *Advances in Protein Chemistry. Volume 74*, edn.; 2007: 95-135.
119. Brailoiu E, Dun SL, Brailoiu GC, Mizuo K, Sklar LA, Oprea TI, Prossnitz ER, Dun NJ: Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system. *J Endocrinol* 2007, 193(2):311-321.
120. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Ando S *et al*: G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. *Cancer Res* 2007, 67(4):1859-1866.
121. Tessema M, Simons PC, Cimino DF, Sanchez L, Waller A, Posner RG, Wandinger-Ness A, Prossnitz ER, Sklar LA: Glutathione-S-transferase-green fluorescent protein fusion protein reveals slow dissociation from high site density beads and measures free GSH. *Cytometry A* 2006, 69A(5):326-334.

122. Ramesh C, Bryant B, Nayak T, Revankar CM, Anderson T, Carlson KE, Katzenellenbogen JA, Sklar LA, Norenberg JP, Prossnitz ER *et al*: Linkage effects on binding affinity and activation of GPR30 and estrogen receptors ER α /ER β with tridentate pyridin-2-yl hydrazine tricarbonyl-Re/(99m)Tc(I) chelates. *J Am Chem Soc* 2006, 128(45):14476-14477.
123. Prossnitz ER, Arterburn JB, Edwards BS, Sklar LA, Oprea TI: Steroid-binding G-protein-coupled receptors: new drug discovery targets for old ligands? *Expert Opinion on Drug Discovery* 2006, 1(2):137-150.
124. Prossnitz ER: GPR30. *UCSD-Nature Molecule Pages* 2006: doi: 10.1038/mp.a003779.003701.
125. Potter RM, Maestas DC, Cimino DF, Prossnitz ER: Regulation of N-formyl Peptide receptor signaling and trafficking by individual carboxyl-terminal serine and threonine residues. *J Immunol* 2006, 176(9):5418-5425.
126. Okun I, Malarchuk S, Dubrovskaya E, Khvat A, Tkachenko S, Kysil V, Ilyin A, Kravchenko D, Prossnitz ER, Sklar L *et al*: Screening for caspase-3 inhibitors: a new class of potent small-molecule inhibitors of caspase-3. *J Biomol Screen* 2006, 11(3):277-285.
127. Makino A, Prossnitz ER, Bunemann M, Wang JM, Yao W, Schmid-Schonbein GW: G protein-coupled receptors serve as mechanosensors for fluid shear stress in neutrophils. *Am J Physiol Cell Physiol* 2006, 290(6):C1633-1639.
128. Edwards BS, Young SM, Oprea TI, Bologa CG, Prossnitz ER, Sklar LA: Biomolecular screening of formylpeptide receptor ligands with a sensitive, quantitative, high-throughput flow cytometry platform. *Nat Protoc* 2006, 1(1):59-66.
129. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, Sklar LA *et al*: Virtual and biomolecular screening converge on a selective agonist for GPR30. *Nat Chem Biol* 2006, 2(4):207-212 Faculty of 1000 Biology.
130. Young SM, Bologa C, Prossnitz ER, Oprea TI, Sklar LA, Edwards BS: High-throughput screening with HyperCyt flow cytometry to detect small molecule formylpeptide receptor ligands. *J Biomol Screen* 2005, 10(4):374-382.
131. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER: A transmembrane intracellular estrogen receptor mediates rapid cell signaling. *Science* 2005, 307:1625-1630.
132. Prossnitz ER, Revankar CM, Arterburn JB, Sklar LA: Estrogen receptors and cell signaling - Response. *Science* 2005, 310(5745):52-53.
133. Oprea TI, Bologa CG, Edwards BS, Prossnitz ER, Sklar LA: Post-high-throughput screening analysis: an empirical compound prioritization scheme. *J Biomol Screen* 2005, 10(5):419-426.
134. Key TA, Vines CM, Wagener BM, Gurevich VV, Sklar LA, Prossnitz ER: Inhibition of chemoattractant N-formyl Peptide receptor trafficking by active arrestins. *Traffic* 2005, 6(2):87-99.
135. Edwards BS, Bologa C, Young SM, Balakin KV, Prossnitz ER, Savchuck NP, Sklar LA, Oprea TI: Integration of Virtual Screening With High Throughput Flow

- Cytometry to Identify Novel Small Molecule Formylpeptide Receptor Antagonists. *Mol Pharmacol* 2005, 68(5):1301-1310.
136. Carter JM, Gurevich VV, Prossnitz ER, Engen JR: Conformational differences between arrestin2 and pre-activated mutants as revealed by hydrogen exchange mass spectrometry. *J Mol Biol* 2005, 351:865-878.
 137. Young SM, Curry MS, Ransom JT, Ballesteros JA, Prossnitz ER, Sklar LA, Edwards BS: High-throughput microfluidic mixing and multiparametric cell sorting for bioactive compound screening. *J Biomol Screen* 2004, 9(2):103-111.
 138. Xue M, Vines CM, Buranda T, Cimino DF, Bennett TA, Prossnitz ER: N-formyl peptide receptors cluster in an active raft-associated state prior to phosphorylation. *J Biol Chem* 2004, 279:45175-45184.
 139. Waller A, Simons PC, Biggs SM, Edwards BS, Prossnitz ER, Sklar LA: Techniques: GPCR assembly, pharmacology and screening by flow cytometry. *Trends Pharmacol Sci* 2004, 25(12):663-669.
 140. Vines CM, Prossnitz ER: Mechanisms of G protein-coupled receptor-mediated degranulation. *FEMS Microbiol Lett* 2004, 236(1):1-6.
 141. Simons PC, Biggs SM, Waller A, Foutz T, Cimino DF, Guo Q, Neubig RR, Tang WJ, Prossnitz ER, Sklar LA: Real-time analysis of ternary complex on particles: direct evidence for partial agonism at the agonist-receptor-G protein complex assembly step of signal transduction. *J Biol Chem* 2004, 279(14):13514-13521.
 142. Revankar CM, Vines CM, Cimino DF, Prossnitz ER: Arrestins block G protein-coupled receptor-mediated apoptosis. *J Biol Chem* 2004, 279(23):24578-24584.
 143. Prossnitz ER, Sklar LA: Chemotactic peptide/Complement Receptors. In: *Encyclopedia of Biological Chemistry. Volume 1*, edn. Edited by Lennarz WJ, Lane MD. San Diego CA: Elsevier Science; 2004: 425-429.
 144. Prossnitz ER: Novel roles for arrestins in the post-endocytic trafficking of G protein-coupled receptors. *Life Sci* 2004, 75:893-899.
 145. Postma B, Poppelier MJ, Van Galen JC, Prossnitz ER, Van Strijp JA, De Haas CJ, Van Kessel KP: Chemotaxis inhibitory protein of *Staphylococcus aureus* binds specifically to the C5a and formylated peptide receptor. *J Immunol* 2004, 172(11):6994-7001.
 146. Edwards BS, Oprea T, Prossnitz ER, Sklar LA: Flow cytometry for high-throughput, high-content screening. *Curr Opin Chem Biol* 2004, 8(4):392-398.
 147. Chigaev A, Zwartz GJ, Buranda T, Edwards BS, Prossnitz ER, Sklar LA: Conformational regulation of alpha 4 beta 1-integrin affinity by reducing agents. "Inside-out" signaling is independent of and additive to reduction-regulated integrin activation. *J Biol Chem* 2004, 279(31):32435-32443.
 148. Waller A, Simons P, Prossnitz ER, Edwards BS, Sklar LA: High throughput screening of G-protein coupled receptors via flow cytometry. *Comb Chem High Throughput Screen* 2003, 6(4):389-397.
 149. Vines CM, Revankar CM, Maestas DC, LaRusch LL, Cimino DF, Kohout TA, Lefkowitz RJ, Prossnitz ER: N-formyl peptide receptors internalize but do not recycle in the absence of arrestins. *J Biol Chem* 2003, 278:41581-41584.

150. Simons PC, Shi M, Foutz T, Cimino DF, Lewis J, Buranda T, Lim WK, Neubig RR, McIntire WE, Garrison J *et al*: Ligand-receptor-G-protein molecular assemblies on beads for mechanistic studies and screening by flow cytometry. *Mol Pharmacol* 2003, 64(5):1227-1238.
151. Shi M, Bennett TA, Cimino DF, Maestas DC, Foutz TD, Gurevich VV, Sklar LA, Prossnitz ER: Functional capabilities of an N-formyl peptide receptor-G(alpha)(i)(2) fusion protein: assemblies with G proteins and arrestins. *Biochemistry* 2003, 42(24):7283-7293.
152. Prossnitz ER: Chemokines and chemokine receptors. *IDrugs* 2003, 6(3):191-194.
153. Key TA, Foutz TD, Gurevich VV, Sklar LA, Prossnitz ER: N-formyl peptide receptor phosphorylation domains differentially regulate arrestin and agonist affinity. *J Biol Chem* 2003, 278(6):4041-4047.
154. Chigaev A, Zwartz G, Graves SW, Dwyer DC, Tsuji H, Foutz TD, Edwards BS, Prossnitz ER, Larson RS, Sklar LA: Alpha4beta1 integrin affinity changes govern cell adhesion. *J Biol Chem* 2003, 278(40):38174-38182.
155. Chigaev A, Buranda T, Dwyer DC, Prossnitz ER, Sklar LA: FRET detection of cellular alpha4-integrin conformational activation. *Biophys J* 2003, 85(6):3951-3962.
156. Vines CM, Xue M, Maestas DC, Cimino DF, Prossnitz ER: Regulation of N-formyl peptide-mediated degranulation by receptor phosphorylation. *J Immunol* 2002, 169(12):6760-6766.
157. Sklar LA, Edwards BS, Graves SW, Nolan JP, Prossnitz ER: Flow cytometric analysis of ligand-receptor interactions and molecular assemblies. *Annu Rev Biophys Biomol Struct* 2002, 31:97-119.
158. Potter RM, Key TA, Gurevich VV, Sklar LA, Prossnitz ER: Arrestin variants display differential binding characteristics for the phosphorylated N-formyl peptide receptor carboxyl terminus. *J Biol Chem* 2002, 277(11):8970-8978.
159. Jackson WC, Bennett TA, Edwards BS, Prossnitz E, Lopez GP, Sklar LA: Performance of in-line microfluidic mixers in laminar flow for high-throughput flow cytometry. *BioTechniques* 2002, 33(1):220-226.
160. Graham TE, Prossnitz ER, Dorin RI: Dexras1/AGS-1 inhibits signal transduction from the Gi-coupled formyl peptide receptor to Erk-1/2 MAP kinases. *J Biol Chem* 2002, 277(13):10876-10882.
161. Key TA, Bennett TA, Foutz TD, Gurevich VV, Sklar LA, Prossnitz ER: Regulation of formyl peptide receptor agonist affinity by reconstitution with arrestins and heterotrimeric G proteins. *J Biol Chem* 2001, 276(52):49204-49212.
162. Gilbert TL, Bennett TA, Maestas DC, Cimino DF, Prossnitz ER: Internalization of the human N-formyl peptide and C5a chemoattractant receptors occurs via clathrin-independent mechanisms. *Biochemistry* 2001, 40(12):3467-3475.
163. Edwards BS, Kuckuck FW, Prossnitz ER, Ransom JT, Sklar LA: HTS flow cytometry: a novel platform for automated high throughput drug discovery and characterization. *J Biomol Screen* 2001, 6(2):83-90.
164. Edwards BS, Kuckuck FW, Prossnitz ER, Okun A, Ransom JT, Sklar LA: Plug flow cytometry extends analytical capabilities in cell adhesion and receptor pharmacology. *Cytometry* 2001, 43(3):211-216.

165. Chigaev A, Blenc AM, Braaten JV, Kumaraswamy N, Kepley CL, Andrews RP, Oliver JM, Edwards BS, Prossnitz ER, Larson RS *et al*: Real time analysis of the affinity regulation of alpha 4-integrin. The physiologically activated receptor is intermediate in affinity between resting and Mn^{2+} or antibody activation. *J Biol Chem* 2001, 276(52):48670-48678.
166. Bennett TA, Key TA, Gurevich VV, Neubig R, Prossnitz ER, Sklar LA: Real-time analysis of G protein-coupled receptor reconstitution in a solubilized system. *J Biol Chem* 2001, 276(25):22453-22460.
167. Bennett TA, Foutz TD, Gurevich VV, Sklar LA, Prossnitz ER: Partial phosphorylation of the N-formyl peptide receptor inhibits G protein association independent of arrestin binding. *J Biol Chem* 2001, 276(52):49195-49203.
168. Sklar LA, Vilven J, Lynam E, Neldon D, Bennett TA, Prossnitz E: Solubilization and display of G protein-coupled receptors on beads for real-time fluorescence and flow cytometric analysis. *BioTechniques* 2000, 28(5):976-980, 982-975.
169. Rane MJ, Prossnitz ER, Arthur JM, Ward RA, McLeish KR: Deficient homologous desensitization of formyl peptide receptors stably expressed in undifferentiated HL-60 cells. *Biochem Pharmacol* 2000, 60(2):179-187.
170. Burchiel SW, Edwards BS, Kuckuck FW, Lauer FT, Prossnitz ER, Ransom JT, Sklar LA: Analysis of free intracellular calcium by flow cytometry: multiparameter and pharmacologic applications. *Methods* 2000, 21(3):221-230.
171. Bennett TA, Maestas DC, Prossnitz ER: Arrestin binding to the G protein-coupled N-formyl peptide receptor is regulated by the conserved "DRY" sequence. *J Biol Chem* 2000, 275(32):24590-24594.
172. Prossnitz ER, Gilbert TL, Chiang S, Campbell JJ, Qin S, Newman W, Sklar LA, Ye RD: Multiple activation steps of the N-formyl peptide receptor. *Biochemistry* 1999, 38(8):2240-2247.
173. Nolan JP, Lauer S, Prossnitz ER, Sklar LA: Flow cytometry: a versatile tool for all phases of drug discovery. *Drug Discov Today* 1999, 4(4):173-180.
174. Maestes DC, Potter RM, Prossnitz ER: Differential phosphorylation paradigms dictate desensitization and internalization of the N-formyl peptide receptor. *J Biol Chem* 1999, 274(42):29791-29795.
175. Gilbert TL, Prossnitz ER, Sklar LA: The uncoupled state of the human formyl peptide receptor. *J Recept Signal Transduct Res* 1999, 19(1-4):327-340.
176. Vilven JC, Domalewski M, Prossnitz ER, Ye RD, Muthukumaraswamy N, Harris RB, Freer RJ, Sklar LA: Strategies for positioning fluorescent probes and crosslinkers on formyl peptide ligands. *J Recept Signal Transduct Res* 1998, 18(2-3):187-221.
177. Rane MJ, Arthur JM, Prossnitz ER, McLeish KR: Activation of mitogen-activated protein kinases by formyl peptide receptors is regulated by the cytoplasmic tail. *J Biol Chem* 1998, 273(33):20916-20923.
178. Quehenberger O, Pan ZK, Prossnitz ER, Cavanagh SL, Cochrane CG, Ye RD: Identification of an N-formyl peptide receptor ligand binding domain by a gain-of-function approach. *Biochem Biophys Res Commun* 1997, 238(2):377-381.
179. Prossnitz ER, Ye RD: The N-formyl peptide receptor: a model for the study of chemoattractant receptor structure and function. *Pharmacol Ther* 1997, 74(1):73-102.

180. Prossnitz ER: Desensitization of N-formylpeptide receptor-mediated activation is dependent upon receptor phosphorylation. *J Biol Chem* 1997, 272(24):15213-15219.
181. Kew RR, Peng T, DiMartino SJ, Madhavan D, Weinman SJ, Cheng D, Prossnitz ER: Undifferentiated U937 cells transfected with chemoattractant receptors: a model system to investigate chemotactic mechanisms and receptor structure/function relationships. *J Leukoc Biol* 1997, 61(3):329-337.
182. Hsu MH, Ember JA, Wang M, Prossnitz ER, Hugli TE, Ye RD: Cloning and functional characterization of the mouse C3a anaphylatoxin receptor gene. *Immunogenetics* 1997, 47(1):64-72.
183. Hsu MH, Chiang SC, Ye RD, Prossnitz ER: Phosphorylation of the N-formyl peptide receptor is required for receptor internalization but not chemotaxis. *J Biol Chem* 1997, 272(47):29426-29429.
184. Browning DD, Pan ZK, Prossnitz ER, Ye RD: Cell type- and developmental stage-specific activation of NF-kappaB by fMet-Leu-Phe in myeloid cells. *J Biol Chem* 1997, 272(12):7995-8001.
185. Ye RD, Pan Z, Kravchenko VV, Browning DD, Prossnitz ER: Gene transcription through activation of G-protein-coupled chemoattractant receptors. *Gene Expr* 1996, 5(4-5):205-215.
186. Roglic A, Prossnitz ER, Cavanagh SL, Pan Z, Zou A, Ye RD: cDNA cloning of a novel G protein-coupled receptor with a large extracellular loop structure. *Biochim Biophys Acta* 1996, 1305(1-2):39-43.
187. Ptasznik A, Prossnitz ER, Yoshikawa D, Smrcka A, Traynor-Kaplan AE, Bokoch GM: A tyrosine kinase signaling pathway accounts for the majority of phosphatidylinositol 3,4,5-trisphosphate formation in chemoattractant-stimulated human neutrophils. *J Biol Chem* 1996, 271(41):25204-25207.
188. Pan ZK, Zuraw BL, Lung CC, Prossnitz ER, Browning DD, Ye RD: Bradykinin stimulates NF-kappaB activation and interleukin 1beta gene expression in cultured human fibroblasts. *J Clin Invest* 1996, 98(9):2042-2049.
189. Vlahos CJ, Matter WF, Brown RF, Traynor-Kaplan AE, Heyworth PG, Prossnitz ER, Ye RD, Marder P, Schelm JA, Rothfuss KJ *et al*: Investigation of neutrophil signal transduction using a specific inhibitor of phosphatidylinositol 3-kinase. *J Immunol* 1995, 154(5):2413-2422.
190. Prossnitz ER, Schreiber RE, Bokoch GM, Ye RD: Binding of low affinity N-formyl peptide receptors to G protein. Characterization of a novel inactive receptor intermediate. *J Biol Chem* 1995, 270(18):10686-10694.
191. Prossnitz ER, Kim CM, Benovic JL, Ye RD: Phosphorylation of the N-formyl peptide receptor carboxyl terminus by the G protein-coupled receptor kinase, GRK2. *J Biol Chem* 1995, 270(3):1130-1137.
192. Schreiber RE, Prossnitz ER, Ye RD, Cochrane CG, Bokoch GM: Domains of the human neutrophil N-formyl peptide receptor involved in G protein coupling. Mapping with receptor-derived peptides. *J Biol Chem* 1994, 269(1):326-331.
193. Ye RD, Quehenberger O, Thomas KM, Navarro J, Cavanagh SL, Prossnitz ER, Cochrane CG: The rabbit neutrophil N-formyl peptide receptor. cDNA cloning, expression, and structure/function implications. *J Immunol* 1993, 150(4):1383-1394.

194. Schreiber RE, Prossnitz ER, Ye RD, Cochrane CG, Jesaitis AJ, Bokoch GM: Reconstitution of recombinant N-formyl chemotactic peptide receptor with G protein. *J Leukoc Biol* 1993, 53(4):470-474.
195. Quehenberger O, Prossnitz ER, Cavanagh SL, Cochrane CG, Ye RD: Multiple domains of the N-formyl peptide receptor are required for high-affinity ligand binding. Construction and analysis of chimeric N-formyl peptide receptors. *J Biol Chem* 1993, 268(24):18167-18175.
196. Prossnitz ER, Quehenberger O, Cochrane CG, Ye RD: The role of the third intracellular loop of the neutrophil N-formyl peptide receptor in G protein coupling. *Biochem J* 1993, 294 (Pt 2):581-587.
197. Prossnitz ER, Quehenberger O, Cochrane CG, Ye RD: Signal transducing properties of the N-formyl peptide receptor expressed in undifferentiated HL60 cells. *J Immunol* 1993, 151(10):5704-5715.
198. Ye RD, Cavanagh SL, Quehenberger O, Prossnitz ER, Cochrane CG: Isolation of a cDNA that encodes a novel granulocyte N-formyl peptide receptor. *Biochem Biophys Res Commun* 1992, 184(2):582-589.
199. Quehenberger O, Prossnitz ER, Cochrane CG, Ye RD: Absence of G(i) proteins in the Sf9 insect cell. Characterization of the uncoupled recombinant N-formyl peptide receptor. *J Biol Chem* 1992, 267(28):19757-19760.
200. Ye RD, Prossnitz ER, Zou AH, Cochrane CG: Characterization of a human cDNA that encodes a functional receptor for platelet activating factor. *Biochem Biophys Res Commun* 1991, 180(1):105-111.
201. Prossnitz ER, Quehenberger O, Cochrane CG, Ye RD: Transmembrane signalling by the N-formyl peptide receptor in stably transfected fibroblasts. *Biochem Biophys Res Commun* 1991, 179(1):471-476.
202. Prossnitz E: Determination of a region of the HisJ binding protein involved in the recognition of the membrane complex of the histidine transport system of *Salmonella typhimurium*. *J Biol Chem* 1991, 266(15):9673-9677.
203. Prossnitz E, Gee A, Ames GF: Reconstitution of the histidine periplasmic transport system in membrane vesicles. Energy coupling and interaction between the binding protein and the membrane complex. *J Biol Chem* 1989, 264(9):5006-5014.
204. Stern MJ, Prossnitz E, Ames GF: Role of the intercistronic region in post-transcriptional control of gene expression in the histidine transport operon of *Salmonella typhimurium*: involvement of REP sequences. *Mol Microbiol* 1988, 2(1):141-152.
205. Prossnitz E, Nikaido K, Ulbrich SJ, Ames GF: Formaldehyde and photoactivatable cross-linking of the periplasmic binding protein to a membrane component of the histidine transport system of *Salmonella typhimurium*. *J Biol Chem* 1988, 263(34):17917-17920.

Review articles and Commentaries

1. Sharma, G., Mauvais-Jarvis, F., Prossnitz, E. R. (2018) Roles of G protein-coupled estrogen receptor GPER in metabolic regulation. *J Steroid Biochem Mol Biol* 176, 31-37.
2. Prossnitz, E. R. (2018) New developments in the rapid actions of steroids and

- their receptors. *J Steroid Biochem Mol Biol* 176, 1-3.
3. Prossnitz, E. R. (2018) GPER modulators: Opportunity Nox on the heels of a class Akt. *J Steroid Biochem Mol Biol* 176, 73-81.
4. Barton, M., Filardo, E. J., Lolait, S. J., Thomas, P., Maggiolini, M., Prossnitz, E. R. (2018) Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives. *J Steroid Biochem Mol Biol* 176, 4-15.
5. Sharma, G. and Prossnitz, E. R. (2017) G-Protein-Coupled Estrogen Receptor (GPER) and Sex-Specific Metabolic Homeostasis. *Adv Exp Med Biol* 1043, 427-453.
6. Barton, M. and Prossnitz, E. R. (2017) Rapid vasodilation to raloxifene: role of oestrogen receptors and off-target effects. *Br J Pharmacol* 174, 4201-4202.
7. Sharma, G. and Prossnitz, E. R. (2016) GPER/GPR30 Knockout Mice: Effects of GPER on Metabolism. *Methods Mol Biol* 1366, 489-502.
8. Prossnitz, E. R. and Hathaway, H. J. (2015) What have we learned about GPER function in physiology and disease from knockout mice? *J Steroid Biochem Mol Biol* 153, 114-26.
9. 2. Prossnitz, E. R. and Arterburn, J. B. (2015) International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators. *Pharmacol Rev* 67, 505-40.
10. Barton, M. and Prossnitz, E. R. (2015) Emerging roles of GPER in diabetes and atherosclerosis. *Trends Endocrinol Metab* 26, 185-92.
11. Prossnitz, E. R. and Barton, M. (2014) Estrogen biology: new insights into GPER function and clinical opportunities. *Mol Cell Endocrinol* 389, 71-83.
12. Prossnitz, E. R. (2012) G protein-coupled estrogen receptor: A new therapeutic target in stroke and traumatic brain/spinal cord injury? *Crit Care Med* 40, 3323-5.
13. Barton, M., Prossnitz, E. R., Meyer, M. R. (2012) Testosterone and secondary hypertension: new pieces to the puzzle. *Hypertension* 59, 1101-3.
14. Prossnitz, E. R. and Barton, M. (2011) The G-protein-coupled estrogen receptor GPER in health and disease. *Nat Rev Endocrinol* 7, 715-26.
15. Meyer, M. R., Prossnitz, E. R., Barton, M. (2011) GPER/GPR30 and Regulation of Vascular Tone and Blood Pressure. *Immunol Endocr Metab Agents Med Chem* 11, 255-261.
16. Meyer, M. R., Prossnitz, E. R., Barton, M. (2011) The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. *Vascul Pharmacol* 55, 17-25.
17. Meyer, M. R., Clegg, D. J., Prossnitz, E. R., Barton, M. (2011) Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors. *Acta Physiol (Oxf)* 203, 259-69.
18. Barton, M., Meyer, M. R., Prossnitz, E. R. (2011) Estrogen-independent activation of estrogen receptors. *Hypertension* 57, 1056-7.
19. Prossnitz, E. R. (2010) GPER (G protein-coupled estrogen receptor 1). *Atlas Genet Cytogenet Oncol Haematol* 14, 114-116.
20. Barton, M., Meyer, M. R., Bolton, J. L., Prossnitz, E. R. (2010) Lung cancer and hormone replacement therapy. *Lancet* 375, 117-8; author reply 118-9.
21. Prossnitz, E. R. and Maggiolini, M. (2009) Mechanisms of estrogen signaling and gene expression via GPR30. *Mol Cell Endocrinol* 308, 32-8.
22. Prossnitz, E. R. and Maggiolini, M. (2009) Non-genomic signaling by steroids. *Mol Cell Endocrinol* 308, 1-2.
23. Prossnitz, E. R. and Barton, M. (2009) Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER.

- Prostaglandins Other Lipid Mediat 89, 89-97.
24. Prossnitz, E. R. (2009) Guide to Receptors and Channels (GRAC), 4th edition: GPE Receptor. *Br. J. Pharmacol.* 1, S000.
 25. Meyer, M. R., Haas, E., Prossnitz, E. R., Barton, M. (2009) Non-genomic regulation of vascular cell function and growth by estrogen. *Mol Cell Endocrinol* 308, 9-16.
 26. Edwards, B. S., Young, S. M., Ivnitsky-Steele, I., Ye, R. D., Prossnitz, E. R., Sklar, L. A. (2009) High-content screening: flow cytometry analysis. *Methods Mol Biol* 486, 151-65.
 27. Prossnitz, E. R., Sklar, L. A., Oprea, T. I., Arterburn, J. B. (2008) GPR30: a novel therapeutic target in estrogen-related disease. *Trends Pharmacol. Sci.* 29, 116-123.
 28. Prossnitz, E. R., Oprea, T. I., Sklar, L. A., Arterburn, J. B. (2008) The ins and outs of GPR30: A transmembrane estrogen receptor. *J Steroid Biochem Mol Biol* 109, 350-353.
 29. Prossnitz, E. R., Arterburn, J. B., Smith, H. O., Oprea, T. I., Sklar, L. A., Hathaway, H. J. (2008) Estrogen action via the transmembrane receptor GPR30. *Annu Rev Physiol* 70, 165-190.
 30. Prossnitz, E. R. and Sklar, L. A. (2007) Modulation of GPCR conformations by ligands, G proteins and arrestins. In *GPCRs: from deorphanization to lead structure identification* (H. Bourne, R. Horuk, J. Kuhnke, and H. Michel, eds), 211-228.
 31. Prossnitz, E. R., Arterburn, J. B., Sklar, L. A. (2007) GPR30: A G protein-coupled receptor for estrogen. *Mol Cell Endocrinol* 265-266, 138-42.
 32. Prossnitz, E. R., Arterburn, J. B., Edwards, B. S., Sklar, L. A., Oprea, T. I. (2006) Steroid-binding G-protein-coupled receptors: new drug discovery targets for old ligands? *Expert Opinion on Drug Discovery* 1, 137-150.
 33. Edwards, B. S., Young, S. M., Oprea, T. I., Bologna, C. G., Prossnitz, E. R., Sklar, L. A. (2006) Biomolecular screening of formylpeptide receptor ligands with a sensitive, quantitative, high-throughput flow cytometry platform. *Nat Protoc* 1, 59-66.
 34. Waller, A., Simons, P. C., Biggs, S. M., Edwards, B. S., Prossnitz, E. R., Sklar, L. A. (2004) Techniques: GPCR assembly, pharmacology and screening by flow cytometry. *Trends Pharmacol Sci* 25, 663-9.
 35. Vines, C. M. and Prossnitz, E. R. (2004) Mechanisms of G protein-coupled receptor-mediated degranulation. *FEMS Microbiol Lett* 236, 1-6.
 36. Edwards, B. S., Oprea, T., Prossnitz, E. R., Sklar, L. A. (2004) Flow cytometry for high-throughput, high-content screening. *Curr Opin Chem Biol* 8, 392-8.
 37. Prossnitz, E. R. (2003) Chemokines and chemokine receptors. *IDrugs* 6, 191-4.
 38. Sklar, L. A., Edwards, B. S., Graves, S. W., Nolan, J. P., Prossnitz, E. R. (2002) Flow cytometric analysis of ligand-receptor interactions and molecular assemblies. *Annu Rev Biophys Biomol Struct* 31, 97-119.
 39. Nolan, J. P., Lauer, S., Prossnitz, E. R., Sklar, L. A. (1999) Flow cytometry: a versatile tool for all phases of drug discovery. *Drug Discov Today* 4, 173-180.
 40. Prossnitz, E. R. and Ye, R. D. (1997) The N-formyl peptide receptor: a model for the study of chemoattractant receptor structure and function. *Pharmacol Ther* 74, 73-102.

Book chapters

1. Sharma, G. and Prossnitz, E. R. (2017) G Protein-coupled Estrogen Receptor (GPER) and Sex-Specific Metabolic Homeostasis. *Adv Exp Med Biol* 1043, 427-453.
2. Prossnitz, E.R., Sklar, L.A. (2006) Modulation of GPCR conformations by ligands, G proteins, and arrestins. In *Ernst Schering Found Symp Proc* (H. Bourne, R. Horuk, J. Kuhnke and H. Michel, eds), Springer-Verlag, Berlin Heidelberg 211-28.
3. Sklar, L.A., Edwards, B.S., Young, S.M., Oprea, T.I., Olah, Bologa, C., Prossnitz, E.R. (2005) HyperCyt – High Throughput Flow Cytometry. In *Drug Discovery Handbook* (S. Cox, ed) Wiley Interscience, Hoboken, NJ 185-226.
4. Simons, P.I., Vines, C.M., Key, T.A., Potter, R.M., Sklar, L.A., Prossnitz, E.R. (2005) Analysis of GTP-binding Protein-coupled Receptor Assemblies by Flow Cytometry. In *Flow Cytometry for Biotechnology* (L. A. Sklar, ed) Oxford University Press, New York 323-346.
5. Prossnitz, E.R., Sklar, L.A. (2004) Chemotactic peptide/Complement Receptors. In *Encyclopedia of Biological Chemistry*, Volume 1 (W. J. Lennarz and M. D. Lane, eds), Elsevier Science, San Diego CA 425-429.
6. Biggs, S., Simons, P.I., Waller, A., Foutz, T., Buranda, T., Prossnitz, E.R., Sklar, L.A. (2004) Analysis in real time of the assembly and disassembly of soluble G protein-coupled receptor-G protein complexes. Wiley and sons.
7. Sklar, L.A., Edwards, B.S., Graves, S., Nolan, J.P., Prossnitz, E.R. (2002) Flow Cytometry for analysis of membrane ligand-receptor interactions and macromolecular assembly. In *Ann. Rev. Biophysics*, Volume 31 97-119.
8. Burchiel, S.W., Edwards, B.S., Kuckuck, F.W., Lauer, F.T., Prossnitz, E.R., Ransom, J.T., Sklar, L.A. (2000) Analysis of free intracellular calcium by flow cytometry: multiparameter and pharmacologic applications. *Methods* **21**, 221-30.

Invited Presentations

1. 2019/04: An Unexpected Role of GPER in Cardiovascular Physiology at Experimental Biology 2019, ASPET Symposium, Orlando, FL.
2. 2018/09: Metabolic Roles of GPER at Rapid Responses to Steroid Hormones, Dublin, Ireland.
3. 2018/07: GPER as a Regulator of Metabolism at The Congress of Steroid Research, Seoul, Korea.
4. 2018/03: GPER as a Mediator of Estrogen Action in Endocrinology and Metabolism at The German Endocrine Society, Bonn, Germany.
5. 2017/05: Cardiovascular Effects of GPER at The Organization for the Study of Sex Differences, Montreal, Canada.
6. 2016/11: Understanding GPER's Functions in Physiology and Disease at Rapid Responses to Steroid Hormones, Richmond, VA.
7. 2016/11: GPER-mediated actions of estrogen in the nervous system at Colorado State University, Ft. Collins, CO.
8. 2016/09: 20 Years of GPER: From Orphan GPCR to Therapeutic Target at The University of Copenhagen, Copenhagen, Denmark.
9. 2016/09: 10 years of GPER: New Insights into Estrogen Biology at Arizona State

- University, Phoenix, AZ.
10. 2016/06: GPR30/GPER: a novel estrogen receptor in carcinogenesis at The NCI CBC Kickoff Conference, Washington, D.C.
11. 2016/02: Estrogen: More than just a sex hormone at New Mexico State University, Las Cruces, NM.
12. 2015/08: GPER and Breast Cancer at MD Anderson Cancer Center, Houston, TX.
13. 2015/04: Ten years of GPER: Where are we now? at The University of Alabama at Birmingham, Birmingham, AL.
14. 2015/01: GPER: Drug Discovery to Therapeutics at The University of New Mexico Cancer Center & Los Alamos National Laboratory Annual Research Retreat, Los Alamos, NM.
15. 2014/03: The Role of GPER in Health and Disease at Tulane University, New Orleans, LA.
16. 2013/05: The Role of Estrogen Receptor GPER in Health and Disease at Loyola University, Chicago, IL.
17. 2013/04: Drug Discovery and Development @ UNM at The Economic Development Advisory Group, UNM, Albuquerque, NM.
18. 2013/04: Regulation of Vascular Tone and Blood Pressure by GPER at Experimental Biology, Boston, MA.
19. 2013/03: Estrogen signaling via G protein-coupled estrogen receptors at The 79th Symposium of the German Society of Experimental and Clinical Pharmacology and Toxicology, Halle, Germany.
20. 2013/02: What Novel Ligands Have Told Us About Estrogen Biology at The UNM Center for Biomedical Engineering, Albuquerque, NM.
21. 2013/01: GPER and Atherosclerosis at The 3rd Annual CVMD Research Day @ UNM, Albuquerque, NM.
22. 2012/12: Drug Discovery, Development and Estrogen Biology @ UNM at The Albuquerque Chamber of Commerce, Albuquerque, NM.
23. 2012/05: Membrane Estrogen Receptor GPER in Health and Disease at The Hong Kong Pharmacology Society, Hong Kong.
24. 2012/05: Roles of the G protein-coupled Estrogen Receptor in Carcinogenesis at Cancer 2012, Hong Kong.
25. 2012/04: What have selective ligands told us about GPER function? at Experimental Biology, San Diego, CA.
26. 2011/04: Steroid Signaling via Non-Traditional Receptors at The American Society of Andrology, Montreal, Canada.
27. 2011/03: New Activities of GPR30 and its Selective Ligands at Congress on Steroid Research, Chicago, IL.
28. 2010/11: Novel Mechanisms of Estrogen Action through GPR30 at The UNM College of Pharmacy, Albuquerque, NM.
29. 2010/10: Mechanisms of Rapid Estrogen Signaling at The International Symposium on Cell Signaling, Florianopolis, Brazil.
30. 2010/09: Novel Mechanisms of Estrogen Signaling via GPR30 at Montana State University, Bozeman, MT.
31. 2010/09: Novel Mechanisms of Estrogen Action through GPR30/GPER at The University of Colorado, Denver, CO.
32. 2010/01: Small Molecule Discovery for the NIH Roadmap by High Throughput Flow Cytometry at High Content Analysis, San Francisco, CA.
33. 2009/12: Mechanisms of Estrogen Action through GPR30/GPER at The

- University of Illinois at Chicago, Chicago, IL.
34. 2009/10: Translating GPR30-Estrogen Biology at The Surgery Research Network Seminar Series, Albuquerque, NM.
 35. 2009/09: Unravelling the Cellular and Physiological Functions of GPR30 at Rapid Responses to Steroid Hormones, Elche, Spain.
 36. 2009/06: New Aspects of Estrogen Action through GPR30 at Albert Einstein Cancer Center, New York, NY.
 37. 2009/03: What has a selective GPR30 estrogen receptor agonist revealed in three years? at Biocomputing @ UNM, Albuquerque, NM.
 38. 2008/11: Emerging Roles for the Estrogen Receptor GPR30 in Physiology and Disease at Albert Einstein College of Medicine, Bronx, NY.
 39. 2008/11: The role of the G protein-coupled estrogen receptor GPR30 in normal and pathophysiology at Rockefeller University, New York, NY.
 40. 2008/09: GPR30 and Gynecological Cancers at Hormonal Steroids and Hormones & Cancer, Quebec City, Canada.
 41. 2008/04: GPR30 and Reproductive Biology at The University of Nebraska Medical Center, Omaha, NE.
 42. 2008/03: The Search for Novel Estrogen Receptor Modulators at Biocomputing @ UNM, Albuquerque, NM.
 43. 2008/02: GPR30 as a novel biomarker and drug target at The 1st International Conference on Drug Design & Discovery, Dubai, UAE.
 44. 2007/12: GPR30: a novel estrogen receptor in cancer and estrogen-related disease at The Albert Einstein Cancer Center, New York, NY.
 45. 2007/12: Mechanisms of estrogen signaling through GPR30 at The University of North Carolina, Chapel Hill, NC.
 46. 2007/11: GPR30 in the brain and neurological disease at The Max Planck Institute for Molecular Genetics, Berlin, Germany.
 47. 2007/11: GPR30 in cancer and disease at Bayer-Schering, Berlin, Germany.
 48. 2007/10: Mechanisms of estrogen action through GPR30 at The Molecular Signaling Section of NIH, Washington, D.C.
 49. 2007/10: The Role of GPR30 in Estrogen Signaling at Washington University, St. Louis, MO.
 50. 2007/09: GPR30: A transmembrane intracellular estrogen receptor mediating rapid cell signaling at Rapid Responses to Steroid Hormones, Dublin, Ireland.
 51. 2007/06: The Role of GPR30 in Estrogen Signaling at Lovelace Respiratory Research Institute, Albuquerque, NM.
 52. 2007/04: The Role of GPR30 in Estrogen Signaling at Then Third ASPET GPCR Colloquium, Wahington, DC.
 53. 2007/03: Targeting Classical Estrogen Receptors and GPR30 at Biocomputing @ UNM, Albuquerque, NM.
 54. 2007/03: Estrogen action mediated by the G protein-coupled receptor GPR30 at Case Western University, Cleveland, OH.
 55. 2007/02: Transmembrane Estrogen Receptors in Reproductive Tissues at The Keystone Symposium on Reproduction: Advances and Challenges, Santa Fe, NM.
 56. 2006/11: GPR30: a novel target for drug discovery at Lilly Corp., Indianapolis, IN.
 57. 2006/10: GPR30, estrogen and the nervous system at Temple University, Philadelphia, PA.
 58. 2006/10: GPR30 and Estrogen Signaling at The Fox Chase Cancer Center, Philadelphia, PA.

59. 2006/10: GPR30 as a Target for Drug Discovery at IBC's Assays and Cellular Targets, Las Vegas, NV.
60. 2006/09: GPR30 and Estrogen at The International Congress on Hormonal Steroids and Hormones and Cancer, Athens, Greece.
61. 2006/06: GPR30: a G protein-coupled estrogen receptor at The Molecular Steroidogenesis Conference, Boston, MA.
62. 2006/06: GPR30 and Estrogen at The Endocrine Society, Boston, MA.
63. 2006/05: New Concepts in Receptor-G protein Coupling at The Ernst Schering Foundation Symposium on GPCRs: from deorphanization to lead structure identification, Berlin, Germany.
64. 2006/04: A Novel Mechanism of Estrogen Signaling at The Institute for Research in Biomedicine, Bellinzona, Switzerland.
65. 2006/04: GPR30: a Novel Target for Endocrine Disruptors at The Swiss National Research Program on Endocrine Disruptors, Zurich, Switzerland.
66. 2006/03: Virtual and Biomolecular Screening Identify Novel Estrogen Receptor Ligands at Biocomputing @ UNM, Albuquerque, NM.
67. 2006/03: Novel Mechanisms of Estrogen Activity at Pathology Grand Rounds, UNM, Albuquerque, NM.
68. 2006/02: Estrogen-mediated signaling via GPR30 at The Keystone Symposium for G Protein-Coupled Receptors: Evolving Concepts and New Techniques, Keystone, CO.
69. 2005/11: GPR30: a Novel Target for Drug Discovery and Diagnostics at Wyeth Pharmaceuticals, College town, PA.
70. 2005/10: GPR30: a Novel Target for Estrogens at Schering AG, Berlin, Germany.
71. 2005/10: GPCRs and Steroids: New Drug Discovery Targets for Old Ligands? at IBC's Assays and Cellular Targets, Seattle, WA.
72. 2005/07: GPR30: a Novel Target for Estrogens at Berlex Biosciences, Richmond, CA.
73. 2005/06: GPCRs and Steroids: An odd couple? at The Second Messengers & Protein Phosphorylation Gordon Research Conference, Biddeford, ME.
74. 2005/03: Isolation for Compounds Specific to Classical and Novel Steroid Receptors at Biocomputing @ UNM, Albuquerque, NM.
75. 2004: Imaging of GPCR signaling and trafficking at The 2nd New Mexico Workshop on Computational Cell Biology: Microscopy, Membrane Biology and Modeling for Biosignaling Research, Santa Fe, NM.
76. 2004: Novel Regulatory Mechanisms of Chemoattractant Receptors at The Great Lakes G Protein-coupled Receptor Retreat, Chateau Bromont, Quebec.
77. 2003: GPCR Activation in the Absence of Arrestins Induces Cell Death at The Apoptosis Minisymposium of the American Society for Cell Biology, San Francisco, CA.
78. 2003/01: Molecular Mechanisms of Chemoattractant GPCR-arrestin Interactions at The Keystone Symposium: Chemokines and Chemokine Receptors, Breckenridge, CO.
79. 2002: G Protein-Coupled Receptors In Disease and Therapeutics at Pathology Grand Rounds, UNM, Albuquerque, NM.
80. 2002: Molecular Mechanisms of Chemoattractant GPCR-arrestin Interactions at The Japanese Biophysical Society, Nagoya, Japan.
81. 2002: Chemoattractant Receptor-mediated Membrane Remodelling at The 6th Membrane Research Forum, Nagoya, Japan.
82. 2002/11: Molecular mechanisms of chemoattractant GPCR-arrestin interactions

- at The Boehringer Ingelheim GPCR Conference, Tarrytown, NY.
83. 2001: Signaling and Processing Mechanisms of Chemoattractant G Protein-coupled Receptors at Cornell University, New York, NY.
84. 2001: Mechanisms of N-formyl peptide receptor processing at The Phagocyte Gordon Research Conference, New London, CT.
85. 2000: Signaling and Processing Mechanisms of Chemoattractant G Protein-coupled Receptors at The Department of Molecular Genetics and Microbiology, UNM, Albuquerque, NM.
86. 2000: G Protein-coupled Receptors: Biology to Biotechnology at ICOS Pharmaceuticals, Bothel, WA.
87. 1997: Activation of Leukocytes by Chemoattractants at New York Medical College, Valhalla, NY.
88. 1997: Mechanisms of Chemoattractant Receptor Activation at The Cleveland Clinic, Cleveland, OH.
89. 1997: Activation Mechanisms of Chemoattractant GPCRs at The University of Pittsburgh, Pittsburgh, PA.
90. 1997: Mechanisms of GPCR activation at The University of Delaware, Newark, DE.
91. 1996: Signaling by Chemoattractant G protein-coupled Receptors at Oregon Health Science University, Portland, OR.
92. 1994: Regulation of Chemoattractant Receptor Activation at 3M, Minneapolis, MN.

Patents

1. Hall, P., Prossnitz, E. R., Hathaway, H. J. (2016) Inhibition and Treatment of Bacterial Infections by Sex-specific GPER Targeting. N12-294PROV.
2. Prossnitz, E. R. and Sharma, G. (2015) Method for treating obesity and diabetes by activating GPR30/GPER. Patent Pending.
3. Prossnitz, E. R., Barton, M., Meyer, M. R. (2015) Targeting GPR30/GPER for treatment of chronic, non-communicable disease conditions involving excess formation of reactive oxygen species. Patent Pending. (Notice of Allowance Issued).
4. Prossnitz, E. R., Revankar, C. M., Sklar, L. A., Arterburn, J. B., Cimino, D. F., Bologa, C. G., Savchuck, N. P., Tkachenko, S. E., Young, S. M., Edwards, B. S., Oprea, T. I. (2013) Compounds for binding to ERA/b and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof U. S. Patent No. **8,487,100**.
5. Simons, P. C., Sklar, L. A., Prossnitz, E. R., Wandinger-Ness, A., Tessema, M. Z., Reed, J. C., Zhai, D. (2011) Glutathione beads and GST fusion proteins U. S. Patent No. **7,785,900**.
6. Prossnitz, E. R., Revankar, C. M., Sklar, L. A., Arterburn, J. B., Cimino, D. F., Bologa, C. G., Savchuck, N. P., Tkachenko, S. E., Young, S. M., Edwards, B. S., Oprea, T. I. (2011) Compounds for binding to ERA/b and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof U. S. Patent No. **7,875,721**.
7. Sklar, L. A., Prossnitz, E. R., Simons, P. C., Waller, A., Cimino, D. F., Biggs, S.

- (2007) Multiplex Analysis for High Throughput Discrimination of GPCR Agonists and Antagonists. U. S. Patent No. **7,232,659**.
8. Sklar, L. A., Buranda, T., Cimino, D. F., Key, T. A., Neubig, R., Simons, P. C., Prossnitz, E. R., Shi, M. (2007) Bead-based Detection of Ligand-GPCR Protein Complexes. U. S. Patent No. **7,189,519**.
 9. Sklar, L. A., Prossnitz, E. R., Vilven-Roberts, J., Neldon, D. (2006) Display of Receptors and Analysis of Binding Interactions and Drug Libraries. U. S. Patent No. **7,018,846**.
 10. Sklar, L. A., Prossnitz, E. R., Neldon, D., Vilven-Roberts, J. (2006) Display of Receptors and Analysis of Binding Interactions and Drug Libraries. U. S. Patent No. **7,109,041**.

Grant Support

Extramural Grant Support

Current

R01 CA194496 Prossnitz, Arterburn (MPI) 09/07/16-08/31/21
Molecular mechanisms and applications of novel ER/GPER-selective ligands
The goal of this project is to improve upon novel lead compounds that selectively target ER α over GPER.

Role: PI

R01 CA163890 Prossnitz (PI) 09/01/18-08/31/23
G protein-coupled estrogen receptor GPER and breast carcinogenesis
The goal of this project is to identify the roles of GPER in breast carcinogenesis and metastasis.

Role: PI

DCI RF#C-3937 Prossnitz (PI) 10/01/16-09/30/20
Targeting GPER to Prevent and Treat Chronic Kidney Disease
The goal of this project is to characterize the role of GPER in chronic kidney disease.

Role: PI

R01 CA193336 Hathaway (PI) 06/01/15-05/31/21
Is tumor adjacent histologically normal tissue primed for tumorigenesis?
The goal of this project is to establish if breast tissue adjacent to tumors, that is graded as histologically normal, contributes to local recurrence.

Role: co-I

R21 AI128159 Hall (PI) 11/22/16-10/31/18
Sex-dependent phagocyte clearance of *Staphylococcus aureus*
The goal of this proposal is to determine the molecular mechanisms driving sex bias in neutrophil efficacy against *S. aureus*.

Role: co-I

UT2 GM130166 Fanger (PI) 09/01/18-08/31/21
ASCEND, Accelerating Solutions for Commercialization and Entrepreneurial Development in the Mountain West IDeA States
The goal of this project is to foster entrepreneurship and commercialization within the western IDeA states.

Role: co-I

P30 CA118100 Willman (PI) 09/01/15-08/31/20
UNM Comprehensive Cancer Center
Prossnitz is co-Director of the Translational Cancer Biology and Signaling Program.
Role: co-I, Program Director

UL1 TR001449 Larson (PI) 08/14/15-03/28/20
University of New Mexico Clinical and Translational Science Center
Prossnitz is leader of the Team Science and Commercialization Module.
Role: co-I, Module Director

P20 GM121176 Deretic (PI) 09/01/17-08/31/22
Autophagy, Inflammation and Metabolism (AIM) in Disease Center
Prossnitz is Associate Director of this Center to develop junior faculty and institutional resources.
Role: co-I

U54 GM104944 Kumar (PI) 07/01/18-06/30/23
Clinical and Translational Research Infrastructure Network IDEA-CTR
Prossnitz is Associate Director of the Career Development Module focusing on mentoring.
Role: co-I

P20 GM103451 Lusetti (PI) 04/01/14-3/31/19
New Mexico IDEA Networks of Biomedical Research Excellence
Prossnitz serves as UNM Liaison and sub-award PI of this IDeA program-funded INBRE to develop junior faculty and state-wide resources.
Role: co-I

Pending

none

Past

NIH Grant R01, CA163890, 08/01/12-05/31/17. "G protein-coupled estrogen receptor GPER and breast carcinogenesis" Total direct costs: \$1,087,500; (PI: Prossnitz)

NIH Grant R01, CA127731, 08/05/08-05/31/15. "Development of GPR30-specific ligands" Total direct costs: \$1,037,500; (PI: Prossnitz, co-PIs: Arterburn, Oprea)

NIH Grant U54, MH084690, 09/01/08-05/30/12. "University of New Mexico Center for Molecular Discovery" Total direct costs: \$10,800,000; (PI: L. A. Sklar; co-I: Prossnitz)

NIH Grant R01, CA118743, 08/23/07-05/31/10. "The Role of GPR30 in Advanced Endometrial Cancer" Total direct costs: \$570,000; (PI: Prossnitz)

NIH Grant R01, CA116662, 06/08/06-03/31/12. "A Novel Intracellular 7TM Estrogen Receptor in Breast" Total direct costs: \$887,500; (PI: Prossnitz)

NIH Grant U54, MH074425, 03/01/05-02/28/08. "NM Molecular Libraries Screening Center" Total direct costs: \$6,498,603; (PI: L. A. Sklar; co-I: Prossnitz)

NIH Grant R01, GM68901, 04/01/04-03/31/10. "Arrestin Activation Probed with Mass Spectrometry" Total direct costs: \$1,130,000; (PI: Prossnitz)

DoD Breast Cancer Research Program Grant BC033052 07/01/04-06/31/05 "Functional Characterization of a Novel Estrogen-Dependent Signaling Pathway in the Mammary Gland" Total award (direct costs) \$75,000; (PI: H. Hathaway; co-PI: Prossnitz)

NIH Grant R01, AI36357, 07/01/01-06/30/06. "Regulation of Chemoattractant Receptor Activation" Total direct costs: \$1,125,000; (PI: Prossnitz)

NIH Grant R24, GM60799, 09/30/99-09/29/04. "7TMR Drug Discovery, Microfluidics and HT Flow Cytometry" Total direct costs: \$2,525,584; (PI: L. A. Sklar; co-PI: Prossnitz)

UNM Cancer Research and Treatment Center Grant, 09/01/98-06/30/99. "Targeting Somatostatin Receptors in Chemotherapy" Total direct costs: \$28,000; New Mexico State Cowboys for Cancer Research. (PI: Prossnitz)

NIH Grant R01, AI43932, 02/01/98-01/31/05. "Mechanisms of Leukocyte Activation and Chemotaxis" Total direct costs: \$926,000; (PI: Prossnitz)

Grant-in-Aid 96009260, 07/01/96-06/31/99. "Mechanisms of Chemoattractant Receptor Activation" Total direct costs: \$120,000; National Chapter, American Heart Association. (PI: Prossnitz)

NIH Grant R29 AI36357, 08/01/94-07/31/99. "Regulation of Chemoattractant Receptor Activation" Total direct costs: \$350,000; (PI: Prossnitz)

UNM Service:

1999-2000 Governmental Relations Committee Member, UNM
2000-pres. UNM Cancer Center Member
2001-2004 Research Allocation Committee Member, UNM HSC
2001-2004 Biomedical Sciences Graduate Program Steering Committee Member, UNM HSC
2002-2004 Dean's Science Advisory Council Member, UNM SOM
2006-2009 UNM Conflict of Interest Committee C Member, UNM HSC
2006-2009 Promotion and Tenure Committee Member, UNM SOM
2006-pres. Human Tissue Repository Scientific Review Committee, Member
2007-pres. MD-PhD Admissions and Oversight Committee Member, UNM SOM
2008-2013 Co-Director, Women's Cancers Program, UNM Cancer Center
2009-2013 Chair, UNM Conflict of Interest Committee, UNM HSC
2011-2015 Director, Novel Translational and Clinical Methods, UNM CTSC
2013-2018 Vice-Chair, UNM HSC Conflict of Interest Committee, UNM HSC

- 2013-2018 Chair, UNM Management of Conflict of Interest Committee, UNM HSC
- 2013-pres. Co-Director, Translational Cancer Biology & Signaling Program, UNM Comprehensive Cancer Center
- 2015-pres. Director, Team Science and Commercialization, UNM CTSC

Teaching/Education

Mentored Faculty

- Christina Salas, Ph.D. Assistant Professor, Department of Orthopedics and Rehabilitation, University of New Mexico
2018-present
- Andrey Dobroff, Ph.D. Assistant Professor, Department of Internal Medicine, University of New Mexico
2017-present
- W. Curtis Hines, Ph.D. Assistant Professor, Department of Biochemistry and Molecular Biology, University of New Mexico
2016-present
- Fu-Shen Liang, Ph.D. Assistant Professor, Department of Chemistry, University of New Mexico
2015-2018 (NM-INBRE)
- Rama Gullapali, M.D. Assistant Professor, Department of Pathology, University of New Mexico
2015-present (NM-INBRE)
- Kevin Houston, Ph.D. Assistant Professor, Department of Chemistry and Biochemistry, New Mexico State University
2014-present (NM-INBRE)
- Meilian Liu, Ph.D. Assistant Professor, Department of Biochemistry and Molecular Biology, University of New Mexico
2014-present (AIM CoBRE, R01 DK110439, awarded 2017)
- Yubin Miao, Ph.D. Assistant/Associate Professor, College of Pharmacy, University of New Mexico
2008-2014 (NCI R01 CA225837, awarded 2018)
- Donghai Dai, Ph.D. Research Assistant Professor, University of New Mexico
2003-2009 (ACS grant, awarded 2006)
- John Engen, Ph.D. Assistant Professor, Dept. of Chemistry, University of New Mexico
2002-2005 (NIH R01 mentor, awarded 2004)
- Tione Buranda, Ph.D. Research Associate Professor, University of New Mexico

1999-2009 (NIH K25 mentor, awarded 2004)

Graduate Student Supervision

Doctorate Program

1999-2002 T. Alexander Key Biomedical Sciences Graduate Program
1999-2005 Ross M. Potter, Biomedical Sciences Graduate Program (Gies fellowship)
2002-2006 Brant Wagener, UNM School of Medicine MD/PhD student (IDIP T32 AI07538, DoD BCRP predoctoral fellowship)
2002-2005 Jennifer Carter, Dept. of Chemistry (co-advisor)
2003-2006 Sean Biggs, Biomedical Sciences Graduate Program (CV T32 HL007736)
2004-2010 Angela Field, Biomedical Sciences Graduate Program (CV T32 HL007736)
2004-2008 Tapan Nayak, Biomedical Sciences Graduate Program/Radiopharmacy
2005-2008 Whitney Petrie, Biomedical Sciences Graduate Program
2005-2010 Megan Dennis, Biomedical Sciences Graduate Program
2007-2013 Allison Scaling, Biomedical Sciences Graduate Program (co-mentor)
2007-2014 Sara Alcon, Biomedical Sciences Graduate Program (co-mentor)
2008-2011 Ryan Brunsing, UNM School of Medicine MD/PhD student (IDIP T32 AI07538; NIH F30 pre-doctoral fellowship)
2008-2012 Nicole Marjon, UNM School of Medicine MD/PhD student (CV T32 HL007736; DoD BCRP pre-doctoral fellowship)
2009-2014 Erin Zekas, Biomedical Sciences Graduate Program (STMC fellowship)
2012-2015 Natalie Fredette, Biomedical Sciences Graduate Program (CV T32 HL007736)
2015-pres. Richard Pepermans, Biomedical Sciences Graduate Program

Thesis Committee Member

Terri L Gilbert, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 1999.
Liz Gaudet, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2001.
Alex Smith, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2002.
Becky Carter, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2002.
Valerie Hernandez, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2004.
Margaret Gibson, Ph.D. Program, Biomedical Sciences Graduate Program. 2001-2004.
Olena Barbash, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2004.
Sanchita Krishna, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2005.
Alex Davis, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2007.
Christine Haaland, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2008.
Canhong Cao, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2008.
Lawrence Tafoya, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2008.
Robin Simons, MS Chemical Engineering, Graduated 2008
Sergio De Haro, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2011.
Zoe Hunter, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2011.
Allison Scaling, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2013.
Sara Alcon, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2014.
Jacob Agola, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2011.

Soumik Basuray, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2013.
 Shanya Jiang, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2014.
 Adam Flook, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2014.
 Ray Kenney, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2015.
 Amanda Peretti, Ph.D. Program, Biomedical Sciences Graduate Program. Graduated 2016.
 Chelsea Saito-Reis, Ph.D. Program, Biomedical Sciences Graduate Program. 2015-present.
 Srijana Pokhrel, Ph.D. Program, Biomedical Sciences Graduate Program. 2016-present.

Classroom Teaching/Tutoring

1998 Medical School Tutor (Molecular Genetics)
 1999-2003 Advanced Cell Biology (Signal Transduction Block Director)
 1999-2003 Advanced Molecular Biology (Protein Structure/Function Block Director)
 1999 Medical School Tutor (Human Sexuality and Reproduction)
 2000-2014 Signal Transduction, Adhesion and Trafficking Journal Club (co-Director)
 2001 Medical School Tutor (Human Sexuality and Reproduction)
 2001 Medical School Lecturer (Human Structure, Function and Development)
 2004 Medical School Tutor (Human Sexuality and Reproduction)
 2004-2018 Experimental Design and Methods in Molecular and Cellular Biosciences (Course Director)
 2009-2013 Ethics in Science (Lecturer)
 2014-2016 MSCR program: Current and Emerging Technologies (Course Director)
 2015-pres. Cancer Biology (Block Director)
 2015-pres. Biodesign (Course co-Director)

Post-doctoral Advisor

Matthew H. Hsu, Ph.D., 1996-1997. Currently: Senior Scientist, Neurocrine Biosciences, San Diego CA
 Susan Jones-Bolin, DVM, Ph.D. 1998-1999. Currently: Senior Scientist, Cephalon Inc., Philadelphia, PA
 Terri L. Gilbert, Ph.D. 1999-2000. Currently: Scientist, Allen Brain Institute, Seattle, WA
 Teresa A. Bennett, Ph.D. 1999-2002. Currently: Senior Scientist, Novasite Pharmaceuticals, San Diego CA
 Mei Shi, MD, Ph.D. 2001-2002.
 Charlotte M. Vines, Ph.D. 2000-2004. (IDIP T32 AI07538, NIH K22). Currently: Assistant Professor, University of Texas at San Antonio
 Mei Xue, MD, Ph.D. 2002-2005
 Chetana Revankar, Ph.D. 2002-2006. Currently: Senior Scientist, Invitrogen Drug Discovery, Madison, WI
 Hugh Mitchell, Ph.D. 2004-2008. Currently: Scientist, Pacific Northwest National Lab
 Matthias Meyer, MD 2011-2013. Currently: Cardiology Resident, Switzerland
 Geetanjali Sharma, Ph.D. 2008-pres. Currently: UNM staff researcher
 Christine D. Woods, Ph.D. (ASERT fellow) 2016-present

Curriculum development

1999-2003 Advanced Cell Biology (Signal Transduction Block Director)
 1999-2003 Advanced Molecular Biology (Protein Structure/Function Block Director)

2001-2003	Medical School Lecturer (Human Structure, Function and Development)
2004-2018	Experimental Design and Methods in Molecular and Cellular Biosciences (Course director)
2015-pres.	Cancer Biology (Block Director)
2015-pres.	Biodesign (Course co-Director)





CAPITAL PROJECT APPROVAL UNM HOSPITALS – UPC – PES RENOVATION

JANUARY 2019

REQUESTED ACTION:

As required by Section 7.12 of Board of Regents Policy Manual, the New Mexico Higher Education Department and the New Mexico State Board of Finance, capital project approval is requested for UPC – PES RENOVATION. For the project described below, UNM Hospitals requests the following actions, with action requested only upon requisite sequential approval and recommendation by any and all committees and bodies:

- Board of Trustee Finance Committee approval of and recommendation of approval to the UNMH Board of Trustees.
- UNMH Board of Trustees approval of and recommendation of approval to the UNM Board of Regents HSC Committee.
- UNM Board of Regents HSC Committee approval and recommendation of approval to the UNM Board of Regents.
- UNM Board of Regents approval

DESCRIPTION:

Remodel of the existing Psychiatric Emergency Services (PES) at the UNM Psychiatric Center (UPC) for expansion of services which includes select program requests per Bernalillo County as follows:

1. Provide a clear separation between adult and pediatric patient populations.
2. Addition of observation room with four (4) adult recliners, and two (2) pediatric patient rooms while maintaining existing flexible patient room, and six (6) patient rooms.
3. Separated restrooms provided for adult patients, pediatric patients, and staff.
4. Expanded observation area with recliners to accommodate adult patients.
5. Interior padded sally port with law enforcement access to include decontamination area.
6. Additional support areas include soiled workroom, patient storage, and medication room.
7. Secured, interior vestibule for patient/visitors screening prior to entering lobby area.
8. Larger registration area with secluded staff access into area.

RATIONALE:

Psychiatric Emergency Services (PES) provides assessment and disposition of patients seeking emergent behavioral health services. Monthly, PES provides care to an average of 650 Adults and 100 Pediatric patients. Currently, PES will serve up to 21 Adult and 4 Pediatric patients with a peak total of 35 patients. These services may include medication administration, vital signs every shift, drug screening, prescriptions for psychotropic medications, crisis counseling, referrals to other support or treatment agencies, or admission to the UNM Psychiatric Center and Children's Psychiatric Center inpatient programs.

Currently, PES contains six patient rooms without providing separation of adult and pediatric patient rooms or restrooms. Proposed separation of patient populations with centralized staff increases safety. The remodel would double the capacity of PES, increase throughput, providing additional community behavioral health services and support. Flexible patient rooms provide additional space to meet adult and pediatric patient demand. The interior sally port with a decontamination area, allows for smooth transition from law enforcement to PES decreasing potential physical harm and infection exposure. The interior vestibule provides an interior screening area for patients/visitors prior to entering common areas of facility.

Patient activity in PES has increased by 80% from FY15 to FY18 and is expected to increase further in FY19. The remodel proposed is expected to allow for improved patient safety and satisfaction. It is expected to allow the PES to accommodate continued growth in a more efficient and effective environment.

PURCHASING PROCESS:

The architectural firm, Dekker Perich Sabatini was hired to provide design utilizing professional services RFP awarded for design of behavioral health facilities. Design documents will be submitted via RFP for qualified public contractors to competitively bid.

FUNDING:

The total project construction budget is estimated at and shall not exceed \$1,300,000. This will be funded over two fiscal years via the UNM Hospital Capital Renovation Fund. Expenditures are expected to be \$500,000 in FY19 and \$800,000 in FY20.



CAPITAL PROJECT APPROVAL

UNM HOSPITALS – UPC – ADULT INPATIENT – INPATIENT BHICU, COMFORT ROOMS

JANUARY 2019

REQUESTED ACTION:

As required by Section 7.12 of Board of Regents Policy Manual, the New Mexico Higher Education Department and the New Mexico State Board of Finance, capital project approval is requested for UPC – Adult Inpatient – Inpatient BHICU, Comfort Rooms. For the project described below, UNM Hospitals requests the following actions, with action requested only upon requisite sequential approval and recommendation by any and all committees and bodies:

- Board of Trustee Finance Committee approval of and recommendation of approval to the UNMH Board of Trustees.
- UNMH Board of Trustees approval of and recommendation of approval to the UNM Board of Regents HSC Committee.
- UNM Board of Regents HSC Committee approval and recommendation of approval to the UNM Board of Regents.
- UNM Board of Regents approval

DESCRIPTION:

Remodel of existing adult inpatient behavioral health units at the UNM Psychiatric Center (UPC). The scope of work includes a phased renovation of the East and West inpatient units to include the following:

1. Provide the following spaces/functions on each Unit.
 - a. Behavioral Intensive Care patient room with visibility from the nurse station
 - b. Comfort room (Sensory Room) as an alternative to seclusion and restraint.
 - c. ADA compliant toilet room
 - d. Nurse station remodel
 - e. Treatment room with direct access off the main corridor
 - f. Dirty and clean utility rooms
 - g. Housekeeping closet (separate from existing electrical infrastructure)
2. Displaced Services in Unit
 - a. Clinician offices will be provided in the Atrium in lieu of displacement within the units due to modifications. Maintained area provided for patient activities.

RATIONALE:

The scope of work includes a phased renovation of the East and West Inpatient Units. The inpatient service provided has a total of 32 adult psychiatric beds divided between 2 units. This is a safety net hospital for acutely ill psychiatric patients most of whom have chronic psychiatric illness. Some of these patients are highly aggressive and may be on street drugs. The average rate of stay is seven days with an 85% occupancy rate.

There are currently no private rooms within the units, making milieu management very difficult at times. Addition of a behavioral health intensive care room with nurse station visibility provides a private space for patients with high acuity and aggressiveness to recover in a less restrictive space, while also keeping other patients on the unit safe. This area would include a bathroom and space for eating and relaxing. Providing a comfort room within each unit allows patients a place for voluntary respite. The addition of ADA compliant restroom and shower provides increased accessibility within units. Nurse station improvements provide for increased staff interaction and patient satisfaction within the units. Providing a treatment room with direct access to the corridor increases staff safety with the process of admitting a patient and physical exams. Removal of non-required office space within the units provides expanded space for development of patient and support areas.

The current housekeeping closet does not meet code having a floor sink within 3 feet of an electrical panel. Separating the electrical panel from the housekeeping closet will bring the room to code compliance.

This proposed remodel is expected to create a better clinical environment for staff and providers and to increase patient satisfaction.

PURCHASING PROCESS:

The architectural firm, Dekker Perich Sabatini was hired to provide design utilizing professional services RFP awarded for design of behavioral health facilities. Design documents will be submitted via RFP for qualified public contractors to competitively bid.

FUNDING:

The total project construction budget is estimated at and shall not exceed \$1,400,000. This will be funded over two fiscal years via the UNM Hospital Capital Fund. Expenditures are estimated at \$500,000 in FY19 and \$900,000 in FY20.



CAPITAL PROJECT APPROVAL
UNM HOSPITALS – UH MAIN – FIRE ALARM SYSTEM

JANUARY 2019

REQUESTED ACTION:

As required by Section 7.12 of Board of Regents Policy Manual, the New Mexico Higher Education Department and the New Mexico State Board of Finance, capital project approval is requested for UH Main – Fire Alarm System. For the project described below, UNM Hospitals requests the following actions, with action requested only upon requisite sequential approval and recommendation by any and all committees and bodies:

- Board of Trustee Finance Committee approval of and recommendation of approval to the UNMH Board of Trustees.
- UNMH Board of Trustees approval of and recommendation of approval to the UNM Board of Regents HSC Committee.
- UNM Board of Regents HSC Committee approval and recommendation of approval to the UNM Board of Regents.
- UNM Board of Regents approval

DESCRIPTION:

Replace the existing fire alarm system with a new, up-to-date, and code compliant system.

RATIONALE:

The existing fire alarm at UH-Main is past its effective use lifespan. Some portions of the system are 1970s vintage and no longer have manufacturer support or replacement parts.

The replacement system will make the UH-Main hospital and surrounding buildings safer for staff, patients, and visitors. The system will have current technology for detecting fires and smoke early, alerting the building occupants that could have visual or hearing impairments, and performing other automated actions with the HVAC system that would not be possible with the current system.

PURCHASING PROCESS:

This procurement is being made under UNM Hospital's price agreement with vendor PLTi (Power Line Technologies), awarded under UNM Hospital's RFP 367-17, Fire Alarm Design, Installation, Maintenance, and Repair.

FUNDING:

The total project is estimated at and shall not exceed \$1,500,000. This will be funded over three fiscal years (FY19 – FY21) via the UNM Hospital Capital Fund.



CAPITAL PROJECT APPROVAL

UNM HOSPITALS –UH Main Roof Replacement- Sections 10 & 11

January 2019

REQUESTED ACTION:

As required by Section 7.12 of Board of Regents Policy Manual, the New Mexico Higher Education Department and the New Mexico State Board of Finance, capital project approval is requested for **UH Main Roof Replacement- Sections 10 & 11**. For the project described below, UNM Hospitals requests the following actions, with action requested only upon requisite sequential approval and recommendation by any and all committees and bodies:

- Board of Trustee Finance Committee approval of and recommendation of approval to the UNMH Board of Trustees.
- UNMH Board of Trustees approval of and recommendation of approval to the UNM Board of Regents HSC Committee.
- UNM Board of Regents HSC Committee approval and recommendation of approval to the UNM Board of Regents.
- UNM Board of Regents approval

DESCRIPTION:

This project includes replacement of a portion of the western area of the roof (Section 10 which is over Tri-Core Labs) and the upper mechanical penthouse roof (Section 11). The project will consist of the removal of the existing roofing membrane and all its components down to concrete deck and installation of new 60 mil TPA (tri-polymer alloy) thermoplastic single ply roof system over tapered insulation.

RATIONALE:

The roof has had several temporary patch repairs is past its life expectancy. The existing membrane has stretched to the point of imminent failure.

PURCHASING PROCESS:

Construction firms were invited to competitively bid by Weatherproofing Technologies, Inc. WTI Vizient contract number CE0360. Notice to Proceed has not been issued. The construction contract is anticipated to be completed by June 30, 2019.

FUNDING:

The total project budget is estimated at \$979,242 and will be funded by the UNM Hospital Capital Fund.



CAPITAL PROJECT APPROVAL

Modern Medical Facility Construction Program Management Services

January 2019

RECOMMENDED ACTION:

As required by Section 7.12 of the Board of Regents Policy Manual, the New Mexico Higher Education Department and the New Mexico State Board of Finance, capital project approval is requested for the contracting of Broaddus & Associates for construction program management services.

PROJECT DESCRIPTION:

UNM Hospital plans to construct an addition to the current hospital that would contain diagnostic and treatment services, surgical suites, and inpatient care rooms. This request is specific to the program services required prior to and during construction.

RATIONALE:

Program management firms serve as the owner's representative during large or complex construction projects. This service is critical for the continuation of the additional hospital tower in terms of supplementing the Hospital's planning and facilities during the construction phase as well as serving as overall coordination of the project. The program management firm will be responsible for pre-construction services to include team selection, program, design and permitting, preconstruction coordination, and will assist management with contract selection/negotiation and vendor procurement.

PURCHASING PROCESS:

Competitive sealed RFP process

FUNDING:

The total project quoted budget is \$6,789,262 and will be funded by the UNM Hospital Capital Initiative Funds or HUD guaranteed financing, as appropriate.



CAPITAL PROJECT APPROVAL

Modern Medical Facility Architectural and Engineering Services

January 2019

RECOMMENDED ACTION:

As required by Section 7.12 of the Board of Regents Policy Manual, the New Mexico Higher Education Department and the New Mexico State Board of Finance, capital project approval is requested for the contracting of an architectural firm to provide schematic design, design development and construction documents and construction administration for the modern medical tower.

PROJECT DESCRIPTION:

UNM Hospital plans to construct an addition to the current hospital that would contain diagnostic and treatment services, surgical suites, and inpatient care rooms. This request is specific to the second phase of architectural services required prior to construction.

RATIONALE:

In 2015, UNMH retained HDR Architecture, Inc. and FBT Architects to prepare a Replacement Hospital Master Development Plan for a 408-Bed Adult Acute Care Hospital. The scope of work comprises a full-service planning solution including: Facility Space Planning; Room-by-Room Space and Equipment Program; Massing Studies, Phased Implementation and Conceptual Renderings as well as Documentation and Graphics. Health Science Center and UNMH leaders continue to evaluate options to modernize and improve the UNMH care delivery platform. Given the recent availability of the UNM Physics building space located just west of UNMH, management re-evaluated this location with HDR and FBT as a possibility for constructing a modern medical addition. This request will continue and add to the work completed in 2015 leading to the construction process.

PURCHASING PROCESS:

Competitive sealed RFP process completed in 2018.

FUNDING:

The total project quoted budget is \$33,858,800 and will be funded by the UNM Hospital Capital Initiative Funds or HUD guaranteed financing, as appropriate.



To: Members of the Board of Regents' Finance & Facilities Committee

From: Eddie Nunez, Director of Athletics
Nicole Dopson, Director of Financial Operations for Academic Affairs

Date: February 5, 2019

Re: Approval of the FY19 Second Quarter Submission to Higher Education Department for the Enhanced Fiscal Oversight Program (EFOP)

In order to respond to concerns brought by the New Mexico Higher Education Department (NMHED), the University has agreed to provide the attached Enhanced Fiscal Oversight Program (EFOP) Report. This report will be provided in addition to the Quarterly Financial Actions Report and Certification that are already required for all higher education institutions.

The report will provide Athletics financial status through reporting templates provided by the Higher Education Department for the Athletics budget exhibits as well as a template for the plan associated with resolving the overall deficit within Athletics budget.

The EFOP report will accompany the report submitted by the Controller's Office until NMHED is satisfied with the University's progress on these issues.

Thank you for your consideration.

NEW MEXICO HIGHER EDUCATION DEPARTMENT



SUSANA MARTINEZ
GOVERNOR

DR. BARBARA DAMRON
CABINET SECRETARY

Subject: New Mexico Higher Education Department
Enhanced Fiscal Oversight Program Designation

Date: October 3, 2017

To: Dr. Chaouki T. Abdallah, President
University of New Mexico

From: Dr. Barbara Damron, Cabinet Secretary
New Mexico Higher Education Department

Dear President Abdallah,

This letter serves as formal notice that the New Mexico Higher Education Department (NMHED), exercising the authority provided pursuant to 21-1-26 NMSA, has placed the University of New Mexico (UNM) under an Enhanced Fiscal Oversight Program (EFOP). The designation is a result of the following recent concerns:

- The most recently submitted Report of Actuals shows the Athletics budget deficit, as reported in Budget Exhibit 21, has increased to (\$4.7 million) for Fiscal Year 2017;
- Significant differences between the deficit budgeted and approved by the UNM Regents, NMHED, and the Department of Finance and Administration (DFA), and the actual deficit reported from FY2011 through FY2017;
- Salaries, benefits and transfers in Exhibit 21A have consistently exceeded budgeted amounts and continue to compound net losses; and
- Scrutiny of UNM Athletics by other parties including the State Auditor's Office and the Legislature require the Department to enact its due diligence and conduct additional fiscal oversight of the UNM Athletics Program.

As such, we will be requesting a meeting with you, Regent President Robert Doughty, Vice President of Finance David Harris, and Athletic Director Eddie Nuñez as part of our continued communication efforts. Items to be discussed include reporting requirements and the establishment of a timeline to remove the structural deficit within the Athletics budget. In addition to the quarterly financial reports that all institutions are required to submit, the following information will be discussed and subsequently required on a quarterly basis:

- Establishment and subsequent status of the payment plan to remove the deficit within the Athletics budget;
- Quarterly reporting of the UNM Athletics financial status through reporting templates provided by NMHED in addition to Budget Exhibits 21, 21a, *et seq.*; and
- Governing Board Meeting Agendas and Minutes (submitted monthly).

The EFOP requirements shall remain in place until further notice. Institutional Auditor Scott Eccles will be making contact with you shortly to schedule a date and time to meet. If you or your staff have any questions, please feel free to contact NMHED Institutional Finance Director Dr. Harrison Rommel at Harrison.Rommel@state.nm.us and include Institutional Auditor Scott Eccles at Scott.Eccles@state.nm.us.

Sincerely,

A handwritten signature in blue ink, appearing to read "Barbara Damron", with a long, sweeping horizontal line extending to the right.

Barbara Damron, PhD, RN, FAAN
NMHED Cabinet Secretary

cc: Robert Doughty III, UNM Regent
David Harris, UNM Vice President of Finance and Administration
Eddie Nuñez, UNM Athletics Director
Hector Balderas, Attorney General
Tim Keller, State Auditor
David Abbey, LFC Director
Travis Dulany, LFC Fiscal Analyst
Duffy Rodriguez, DFA Cabinet Secretary
Cinthia Martinez, State Budget Division Principal Analyst
Leila Burrows, SBOF Deputy Director
Andrew Jacobson, NMHED Deputy Cabinet Secretary
Jeneva LiRosi, NMHED General Counsel
Dr. Harrison Rommel, NMHED Finance Director
Scott Eccles, NMHED Institutional Auditor
Debbie Garcia, NMHED Senior Budget Analyst



Exhibit 21 - UNM MAIN Campus
Summary of Intercollegiate Athletics

		Original Approved Budget 2019				Actuals Quarter 1 - FY19				Actuals Quarter 2 - FY19				Actuals Quarter 3 - FY19				Actuals Quarter 4 - FY19				Increase / Decrease YTD			
		FTE	Unrestricted	FTE	Restricted	FTE	Unrestricted	FTE	Restricted	FTE	Unrestricted	FTE	Restricted	FTE	Unrestricted	FTE	Restricted	FTE	Unrestricted	FTE	Restricted	FTE	Unrestricted	FTE	Restricted
Revenues	Tuition and Fees		3,681,708		0		1,936,355		0		0												1,745,353		0
	State Appropriations		2,641,500		0		666,500		0		654,300												1,320,700		0
	Federal Grants and Contracts		0		30,601		0		0		0												0		30,601
	State Grants and Contracts		0		25,500		0		0		0												0		25,500
	Private Gifts Grants and Contracts		0		0		0		0		0												0		0
	Sales and Services		10,173,679		0		1,915,790		0		3,075,432												5,182,457		0
	Other Sources		14,726,056		0		3,001,828		0		4,126,012												7,598,216		0
	Total Revenues		31,222,943		56,101		7,520,474		0		7,855,744		0		0		0		0		0		15,846,725		56,101
Beginning Balance	Beginning Balance		(4,713,999)				(4,492,380)				(4,635,846)												4,414,227		0
Total Available																							20,260,952		56,101
Expenditures	Administrative Professional	92.00	9,131,345		0		2,369,423		0		2,389,425											92.00	4,372,497	0.00	0
	Faculty Salaries		5,000		0		1,000		0		1,500											0.00	2,500	0.00	0
	Federal Workstudy Salaries		0	2.00	30,601		0		0		0											0.00	0	2.00	30,601
	GA TA RA PA Salary	8.00	246,854		0		58,933		0		68,883											8.00	119,038	0.00	0
	Other Salaries	49.00	1,482,092		0		82,163		0		160,252											49.00	1,239,676	0.00	0
	State Workstudy Salaries		0	1.00	25,500		0		0		259											0.00	(259)	1.00	25,500
	Student Salaries	1.00	19,000		0		8,408		0		13,812											1.00	(3,220)	0.00	0
	Support Staff Salary	3.00	114,999		0		17,892		0		17,646											3.00	79,461	0.00	0
	Technician Salary	8.00	273,554		0		66,872		0		90,790											8.00	115,893	0.00	0
	Accrued Annual Leave		0		0		0		0		0												0		0
	Fica		655,476		0		140,766		0		129,672												385,038		0
	Group Insurance		954,374		0		165,157		0		186,914												602,302		0
	Medicare		22,657		0				0		0														0
	Other Staff Benefits		364,479		0		88,146		0		90,258												186,076		0
	Retirement		1,185,134		0		275,804		0		275,338												633,992		0
	Tuition Waivers		78,500		0		43,888		0		1,102												33,510		0
	Unemployment Compensation		5,980		0		1,776		0		1,862												2,342		0
	Workers Compensation		5,043		0		2,688		0		2,542												(187)		0
	Charge Inst. Support		0		0		32,750		0		32,750												(65,500)		0
	Contract Services		1,847,860		0		259,561		0		313,616												1,274,684		0
	Cost of Good Sold		550		0		0		0		0												550		0
	Electricity		330,000		0		62,898		0		83,509												183,593		0
	Equipment		221,669		0		61,827		0		47,551												112,290		0
	Fuel Heat Cool		60,870		0		609		0		10,654												49,607		0
	Officials Expense 63T3		594,250		0		7,040		0		184,855												402,355		0
	Services		0		0		0		0		0												0		0
	Sewer Other		182,800		0		26,364		0		38,930												117,506		0
	Student Awards and Aid		4,750,000		0		2,226,796		0		497,140												2,026,064		0
	Supplies Expense		6,543,784		0		1,661,058		0		2,449,266												2,433,460		0
	Travel		182,500		0		9,269		0		34,282												138,949		0
	Travel-Group		2,814,700		0		854,145		0		1,064,915												895,641		0
	Travel-Recruiting		812,777		0		153,515		0		200,538												458,724		0
	Internal Service Ctr		0		0		(57,070)		0		(208,415)												265,486		0
	Internal Sales		0		0		0		0		0												(636,895)		0
Total Expenditures		161.00	32,886,247	3.00	56,101	0.00	8,621,676	0.00	0	0.00	8,179,844	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	161.00	16,062,070	3.00	56,101
Transfers (IN) or OUT	Transfers (IN) or OUT		(1,663,304)				(957,737)				(68,672)														
Ending Balance			(4,713,999)				(4,635,846)				(4,891,274)				0		0		0				4,835,777		

Exhibit 21a - UNM
MAIN Campus - Detail

Budget Unit 350 - Administration

		Original Budget 2019		Actuals Quarter 1 - FY19		Actuals Quarter 2 - FY19		Actuals Quarter 3 - FY19		Actuals Quarter 4 - FY19		Increase / Decrease YTD	
		FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted
Revenues	Tuition and Fees		3,681,708		1,936,355		-						1,745,353
	State Appropriations		2,641,500		666,500		654,300						1,320,700
	Private Gifts Grants and Contracts		-		-		-						-
	Sales and Services		3,589,879		450,929		631,950						2,507,000
	Other Sources		4,479,635		3,001,684		4,126,156						(2,648,205)
Total Revenues		-	14,392,722	-	6,055,468	-	5,412,406	-	-	-	-		2,924,848
Beginning Balance			(4,713,999)		(3,865,512)		(647,296)		-		-		(201,191)
Total Available			9,678,723		2,189,956		4,765,110		-		-		2,723,657
Expenditures	Administrative Professional	31.50	2,292,949		528,067		506,877					31.50	1,258,005
	Faculty Salaries	0.06	5,000		1,000		1,500					0.06	2,500
	Federal Workstudy Salaries		-		-		-					-	-
	GA TA RA PA Salary	6.68	204,721		33,464		36,696					6.68	134,561
	Other Salaries	40.08	764,020		62,633		72,109					40.08	629,278
	State Workstudy Salaries		-		-		259					-	(259)
	Student Salaries	0.52	10,000		7,407		12,149					0.52	(9,556)
	Support Staff Salary	2.00	78,780		9,907		7,255					2.00	61,618
	Technician Salary	7.75	273,554		65,197		86,074					7.75	122,283
	Accrued Annual Leave		-		-		-					-	-
	Fica		199,993		42,628		41,672					-	115,693
	Group Insurance		297,244		64,925		75,924					-	156,395
	Other Staff Benefits		111,369		24,733		24,537					-	62,099
	Retirement		363,387		88,996		79,643					-	194,748
	Tuition Waivers		58,500		30,045		-					-	28,455
	Unemployment Compensation		1,830		467		471					-	892
	Workers Compensation		1,568		957		623					-	(12)
	Charge Inst. Support		-		32,750		32,750					-	(65,500)
	Contract Services		1,393,210		233,789		147,064					-	1,012,357
	Cost of Good Sold		550		-		-					-	550
	Electricity		330,000		-		-					-	330,000
	Equipment		70,844		6,206		12,747					-	51,891
	Fuel_Heat_Cool		60,000		-		-					-	60,000
	Officials Expense 63T3		23,000		280		5,600					-	17,120
	Services		-		-		-					-	-
	Sewer_Other		175,000		543		-					-	174,457
	Student Awards and Aid		4,750,000		2,200,046		(1,756,458)					-	4,306,412
	Supplies_Expense		4,116,530		1,143,025		1,430,639					-	1,542,866
	Travel		65,450		1,759		15,518					-	48,173
	Travel-Group		221,500		68,857		39,713					-	112,930
	Travel-Recruiting		187,027		2,775		-					-	184,252
	Internal Service Ctr Internal Sales		-		(13,692)		(1,692)					-	15,384
Total Expenditures		88.59	16,056,026	-	4,636,764	-	871,670	-	-	-	-	88.59	10,547,592
Transfers (IN) or OUT	Trsfr From Auxiliaries		-		-		-					-	-
	Trsfr From Endowments		(789,039)		-		-					-	(789,039)
	Trsfr From I G		(254,100)		(213,528)		(13,524)					-	(27,048)
	Trsfr From Plant Fund Minor		(774,000)		(774,000)		-					-	-
	Trsfr From Public Service		-		-		-					-	-
	Trsfr To Athletics		-		-		-					-	-
	Trsfr To Auxiliaries		-		-		-					-	-
	Trsfr To Debt Service		56,423		14,106		14,106					-	28,211

Trsfr To I G	-	2,405	-	-	-	(2,405)
Trsfr To Plant Fund Minor	-	5,868	-	-	-	(5,868)
Trsfr To Student Aid	-	-	-	-	-	-
Trsfr To Student Social Cultural	97,412	97,412	-	-	-	-
Total Transfers (IN) or OUT	- (1,663,304)	- (867,737)	- 582	- -	- -	(796,149)

Ending Balance		(4,713,999)		(1,579,071)		3,892,858		-		-		(7,027,786)	
Budget Unit 351 - Basketball													
		FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted		
Revenues	Sales and Services		3,800,000		7,421		1,621,490						2,171,089
	Other Sources		-		145		(145)						-
Total Revenues			3,800,000		7,566		1,621,345		-		-		2,171,089
Beginning Balance			-		-		-		-		-		-
Total Available			3,800,000		7,566		1,621,345		-		-		2,171,089
Expenditures	Administrative Professional	8.00	1,414,965		494,164		478,479					8.00	442,322
	Other Salaries		544,172		-		22,961					-	521,211
	Student Salaries	0.47	9,000		1,001		1,664					0.47	6,335
	Support Staff Salary		-		-		337					-	(337)
	Technician Salary		-		60		613					-	(673)
	Fica		73,437		16,880		14,567					-	41,990
	Group Insurance		109,148		12,127		13,838					-	83,183
	Other Staff Benefits		40,895		11,299		11,090					-	18,506
	Retirement		133,435		26,476		26,835					-	80,124
	Unemployment Compensation		672		346		352					-	(26)
	Workers Compensation		576		316		577					-	(317)
	Contract Services		153,040		70		25,447					-	127,523
	Equipment		2,650		3,167		391					-	(908)
	Officials Expense 63T3		152,500		-		-					-	152,500
	Sewer_Other		-		-		-					-	-
	Student Awards and Aid		-		8,750		121,673					-	(130,423)
	Supplies_Expense		659,010		54,273		113,081					-	491,656
	Travel		26,500		898		2,121					-	23,481
	Travel-Group		360,000		-		141,383					-	218,617
	Travel-Recruiting		120,000		36,101		34,981					-	48,918
	Internal Service Ctr Internal Sales		-		-		(185,681)					-	185,681
Total Expenditures		8.47	3,800,000	-	665,928	-	824,709	-	-	-	-	8.47	2,309,363
Transfers (IN) or OUT	Trsfr From I G						-						-
	Trsfr From Plant Fund Minor				(90,000)		(29,479)						119,479
Ending Balance			-		(568,362)		826,115		-		-		(257,753)
Budget Unit 352 - Football													
		FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted
Revenues	Sales and Services		2,300,000		1,424,390		561,005						314,605
	Other Sources		3,971,415				-						3,971,415
Total Revenues			6,271,415		1,424,390		561,005		-		-		4,286,020
Beginning Balance			-		-		-		-		-		-
Total Available			6,271,415		1,424,390		561,005		-		-		4,286,020
Expenditures	Administrative Professional	13.00	2,503,452		635,159		630,382					13.00	1,237,911
	GA TA RA PA Salary	1.38	42,133		17,669		20,386					1.38	4,078
	Other Salaries	3.67	70,000		11,167		35,429					3.67	23,404
	Student Salaries		-		-		-					-	-
	Support Staff Salary		-		114		181					-	(295)
	Technician Salary		-		630		2,185					-	(2,815)
	Accrued Annual Leave		-		-		-					-	-
	Fica		160,914		32,740		21,587					-	106,587
	Group Insurance		239,162		33,071		37,740					-	168,351
	Other Staff Benefits		89,607		22,830		22,690					-	44,087

Retirement	292,380	60,578	60,998	-	170,804
Tuition Waivers	20,000	11,234	1,102	-	7,664
Unemployment Compensation	1,472	453	468	-	551
Workers Compensation	1,262	835	702	-	(275)
Contract Services	217,400	21,144	111,485	-	84,771
Equipment	25,600	8,244	3,715	-	13,641

	Officials Expense 63T3	162,000	-	-	163,915	-	-	-	(1,915)		
	Services	-	-	-	-	-	-	-	-		
	Sewer_Other	7,800	-	-	4,075	-	-	-	3,725		
	Student Awards and Aid	-	14,000	-	846,501	-	-	-	(860,501)		
	Supplies_Expense	1,162,683	303,675	-	705,018	-	-	-	153,990		
	Travel	40,550	595	-	2,464	-	-	-	37,491		
	Travel-Group	1,000,000	628,418	-	268,838	-	-	-	102,744		
	Travel-Recruiting	235,000	2,555	-	90,300	-	-	-	142,145		
	Internal Service Ctr Internal Sales	-	(39,978)	-	(848)	-	-	-	40,826		
Total Expenditures		18.05	6,271,415	-	1,765,133	-	3,029,313	-	-	18.05	1,476,969
Transfers (IN) or OUT											
	Trsfr From Plant Fund Minor	-	-	-	-	-	-	-	-	-	-
	Trsfr To Plant Fund Major	-	-	-	-	-	-	-	-	-	-
Ending Balance		-	-	(340,743)	(2,468,308)	-	-	-	-	-	2,809,051
Budget Unit 353 - Other Mens Sports											
		FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted
Revenues	Sales and Services		61,000		15,250		30,564				15,186
	Other Sources		1,706,725		-		-				1,706,725
Total Revenues			1,767,725		15,250		30,564		-	-	1,721,911
Beginning Balance			-		-		-		-		-
Total Available			1,767,725		15,250		30,564		-	-	1,721,911
Expenditures	Administrative Professional	8.00	746,641		204,483		213,483			8.00	328,675
	GA TA RA PA Salary		-		7,800		7,800			-	(15,600)
	Other Salaries	1.83	34,900		3,074		6,524			1.83	25,302
	Support Staff Salary		-		-		-			-	-
	Technician Salary		-		200		782			-	(982)
	Fica		54,013		13,845		12,104			-	28,064
	Group Insurance		60,437		11,637		13,164			-	35,636
	Medicare		22,657		-		-			-	22,657
	Other Staff Benefits		29,545		7,632		8,298			-	13,615
	Retirement		92,279		27,847		30,132			-	34,300
	Unemployment Compensation		478		145		155			-	178
	Workers Compensation		326		162		165			-	(1)
	Contract Services		4,700		216		1,462			-	3,022
	Equipment		44,000		23,591		3,314			-	17,095
	Fuel_Heat_Cool		520		-		38			-	482
	Officials Expense 63T3		80,000		6,760		5,660			-	67,580
	Student Awards and Aid		-		-		257,866			-	(257,866)
	Supplies_Expense		179,429		48,283		83,415			-	47,731
	Travel		15,850		497		444			-	14,909
	Travel-Group		323,500		49,384		130,488			-	143,628
	Travel-Recruiting		78,450		24,207		19,420			-	34,823
Total Expenditures		9.83	1,767,725	-	429,763	-	794,714	-	-	-	543,248
Transfers (IN) or OUT											
	Trsfr To Plant Fund Minor	-	-	-	-	-	-	-	-	-	-
Ending Balance		-	-	(414,513)	(764,150)	-	-	-	-	-	1,178,663
Budget Unit 354 - Other Womens Sports											
		FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted
Revenues	Sales and Services		422,800		17,800		230,424				174,576
	Other Sources		4,568,281		-		-				4,568,281
Total Revenues			4,991,081		17,800		230,424		-	-	4,742,857
Beginning Balance			-		-		20,430		-	-	(20,430)
Total Available			4,991,081		17,800		250,854		-	-	4,722,427
Expenditures	Administrative Professional	31.00	2,173,338		507,549		560,204			31.00	1,105,585
	GA TA RA PA Salary		-		-		4,000			-	(4,000)
	Other Salaries	3.62	69,000		5,289		23,230			3.62	40,481

Support Staff Salary	1.00	36,219	7,871	9,872			1.00	18,476
Technician Salary		-	785	1,134			-	(1,919)
Fica		167,119	34,674	39,740			-	92,705
Group Insurance		248,383	43,397	46,249			-	158,737
Other Staff Benefits		93,063	21,652	23,642			-	47,769

	Retirement	303,653		71,907		77,730						-	154,016
	Tuition Waivers	-		2,608		-						-	(2,608)
	Unemployment Compensation	1,528		365		416						-	747
	Workers Compensation	1,311		418		475						-	418
	Contract Services	79,510		4,342		28,157						-	47,011
	Equipment	78,575		20,619		27,386						-	30,570
	Fuel_Heat_Cool	350		-		38						-	312
	Officials Expense 63T3	176,750		-		9,680						-	167,070
	Services	-		-		-						-	-
	Sewer_Other	-		-		-						-	-
	Student Awards and Aid	-		4,000		1,027,558						-	(1,031,558)
	Supplies_Expense	426,132		111,356		116,466						-	198,310
	Travel	34,150		5,519		13,737						-	14,894
	Travel-Group	909,700		107,485		484,493						-	317,722
	Travel-Recruiting	192,300		87,877		55,837						-	48,586
	Internal Service Ctr Internal Sales	-		(3,400)		(20,195)						-	23,595
Total Expenditures		35.62	4,991,081	-	1,034,313	-	2,529,849	-	-	-	-	35.62	1,426,919
Transfers (IN) or OUT	Trsfr From I G		-		-		-		-		-		-
	Trsfr From Plant Fund Minor		-		-		(39,775)		-		-		-
	Trsfr To Plant Fund Minor		-		-		-		-		-		-
Ending Balance			-		(1,016,513)		(2,239,220)		-		-		3,295,508
Budget Unit 409 - Utilities													
		FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted
Revenues	Other Sources						-						-
Total Revenues			-		-		-		-		-		-
Beginning Balance					4,095		(4,095)						-
Total Available			-		4,095		(4,095)		-		-		-
Expenditures	Electricity				62,898		83,509					-	(146,407)
	Fuel_Heat_Cool				609		10,578					-	(11,187)
	Sewer_Other				25,821		34,855					-	(60,676)
	Supplies_Expense				447		644					-	(1,091)
Total Expenditures			-		89,775		129,586		-		-		(219,361)
Transfers (IN) or OUT			-		-		-		-		-		-
Ending Balance			-		(85,680)		(133,681)		-		-		219,361
Budget Unit 437 - Miscellaneous													
		FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted	FTE	Unrestricted
Revenues	Federal Grants and Contracts											-	-
	State Grants and Contracts											-	-
	Other Sources											-	-
Total Revenues			-		-		-		-		-		-
Beginning Balance			-		-		-		-		-		-
Total Available			-		-		-		-		-		-
Expenditures	Federal Workstudy Salaries											-	-
	State Workstudy Salaries											-	-
	Contract Services											-	-
	Officials Expense 63T3											-	-
	Supplies_Expense											-	-
Total Expenditures			-		-		-		-		-		-
Transfers (IN) or OUT			-		-		-		-		-		-
Ending Balance			-		-		-		-		-		-

	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026	FY2027	FY2028	FY2029 (1)
Beginning Fund Balance (Deficit)	(4,713,999)	(4,492,380)	(4,492,380)	(4,005,052)	(3,517,723)	(3,030,395)	(2,543,066)	(2,055,737)	(1,568,409)	(1,081,080)	(593,751)	(106,423)
Recurring Fund Balance (Deficit)												
Net Balance (Deficit)	(4,713,999)	(4,492,380)	(4,492,380)	(4,005,052)	(3,517,723)	(3,030,395)	(2,543,066)	(2,055,737)	(1,568,409)	(1,081,080)	(593,751)	(106,423)
Revenues	32,944,217	32,097,208	31,123,208	30,739,504	30,739,504	30,739,504	30,739,504	30,739,504	30,739,504	30,739,504	30,739,504	30,739,504
Other Sources	814,207	789,039	(383,704)									
Subtotal Revenues	33,758,424	32,886,247	30,739,504	30,739,504	30,739,504	30,739,504	30,739,504	30,739,504	30,739,504	30,739,504	30,739,504	30,739,504
Expenses	33,541,301	34,373,643	33,723,643	30,252,176	30,252,176	30,252,176	30,252,176	30,252,176	30,252,176	30,252,176	30,252,176	30,252,176
Cost containment (reduction in expenses)	(4,496)	(737,396)	(2,496,467)									
Grant-aid subsidies (reduction in expenses)		(750,000)	(975,000)									
Subtotal Expenses	33,536,805	32,886,247	30,252,176	30,252,176	30,252,176	30,252,176	30,252,176	30,252,176	30,252,176	30,252,176	30,252,176	30,252,176
Transfers	0	0	0	0	0	0	0	0	0	0	0	0
Net Annual Balance (2)	221,619	0	487,329	487,329	487,329	487,329	487,329	487,329	487,329	487,329	487,329	487,329
Ending Fund Balance (Deficit)	(4,492,380)	(4,492,380)	(4,005,052)	(3,517,723)	(3,030,395)	(2,543,066)	(2,055,737)	(1,568,409)	(1,081,080)	(593,751)	(106,423)	380,906

(1) 10 year deficit reduction plan beginning in FY20 to FY29

(2) Annual contribution to the accumulated deficit per deficit reduction plan

(3) The deficit reduction plan was approved by the Board of Regents at their April 17th, 2018 meeting. The plan calls for an infusion of dollars in FY18 and FY19 along with cost containment in those years. Additional significant reductions in spending in FY20 will occur and those will be applied forward through the term of the plan.

STC.UNM

SUPPORTING TECHNOLOGY TRANSFER AND
CATALYZING ECONOMIC DEVELOPMENT AT
THE UNIVERSITY OF NEW MEXICO

ANNUAL REPORT TO THE BOARD OF REGENTS OF THE UNIVERSITY OF NEW MEXICO

Presented by Lisa Kuuttila
CEO & Chief Economic Development Officer
STC.UNM

February 5, 2019

STC.UNM CEO'S REPORT

Presentation Outline

- ❖ FY 2018 STC.UNM Audit Results
- ❖ STC Board of Directors
- ❖ FY 2018 STC.UNM Building a Rainforest in the Desert
- ❖ FY 2018 STC.UNM Data, Income Analysis and Forecast



**SUPPORTING TECHNOLOGY TRANSFER AND
CATALYZING ECONOMIC DEVELOPMENT AT
THE UNIVERSITY OF NEW MEXICO**

(A Blended Component Unit of the University of New Mexico)

Financial Statements

June 30, 2018 and 2017

(With Report of Independent Auditors Thereon)

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Table of Contents

	Page
Official Roster (unaudited)	i
Report of Independent Auditors	1
Management's Discussion and Analysis (unaudited)	3
Basic Financial Statements:	
Statements of Net Position	6
Statements of Revenues, Expenses, and Changes in Net Position	7
Statements of Cash Flows	8
Notes to Financial Statements	9
Required Governmental Reporting:	
Report of Independent Auditors on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	21
Schedule of Findings	23
Schedule of Prior Audit Findings	24
Exit Conference	25

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Official Roster (unaudited)

June 30, 2018

Officers

Ms. Sandra Begay	Chair
Ms. Terri Cole	Vice Chair
Dr. Joseph L. Cecchi	Vice Chair
Dr. John H. Stichman	Secretary/Treasurer
Ms. Elizabeth Kuuttila	CEO & Chief Economic Development Officer
Ms. Denise M. Bissell	Assistant Secretary

Committee Chairs

Ms. Sandra Begay	Chair, Executive Committee and Nominating Committee
Dr. John H. Stichman	Chair, Finance and Compensation Committee
Ms. Maria Griego-Raby	Chair, Endowment Fund Committee
Mr. Chuck Wellborn	Chair, Co-Investment Fund Committee

Board Members

Dr. Chaouki T. Abdallah	Ms. Sandra Begay
Dr. Joseph L. Cecchi	Ms. Terri Cole
Dr. Robert H. Fisher	Mr. David W. Harris
Ms. Maria Griego-Raby	Ms. Elizabeth Kuuttila
Mr. Jamie Koch	Mr. Terry Laudick
Dr. Richard S. Larson	Dr. Gabriel P. Lopez
Ms. Cindy McGill	Mr. Robert H. Nath
Dr. Gregg L. Mayer	Dr. Eric R. Prossnitz
Dr. Paul B. Roth	Mr. Pedro F. Suarez
Dr. John H. Stichman	Mr. Chuck I. Wellborn
Mr. Gary Tonjes	Mr. J.E. (Gene) Gallegos
Dr. Craig G. White	Ms. Kimberly C. Sawyer
Dr. Alton D. Romig, Jr.	Dr. Julie E. Coonrod
Dr. John C. Stormont	Mr. David W. Gibson
Dr. Garnett S. Stokes	



Report of Independent Auditors

The Board of Directors
STC.UNM
And
Mr. Wayne Johnson
New Mexico State Auditor

Report on the Financial Statements

We have audited the accompanying financial statements of STC.UNM, which comprise the statements of net position as of June 30, 2018 and 2017, and the related statements of revenues, expenses, and changes in net position and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of STC.UNM as of June 30, 2018 and 2017, and the changes in its net position and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Other Matters

Required Supplementary Information

Accounting principles generally accepted in the United States of America require that the management's discussion and analysis on pages 3 through 5 be presented to supplement the basic financial statements. Such information, although not a part of the basic financial statements, is required by the Governmental Accounting Standards Board who considers it to be an essential part of financial reporting for placing the basic financial statements in an appropriate operational, economic, or historical context. We have applied certain limited procedures to the required supplementary information in accordance with auditing standards generally accepted in the United States of America, which consisted of inquiries of management about the methods of preparing the information and comparing the information for consistency with management's responses to our inquiries, the basic financial statements, and other knowledge we obtained during our audit of the basic financial statements. We do not express an opinion or provide any assurance on the information because the limited procedures do not provide us with sufficient evidence to express an opinion or provide any assurance.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated September 25, 2018 on our consideration of STC.UNM's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of STC.UNM's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering STC.UNM's internal control over financial reporting and compliance.

Mess Adams LLP

Albuquerque, New Mexico
September 25, 2018

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Management's Discussion and Analysis

June 30, 2018 and 2017

This management's discussion and analysis (MD&A) of the STC.UNM (formerly known as Science & Technology Corporation @ UNM) (the Corporation) provides an overview of the Corporation's financial performance for the fiscal years ended June 30, 2018, 2017 and 2016.

Overview of the Financial Statements

The statements of net position of the Corporation provide both long-term and short-term information about the Corporation's overall financial status. The statements of revenues, expenses, and changes in net position provide information about the operating revenues and expenses and nonoperating revenues and expenses of the Corporation. The statements of cash flows provide information about the sources and uses of cash by the Corporation.

Condensed Financial Information

		June 30		
		2018	2017	2016
Current assets	\$	2,924,649	2,390,591	2,765,855
Capital assets, net		28,443	16,556	21,047
Investment in stock		1,394	20,371	444
Total assets	\$	<u>2,954,486</u>	<u>2,427,518</u>	<u>2,787,346</u>
Current liabilities		<u>1,824,675</u>	<u>1,433,210</u>	<u>1,944,058</u>
Net position				
Investment in capital assets		28,443	16,556	21,047
Unrestricted		<u>1,101,368</u>	<u>977,752</u>	<u>822,241</u>
Total liabilities and net position	\$	<u>2,954,486</u>	<u>2,427,518</u>	<u>2,787,346</u>
Operating revenues	\$	4,524,951	4,226,568	4,918,045
Operating expenses		<u>4,440,054</u>	<u>4,139,557</u>	<u>4,652,652</u>
Operating income		<u>84,897</u>	<u>87,011</u>	<u>265,393</u>
Nonoperating revenues		50,606	64,009	43,354
Nonoperating expenses		-	-	(7,217,513)
Change in net position		135,503	151,020	(6,908,766)
Net position, beginning of year		<u>994,308</u>	<u>843,288</u>	<u>7,752,054</u>
Net position, end of year	\$	<u>1,129,811</u>	<u>994,308</u>	<u>843,288</u>

Financial Position

The Corporation's current assets increased by \$534,058 as of June 30, 2018 to \$2,924,649 compared to \$2,390,591 as of June 30, 2017; and current assets decreased by \$375,264 as of June 30, 2017 to \$2,390,591

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Management's Discussion and Analysis

June 30, 2018 and 2017

compared to \$2,765,855 as of June 30, 2016. The increase from fiscal year 2017 to fiscal year 2018 was primarily attributable to increased activity level in accounts receivable related to one large receivable balance from a license agreement outstanding as of June 30, 2018.

Current liabilities increased by \$391,465 as of June 30, 2018 to \$1,824,675 compared to \$1,433,210 as of June 30, 2017; and decreased by \$510,848 as of June 30, 2017 to \$1,433,210 compared to \$1,944,058 as of June 30, 2016. The change from fiscal year 2017 to fiscal year 2018 is primarily attributable to an increase in accrued royalty sharing of \$371,328 associated primarily with two receivables from two license agreements outstanding as of June 30, 2018.

Capital Assets

Capital asset purchases during fiscal years 2018, 2017, and 2016 were \$21,520, \$3,922, and \$8,210, respectively, for buildings, software, leasehold improvements, computer equipment, and furniture and had depreciation expense of \$8,995, \$8,413, and \$51,411, respectively.

Comparison of Fiscal 2018 to Fiscal 2017 Results of Operations

Total operating revenues increased by \$298,383 from \$4,226,568 in fiscal year 2017 to \$4,524,951 for fiscal year 2018. The majority of the increase is directly attributable to increased licensing and royalty activity through the fiscal year. Licensing and royalty revenues, net increased by \$235,275 in fiscal year 2018 compared to fiscal year 2017. Additionally, patent costs reimbursements decreased by \$93,392 compared to fiscal year 2017 which was primarily offset by increased economic development funding associated with a grant award from New Mexico Gas Company and increased sponsorship funding associated with the Corporation's subaward activities.

Total operating expenses increased by a net of \$300,497 for fiscal year 2018 compared to fiscal year 2017. General and administrative expenses increased by \$276,296 from the prior year due to increased rents and costs associated with the relocation of the Corporation. Licensing distributions increased by \$58,327 and economic development initiative expenses increased by \$58,391 which were primarily offset by a decrease in patent costs of \$93,099 from the prior year.

Comparison of Fiscal 2017 to Fiscal 2016 Results of Operations

Total operating revenues for fiscal year 2017 of \$4,226,568 decreased from \$4,971,451 for fiscal year 2016, a net decrease of \$744,883. The majority of the decrease is directly attributable to decreased licensing activity through the fiscal year. Licensing revenues decreased by \$692,217 in fiscal year 2017 compared to fiscal year 2016. Additionally, the Corporation was not awarded any grant awards as they had in the previous year. Grant award revenues decreased by \$250,000 in fiscal year 2017 compared to fiscal year 2016.

Total operating expenses decreased by a net of \$513,094 for fiscal year 2017 compared to fiscal year 2016. Innovate ABQ related expenses decreased by \$149,758 from the prior year due to the transfer of Innovate ABQ from the Corporation to Innovate ABQ.

Patent cost expenses decreased by \$121,600 from prior fiscal year attributable to reduced licensee-driven patent activities. Licensing distributions expenses decreased by \$276,235 from the prior year due to decrease in licenses during the year.

STC.UNM
(A Blended Component Unit of the University of New Mexico)
Management's Discussion and Analysis
June 30, 2018 and 2017

Economic Conditions

The uncertainty of the general economic condition impacts university technology transfer offices such as the Corporation. The stability of the economy will be critical in the venture capital industry, which provides funding for start-up companies that may license university intellectual property.

Contacting the Company's Management

This report is meant to accurately describe the financial condition and position of the Corporation.

If you have any questions about this report or need additional financial information, contact STC.UNM at 101 Broadway Blvd NE, Suite 1100, Albuquerque, New Mexico 87102.

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Statements of Net Position
June 30, 2018 and 2017

Assets	2018	2017
Current assets:		
Cash and cash equivalents	\$ 1,174,759	1,053,737
Investments	729,741	683,101
Accounts receivable, net	1,020,149	653,753
Total current assets	<u>2,924,649</u>	<u>2,390,591</u>
Capital assets:		
Furniture and equipment	289,876	268,994
Accumulated depreciation	<u>(261,433)</u>	<u>(252,438)</u>
Total capital assets, net	<u>28,443</u>	<u>16,556</u>
Investment in stock	<u>1,394</u>	<u>20,371</u>
Total assets	<u><u>\$ 2,954,486</u></u>	<u><u>2,427,518</u></u>
Liabilities and Net Position		
Current liabilities:		
Accounts payable	\$ 189,309	229,580
Due to University of New Mexico	412,050	371,296
Accrued royalty sharing, net	1,056,099	684,771
Accrued expenses	<u>167,217</u>	<u>147,563</u>
Total current liabilities	<u>1,824,675</u>	<u>1,433,210</u>
Net position:		
Investment in capital assets	28,443	16,556
Unrestricted	<u>1,101,368</u>	<u>977,752</u>
Total net position	<u>1,129,811</u>	<u>994,308</u>
Total liabilities and net position	<u><u>\$ 2,954,486</u></u>	<u><u>2,427,518</u></u>

See accompanying notes to financial statements.

STC.UNM
(A Blended Component Unit of the University of New Mexico)
Statements of Revenues, Expenses, and Changes in Net Position
Years ended June 30, 2018 and 2017

	<u>2018</u>	<u>2017</u>
Operating revenues:		
Operational funding from UNM	\$ 794,000	794,000
Patent funding from UNM	952,000	952,000
Economic development funding from UNM and others	338,000	288,000
Patent cost reimbursement, net	621,413	714,805
Licensing and royalties, net	1,470,078	1,234,803
Rental income	112,927	49,344
Other	236,533	193,616
Total operating revenues	<u>4,524,951</u>	<u>4,226,568</u>
Operating expenses:		
Patent costs incurred	1,442,560	1,535,659
Licensing distributions	862,699	804,372
Depreciation	8,995	8,413
Economic development initiative	403,419	345,028
General and administrative	1,722,381	1,446,085
Total operating expenses	<u>4,440,054</u>	<u>4,139,557</u>
Operating income	<u>84,897</u>	<u>87,011</u>
Nonoperating revenues:		
Investment income	18,394	19,102
Net increase in fair value of investments	32,212	44,907
Total nonoperating revenues	<u>50,606</u>	<u>64,009</u>
Change in net position	135,503	151,020
Net position, beginning of year	<u>994,308</u>	<u>843,288</u>
Net position, end of year	<u>\$ 1,129,811</u>	<u>994,308</u>

See accompanying notes to financial statements.

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Statements of Cash Flows
Years ended June 30, 2018 and 2017

	2018	2017
Cash flows from operating activities:		
Payments to suppliers and employees	\$ (2,146,417)	(1,902,754)
Receipts for operational funding revenue from UNM	794,000	794,000
Receipts for patent funding revenue from UNM	952,000	952,000
Receipts for co-investment funding from UNM	100,000	674,600
Payment to start up companies for co-investment funding	(100,000)	(674,600)
Receipts for economic development initiatives funding revenue from UNM	338,000	288,000
Receipts from sponsorships and other	268,034	203,676
Payment for patent costs incurred	(1,442,560)	(1,513,388)
Receipts for patent cost reimbursements	656,993	531,468
Receipts from licensees	1,036,601	1,690,499
Payment for licensing distribution expense	(450,617)	(1,234,085)
Receipt of rental income	112,927	49,344
Net cash provided by (used in) operating activities	<u>118,961</u>	<u>(141,240)</u>
Cash flows from capital and related financing activities:		
Acquisition of capital assets	(21,520)	(3,922)
Proceeds from sale of capital assets	638	-
Net cash used in capital and related financing activities	<u>(20,882)</u>	<u>(3,922)</u>
Cash flows from investing activities:		
Investments purchased	(257,510)	(936,558)
Investment proceeds	261,476	940,697
Investment in stock	-	(19,808)
Proceeds from sale of stock	18,977	-
Net cash provided by (used in) investing activities	<u>22,943</u>	<u>(15,669)</u>
Net change in cash and cash equivalents	121,022	(160,831)
Cash and cash equivalents, beginning of year	1,053,737	1,214,568
Cash and cash equivalents, end of year	<u>\$ 1,174,759</u>	<u>1,053,737</u>
Reconciliation of operating income to net cash provided by (used in) operating activities:		
Operating income	\$ 84,897	87,011
Adjustments to reconcile to net cash provided by (used in) operating activities:		
Depreciation	8,995	8,413
Bad debt expense	116,188	-
Changes in operating assets and liabilities:		
Accounts receivable, net	(482,584)	274,184
Accounts payable	(40,271)	38,862
Due to UNM	40,754	(92,538)
Accrued royalty sharing, net	371,328	(337,353)
Accrued expenses and other	19,654	(119,819)
Net cash provided by (used in) operating activities	<u>\$ 118,961</u>	<u>(141,240)</u>

See accompanying notes to financial statements.

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Notes to Financial Statements

June 30, 2018 and 2017

(1) Organization

STC.UNM (formerly known as Science & Technology Corporation @ UNM) (the Corporation) is a component unit of The University of New Mexico (UNM). The Corporation was organized on April 26, 1993 to facilitate the commercialization of UNM faculty inventions and to manage UNM's Science & Technology Park in Albuquerque, New Mexico. On December 14, 2004, UNM and STC.UNM entered into a revised Memorandum of Agreement (MOA) containing the expectations and performance obligations UNM is seeking from the Corporation. The MOA may be terminated at any time by either party, at which point all property of the Corporation shall be transferred to UNM or other successor organization designated by resolution of the UNM Board of Regents. The Corporation was incorporated under the State of New Mexico's University Research Park and Economic Development Act. As of June 30, 2018, the governing board consisted of 29 members, including 11 members of certain officers and faculty of UNM, the President of the Corporation, and 18 members of the community. The Corporation has no component units.

(2) Summary of Significant Accounting Policies

(a) Measurement Focus, Basis of Accounting, and Financial Statement Presentation

As a component unit of UNM, the Corporation prepared its financial statements in accordance with the accounting disclosure requirements under the Governmental Accounting Standards Board (GASB) pronouncements as the Corporation meets the criteria of a governmental not-for-profit. The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. The significant accounting policies are summarized below.

The Corporation's financial statements are reported using the flow of economic resources measurement focus and the full accrual basis of accounting. Accordingly, revenue is recognized when earned and expenses are recognized as soon as the liability is incurred.

Operating revenues and expenses are those incurred that relate directly to facilitating commercialization of UNM faculty, staff, and student inventions. All other revenues and expenses are considered nonoperating.

(b) Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain amounts and disclosures during the reporting period. Accordingly, actual results could differ from those estimates.

(c) Cash and Cash Equivalents

Cash and cash equivalents include deposits and funds invested in overnight repurchase securities. The Corporation is not subject to statutory or policy restrictions on the types of deposits held.

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Notes to Financial Statements

June 30, 2018 and 2017

For purposes of the statements of cash flows, the Corporation considers all cash on hand and in banks and all highly liquid securities with original maturities less than 90 days to be cash equivalents.

(d) Accounts Receivable

Accounts receivable represent the amount earned based on existing terms under license agreements but uncollected on accrued royalties earned from customers.

Accounts receivable are carried at original amount billed less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received. There was an allowance for doubtful accounts of \$92,867 recorded during 2018. There was no allowance for doubtful accounts recording during 2017.

An account receivable is considered to be past due if any portion of the receivable balance is outstanding for more than 90 days. Interest is not charged on past due accounts receivable.

(e) Capital Assets

Capital assets are carried at cost. Depreciation is provided on the straight-line method based on estimated useful lives of three to seven years, except for depreciation of buildings, which have useful life of 30 years. Capital assets costing over \$1,000 and with a useful life greater than a year are capitalized. Repairs and maintenance expenses are charged to expense as incurred.

(f) Patent Costs

UNM, a related party, provides annual funding for patent costs. The funding revenue is deferred on receipt. As patent costs are incurred, expense is recognized and an equal amount of the deferred revenue is recognized as income.

(g) Revenue Recognition

Upfront, nonrefundable licensing fees are recognized when earned. These fees are ordinarily earned when a license agreement is signed and the Corporation has no further obligations with respect to the license. Minimum annual royalty income is accrued as it is earned, if it is determined that collection is reasonably assured. Licensing fees and minimum annual royalty income accrued were \$1,020,149 and \$653,753 as of June 30, 2018 and 2017, respectively. As of June 30, 2018 the Corporation had bad debt expense related to royalties and licenses of \$69,699. The Corporation netted bad debt expense with the corresponding revenue. There was no bad debt expense recorded as of June 30, 2017.

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Notes to Financial Statements

June 30, 2018 and 2017

Operational and patent cost funding from UNM is recognized when all eligibility requirements have been met. Patent cost reimbursement is recognized when earned. As of June 30, 2018, the Corporation had \$46,489 of bad debt expense related to patent cost reimbursement. The Corporation netted bad debt expense with the corresponding revenue. There was no bad debt expense recorded as of June 30, 2017.

(h) *Income Taxes*

The Corporation has received a determination letter from the Internal Revenue Service (IRS) that it is an organization described in Internal Revenue Code Section 501(c)(3). As such, it would be exempt from federal income tax on income generated from activities related to its exempt function.

(i) *Accrued Employee Benefits*

The Corporation's employees may accumulate paid personal time, which is payable to the employee upon termination or retirement. Personal time costs are recognized as a liability when earned by the employee.

(j) *Investments*

The investment portfolio is valued based on quoted market values. The portfolio primarily consists of mutual funds. Investments in stock consist of ownership interest in start-up companies and are carried at cost basis.

(k) *Net Position*

Net position is classified as follows:

Invested in capital assets (net of related debt) is intended to reflect the portion of net position that is associated with non-liquid, capital assets less outstanding capital asset-related debt. The Corporation does not have any debt related to its capital assets.

Restricted net position is the net position that has third-party (statutory or granting agency) limitations on its use. There was no restricted net position as of June 30, 2018 and 2017.

Unrestricted net position represents liquid assets available for use.

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Notes to Financial Statements

June 30, 2018 and 2017

(3) Cash, Cash Equivalents, and Investments

	<u>2018</u>	<u>2017</u>
Cash and cash equivalents:		
Cash on deposit at financial institution	\$ 1,167,331	1,045,612
Cash equivalents not considered deposits:		
Money market accounts	7,328	8,025
Petty cash	<u>100</u>	<u>100</u>
Total cash and cash equivalents	<u>\$ 1,174,759</u>	<u>1,053,737</u>
Investments:		
Mutual funds:		
Domestic fixed income	\$ 20,681	248,760
International fixed income	70,365	20,222
Domestic equity	417,386	268,994
International equity	163,336	124,855
Real estate	<u>57,973</u>	<u>20,270</u>
Total investments	<u>\$ 729,741</u>	<u>683,101</u>

(a) Custodial Credit Risk

Custodial credit risk is the risk that in the event of a bank failure, the entity's deposits may not be returned to it. The Corporation maintains cash and cash equivalents in interest-bearing transaction accounts with financial institutions and, as such, the accounts are insured by the Federal Deposit Insurance Corporation up to \$250,000. The Corporation does not believe there is any significant credit risk related to their deposits. The Corporation does not require collateral on its cash deposits in excess of \$250,000.

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Notes to Financial Statements

June 30, 2018 and 2017

As of June 30, the Corporation's deposits were exposed to custodial credit risk as follows:

Bank name/ account	Account type	Financial statement balance	Outstanding checks	Bank balance
Bank of the West:				
Operating	Checking	\$ 1,167,331	211,204	1,378,535
Money market account		7,328	—	7,328
Less FDIC insurance				(257,328)
Uninsured and uncollateralized at June 30, 2018				<u>\$ 1,128,535</u>

The following schedule details the Corporation's deposit accounts at June 30, 2017:

Bank name/ account	Account type	Financial statement balance	Outstanding checks	Bank balance
Bank of the West:				
Operating	Checking	\$ 1,045,612	162,574	1,208,186
Money market account		8,025	—	8,025
Less FDIC insurance				(258,025)
Uninsured and uncollateralized at June 30, 2017				<u>\$ 958,186</u>

(b) Investment Policy

Up until February 2018, the Corporation had its funds in the "Moderate" investment objective options under the TIAA Portfolio Advisor Investment Strategy of "Passive Meet/Beat Market." Due to positive economic actual returns in the marketplace and long-term forecasts, the Corporation changed its investment objective options to "Aggressive" under the "Passive Meet/Beat Market" TIAA Portfolio Advisor Investment Strategy. TIAA has a general investment account policy developed for the Corporation's funds. The policy establishes an understanding as to the investment goals, objectives, and management policies for this specific portfolio. The objective of the fund is an emphasis on the total return of the portfolio with some consideration on additional customization options. Investments are primarily in equity securities and other asset classes, with growth as the primary objective. Fixed income securities are utilized for risk control. Real assets are utilized for diversification and complementary strategies may be utilized to improve the return/risk relationship of the portfolio. The risk of tolerance of the Corporation can currently be described as "aggressive/long-term". The performance of the portfolio will be monitored, measured, and reported by TIAA to the Corporation.

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Notes to Financial Statements

June 30, 2018 and 2017

(c) Interest Rate Risk and Credit Risk

Interest rate risk is the risk that changes in interest rates will adversely affect the fair value of an investment. Credit risk is the risk that the credit quality of investments fluctuates or downgrades from the time of purchase or the risk that an issuer of an investment will not fulfill its obligations. The Corporation's investments subject to interest rate and credit risk are the fixed income mutual funds. The Corporation's investment policy limits interest rate risk by limiting the percentage of assets invested in bond funds and by requiring the weighted average duration of its portfolio of bond funds to not exceed the duration of the Barclays Aggregate Bond Index by more than two years. The Corporation's investment policy limits credit risk by requiring that domestic investment grade bond funds held have a credit rating of BBB or above at purchase, and by limiting the percentage of assets invested in bond funds.

The Corporation had the following investments and maturities at June 30, 2018 and 2017.

June 30, 2018						
Investment type	Fair value	Weighted average investment maturities (in years)				Not available
		Less than 1	1 – 5	6 – 10	More than 10	
Fixed income:						
Domestic bond mutual funds	\$ 20,681	—	—	—	—	20,681
International bond mutual funds	70,365	—	—	70,365	—	—
	<u>\$ 91,046</u>	<u>—</u>	<u>—</u>	<u>70,365</u>	<u>—</u>	<u>20,681</u>
June 30, 2017						
Investment type	Fair value	Weighted average investment maturities (in years)				Not available
		Less than 1	1 – 5	6 – 10	More than 10	
Fixed income:						
Domestic bond mutual funds	\$ 248,760	—	69,470	179,290	—	—
International bond mutual funds	20,222	—	—	20,222	—	—
	<u>\$ 268,982</u>	<u>—</u>	<u>69,470</u>	<u>199,512</u>	<u>—</u>	<u>—</u>

The following tables provide information on the credit ratings associated with the Corporation's investments in debt securities at June 30, 2018 and 2017.

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Notes to Financial Statements

June 30, 2018 and 2017

June 30, 2018										
Investment type	Fair value	AAA	AA	A	BBB	BB	B	Below B	NR	Not available
Fixed income:										
Domestic bond mutual funds	\$ 20,681	—	—	—	—	—	20,681	—	—	—
International bond mutual funds	70,365	22,235	—	21,910	—	—	26,220	—	—	—
	<u>\$ 91,046</u>	<u>22,235</u>	<u>—</u>	<u>21,910</u>	<u>—</u>	<u>—</u>	<u>46,901</u>	<u>—</u>	<u>—</u>	<u>—</u>
June 30, 2017										
Investment type	Fair value	AAA	AA	A	BBB	BB	B	Below B	NR	Not available
Fixed income:										
Domestic bond mutual funds	\$ 248,760	69,079	152,637	—	—	—	27,044	—	—	—
International bond mutual funds	20,222	—	—	—	—	—	—	—	20,222	—
	<u>\$ 268,982</u>	<u>69,079</u>	<u>152,637</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>27,044</u>	<u>—</u>	<u>20,222</u>	<u>—</u>

(d) Foreign Currency Risk

Foreign currency risk is the risk that changes in exchange rates will adversely affect the fair value of an investment or a deposit. All foreign investments of the Corporation are in mutual funds, as disclosed elsewhere in this note.

(e) Net Increase in Fair Value of Investments

During the years ended June 30, the Corporation experienced realized gains and unrealized losses on investments held as follows:

2018:

Realized losses	\$	(3,569)
Unrealized gains		<u>35,781</u>
Net increase in fair value of investments	\$	<u>32,212</u>

2017:

Realized gains	\$	80,359
Unrealized losses		<u>(35,452)</u>
Net increase in fair value of investments	\$	<u>44,907</u>

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Notes to Financial Statements

June 30, 2018 and 2017

(f) Fair Value Measurement

The Corporation categorizes its fair value measurements within the fair value hierarchy established by generally accepted accounting principles. The hierarchy is based on the valuation inputs used to measure the fair value of the asset.

- *Level 1* inputs are quoted prices (unadjusted) for identical assets in active markets, accessible at the measurement date. Level 1 inputs include exchange markets, dealer markets, brokered markets, and principal-to-principal markets.
- *Level 2* inputs are inputs, other than quoted prices included within Level 1, that are observable for an asset, either directly or indirectly. Level 2 inputs include quoted prices for similar assets in active markets and quoted prices for identical or similar assets in markets that are not active.
- *Level 3* inputs are unobservable inputs for an asset.

Investments that do not have a readily determinable fair value are recorded using net asset value (NAV). NAV is generally provided by the investment managers, but the Corporation considers the reasonableness of the NAV, based on market information, to arrive at the fair value estimates for each investment.

The Corporation has the following recurring fair value measurements as of June 30, 2018:

	Fair value	Quote prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Investments:				
Mutual funds:				
Domestic fixed income	\$ 20,681	20,681	—	—
International fixed income	70,365	70,365	—	—
Domestic equity	417,386	417,386	—	—
International equity	163,336	163,336	—	—
Real estate	57,973	57,973	—	—
Total investments	\$ 729,741	729,741	—	—

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Notes to Financial Statements

June 30, 2018 and 2017

The Corporation has the following recurring fair value measurements as of June 30, 2017:

	Fair value	Quote prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Investments:				
Mutual funds:				
Domestic fixed income	\$ 248,760	248,760	—	—
International fixed income	20,222	20,222	—	—
Domestic equity	268,994	268,994	—	—
International equity	124,855	124,855	—	—
Real estate	20,270	20,270	—	—
Total investments	\$ 683,101	683,101	—	—

(4) Capital Assets

The Corporation has the following capital assets as of June 30:

2018				
	Beginning balance	Increases	Decreases	Ending balance
Capital assets being depreciated:				
Furniture and equipment	\$ 268,994	21,520	(638)	289,876
Accumulated depreciation	(252,438)	(8,995)	—	(261,433)
Capital assets, net	\$ 16,556	12,525	(638)	28,443
2017				
	Beginning balance	Increases	Decreases	Ending balance
Capital assets being depreciated:				
Furniture and equipment	\$ 265,072	3,922	—	268,994
Accumulated depreciation	(244,025)	(8,413)	—	(252,438)
Capital assets, net	\$ 21,047	(4,491)	—	16,556

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Notes to Financial Statements

June 30, 2018 and 2017

(5) Commitments and Contingencies

(a) *Occupancy Agreement*

Effective January 31, 2008 through August 14, 2017, the Corporation was subject to an occupancy agreement with UNM for lease of office facilities, as amended. The Corporation entered into a new occupancy agreement with UNM for lease of the new office facilities, effective August 15, 2017 with an end date of August 31, 2027. Future minimum payments required under the occupancy agreements are as follows:

Year ending June 30, 2019	\$ 233,332
Year ending June 30, 2020	233,332
Year ending June 30, 2021	233,332
Year ending June 30, 2022	233,332
Year ending June 30, 2023	252,776
Years ending June 30, 2024 to 2028	<u>1,069,438</u>
	<u>\$ 2,255,542</u>

Rent expense in fiscal years 2018 and 2017 was \$214,186 and \$98,626, respectively.

The Corporation entered into sublease agreement with a third party, effective September 1, 2017 through August 15, 2022. The future minimum receipts required under the sublease are \$86,403 each fiscal year. The Corporation also enters into various short-term monthly agreements with venture lab tenants for virtual and physical space. The Corporation recorded \$112,927 and \$49,344 of rental/occupancy income associated with these agreements in fiscal year 2018 and 2017, respectively.

(b) *Risk Management*

The Corporation is exposed to various risks of loss from torts; theft of, damage to, and destruction of assets; business interruption; errors and omissions; and natural disasters. The Corporation is insured under the UNM's Risk Management for liability and casualty insurance, and through a private carrier for director and officer liability insurance. There have been no significant reductions in coverage from the prior year and there have been no settlements in any of the past years.

(6) Defined Contribution Plan

The Corporation sponsors a defined contribution retirement plan for eligible employees. Employees may contribute up to the maximum allowed by the IRS. In fiscal years 2018 and 2017, the Corporation matched employee contributions below 7.975% commensurately; employee contributions that equaled or exceeded 7.975% were matched up to 12.4% of the employee's base salary. There is no vesting period. The Corporation's contributions were \$78,397 and \$75,874 in fiscal years 2018 and 2017, respectively. Employee contributions were \$72,539 and \$66,714 in fiscal years 2018 and 2017, respectively.

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Notes to Financial Statements

June 30, 2018 and 2017

(7) Incentive Compensation Plan

The Corporation has an incentive compensation plan in which the finance and compensation committee of the Corporation's Board of Directors (STC Board) has the discretion to provide a cash and/or equity incentive award based on performance. Equity incentive awards are paid to eligible employees upon the Corporation's liquidation of stock held. Cash bonuses awarded to employees were \$65,876 and \$67,219 in fiscal years 2018 and 2017, respectively. No equity incentive awards were made to employees during 2018 and 2017.

(8) STC Quasi-Endowment

During fiscal year 2010, the STC Board approved an internal STC.UNM endowment policy for management of large one-time license-fee related payments received by the Corporation. The endowment policy was revised in 2011 so if the Corporation's net position balance exceeds \$500,000 then the excess balance may be allocated as follows: 80% to the STC Quasi-Endowment, the interest from which could be used to fund STC operations; and 20% to the STC Strategic Initiatives Fund to be used for the inventor recognition awards program, the gap fund program, and other strategic initiatives of STC, as determined by the STC Board's Executive Committee. Reallocation of balances between the Quasi-Endowment, Strategic Initiatives Fund, and other net position balances may be made at the discretion of the STC Finance Committee. The STC Board designated endowment of \$500,000 is accounted for and included under unrestricted net position.

(9) Co-Investment Fund

Based on a working relationship with the UNM Foundation, a related party, during fiscal year 2014, the Corporation approved the STC.UNM Policy on Investment from Co-Investment Fund. The UNM Foundation revised its Consolidated Investment Fund Policy (the Policy) to set aside \$1,000,000 for their investment in private start-up companies, which were started based on technology transferred and licensed from the Corporation. Under the Policy, any positive returns realized and received by the Co-Investment Fund in the future shall be shared ten percent by the Corporation and ninety percent by the UNM Foundation. The Policy agreement was amended on October 21, 2016 removing the \$1,000,000 threshold.

During fiscal year 2018, the Corporation approved one proposal from a start-up company and provided successful co-investments totaling \$100,000 based on direct pass-through funding from the UNM Foundation to STC per the terms of the policy.

During fiscal year 2017, the Corporation approved five proposals from start-up companies and provided for co-investments totaling \$470,000 based on direct pass-through funding from the UNM Foundation to STC in the amount of \$470,000 per terms of the policy. Two of the five approved proposals in the amount of \$170,000 were unsuccessful and the money was returned by the Corporation back to the UNM Foundation during fiscal year 2017.

STC.UNM
(A Blended Component Unit of the University of New Mexico)
Notes to Financial Statements
June 30, 2018 and 2017

(10) Subsequent Events

Subsequent events are evaluated by management through the date the accompanying financial statements are available to be issued, which is September 25, 2018.



Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

The Board of Directors
STC.UNM
And
Mr. Wayne Johnson
New Mexico State Auditor

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of STC.UNM, which comprise the statement of net position as of June 30, 2018, and the related statement of activities and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated September 25, 2018.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered STC.UNM's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of STC.UNM's internal control. Accordingly, we do not express an opinion on the effectiveness of STC.UNM's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether STC.UNM's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Mess Adams LLP

Albuquerque, New Mexico
September 25, 2018

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Schedule of Findings
Year ended June 30, 2018

No matters were reported.

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Schedule of Prior Year Findings

Year ended June 30, 2018

2017-001 Accruals and Account Reconciliations-Material Weakness-Corrected

2017-002 Lack of Policies and Procedures-Significant Deficiency-Corrected

STC.UNM
(A Blended Component Unit of the University of New Mexico)

Exit Conference
Year ended June 30, 2018

An exit conference was held on September 25, 2018. During this meeting, the contents of this report were discussed with the following individuals:

STC.UNM (a component unit of the University of New Mexico)

Elizabeth Kuuttila, CEO and Chief Economic Development Officer

Sandra Begay, Board Chair

Kimberly Pena, CFO

Preston Hendrix, Controller

John Stichman, Board Secretary/Treasurer

Gabriel Lopez, Board Member

David Harris, Board Member

Moss Adams LLP

Lisa Todd, Partner

STC.UNM (a component unit of the University of New Mexico) is responsible for the contents of the financial statements. Moss Adams LLP assisted with the preparation of the financial statements.

STC.UNM BOARD OF DIRECTORS



Ms. Sandra Begay
Chair, STC Board of Directors



Ms. Terri L. Cole
Vice Chair, STC Board of Directors



Dr. Joseph Cecchi
Vice Chair, STC Board of Directors



Dr. John H. Stichman
Secretary & Treasurer,
STC Board of Directors



Ms. Elizabeth (Lisa) Kuuttila
CEO & Chief Economic Development Officer,
STC.UNM



Dr. Julie A. Coonrod



Dr. Robert Fisher



Mr. Gene Gallegos, Esq.



Mr. David W. Gibson



Ms. Maria Griego-Raby



Mr. James Koch



Dr. Richard Larson



Mr. Terry Laudick



Dr. Gabriel Lopez



Dr. Gregg L. Mayer



Ms. Cindy McGill



Mr. Robert Nath



Dr. Eric Prossnitz



Dr. Alton Romig, Jr.



Dr. Paul Roth



Ms. Kimberly Sawyer



Dr. Garnett S. Stokes



Dr. John C. Stormont



Mr. Pedro Suarez, Esq.



Mr. Gary Tonjes



Mr. Charles Wellborn




Dr. Craig White



Dr. Richard L. Wood



STC STAFF ORGANIZATIONAL CHART




BUILDING A RAINFOREST IN THE DESERT FY 2018

FY 2018 STC.UNM Vision and Goals

BUILDING A RAINFOREST IN THE DESERT FY 2018

- ❖ Supporting Technology Transfer
- ❖ Catalyzing Economic Development



BUILDING A RAINFOREST IN THE DESERT FY 2018

FY 2018 Accomplishments

BUILDING A RAINFOREST IN THE DESERT FY 2018

Metrics

METRICS

	FY 2014	FY 2015	FY 2016	FY 2017	FY 2018 (Goal)	FY 2018 (Actual)	% of Goal
Disclosures	119	125	102	114	115	107	93%
New U.S. Patent Applications Filed	95	99	77	68	--	93	---
Issued U.S. Patents	45	46	69	73	--	51	---
Option/License Agreements	56	50	54	58	50	52	104%
Start-up Companies	9	9	12	12	10	11	110%
Patent Expenses							
• Licensee Initiated	\$632,041	\$647,381	\$580,294	\$690,153	\$545,000	\$604,020	111%
• STC Initiated	\$844,577	\$962,741	\$1,080,511	\$845,506	\$841,670	\$829,374	99%
License Revenues	\$1,072,923	\$2,043,291	\$1,927,045	\$1,335,632	\$1,738,017	\$1,459,205	84%
Patent Cost Reimbursement Revenues	\$646,026	\$686,256	\$623,677	\$714,805	\$545,000	\$621,413	114%
Combined License & Patent Cost Reimbursement Revenues	\$1,718,949	\$2,729,547	\$2,550,722	\$2,050,437	\$2,283,017	\$2,080,618	91%

BUILDING A RAINFOREST IN THE DESERT FY 2018

Lobo Rainforest – Create a Robust Ecosystem

MARKETING ACTIVITIES

FY 2018

❖ Novelty Searches

- Performed 103 for technologies in FY2018

❖ Information Disclosure Statements

- 926 references collected in-house in FY2018

❖ Non-Confidential Summaries (NCSs)

- Drafted 94 NCSs in FY2018

❖ Marketing/Event Campaigns

- Executed 76 email campaigns for technologies in FY2018
 - Approx. 267 technologies marketed
- Executed 79 email campaigns for outreach/events in FY2018

MARKETING DATA

FY 2018


- ❖ **Of the 76 email campaigns executed in FY2018**
 - 2692 marketing interactions from email campaigns
 - 222 interactions from targeted Outlook emails

- ❖ **Interactions accounted for approx. 72 serious leads in which companies requested more information about technologies**

- ❖ **Sophia Knowledge Management System**
 - 304 current inventor users

MARKETING DATA CHART

FY 2018



FLINTBOX ACTIVITIES

FY 2018


❖ **STC currently has 539 technologies posted on Flintbox**

- 119,180 total page views of 668 different records in FY 2018 Q1
- Average of about 1400 views per day
- Most viewed technologies in FY 2018 Q1
 - End-user direct licensing: Couette Cell for Demonstrating Laminar Flow (STC Ref. 2009-074)
 - Technology Portfolio Q1: Low-Profile, High Tension Mesh Plate for Subcutaneous Fracture Fixation (STC Ref. 2013-112)
- Q2-Q4 data unavailable due to Flintbox upgrade
- Currently have 10 products available for licensing online
 - 1 order from Flintbox in FY 2018
 - 1 Couette Cell for Demonstrating Laminar Flow (Plan Only)

STC WEBSITE



[Home](#) | [News/Events](#) | [Technologies](#) | [Inventors](#) | [Entrepreneurs](#) | [VentureLab](#) | [Economic Development](#) | [About](#)



IN THE SPOTLIGHT...

❖ Website Statistics FY2018

- STC Main Website – 18,841 total visits (-8% from previous Qtr.), 30,563 total page views (-6.7% from previous Qtr.)
- Visits came from 119 different countries

CECCHI VENTURELAB ACTIVITIES

FY 2018

❖ CVL Program Participants

- CVL provided services to 14 physical tenants and 16 virtual program participants in FY 2018
- Physical Tenants
 - Active (9 companies): BioSafe Defense; Yedomia Consultants; Enthentica; InnoBright Technologies; OptiPulse, Inc; Osazda Energy; Pencil-In/MyLens; Blanchfield CO.
 - Inactive (5 companies): ActoProbe, LLC; BlueCom Systems; ElectroSeq, LLC; EquiSeq, Inc.; Air Force Research Laboratory
- Virtual Program Participants
 - Active (6 companies): Verus Research; Kansai TLO; Adaptive Biomedical Design; Kristina Trujillo; Raphael Lobato; Edwin Nemoto
 - Inactive (10 companies): VisionQuest Biomedical; ODMR Technologies; James Costanza; Yedomia Consultants; Pencil-In; CleanSpot Technologies; Enthentica, Inc.; Sandia Bio; DearDrDora.com LLC; BioZera, LLC
- Prospective Participants
 - FisherSci; Viewpoint; Molecular Targeting; Pascal Biosciences; VIC Technologies; Nob Hill Therapeutics; Damour; Mike Wallace; Tom Corbitt; ClearStream; John Chavez; BennuBio; Spincentica; James Goldberg

NEW START-UP OPTIONS/LICENSES SIGNED

FY 2018


- Damour Systems, PBC
 - License signed
- Pascal Biosciences
 - Option signed
- Clearstream Technologies
 - Option signed
- InBios International Inc.
 - License signed
- Memzyme, Inc.
 - Option signed
- SpinCeutica, Inc.
 - Option signed

- BennuBio
 - Option signed
- IC-Safety, LLC
 - Option signed
- BioZera, LLC
 - Option signed
- AgilVax, Inc.
 - Option signed
- Drywired, LLC
 - Option signed
- ShearIT
 - Option signed
- MyLens, Inc.
 - Option signed

- Adapative Biomedical Design, LLC
 - Option signed
- Osazda Energy, LLC
 - License signed
- ex-PAN-cf
 - Option signed
- KT Amigas
 - Option signed
- Viewpoint Molecular Targeting
 - License signed

START-UP COMPANIES

New Mexico vs. Out-of-State



JULY E-NEWSLETTER

FY 2019



Building a Rainforest in the Desert

Welcome to the first edition of the STC.UNM e-newsletter



UNM Ranked 32nd in Granted U.S. Utility Patents Worldwide!



UNM made the list of top 100 worldwide universities with the largest number of issued US patents for the fifth year in a row (recognized by the National Academy of Inventors (NAI) and the Intellectual Property Owners Association (IPO)).

[Read more](#)

[Check out our list of fourth quarter issued patents](#)

STC Metrics for Fiscal Year 2018

51 U.S. Issued patents

11 Start-ups

107 Invention disclosures



[Spring Statewide Technology Showcase Draws Investors and Industry Reps to New Mexico](#)



[UNM Inaugural Health Hackathon a Success](#)



New Startup at the Lobo Rainforest Building Creating Next Gen Solution to Cloud Vulnerability



Lens Team: Cody Eilar, Mark Chavez, Charles Wisoff, Kyle Guin

Native New Mexican Mark Chavez has started a company called Lens which could lead us away from the cloud and into the light. Chavez, along with co-investors and a fresh influx of capital from STC's Co-Investment Fund, is working right now at the Lobo Rainforest Building in downtown Albuquerque to create a new way to give online users control over their own data.

[Read more](#)

MARKETING COLLATERAL

- ❖ Updated all STC Materials with new Lobo Rainforest Building address
- ❖ New Lobo Rainforest Building brochure
- ❖ Included in STC folders



MARKETING VIDEO

❖ Sang M. Han, 2018 Innovation Fellow



BUILDING A RAINFOREST IN THE DESERT FY 2018


Build Innovate New Mexico Partnerships

GROW INNOVATE NEW MEXICO

- ❖ Members: STC.UNM, New Mexico State University, New Mexico Tech, Sandia National Laboratories, Los Alamos National Laboratory, Air Force Research Laboratory

INNOVATE NEW MEXICO®

Discover The State of Innovation



INNOVATE NEW MEXICO TECHNOLOGY SHOWCASE

October 17, 2017



- ❖ **Keynote Speaker: Louis P. Berneman, EdD, CLP, Founding Partner, Osage University Partners**
- ❖ **Lunchtime Panel - Startup Companies in New Mexico, featuring DefendSix Corp., Pajarito Powder, Agilvax, and Advanced Manufactured Power Solutions, LLC (AMPS)**
- ❖ **Technology Presentations:**
 - Optical Rubidium Atomic Frequency Standard, Kyle Martin (AFRL)
 - Flow Cytometry: New Time-Dependent Technologies, Jessica P. Houston, PhD (NMSU)
 - A Solution for Drug Resistant Skin Infections and Wounds, Danielle Turner, PhD and Snezna Rogelj, PhD (NM Tech)
 - Optimized Surface Dimpling for Commercial Vehicles, Aircraft, and Energy Applications, Sal Rodriguez, PhD (Sandia Labs)
 - Transgenic Approaches to Improving Crop Plants - Increasing Biomass and Yields, Champa Gopalan, PhD (NMSU)
 - Crack-Tolerant Advanced Metallization for PV, Sang Han, PhD (UNM)
 - Compact Environmental Anomaly Sensor, Lt. David Stiles (AFRL)
 - Internet for Everyone Using Air-Buoyant Vessels, Miles Beaux (Los Alamos)
 - High Sensitivity Bearing Tester, Brendan L. Nation (Sandia Labs)
 - Electrochemical Quantitation of Antinuclear Antibodies at the Point-of-Care, Robert Rubin, PhD (UNM)
 - Simple and Reliable Precious Metal Separations, Benjamin Stein (Los Alamos)
 - Rare Earth Oxide Composites, Nikolai Kalugin, PhD (NM Tech)

INNOVATE NEW MEXICO TECHNOLOGY SHOWCASE

October 17, 2017



INNOVATE NEW MEXICO TECHNOLOGY SHOWCASE

May 1, 2018

- ❖ **Keynote Speaker:**
Dr. Robert Peterkin, Director of the Albuquerque Operations for General Atomics Electromagnetic Systems (GA-EMS)
- ❖ **Lunchtime Panel** - Companies in New Mexico, featuring RiskSense, Inc., MagPi Innovations, NTxBIO, OptiPulse, Inc., and Osazda Energy, LLC.
- ❖ **Technology Presentations:**
 - *Dif-Fix: Get Your Gut Back*, /Anand Kumar, PhD (Los Alamos)
 - *bioZera – 3D Bio-Printing*, Christina Salas, PhD (UNM)
 - *Digitally Unclonable Function (DUF)*, Peter Choi, PhD (Sandia)
 - *Optically Levitated Nanoparticle Accelerometer*, Maxwell Gregoire, PhD (AFRL)
 - *Ultrafast X-Ray Imager (UXI)*, Marcos Sanchez (Sandia)
 - *Assessing the Condition of Railroad Bridges Using Unmanned Aerial Vehicles (UAVs)*, Fernando Moreu, PhD, PE (UNM)
 - *Ultra-High Vacuum System Assembly Tool*, Oscar Martinez, PhD (AFRL)
 - *Rapid Sepsis Sensor*, Jessica Kubicek-Sutherland, PhD (Los Alamos)
 - *Alert Cardio: Low Power Integrated System for Real-Time Arrhythmia Detection*, Wei Tang, PhD (NMSU)
 - *Prosthetic Sleeve Liner*, Neda Sanatkaran, PhD (NMSU)



May 1, 2018
8:00 am - 5:00 pm
Albuquerque, New Mexico

INNOVATE NEW MEXICO®
Discover The State of Innovation

Attend this special collaborative event, sponsored by PhRMA, which will highlight research and technology opportunities, start-up companies, and economic development resources from the leading research institutions in the state of New Mexico!

Innovate New Mexico Technology Showcase

Representatives and researchers/investigators from all 6 research institutions in New Mexico, including the University of New Mexico, the Air Force Research Lab, Los Alamos National Lab, Sandia National Labs, New Mexico Tech and New Mexico State University will be in attendance.

Early registration is \$30, space is limited. Register at: <https://innovate-new-mexico.eventbrite.com>

Showcase will be held at Sandia Golf Club, 30 Rainbow Road, Albuquerque, NM 87113.

Logos: MEP, STC.UNM, PhRMA, AFRL, Sandia National Laboratories, Los Alamos National Laboratory, NEW MEXICO TECH, THE UNIVERSITY OF NEW MEXICO, NEW MEXICO, NM STATE UNIVERSITY



INNOVATE NEW MEXICO TECHNOLOGY SHOWCASE

May 1, 2018



INNOVATE NEW MEXICO

Website and Social Media



InnovateNewMexico.com
Follow @InnovateNewMexico/@InnovateNM

BUILDING A RAINFOREST IN THE DESERT FY2018

Grow Partnerships and Diversify Income

INNOVATION ACADEMY

Program Data



860

Students registered for iA



29

Student-run companies currently in business



143

iA approved courses taught each semester



85

Students received academic credit for starting their business



\$1.3 million

in venture funding for student-run businesses



Program progress

- >50% female, >50% students of color, >65% first generation college students
- 350 attendees to the 12-week Startup School
- Pitch Competitions had over 190 companies/groups and over \$50,000 in prize money
- 6-credit accelerator program with Creative Startups launching August 2017
- 82 students enrolled in 2+1+2 Associates to MBA



INNOVATION ACADEMY

Activities

- ❖ Innovation, Creativity, & Entrepreneurship Student Internship Fairs
 - August 29, 2017
 - March 29, 2018
- ❖ Create Your Own Job Fair
- ❖ Create, Sell, Bank Class launched this fall 2017 and continued in spring 2018
- ❖ Grant(s) (IA & STC joint)
 - Awarded NSF I-Corps Site Proposal
 - Launched program in Fall 2017
 - Applied to EDA University Center
- ❖ Pitch Competitions



Student Internship Fair – Fall 2017

LOBO RAINFOREST I-CORPS SITE

- ❖ To encourage and support entrepreneurs from all disciplines and backgrounds at UNM to commercialize their projects, create new start-up businesses, generate licensing agreements and business models, and submit fundable proposals to the I-Corps program
- ❖ Receive up to \$3,000 to participate in the customer discovery process of a STEM-related innovation
- ❖ 2 cohorts per year
- ❖ Program consists of workshops and meetings over 10 weeks, where teams work to validate the market size, value propositions, and customer segments of their innovations
- ❖ First Cohort started in October 2017
- ❖ <http://loborainforest.com/icorps/>



LOBO RAINFOREST I-CORPS SITE

Fall 2017 Cohort

Teams

- ❖ Adaptive Biomedical Design – Hydrogels for drug delivery to improve patient experience
- ❖ Pencil-In – A phone application allowing users to scan dates, schedules, and calendars into their own calendar by taking a photo of the subject. Also includes a business card-to-contact scanner and document-to-note scanner
- ❖ Mnemosyne Informatics, LLC – Empathic AI modeling training through gamification
- ❖ Metallum Innova – Visualization software that maps exact location of a nasogastric feeding tube while minimizing exposure to ionizing radiation using an array of metal detectors
- ❖ RAIDS - (Remote Autonomous Insecticide Delivery SystemBamConn LLC) – Bamboo connectors to provide a moment resisting joint when combining 3 or more bamboo poles with 4-14 inch diameters. A quick, low-cost, sustainable alternative to 2-4 story commercial buildings
- ❖ SMILAB (Smart Management of Infrastructure Laboratory) – Low-cost, efficient real-time sensing platform to collect railroad bridge displacement data and assess bridge condition
- ❖ Clearstream Technologies LLC – A client/server software framework that allows video streaming users to control video quality based on constraints they define and the preferences they specify
- ❖ Shower Chaise – Modular shower chair which eases bathing for those with physical limitations
- ❖ Pressure Ulcer Relief (PUR) Technologies – A commercialized bed pad, used at home, that continually inflates and deflates at random pressure spots



LOBO RAINFOREST I-CORPS SITE

Spring 2018 Cohort

- ❖ Specialized Vial Rack for phlebotomist and nurses
- ❖ Triage System for emergency rooms and urgent care
- ❖ Adaptive Biomedical Design, Sidekick wheelchair accessories
- ❖ BioTUMS, an alternative treatment to fecal microbiota transplant
- ❖ Phytography to monitor the onset of moderate drought stress
- ❖ Novel Virus-Like Particle (VLP)-Based Vaccines Against Alzheimer's Disease Tau Pathology
- ❖ Early detection of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases
- ❖ Zeppelin, a platform for all event needs
- ❖ Arkr, augmented reality technology to attach media (gifs, videos) to posters
- ❖ Technology Collaborations, collaborative technology products and systems



LOBO RAINFOREST I-CORPS SITE

National Labs

- ❖ Teams from both Sandia and AFRL-NM will be participating in the National Labs Lobo Rainforest I-Corps Site
- ❖ Launching in Fall 2018
- ❖ Labs are providing program support and team funding
- ❖ 10 weeks of training and meetings



RAINFOREST STUDENT PITCH COMPETITION

This is a community initiative to help recognize our student entrepreneurs in the state!

- ❖ Hosted by STC.UNM and the UNM Innovation Academy
- ❖ **Next competition on November 5, 2018 at Bow and Arrow.**
- ❖ Student entrepreneurs present their innovative ideas for products, services or technologies in 60-90 second presentations before entrepreneurs, investors, and business professionals in the community
- ❖ Competition open to students from any university in the state of New Mexico



RAINFOREST STUDENT PITCH COMPETITION

November 13, 2017



- ❖ *10 Finalists*
- ❖ *5 Winners split \$5,000*



- ❖ Sponsors included UNM School of Engineering, Nusenda Credit Union, Jaynes, Signet, Dekker/Perich/Sabatini, Bow & Arrow (donated space)

STUDENT BUSINESSES

Pitch competition companies in business

- ❖ BioSafe Defenses
- ❖ EcoPesticides
- ❖ Cornivore
- ❖ Armis
- ❖ \$ave \$quad
- ❖ Pencil-In
- ❖ Ale Republic
- ❖ Blossom Beauty
- ❖ TABS
- ❖ Back to Earth (raised over \$1M in crowdfund campaign)
- ❖ Inde Beat
- ❖ Saavy
- ❖ CRAFTED ABQ
- ❖ RepUniversity
- ❖ Shutter Bombs, LLC
- ❖ Adaptive Biomedical Design
- ❖ Dipped by Dee
- ❖ Kaiser Music LLC

UNM Health Hackathon

May 18-20, 2018


- ❖ A new program aimed at generating new ideas that could improve medical treatment and patient care held its first hackathon at the UNM Health Sciences
- ❖ 70 attendees
- ❖ 11 teams of physicians, surgeons, faculty, postdocs, and students and community members
- ❖ Two \$10,000 awards provided by the UNM Clinical & Translational Science Center
 - Visi Stik, an improved cane for the visually impaired that senses the environment in 3D.
 - Flex Trach, an improved laryngoscope design for intubations.



STC SOCIAL MEDIA ACTIVITIES

FY 2018

Followers



APLU CICEP REPORT

Technology Transfer Evolution

- ❖ APLU examining how university technology transfer is evolving, in the context of broader economic engagement strategies.
- ❖ One topic included is “Adapting Innovation Management Structures”
 - Aligning and connecting innovation management with industry liaison, research parks, entrepreneurship, economic development, and other related activities
 - Reporting structure for different aspects of economic engagement, including where innovation management is placed in the organization, to whom it reports, and which units it directly supervises or works with laterally
 - People and skill sets
- ❖ The Innovate New Mexico Initiative was highlighted as doing well in the “Adapting Innovation Management Structures” topic.



CONFERENCES, GRANTS, AGREEMENTS IN JAPAN

FY 2018

❖ Conferences

- Hack Osaka 2018
- Nano Tech Japan 2018
- EDGE Next Symposium
- Innovation Stream Kansai
- Get in the Ring 2018

❖ Grants

- Hakuodo AD+Venture Challenges
 - Submitted a plan for pitch event and have winners come over to STC for internship program
 - Only one project selected for \$500,000 – Not awarded
- Osaka Prefecture University MEXT Leading Graduate Program – applied

❖ International Virtual Office Agreement

- Monthly Fee to access STC staff and interns for marketing and research
 - Osaka University
 - Kansai TLO – January to June 2018, \$3000 fee

PROFESSOR VISITS TO JAPAN

- ❖ Under the MOU between UNM College of Education, Health Sciences and Sports Science, and University of Tsukuba, Department of Sports Science, two students from UNM HESS and Associate Dean Gloria Napper Owen attended Tsukuba Summer Institute in Japan
- ❖ Dinner with Dr. Joe Cecchi and Amy
- ❖ Dr. Plamen Atanasov visit to Kwansei Gakuin University and Spring 8
- ❖ Dr. Andrea Mammoli



NEDO DELEGATION VISIT FOR COMPLETION OF US-JAPAN SMART GRID PROJECT



- ❖ Completion of 9 years of US-Japan Smart Grid Demonstration Project
- ❖ NEDO & Mitsubishi Research Institute funded Dr. Andrea Mammoli (CEET)


Agenda

10:30AM	Welcome from UNM and project overview (Andrea Mammoli)
10:35AM	Prescient scenario generator and VPP rolling horizon scheduler (Andrea Staid, Jay Johnson and Ricky Conception)
11:00AM	MPC dispatcher (Yasser Yasaei)
11:15AM	Residential load synthesis (Andrea Mammoli + Victor Ayon)
11:30AM	Load forecasting (Manel Martinez + Miguel Angel Hombrados Herrera)
11:45AM	Database structure (Matt Robinson)
12:00PM	Opal RT distribution system simulation (Nick Heine)
12:15PM	Q&A
12:30PM	Demonstration of system operation

JAPAN UNIVERSITY RANKING

❖ Japan University Ranking that STC has as connections:

1. Kyoto University
1. University of Tokyo
8. Osaka University
9. University of Tsukuba
19. Chiba University
20. Kanazawa Univ.
31. Kansei Gakuin Univ.
36. Kumamoto Univ.
54. Shinshu Univ.
65. Osaka Prefecture Univ.
84. Seikei Univ.
99. University of Ryukyus
151. Mukogawa Women's Univ.




https://www.timeshighereducation.com/rankings/japan-university/2018#!page/0/length/25/sort_by/rank/sort_order/asc/cols/stats

INCOME SUMMARY

	FY 2017	FY 2018
License Income	\$1,335,632	\$1,459,205
Patent Reimbursement	\$714,805	\$621,413
Training	\$9,000	\$32,229
Grants	--	\$50,000
CVL Participation Fees	\$49,344	\$43,199
Sponsorships – Innovate NM	\$45,624	\$29,519
Sponsorships – Pitch competition	\$9,723	\$9,000
Sponsorships – Innovation Awards	\$30,913	\$29,385
AFRL Activity – Training, Rent, STEM	--	\$193,088
Total	\$2,195,041	\$2,467,038

REVENUE DIVERSIFICATION

FY2018



BUILDING A RAINFOREST IN THE DESERT FY2018

Build Research and Other Connections for
UNM

CONNECTIONS

Partnership Intermediary Agreement with AFRL thru New Mexico Tech – FY 2018

❖ **STC Members Providing Support For AFRL:**

- Arlene Mirabal, Marketing Manager, AFRL PIA Project Manager
- Gabe Wilkinson, Commercialization Assistant
- Innovation Interns

❖ **FY 2018 Training Activities:**

- Bi-weekly Meetings Including Operations, Marketing, IP, and Innovation
- Training Sessions for Wellspring Sophia Software System
- Training seminars:
 - In-reach
 - Commercialization/marketing
 - Anatomy of Licensing Agreements
 - Sophia Marketing Module
 - Licensing Terms
 - Commercialization Process & Flow Chart
 - Social Media Technology Marketing
 - Inventor Recognition
 - Agreements in Sophia
 - Queries and Reporting in Sophia

CONNECTIONS

Partnership Intermediary Agreement with AFRL thru New Mexico Tech – FY 2018

❖ **FY 2018 Marketing Activities:**

- Weekly Marketing Meetings
- Prior-art Searches (Invention Portfolio and Poster Session)
 - 15 prior art searches in Q2
 - 4 prior art searches in Q3
 - 4 prior art searches in Q4
- Marketing Campaigns and Reports on AFRL Technology and IP Portfolio
 - Of the 13 email campaigns executed in FY2018
 - 870 marketing interactions from email campaigns
 - 11 serious leads/responses requesting more information

● Development of Technology Reports

- Raman Amplifiers – covering 6 technologies
- Fiber Laser Amplifiers – covering 5 technologies
- Permanent Magnets – covering 1 technology
- Wavefront Control/Adaptive Optics – covering 1 technology
- Deployable Structures – covering 6 technologies
- Magnetrons – covering 3 technologies
- Laser Beam Combiners – covering 7 technologies
- Vibration Isolation – covering 1 technology

JOINTLY-OWNED INVENTIONS

Activity with Sandia and LANL

	Sandia	LANL
Jointly-owned inventions	201	41
• Active	104	20
• Closed	97	21
Number of commercialization agreements	98	23
Number in which STC has taken lead	74	23
Number of option and license agreements executed with STC as lead	32	5
Number of option and license agreements executed with partners as lead	5	-
Income from option and license agreements with STC as lead	\$10,721,173 ^(a)	\$310,363
Start-ups from option and license agreements with STC as lead	6	2
Income from option and license agreements with partners as lead	\$134,950	\$-0-
Start-ups from option and license agreements with partners as lead	2	-

- ❖ Currently have 21 outstanding commercialization agreements with Sandia
- ❖ 5 new joint inventions with Sandia disclosed during FY 2018
- ❖ 10 commercialization agreements with Sandia executed during FY 2018

(a) Gross licensing income composed of pooled technologies that also include other non-jointly-owned technologies

UNM RESEARCH

Task Force on Enhancing Corporate-Funded Research


❖ General objectives

- Assess the current mechanisms by which UNM is successful in securing industrially-funded research
- Propose new initiatives that are likely to enhance our competitiveness in this area
- Develop mechanisms for assessment of new initiatives that are implemented

❖ Members

- Chairs: Dr. Gabriel Lopez and Dr. Richard Larson
- Lisa Kuuttila, CEO, STC.UNM
- Jeff Norenberg, Radiopharmaceutical Sciences
- Steven Brueck, Center for High Technology Materials (CHTM)
- Eric Prossnitz, Internal Medicine
- Jeremy Edwards, Chemistry & Chemical Biology
- Angela Wandinger-Ness, Pathology
- Edl Schamiloglu, Electrical & Computer Engineering

STC'S ECONOMIC DEVELOPMENT ACTIVITES



ECONOMIC DEVELOPMENT ACTIVITIES

UNM Rainforest Forum

- ❖ Formerly the UNM Economic Development Forum
- ❖ Over 200 members from the business community
- ❖ Monthly meetings beginning August 24, 2012, meetings now quarterly
- ❖ FY 2018 topics/presenters:

Speaker	Date	Topic
Lobo Rainforest Building Team	8/25/17	Ribbon Cutting and Open House
Matt Fetrow, AFRL-New Mexico	11/9/17	Update on AFRL and partnership with STC
Lobo Rainforest Panel <ul style="list-style-type: none">• Rob Delcampo, Innovation Academy• Kyle Guin, Lobo Rainforest Student• Matthew Fetrow, AFRL• Mary Monson, Sandia• Lisa Kuuttila, STC• Mathis Shinnick, OptiPulse	2/8/18	Organizations and activities in the Lobo Rainforest Building
Dr. Martin Kistin, Project ECHO	5/10/18	Project ECHO

ECONOMIC DEVELOPMENT ACTIVITIES

UNM Economic Development Council

- ❖ 39 members
- ❖ Monthly meetings beginning June 26, 2013
- ❖ FY 2018 topics/presenters:

Speaker	Date	Topic
Lobo Rainforest Building Ribbon Cutting	8/25/17	Lobo Rainforest Building
Lisa Kuuttila, STC.UNM	9/26/17	Update on UNM Economic Development Activities
Dana Feldman, Director, Cultural Services, COA	10/26/17	Overview of City of Albuquerque's Cultural Services' programs and department
Julia Wise, PhD, Manager of the Office of Science and Technology, State of NM Economic Development Department	11/30/17	NMEDD Overview and Programs
Fred Mondragon, Interim Director, City of Albuquerque	1/25/18	City's plans for Economic Development
Tim Nitti, President & CEO, New Mexico Partnership	2/22/18	New Mexico Partnership's activities
Tom Neale, Director of Real Estate, University of New Mexico	3/22/18	Discussion of future plans on south campus
Deanna Archuleta, Interim Economic Development Director, Bernalillo County	4/26/18	Bernalillo County Economic Development

ECONOMIC DEVELOPMENT ACTIVITIES

UNM Economic Impact Report

- ❖ \$50,000 grant from New Mexico Gas Company/Emera, Inc.
- ❖ Conduct a UNM economic impact study that will measure the economic impact of UNM.
- ❖ The study will be conducted by Kelly O'Donnell, O'Donnell Economics and Strategy.
- ❖ Report to be released August 2018



BUILDING A RAINFOREST IN THE DESERT FY 2018

Grow Event Program at Lobo Rainforest

STC AND SCORE OFFICE HOURS

- ❖ Office hours with SCORE and STC (formerly New Ventures Café)
- ❖ Held on the last Friday of each month
 - SCORE Mentors meet with UNM students, faculty, and start-ups to discuss technology/business ideas
 - STC staff members available to meet to answer questions related to the technology-transfer process. UNM Faculty are also welcome and encouraged to stop by to get any documentation signed related to their intellectual property. Notary available as well.



NAVAJO NATION ANNOUNCEMENT

WELCOME NAVAJO NATION UNM STUDENTS TO THE LOBO RAINFOREST BUILDING!

Friday, January 12, 2018
10:30 am—noon
Lobo Rainforest Building
101 Broadway Blvd. NE, Albuquerque, NM 87102

Dolly Manson, Ph.D., UNM Professor, Navajo Linguistics
Navajo Invocation

Robert M. Doughty, President, UNM Board of Regents
Welcome and Vision of Partnership with Navajo Nation
Introduction of Special Guests

David W. Harris, UNM Executive Vice President & Chief Operating Officer
Lobo Rainforest Background and Vision

Terry Laudick, Board Vice Chair, Innovate ABQ, Inc., President and CEO, Nusenda Credit Union
Innovate ABQ Public/Private Partnership

Sandra Begay, Chair, STC, UNM Board of Directors
STC Board Comments
Introduction of Navajo Nation President

Russell Begaye, President, Navajo Nation
Navajo Nation Goals for Partnership

Jonathan Nez, Vice President, Navajo Nation

Amber Kanazbah Crotty, Honorable Council Delegate, 23rd Navajo Nation Council

Robert G. DelCampo, Ph.D., Executive Director, UNM Innovation Academy
Innovation Academy Programming Partnership

Lisa Kuuttila, President & CEO, STC, UNM
Opportunities for Collaboration with Navajo Nation

Hanging of Navajo Nation Flag and Plaque (floors 5 & 6)

Conclusion & Tours

STC.UNM THE UNIVERSITY OF
NEW MEXICO



- ❖ The University of New Mexico and Navajo Nation have announced a partnership to provide residence hall space for 118 Navajo students at Lobo Rainforest
- ❖ Navajo Nation will pay UNM the sum of \$1,457,300 for occupancy of the fifth and sixth floors of the building



February 5, 2019

LOBO RAINFOREST BUILDING

lobo RAINFOREST



LOBO RAINFOREST MENTOR PROGRAM

Mentors and Student Ambassador

- ❖ The primary goal of the Lobo Rainforest Mentor program is to engage UNM students and faculty with seasoned entrepreneurs and business executives. Through various activities and office hours, mentors will provide guidance, coaching, perspective, and connections to enhance entrepreneurship at UNM.



Wayne Laslie



Susan Cornelius



Terry Dunlay



Gregg Mayer



Mathis Shinnick

- ❖ Others invited

- ❖ Kyle Guin, Student Ambassador



February 5, 2019

BUILDING A RAINFOREST IN THE DESERT FY 2018

Internal UNM Support

2018 STC CALENDAR



January



Christos Christodoulou, Ph.D.

February



Edgar C. Boedeker, M.D.

March



David T. Hanson, Ph.D.

April



Erin D. Milligan, Ph.D.

May



John T. McGraw, Ph.D.

June



Nora Perrone-Bizzozero, Ph.D.

July



Susan R. Atlas, Ph.D.

August



Alexandre Chigaev, Ph.D.

September



Christina Salas, Ph.D.

October



Richard C. Harvey, Ph.D.

November



Edl Schamiloglu, Ph.D.

December



Mark Hauswald, M.D.

INVENTOR HONORS



NATIONAL ACADEMY
of INVENTORS
FELLOW



2017 Fellow

Cheryl L. Willman, M.D.

Distinguished Professor of Pathology
Director & CEO of the UNM
Comprehensive Cancer Center



2017 Fellow

Plamen B. Atanassov, Ph.D.

Distinguished Professor of Chemical and
Biological Engineering
Director of the UNM Center for Micro-
Engineered Materials



2016 Fellow

Gabriel P. López, Ph.D.

Vice President for Research
Professor, Department of Chemical &
Biological Engineering
Founding Director and Member, Center for
Biomedical Engineering
The University of New Mexico



2015 Fellow

C. Jeffrey Brinker, Ph.D.

Distinguished and Regents'
Professor, Department of Chemical &
Biological Engineering
Professor, Department of Molecular Genetics &
Microbiology
Member, UNM Cancer Center
The University of New Mexico




2015 Fellow

Steven R. J. Brueck, Ph.D.

Distinguished & Professor Emeritus
Department of Electrical & Computer
Engineering
Department Physics & Astronomy
Center for High Technology Materials
The University of New Mexico

NAI RANKING



“UNM's ranking is certainly due to STC.UNM's efforts in setting [the] tone for IP at UNM. If the results were normalized to the size of the research funding, I'm sure UNM would be near the top!!!!”

Steve Brueck
2010 Innovation Fellow
National Academy of Inventors Fellow


Top 100 Worldwide Universities Granted U.S. Utility Patents in 2017

1	UNIVERSITY OF CALIFORNIA, THE REGENTS OF	524	28	KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY	76
2	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	306	29	UNIVERSITY OF MINNESOTA, THE REGENTS OF	75
3	UNIVERSITY OF TEXAS	219	30	KING SAUD UNIVERSITY	72
4	STANFORD UNIVERSITY	204	31	RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK	69
5	TSINGHUA UNIVERSITY	176	32	SCIENCE & TECHNOLOGY CORPORATION AT UNIVERSITY OF NEW MEXICO	67
6	KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS	167	33	UNIVERSITY OF UTAH RESEARCH FOUNDATION / UNIVERSITY OF UTAH	66
7	JOHNS HOPKINS UNIVERSITY	164	34	KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION	63
8	WISCONSIN ALUMNI RESEARCH FOUNDATION	162	35	SUNGKYUNKWAN UNIVERSITY RESEARCH & BUSINESS FOUNDATION	62
9	HARVARD COLLEGE, PRESIDENT AND FELLOWS	156	36	INDUSTRY-ACADEMIC COOPERATION FOUNDATION YONSEI UNIVERSITY	59
10	CALIFORNIA INSTITUTE OF TECHNOLOGY	150	37	RUTGERS UNIVERSITY	57
11	UNIVERSITY OF MICHIGAN	128	37	VANDERBILT UNIVERSITY	57
12	UNIVERSITY OF SOUTH FLORIDA	116	39	TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD.	56
13	UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED / UNIVERSITY OF FLORIDA	111	40	CARNEGIE-MELLON UNIVERSITY	55
14	NORTHWESTERN UNIVERSITY	106	41	SEOUL NATIONAL UNIVERSITY RESEARCH & DEVELOPMENT BUSINESS FOUNDATION	54
15	CORNELL UNIVERSITY	102	41	UNIVERSITY OF SOUTHERN CALIFORNIA	54
15	UNIVERSITY OF PENNSYLVANIA	102	43	CASE WESTERN RESERVE UNIVERSITY	53
17	ARIZONA STATE UNIVERSITY	100	43	GEORGIA TECH RESEARCH CORP.	53
17	PURDUE RESEARCH FOUNDATION	100	45	PENN STATE RESEARCH FOUNDATION, INC.	52
19	COLUMBIA UNIVERSITY	98	45	POSTECH ACADEMY-INDUSTRY FOUNDATION	52
20	NEW YORK UNIVERSITY	95	45	UNIVERSITY OF MASSACHUSETTS	52
21	UNIVERSITY OF PITTSBURGH	94	48	ÉCOLE POLYTECHNIQUE, FÉDÉRALE DE LAUSANNE	51
22	UNIVERSITY OF WASHINGTON	92	48	NATIONAL TAIWAN UNIVERSITY	51
23	NATIONAL TSING HUA UNIVERSITY	87	48	UNIVERSITY OF MARYLAND	51
24	UNIVERSITY OF ILLINOIS	85	48	YALE UNIVERSITY	51
25	UNIVERSITY OF CHICAGO / UCHICAGO ARGONNE LLC	84	52	THE UNIVERSITY OF TOKYO	48
26	UNIVERSITY OF NORTH CAROLINA	82			
27	DUKE UNIVERSITY	78			

REPORT: UNM RANKS 32ND WORLDWIDE FOR PATENTS



2018 INNOVATION AWARDS



2018 INNOVATION AWARDS

Awards Dinner Program

Thursday, April 12, 2018 • UNM Student Union Building (SUB) • Ballrooms B & C

Recognizing University of New Mexico Faculty, Staff and Students Who Have Received Issued U.S. Patents, Trademarks and Registered Copyrights (March 1, 2017 - February 28, 2018)

Honoring the 2018 STC.UNM Innovation Fellow

Honoring 2017 National Academy of Inventors (NAI) Fellows from UNM

5:00 pm Reception Begins
Networking and visiting startup company tables
Hors d'oeuvres served

6:00 pm Program Begins
Dinner served

Welcome

Sandra Begay
Chair, STC.UNM Board of Directors
Principal Member of the Technical Staff
Tribal Energy Program
Sandia National Laboratories

Opening Remarks and Introduction of Keynote Speaker

Garnett S. Stokes, Ph.D.
President
The University of New Mexico

Keynote Speaker

David S. Joseph
Co-Founder, President & CEO, Chairman
Avisa Pharma, Inc.

Comments from Main Campus Senior Administration

Gabriel P. López, Ph.D.
Vice President for Research
Office of the Vice President for Research
The University of New Mexico

Comments from Health Sciences Center Senior Administration

Richard S. Larson, M.D., Ph.D.
Executive Vice Chancellor
Vice Chancellor for Research
Health Sciences Center
The University of New Mexico

Presentation of Awards to Inventors

Lisa Kuuttila
CEO & Chief Economic Development Officer
STC.UNM

Special Recognition of Steven R. J. Brueck, Ph.D.

Lisa Kuuttila

Honoring 2017 National Academy of Inventors (NAI) Fellows

Lisa Kuuttila

2017 NAI Fellow

Cheryl L. Willman, M.D.
Distinguished Professor, Dept. of Pathology
Director & CEO, Comprehensive Cancer Center
The University of New Mexico

2017 NAI Fellow

Plamen B. Atanassov, Ph.D.
Distinguished Professor, Dept. of Chemical & Biological Engineering
Director, Center for Micro-Engineered Materials
The University of New Mexico

Presentation of 2018 STC.UNM Innovation Fellow Award

Sandra Begay


2018 STC.UNM Innovation Fellow

Sang M. Han, Ph.D.
Professor, Dept. of Chemical & Biological Engineering
Professor, Dept. of Electrical & Computer Engineering
The University of New Mexico

Closing Remarks

Sandra Begay

7:30 pm Reception Ends



2018 INNOVATION AWARDS

63 UNM inventors received patents

56 U.S. patents issued

42 patents from UNM main campus

14 patents from HSC

Feedback

“I want to commend you and your team in putting together a very impressive show highlighting the contributions of UNM faculty and researchers.... You all need to be applauded for such a fine undertaking. I am glad the UNM president attended and got to see the whole ceremony.”

**Abhaya K. Datye, Distinguished
Regents Professor & Department
Chair, Chemical & Biological
Engineering**

“I would also like to thank you and your team for putting together an outstanding evening at the STC Innovation Awards Dinner. It is a truly special event that celebrates accomplishments and our community. I enjoy it enormously and will have to work hard on getting one of our pending patents allowed so we can join again in 2019 ;-).”

**Angela Wandinger-Ness, Vice Chair for
Research, Pathology**


Many Lifesaving or Life Improving Blockbuster Products or Companies Emerged from University Research

Genentech
A Member of the Roche Group

GARDASIL[®] 9
Human Papillomavirus
9-valent Vaccine, Recombinant

Akamai

Google




LYRICA[®]
PREGABALIN

Enbrel[®]
etanercept



Lex Machina[™]
a LexisNexis[®] Company

Xalatan[®]



Bigliani/Flatow[®]
The Complete
Shoulder
Solution TSA
Surgical Technique


FireEye[®]



Remicade[®]
INFLIXIMAB



vmware[®]



RSA[®]

COUMADIN[®]
(Warfarin Sodium Tablets, USP) Crystalline
1 mg 2 mg 2.5 mg 3 mg 4 mg 5 mg 6 mg 7.5 mg 10 mg



CRISPR[®]
THERAPEUTICS

editas[®]
MEDICINE



Oculus



Blu-ray Disc[™]

Kite
A GILEAD Company

Juno
THERAPEUTICS



duolingo



Blue LED

February 5, 2019

Compiled by Columbia Technology Ventures

BUILDING A RAINFOREST IN THE DESERT FY 2018

FY 2018 Data, Income Analysis & Forecast


DATA, INCOME ANALYSIS, & FORECAST

❖ FY 2018 Data

- STC filed first-time patent applications on 76 of the 107 patent disclosures in FY2018 (71% vs. 50% in FY2017)
- STC generated \$255,628 of new (agreements) license revenues in FY2018, representing 18% of total license revenues (vs. \$734,256 of new revenues in FY2017 – 55% of total)
- Of the 107 total disclosures (patents & copyrights) received in FY2018, representing 81 lead inventors, 37 were first-time inventors (46% vs. 44% in FY2017)

PATENT ANALYSIS


Trends in Patent Activity



	FY15	FY16	FY17	FY18
Provisional Filings	158	147	137	153
Non-Provisional	172	165	112	119
Notice of Allowance	57	58	74	49

DATA, INCOME ANALYSIS, & FORECAST

**License and Patent Cost Reimbursement Income
(excludes assertion license revenues)**




DATA, INCOME ANALYSIS, & FORECAST

STC License Revenues - Actual & Forecast Assumptions (same assumptions as prior year projections)


- ❖ Minimum numbers for FY2019 through FY2021 represent minimum fees and payments from existing licenses.
- ❖ FY2019 mid-level represents approx. \$632,000 of new license income. FY2019 upper end represents \$750,000 of new license income.
- ❖ FY2020 mid-level represents \$500,000 of new license income and/or minimums from deals closed in FY2019. FY2021 upper end represents \$600,000 of new license income and/or minimums from deals closed in FY2019.
- ❖ FY2021 mid-level represents \$400,000 of new license income and/or minimums from deals closed in FY2019 and FY2020. FY2021 upper end represents \$550,000 of new license income and/or minimums from deals closed in FY2019 and FY2020.
- ❖ No equity liquidations included.
- ❖ No forecasted terminations of agreements included.
- ❖ No unknown substantial earned royalties forecasted.

STC LICENSE REVENUES

Updated 3-year Forecast




PATENT REIMBURSEMENT REVENUES




PATENT COSTS INCURRED

STC-INITIATED; NON-LICENSEE REIMBURSED



TOTAL NUMBER OF LICENSES/OPTIONS YIELDING REVENUES





The University of New Mexico
Purchasing Department
MSC01 1240
1 University of New Mexico
Albuquerque, NM 87131-0001

To: Craig White, Interim Senior VP for Finance and Administration
From: Bruce Cherrin, Chief Procurement Officer
Subject: **Contract Approval**
Date: January 25, 2019

The following is being submitted for approval per Regent Policy 7.4. This will need to proceed to the full Board of Regents for approval.

UNM Division of Human Resources – Life and Disability Insurance Carriers

History

UNM offers life and disability to eligible employees and retirees. UNM's current life and disability carrier is the Standard Insurance Company and has been in place since January 1, 2012. Basic life insurance and long-term disability (LTD) are funded by a combination of employee/retiree and employer funds. Supplemental life, accidental death and dismemberment (AD&D) and short-term disability (STD) are 100% paid by employees/retirees.

Summary of Committee Activity

Proposals for RFP # 2062-19 were solicited via UNM's LoboMart system on October 11, 2018 on behalf of the Division of Human Resources for life and disability insurance plans. There were a total of 7 responses received by the November 2, 2018 deadline.

Proposals and evaluation criteria were distributed to the 5-member evaluation committee on November 3, 2018. The Committee included representation from the Division of Human Resources-Benefits Department, a faculty member and staff member of the Faculty & Staff Benefits Committee, and an HSC faculty member. Aon, UNM's Benefits Consultant, provided the financial analysis. In accordance with appropriate selection criteria established for the procurement, the written proposals were evaluated for responsiveness to UNM requirements. Four finalists were identified and invited to an onsite interview and asked to provide a best and final quote.

Finalists: The Hartford, MetLife, The Standard and Minnesota Life/Securian (Life Coverage only)

The following criteria was used by the RFP evaluation committee to determine the finalists:

- The purchase price, as well as the total long-term cost to UNM to acquire the offeror's services
- The quality and reputation of the Offeror and of the Offeror's services, to include the breadth and stability of the Offeror's company
- Completeness and responsiveness of the offeror's proposal in meeting UNM's needs
- The financial strength of the offeror
- Qualifications/experience of the administrative team proposing to service UNM's needs.

After finalist interviews and analysis of best and final offers, The Hartford was the highest scoring carrier. The selection committee recommends awarding The Hartford for all life and disability lines of coverage. The selection of The Hartford will result in savings to UNM and UNM employees of approximately \$750,000 annually. Hartford has provided a five year rate guarantee for life insurance and four year rate guarantee for LTD.

Timeline

February 2019:	Award Contracts (Purchasing)
March-June 2019:	Finalize agreements and group insurance policies
April/May 2019:	Open Enrollment
June 2019:	Audit and Finalize Open Enrollment

Cost	Employee or Employer Paid	Current Est. Annual Cost (The Standard)	Proposed Est. Annual Cost (The Hartford)	Savings	Estimated Annual Lives (RFP)
Basic Life	Employer	\$376,724	\$295,729	(\$80,996)	
	Employee	\$251,150	\$197,152	(\$53,997)	
	Total	\$627,874	\$492,881	(\$134,993)	5,215
Voluntary Life/AD&D (Employee, Spouse & Child)	Employee	\$1,973,753	\$1,549,396	(\$424,357)	3,079
LTD	Employer	\$414,680	\$364,918	(\$49,762)	
	Employee	\$276,453	\$243,279	(\$33,174)	
	Total	\$691,133	\$608,197	(\$82,936)	2,691
STD	Employee	\$249,711	\$137,341	(\$112,370)	1,478
Monthly Premium Example (\$50,000 annual salary)					
Basic Life	Employee	\$2.26	\$1.78	(\$.48)	
	Employer	\$3.39	\$2.67	(\$.72)	
	Total	\$5.65	\$4.45	(\$1.20)	
Voluntary Life	1 X Salary	\$5.00	\$3.95	(\$1.05)	
LTD	Employee	\$2.85	\$2.50	(\$.35)	
	Employer	\$4.28	\$3.75	(\$.53)	
	Total	\$7.13	\$6.25	(\$.88)	
STD	Employee	\$12.50	\$6.88	(\$5.62)	
Employee Total Monthly Savings				(\$7.50)	

UNM Medical Plan FY 2020 Strategy

Presented to Board of Regents
February 12, 2019




FY 2020 Cost Projections

Eric Weinstein, Aon

Trends

- Average UNM premium increase since FY11 has been 3.3%
- Average national trend rates over the same period of time have averaged 4.5%

Total Costs Per Employee Per Year



Trends

A	E	F	G	H	I	J	K
FISCAL YEAR	AVERAGE ENROLLMENT	CHANGE IN ENROLLMENT	UNM AVG. PREM. % INCR.	NATIONAL AVG. PREM.% INCR.*	TOTAL COST	TOTAL COST PER EE PER YEAR	NUMBER OF CLAIMANTS OVER \$250,000
FY11	6,460	2%	2.0%	8.5%	\$54,980,675	\$8,511	7
FY12	6,414	-1%	0.0%	4.9%	\$58,795,855	\$9,167	13
FY13	6,627	3%	9.0%	3.3%	\$57,390,085	\$8,660	9
FY14	6,727	2%	6.0%	4.4%	\$63,853,491	\$9,492	10
FY15	6,959	3%	0.0%	3.2%	\$66,219,757	\$9,516	6
FY16	6,988	0%	0.0%	3.1%	\$67,955,879	\$9,725	10
FY17	6,943	-1%	4.5%	3.9%	\$66,379,278	\$9,561	4
FY18	6,785	-2%	5.1%	4.5%	\$72,279,042	\$10,653	14

* Based on Aon's HHVI database (over 10 million participants). Net of plan design and vendor negotiations.

- Total contributions fund for all medical and pharmacy claims, excess stop-loss insurance, ASO fees, and ACA transitional reinsurance costs.
- Total costs exclude internal fees, interest income, and pharmacy rebates.

FY 2020 Cost Projection

- FY '20 rates are projected to be 5% higher than current rates
 - Initial projections resulted in a 7% increase to rates, however the renewal was adjusted to 5% considering the following:
 - Utilizing the proposed FY 20 plan designs, adjustments were made to the medical annual trend rate, anticipating UNM's preferred pricing and medical management capabilities
 - Adjustments were also made to the higher than normal large claim activity in CY 2018 which is less likely to repeat in the same fashion in FY 20
- UNM should experience renewals +/- 3% of the annual trend rate of approximately 6.0% in any given year
- Since FY '11 UNM's premiums have increased an average of 3.3% per year with very few plan design changes compared to a national average of 4.5% annually



These are a few changes that keep UNM's increases below national averages:

1. Rx Coalition
2. Plan Design Changes
3. Dependent Verification
4. Utilization of UNM facilities

FY 2020 Cost Projection Budget Impact

Campus	Pooled I&G	Self Supporting I&G	Non-I&G	Grand Total
Main	\$746,648	\$21,266	\$466,402	\$1,234,316
HSC	\$253,815	\$10,677	\$656,537	\$921,029
Branches	\$72,497	\$3,820	\$3,162	\$79,479
Grand Total	\$1,072,959	\$35,762	\$1,126,102	\$2,234,823

- UNM impact based on approximately 63% UNM contribution/ 37% employee contribution

Status Quo Monthly Contributions

Monthly Contributions

	<\$35k (80/20)			\$35k-\$50k (70/30)			\$50k+ (60/40)		
	FY 19			FY 19			FY 19		
	UNMTH	BCBS	PHP	UNMTH	BCBS	PHP	UNMTH	BCBS	PHP
Employee Only	\$98	\$101	\$128	\$147	\$152	\$192	\$196	\$202	\$256
Employee + Spouse	\$201	\$207	\$263	\$301	\$311	\$395	\$402	\$414	\$526
Employee + Child(ren)	\$181	\$187	\$237	\$272	\$281	\$356	\$362	\$374	\$475
Employee + Family	\$285	\$294	\$373	\$428	\$441	\$560	\$570	\$588	\$746

Monthly Contributions

	<\$35k (80/20)			\$35k-\$50k (70/30)			\$50k+ (60/40)		
	FY 20			FY 20			FY 20		
	UNMTH	BCBS	PHP	UNMTH	BCBS	PHP	UNMTH	BCBS	PHP
Employee Only	\$103	\$106	\$134	\$154	\$159	\$202	\$205	\$212	\$269
Employee + Spouse	\$211	\$217	\$276	\$316	\$326	\$414	\$422	\$435	\$552
Employee + Child(ren)	\$190	\$196	\$249	\$285	\$295	\$374	\$380	\$393	\$498
Employee + Family	\$299	\$308	\$392	\$449	\$463	\$587	\$599	\$617	\$783

- Assumes a 5% increase to all plans and all tiers
- Assumes no plan design changes

Monthly Employee Contribution Change

Monthly Contribution Impact

	<\$35k (80/20)			\$35k-\$50k (70/30)			\$50k+ (60/40)		
	FY 20 vs. FY 19			FY 20 vs. FY 19			FY 20 vs. FY 19		
	UNMTH	BCBS	PHP	UNMTH	BCBS	PHP	UNMTH	BCBS	PHP
Employee Only	\$5	\$5	\$6	\$7	\$8	\$10	\$9	\$10	\$13
Employee + Spouse	\$10	\$10	\$13	\$15	\$16	\$20	\$20	\$21	\$26
Employee + Child(ren)	\$9	\$9	\$12	\$14	\$14	\$18	\$18	\$19	\$23
Employee + Family	\$14	\$15	\$19	\$21	\$22	\$28	\$29	\$29	\$37

Assumes a 5% increase to all plans/tiers and no plan design changes

FY 2020 Medical Plan Options Proposal

Joey Evans, Director, University Benefits

FY 2020 Objectives


5% increase projected based on
CY 18 claims experience




■ FY 2020 Objectives: Create foundation to “Bend the Trend” going forward:

- Combine current UNM Team Health (UNMTH) and BCBS populations into one plan.
- Proposed Name: UNM LoboHealth
- Increase utilization of Tier 1 network within UNM LoboHealth and provide the framework for sustainable benefits in the future.
- Continue to provide choice for how UNM employees and dependents receive their health care.
- Provide a simplified and financially predictable benefit structure for UNM LoboHealth Network.
- Reduce administrative redundancy.

FY 2020 Proposed Medical Plan Choices



No approval required to access care outside of Tier 1



Plan design will remain the same as current

FY 2020 Proposal: UNM LoboHealth

NETWORK STRUCTURE

- Current UNMTH network will be Tier 1 for combined population
 - Includes UNM Health System, Davita, First Choice Community Health and various additional BCBS providers
 - Additional BCBS providers primarily include Lab and X-ray, Medical Supplies, Mental Health, Rehab/PT, Fertility
- LoboHealth Network plan design enhancements to encourage increased Tier 1 access
 - Increased utilization of LoboHealth Network helps to reduce overall plan costs

NETWORK COMMITMENTS

- UNM LoboHealth network to provide priority scheduling and clinic navigation for Tier 1
 - Commitment to access standards to meet national standards
 - Increase marketing and accessibility of LoboCare Clinic
 - Publish network access metrics on predetermined frequency including length to appointment, number of patients referred outside Tier 1 and other metrics
- Escalation process with BCBS, UNMTH and UNM Benefits to resolve access/service complaints

FY 2020 Proposed Plan Design

Plan Design Major Categories	FY 2019 UNM Team Health		FY 2019 BCBS		FY 2020 Combined	
Number of Employees	1,313		4,117		5,430	
Total Lives Covered	2,450		7,900		10,350	
Percent of Claims in Tier 1	~85%		~50%		Projected ~63%	
Deductible- Individual/Family(Only Applicable to Coinsurance)	\$600/\$1,200		\$600/\$1,200		\$600/\$1,200	
OOP Max-Individual/Family (Includes Tier I and Tier II cost share and combined with Rx cost share)	\$3,000/\$6,000		\$3,000/\$6,000		\$3,000/\$6,000	
Plan Cost Share	Tier I Cost Share	Tier II Cost Share	Tier I Cost Share	Tier II Cost Share	Tier I Cost Share PROPOSED	Tier II Cost Share PROPOSED
PCP Visit	\$25 Copay	\$30 Copay	\$25 Copay	\$30 Copay	\$10 Copay	\$30 Copay
Specialist Visit	\$35 Copay	\$45 Copay	\$35 Copay	\$45 Copay	\$20 Copay	\$45 Copay
Complex Diagnostic (MRI, CT, PET, Nuclear Med)	Deductible + 10%	Deductible + 30%	Deductible + 15%	Deductible + 25%	\$150 Copay	Deductible + 25%
Outpatient Procedures	Deductible + 10%	Deductible + 30%	Deductible + 15%	Deductible + 25%	\$250 Copay	Deductible + 25%
Inpatient	Deductible + 10%	Deductible + 30%	Deductible + 15%	Deductible + 25%	\$500 Copay	Deductible + 25%

Projected 5% overall increase is **not** impacted by the proposed Tier 1 Network plan design enhancements because the money saved by employees at the time of service is offset by the favorable pricing arrangements within Tier 1.

FY 2020 Proposed Plan Design Examples

Health Care Service	FY 2019 UNM Team Health Network Out-Of-Pocket Costs	FY 2020 LoboHealth Network Out-Of-Pocket Costs
Hospitalization for Delivery of a baby	\$600 Deductible + \$640 coinsurance = approximately \$1,240 assuming delivery total cost of \$7,000	\$500 Copay Out-Of-Pocket savings of approximately \$740
MRI	\$600 Deductible + \$40 coinsurance = \$640 assuming total cost of \$1,000	\$150 Copay Out-Of-Pocket savings of approximately \$490
Outpatient Knee Surgery	\$600 Deductible + \$340 coinsurance = \$940 assuming total costs of \$4,000	\$250 Copay Out-Of-Pocket savings of approximately \$690
Four PCP Visits	\$25 Copay X 4 = \$100	\$10 Copay X 4 = \$40 Out-Of-Pocket savings of approximately \$60
Two Specialist Visits	\$35 Copay X 2 = \$70	\$20 Copay X 2 = \$40 Out-Of-Pocket savings of approximately \$30

By accessing Tier 1, employees may experience significant savings for most utilized care at the time of service.

Proposed Monthly Contributions

Monthly Contributions

	<\$35k (80/20) FY 19	
	UNMTH	BCBS
Employee Only	\$98	\$101
Employee + Spouse	\$201	\$207
Employee + Child(ren)	\$181	\$187
Employee + Family	\$285	\$294

	\$35k-\$50k (70/30) FY 19	
	UNMTH	BCBS
	\$147	\$152
	\$301	\$311
	\$272	\$281
	\$428	\$441

	\$50k+ (60/40) FY 19	
	UNMTH	BCBS
	\$196	\$202
	\$402	\$414
	\$362	\$374
	\$570	\$588

- FY 20 Rates reflect the overall projected 5% increase
- The overall 5% increase is allocated differently for the combined plan due to the FY19 different price points

Monthly Contributions

	<\$35k (80/20) FY 20	
	UNM LoboHealth	
Employee Only	\$105	
Employee + Spouse	\$216	
Employee + Child(ren)	\$195	
Employee + Family	\$307	

	\$35k-\$50k (70/30) FY 20	
	UNM LoboHealth	
	\$158	
	\$324	
	\$293	
	\$460	

	\$50k+ (60/40) FY 20	
	UNM LoboHealth	
	\$211	
	\$432	
	\$391	
	\$614	



THE UNIVERSITY OF
NEW MEXICO



Athletics' FY19 Budget and Actuals (Exhibit P21)

Updated through December 31, 2018 (YTD)

Schedule A: (FY19 Budget and Actuals)- This schedule details out pooled revenues and directed revenues by sport for FY19 budget and actuals year-to-date through December 31, 2018. Please note that a majority of revenues are pooled centrally into Athletics and are not distributed by sport, however ticket sales and game guarantees are distributed by sport.

This report also compares FY19 budget to monthly actuals, and FY19 year-to-date monthly actuals to prior year-to-date monthly actuals. Major variances are due to the restructure of the chart of accounts, timing on when revenue accruals and expenses were posted in the prior year, and differences in institutional transfers.

Schedule B: (Expenses by Sports)- This schedule details out the FY19 expense budget and year-to-date expense actuals through December 31, 2018. Please note grant-in-aid expenses have been budgeted based on prior year actuals, FY19 year-to-date actuals have been allocated to individual sports as expenses post throughout the fiscal year.



Schedule A

FY19 Budget and Monthly Actuals by Exhibit P21

Revenue/Expense Description (2)	FY19 Original Budget	FY19 Revised Budget	Fiscal Year 2018-19 (FY19)												FY19 YTD	FY19 Budget to Projected Actuals Variance	Actuals % of Revised Budget	FY18 YTD Actuals (December)	FY19 YTD vs. FY18 YTD Actuals
			July	August	September	October	November	December	January	February	March	April	May	June					
Pooled Revenues																			
NCAA/Mountain West Conference	4,750,000	4,750,000	532,639	395,833	395,833	395,833	395,833	395,833							2,511,804	(2,238,196)	52.9%	2,540,338	(28,533)
Media Rights/Sponsorship/Licensing	5,625,000	5,625,000	413,042	413,042	413,042	413,042	413,042	413,042							2,478,252	(3,146,748)	44.1%	2,270,208	208,043
Commissions	800,000	800,000	73,333	73,333	73,333	73,333	73,333	73,333							439,999	(360,001)	55.0%	225,000	214,999
Naming Rights	200,000	200,000	-	-	-	-	-	-							-	(200,000)	0.0%	-	-
Student Fees	3,681,708	3,681,708	211,580	402,038	1,322,737	-	-	-							1,936,355	(1,745,353)	52.6%	2,154,138	(217,783)
Fundraising	2,400,000	2,400,000	200,000	200,000	200,000	200,000	200,000	200,000							1,200,000	(1,200,000)	50.0%	1,625,000	(425,000)
State Appropriation	2,641,500	2,641,500	218,200	218,100	230,200	218,100	218,100	218,100							1,320,800	(1,320,700)	50.0%	1,308,700	12,100
Facility Rental/Merchandise/GIK	2,400,000	2,400,000	5,003	8,318	800	4,192	36,397	955,818							1,010,528	(1,389,472)	42.1%	764,064	246,463
Special Events and Other Revenues	2,035,000	2,035,000	96,898	126,009	97,871	118,984	203,219	267,986							910,967	(1,124,033)	44.8%	1,582,530	(671,564)
Transfers to/from Campus	974,000	974,000	973,806	(10,011)	(6,058)	(194)	69,060	(194)							1,026,409	52,409	105.4%	1,536,169	(509,760)
Land Proceed Transfer	789,039	789,039	-	-	-	-	-	-							-	(789,039)	0.0%	-	-
Sub-total	26,296,247	26,296,247	2,724,502	1,826,662	2,727,758	1,423,290	1,608,984	2,523,918	-	-	-	-	-	-	12,835,114	(13,461,133)	48.8%	14,006,148	(1,171,034)
Directed Revenues (by Sports)																			
Men's Basketball Tickets	3,800,000	3,800,000	-	-	-	4,096	1,034,144	744,986							1,783,226	(2,016,774)	46.9%	1,793,449	(10,223)
Football Tickets	1,200,000	1,200,000	-	-	323,610	141,701	415,784	-							881,095	(318,905)	73.4%	1,382,790	(501,695)
Women's Basketball Tickets	375,000	375,000	-	-	-	15,167	64,752	109,137							189,055	(185,945)	50.4%	227,625	(38,570)
Other Sports Tickets (1)	115,000	115,000	-	13,180	19,570	40,375	6,498	-							79,623	(35,377)	69.2%	144,188	(64,565)
Football Game Guarantees	1,100,000	1,100,000	-	-	1,100,000	-	-	-							1,100,000	-	100.0%	1,100,000	-
Sub-total	6,590,000	6,590,000	-	13,180	1,443,180	201,339	1,521,177	854,123	-	-	-	-	-	-	4,032,999	(2,557,002)	61.2%	4,648,051	(615,053)
Total	32,886,247	32,886,247	2,724,502	1,839,842	4,170,938	1,624,629	3,130,161	3,378,041	-	-	-	-	-	-	16,868,112	(16,018,135)	51.3%	18,654,199	(1,786,087)
Expenses																			
Salaries	11,272,844	11,272,844	865,392	849,356	889,942	861,724	978,959	901,883							5,347,257	(5,925,587)	47.4%	5,617,468	(270,212)
Payroll Benefits	3,271,643	3,271,643	225,618	225,833	266,773	233,767	235,828	218,093							1,405,912	(1,865,731)	43.0%	1,542,629	(136,717)
Communication Charges	110,268	110,268	4,993	5,337	7,204	5,364	5,095	7,579							35,573	(74,695)	32.3%	47,707	(12,135)
Other Expense	782,164	782,164	34,757	79,947	103,719	92,249	113,875	1,046,277							1,470,824	688,660	188.0%	1,192,515	278,309
Patient Care Costs	98,300	98,300	26,137	15,400	15,241	4,865	8,304	5,905							75,852	(22,448)	77.2%	109,370	(33,518)
Plant Maintenance	250,457	250,457	33,972	6,235	11,390	24,648	15,974	15,645							107,865	(142,592)	43.1%	128,950	(21,086)
Services	4,967,038	4,967,038	107,701	181,741	218,202	649,935	213,078	214,842							1,585,500	(3,381,538)	31.9%	1,890,269	(304,769)
Student Costs (includes Grant-in-Aid)	5,694,190	5,694,190	108,655	1,737,125	808,184	350,172	271,307	84,549							3,359,992	(2,334,198)	59.0%	3,338,679	21,313
Supplies	2,055,696	2,055,696	287,004	251,795	203,412	125,710	204,799	65,006							1,137,726	(917,970)	55.3%	1,096,323	41,403
Travel	3,809,977	3,809,977	680,575	212,352	124,882	445,800	412,537	441,397							2,317,543	(1,492,434)	60.8%	2,285,219	32,324
Utilities	573,670	573,670	(13,936)	51,768	52,039	42,561	16,907	73,624							222,964	(350,706)	38.9%	244,447	(21,483)
Total	32,886,247	32,886,247	2,360,868	3,616,891	2,700,989	2,836,795	2,476,665	3,074,799	-	-	-	-	-	-	17,067,006	(15,819,241)	51.9%	17,493,575	(426,569)
Net	-	-	363,634	(1,777,049)	1,469,950	(1,212,167)	653,496	303,242	-	-	-	-	-	-	(198,894)	(198,894)	-0.6%	1,160,624	(1,359,518)

(1) Other sports tickets include men's and women's soccer and track, baseball, softball, and volleyball

(2) Actuals through December 31, 2018

(3) Does not include accumulated deficit

FY19 Budgeted Expenses and Year-to-Date (YTD) Actuals by Sport Exhibit P21 (1)

Football			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	2,615,585	1,353,302	1,262,283
Payroll Benefits	804,797	307,028	497,769
Communication Charges	28,550	10,252	18,298
Other Expense	79,908	43,433	36,475
Patient Care Costs	18,000	8,364	9,636
Plant Maintenance	83,407	47,724	35,683
Services	1,003,600	667,501	336,099
Student Costs/Grant-in-Aid (2)	1,724,282	1,206,688	517,594
Supplies	305,350	193,735	111,615
Travel	1,275,550	993,170	282,380
Utilities	7,800	4,075	3,725
Total	7,946,829	4,835,272	3,111,556

Men's Baseball			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	357,672	190,336	167,336
Payroll Benefits	107,609	43,602	64,007
Communication Charges	1,460	270	1,190
Other Expense	7,852	3,035	4,817
Patient Care Costs	-	1,920	(1,920)
Plant Maintenance	-	-	-
Services	55,760	1,135	54,625
Student Costs/Grant-in-Aid (2)	233,545	108,954	124,591
Supplies	78,230	56,279	21,951
Travel	168,100	28,406	139,694
Utilities	-	-	-
Total	1,010,228	433,937	576,291

Women's Softball			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	183,000	83,824	99,176
Payroll Benefits	65,294	28,841	36,453
Communication Charges	2,400	405	1,995
Other Expense	3,942	1,688	2,254
Patient Care Costs	-	-	-
Plant Maintenance	-	122	(122)
Services	28,800	797	28,003
Student Costs/Grant-in-Aid (2)	238,818	88,592	150,226
Supplies	27,300	25,996	1,304
Travel	140,100	18,131	121,969
Utilities	-	-	-
Total	689,654	248,397	441,257

Men's Basketball			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	2,018,137	999,279	1,018,858
Payroll Benefits	373,163	134,703	238,460
Communication Charges	15,560	2,934	12,626
Other Expense	59,150	11,912	47,238
Patient Care Costs	7,500	5,771	1,729
Plant Maintenance	34,900	6,632	28,268
Services	746,240	52,219	694,021
Student Costs/Grant-in-Aid (2)	275,374	184,900	90,474
Supplies	103,850	62,516	41,334
Travel	541,500	215,484	326,016
Utilities	-	-	-
Total	4,175,374	1,676,352	2,499,022

Women's Basketball			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	768,086	395,074	373,012
Payroll Benefits	258,590	111,885	146,705
Communication Charges	2,920	765	2,155
Other Expense	16,319	7,908	8,411
Patient Care Costs	-	1,000	(1,000)
Plant Maintenance	7,400	1,837	5,563
Services	290,250	50,361	239,889
Student Costs/Grant-in-Aid (2)	239,448	163,320	76,128
Supplies	48,850	22,336	26,514
Travel	343,628	233,403	110,226
Utilities	-	-	-
Total	1,975,491	987,887	987,604

Men's Soccer			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	225,969	122,339	103,630
Payroll Benefits	63,810	40,407	23,403
Communication Charges	2,420	686	1,734
Other Expense	5,628	4,069	1,559
Patient Care Costs	1,000	1,886	(886)
Plant Maintenance	-	-	-
Services	34,025	21,343	12,682
Student Costs/Grant-in-Aid (2)	213,722	87,130	126,591
Supplies	19,825	38,327	(18,502)
Travel	120,750	126,091	(5,341)
Utilities	-	-	-
Total	687,149	442,278	244,871

Women's Soccer			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	196,000	100,950	95,050
Payroll Benefits	70,889	34,430	36,459
Communication Charges	1,060	300	760
Other Expense	3,491	4,626	(1,135)
Patient Care Costs	-	152	(152)
Plant Maintenance	-	252	(252)
Services	4,200	2,481	1,719
Student Costs/Grant-in-Aid (2)	304,393	132,643	171,749
Supplies	15,250	17,082	(1,832)
Travel	127,100	151,405	(24,305)
Utilities	-	-	-
Total	722,383	444,322	278,061

Men's Golf			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	163,000	83,371	79,629
Payroll Benefits	50,816	29,693	21,123
Communication Charges	320	271	49
Other Expense	2,534	2,114	420
Patient Care Costs	-	-	-
Plant Maintenance	-	-	-
Services	450	4,480	(4,030)
Student Costs/Grant-in-Aid (2)	97,381	40,355	57,026
Supplies	2,475	16,444	(13,969)
Travel	61,250	50,331	10,919
Utilities	520	38	482
Total	378,746	227,097	151,649

Women's Golf			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	144,905	73,708	71,197
Payroll Benefits	41,064	28,547	12,517
Communication Charges	560	-	560
Other Expense	2,319	2,000	319
Patient Care Costs	-	-	-
Plant Maintenance	-	-	-
Services	3,800	10,105	(6,305)
Student Costs/Grant-in-Aid (2)	113,191	55,775	57,416
Supplies	8,560	18,885	(10,325)
Travel	56,000	31,350	24,650
Utilities	350	38	312
Total	370,749	220,408	150,341

Men's Tennis			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	103,000	48,100	54,900
Payroll Benefits	24,698	11,585	13,114
Communication Charges	290	135	155
Other Expense	2,750	1,328	1,423
Patient Care Costs	-	-	-
Plant Maintenance	-	-	-
Services	15,810	2,640	13,170
Student Costs/Grant-in-Aid (2)	53,071	27,076	25,995
Supplies	15,300	10,692	4,608
Travel	48,700	19,610	29,090
Utilities	-	-	-
Total	263,619	121,164	142,455

Women's Tennis			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	105,000	50,520	54,480
Payroll Benefits	30,729	17,813	12,916
Communication Charges	610	330	280
Other Expense	2,481	1,156	1,325
Patient Care Costs	-	-	-
Plant Maintenance	-	-	-
Services	12,910	3,194	9,716
Student Costs/Grant-in-Aid (2)	157,622	63,303	94,319
Supplies	13,615	15,838	(2,223)
Travel	50,500	13,812	36,688
Utilities	-	-	-
Total	373,467	165,966	207,501

Cross Country (M/W) (3)			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	153,188	76,771	76,417
Payroll Benefits	57,154	25,991	31,163
Communication Charges		-	-
Other Expense	2,885	2,226	659
Patient Care Costs		111	(111)
Plant Maintenance		487	(487)
Services	6,750	3,697	3,053
Student Costs/Grant-in-Aid (2)	314,034	115,540	198,494
Supplies	17,813	1,853	15,960
Travel	107,555	69,462	38,093
Utilities		-	-
Total	659,379	296,138	363,241

Track (M/W) (3)			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	153,188	85,883	67,305
Payroll Benefits	57,154	28,003	29,151
Communication Charges	560	300	260
Other Expense	3,078	1,991	1,087
Patient Care Costs	-	485	(485)
Plant Maintenance	12,350	-	12,350
Services	6,750	3,627	3,123
Student Costs/Grant-in-Aid (2)	314,034	115,658	198,376
Supplies	17,813	18,775	(962)
Travel	97,600	33,065	64,535
Utilities	-	-	-
Total	662,527	287,788	374,739

Women's Volleyball (4)			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	132,914	62,578	70,336
Payroll Benefits	42,351	18,941	23,410
Communication Charges	1,605	632	973
Other Expense	3,372	3,111	261
Patient Care Costs	-	-	-
Plant Maintenance	15,300	1,154	14,146
Services	52,950	19,146	33,804
Student Costs/Grant-in-Aid (2)	229,360	117,006	112,354
Supplies	33,650	16,788	16,862
Travel	94,650	103,845	(9,195)
Utilities	-	-	-
Total	606,152	343,200	262,952

Sand Volleyball (4)			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	113,514	56,876	56,638
Payroll Benefits	42,351	17,858	24,493
Communication Charges	-	-	-
Other Expense	1,174	419	755
Patient Care Costs	-	-	-
Plant Maintenance	3,000	-	3,000
Services	-	-	-
Student Costs/Grant-in-Aid (2)	38,957	8,981	29,976
Supplies	500	-	500
Travel	32,250	-	32,250
Utilities	-	-	-
Total	231,746	84,133	147,613

Skiing (M/W)			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	132,162	59,648	72,514
Payroll Benefits	49,310	25,207	24,103
Communication Charges	350	165	185
Other Expense	14,874	1,717	13,157
Patient Care Costs	-	-	-
Plant Maintenance	9,600	4,504	5,096
Services	7,000	1,944	5,056
Student Costs/Grant-in-Aid (2)	137,010	80,233	56,778
Supplies	21,260	9,310	11,950
Travel	102,950	43,491	59,459
Utilities	-	-	-
Total	474,516	226,216	248,301

Swimming/Diving			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	146,000	74,103	71,897
Payroll Benefits	54,473	25,757	28,716
Communication Charges	350	165	185
Other Expense	3,251	2,221	1,030
Patient Care Costs	-	-	-
Plant Maintenance	-	-	-
Services	1,200	180	1,020
Student Costs/Grant-in-Aid (2)	192,740	119,941	72,799
Supplies	26,195	3,954	22,241
Travel	95,900	56,984	38,916
Utilities	-	-	-
Total	520,109	283,305	236,803

Spirit			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	-	-	-
Payroll Benefits	-	-	-
Communication Charges	-	165	(165)
Other Expense	960	668	292
Patient Care Costs	-	-	-
Plant Maintenance	500	-	500
Services	11,525	4,810	6,715
Student Costs/Grant-in-Aid (2)	-	-	-
Supplies	8,800	4,659	4,141
Travel	17,200	34,923	(17,723)
Utilities	-	-	-
Total	38,985	45,225	(6,240)

Administration/Events/Other Operating (5)			
Expense Description	FY19 Budget	FY19 YTD Actuals	FY19 Budget to Actuals Variance
Salaries	3,561,524	1,430,594	2,130,930
Payroll Benefits	1,077,391	475,621	601,770
Communication Charges	51,253	17,800	33,453
Other Expense	566,196	1,375,204	(809,008)
Patient Care Costs	71,800	56,163	15,637
Plant Maintenance	84,000	45,152	38,848
Services	2,685,018	735,839	1,949,179
Student Costs/Grant-in-Aid (2)	817,209	643,897	173,312
Supplies	1,291,060	604,259	686,801
Travel	328,694	94,579	234,115
Utilities	565,000	218,813	346,187
Total	11,099,145	5,697,921	5,401,224

Total	32,886,247	17,067,006	15,819,241
--------------	-------------------	-------------------	-------------------

(1) Does not include special events and bowl games; Actuals through December 31, 2018

(2) Grant-in-Aid was budgeted based on FY18 actuals, FY19 actuals will be allocated to individual sports as expenses post

(3) M/W track and cross-country coaches salaries split 50/50 between sports.

(4) Women's volleyball and sand volleyball's coaches salaries split 50/50 between sports.

(5) Includes Events Management, Special Events, Bowl Games, Championships, Gifts-in-Kind, Parking, Concessions, Ticket Office, Administration, Business Office, Leagues and Clubs, Compliance, Advisement, Facility Rentals, Sports Camps, Utilities, Student Assistance Funds, Life skills, Pre Season Training, Athletic Vans, Insurance, Marketing and Media Relations

Update on UNM Press

Information will be presented at the meeting.

Regent Advisors' Comments/Reports

Comments will be given at the meeting.

Reports may be included in the agenda eBook.



Board of Regents' Report
UNM Alumni Association and Alumni Relations Office
February, 2019

Student Engagement

- February 7 - International Student Career Development Workshop

- Trailblazers:
 - Spring Semester Recruitment
 - Trailblazer & Alumni Reunion in planning stages

Alumni Engagement

Alumni Engagement

Homecoming 2019 will be celebrated **October 21-26** culminating with the Homecoming Football Game on Saturday, October 26 against the Hawai'i Rainbow Warriors.

- Regional Chapters and Alumni Outreach Calendar
 - Austin Chapter
 - February 23 - Lobo Day – “Science of Beer” with UNM’s Professor Mark Stone, Civil Engineering
 - Dallas/Fort Worth Chapter
 - January 12 – Men’s Basketball Game Watch vs. CSU -7 attended
 - February 24 – Lobo Day Brunch, Dr. Horton Newsom, Brookhaven CC, 10 am
 - D.C. Chapter
 - March 31 – Lobo Day Brunch, Dr. Rob del Campo
 - Las Vegas Chapter
 - January 22 – at UNM vs. UNLV Men’s Basketball Game, 7 pm
 - Norcal Chapter
 - February 26 SJSU Pre-game Social
 - March 2 - Lobo Day Potluck

San Diego Chapter

January 15 – at UNM vs. SDSU Men's Basketball Game, 9 pm

February 5 – Men's Basketball Game Watch, SD Brewing Co., 8 pm

Seattle Chapter

January 26 – New Year's Party, home of Paul Schafer

LOBOS COAST TO COAST MEN'S BASKETBALL GAME WATCH vs NEVADA, 4 pm, MT

Albuquerque Chapter – Hops Brewery

Young Alumni Chapter – Hops Brewery; Farmington at No Worries Sports Bar,
Las Cruces, Las Vegas at JC's New York Pizza Dept., Ruidoso at El Camino Nuevo
Mexican

Native American Chapter – Hops Brewery

Dallas/Fort Worth Chapter – Redrock Bar & Grill

Los Angeles Chapter - LA Aleworks

New York Chapter – Blondies Sports

Orlando Alumni Group – Craig Miller's Field House

Phoenix Chapter – Half Moon Windy City Sports Grill

San Diego Chapter – San Diego Brewing Co.

Washington DC Chapter – Mission at Dupont Circle

Lincoln, NE – Dino's Crafted Burgers & Pizza

Denver, CO – Sloan's Lake Tap and Burger

- Campus and Constituent Chapters/Groups

January 17 - Native American Alumni Chapter Membership Meeting & Social – 17
attended

January 4-6 - The History Alumni Group hosted a planning session and reception with
the American History Association Conference in Chicago – 15 attended

January 24 – School of Architecture & Planning Alumni Chapter hosted Visioning
Workshop & Social – 12 attended

February 20 – Veterans Alumni Chapter Membership Meeting & Social, Hodgkin Hall,
5:30 – 7:30 pm.

February 28 – American Studies Alumni Group – Alumni Planning Meeting, Hodgkin Hall,
5:30 – 7:30 pm.

Other Alumni Outreach

- January 17 – Lobo Living Room: Who is Safe in CyberSpace? Centennial Engineering
Auditorium, 5:30 – 8 pm – 85 attended

- Dinners for 12 Lobos – 9 Alumni will host dinners February 28, March 1 & 2 to celebrate UNM's birthday and create opportunities for student, alumni, faculty and staff networking and friendships

Other Alumni Outreach

- February 7 – Winter Awards Dinner at Hotel Albuquerque, 5:45 p.m. Recognizing:

Dr. Amy Wohlert	Rodey Award
Dr. Bernard Fuemmeler	Zimmerman Award
Bradford Zeikus	Fergusson Award
Dr. Christian Koops	Faculty Teaching Award

Lobos for Legislation

UNM Day was held on January 28th. The Alumni Association held a legislator appreciation reception for legislators, alumni, student leaders, and UNM administrators with more than 300 in attendance.

COMMUNICATIONS

Website *January 1-31*

Pages	Unique Views
Website (Page views)	9,131
1. Scholarships	187
2. Home	928
3. Scholarship Criteria	38
4. Online Community	255
5. Travel	169
iModules	
1. Email Marketing Unsubscribe	255
2. Community Login	417
3. Diploma Address Verification	0
4. First-Time Login	101
Technology (Sessions)	6,206
1. Desktop	3,734

2. Mobile	2,122
3. Tablet	350
New Visitors	4,368
Returning Visitors	1,090

Online Community *January 1 - 31*

New registered members	39
New members	590
New non-members	534
Profile account created	384
Unique profile updates	83
Unique logins	101
Total in Community	351,460

Broadcast Emails

In January, the Alumni Relations Office sent 26 emails, including the Howler on January 10 and reminder emails for events.

No. of addressees*	Opens	Clicks	Bounces	Unsubscribes
301,262	41,058	2,030	18,006	312

** Total number of people sent to (people can receive multiple emails to comprise this total)*

Social Media

Social media statistics for January 2019:

	Facebook	Instagram
Followers (as of 2/5/2019)	4,966	1,037
Posts	13	6
Total impressions for the month	30,363	3,356
Link clicks	1,647	—

Howler Statistics

The Howler monthly e-newsletter statistics:

	Oct. 2018	Nov. 2018	Dec. 2018	Jan. 2018
Delivered	94,781	95,747	94,717	94,197
Bounces	3,103	3,043	4,963	5,195
Opened	11,658	12,384	11,211	10,882
Clicks	302	397	415	269
Unsubscribes	106	95	93	89

Marketing & Communications

January 2019 had several active integrated marketing and communications plans created and executed – including graphic design of collateral pieces and website updates and forms to take RSVPs, etc – in support of events and programs, including:

1. Chapter Basketball Watch Parties
2. Chapter Planning Meetings
3. Chapter New Year's Celebrations
4. Lobo Living Room: Who is Safe in Cyberspace
5. Alumni Association Legislator Appreciation Reception